var data = `[
  {
    "newstxt": "Approval (third indication) announced October 3, 2017. ", 
    "company": "AbbVie Inc.", 
    "indication": "Forehead lines", 
    "name": "Botox", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint at interim analysis - May 17, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Glioblastoma (rGBM)", 
    "name": "Depatuxizumab mafodotin ABT-414", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoints - April 19, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Squamous non-small cell lung cancer (NSCLC) and triple negative breast cancer (TNBC)", 
    "name": "Veliparib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved November 13, 2013.", 
    "company": "AbbVie Inc.", 
    "indication": "Relapsed or refractory MCL mantle cell lymphoma", 
    "name": "Ibrutinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved February 12, 2014.", 
    "company": "AbbVie Inc.", 
    "indication": "Cancer - Chronic Lymphocytic Leukemia Who Have Received at Least One Prior Therapy", 
    "name": "Imbruvica", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved July 19, 2014.", 
    "company": "AbbVie Inc.", 
    "indication": "Deletion 17p", 
    "name": "Imbruvica", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved December 19, 2014.", 
    "company": "AbbVie Inc.", 
    "indication": "HCV - genotype 1", 
    "name": "VIEKIRA PAK", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved January 29, 2015 - PCYC", 
    "company": "AbbVie Inc.", 
    "indication": "Waldenström’s Macroglobulinemia", 
    "name": "IMBRUVICA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 initiation announced January 25, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Alzheimer's disease ", 
    "name": "ABBV-8E12", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - July 29, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic migraine", 
    "name": "ATOGEPANT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Diabetic Gastroparesis", 
    "name": "RELAMORELIN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "AbbVie Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Cenicriviroc (CVC)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL issued June 26, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Age-related macular degeneration (AMD)", 
    "name": "ABICIPAR", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approved January 19, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Facial Erythema (Redness) Associated with Rosacea", 
    "name": "Oxymetazoline HCl cream 1.0%", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 14, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Biosimilar candidate to Avastin (bevacizumab)", 
    "name": "MVASITM (bevacizumab-awwb)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced June 11, 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)", 
    "name": "Venclexta (MURANO)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due in 2021.", 
    "company": "AbbVie Inc.", 
    "indication": "Relapsed or refractory multiple myeloma", 
    "name": "Venetoclax - CANOVA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced April 23, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Psoriasis ", 
    "name": "Risankizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 2, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Second-line Chronic graft-versus-host disease (GVHD)", 
    "name": "Imbruvica", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to commenced 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Psoriatic Arthritis", 
    "name": "ABT-494", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 pivotal data released March 22, 2018. ORR of 16% + overall survival 5.6 months noted. Abstract 8507.", 
    "company": "AbbVie Inc.", 
    "indication": "Third-line Small Cell Lung Cancer ", 
    "name": "Rova-T (TRINITY)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial met primary and secondary endpoints - October 31, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Atopic Dermatitis", 
    "name": "Upadacitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Marginal zone lymphoma", 
    "name": "Imbruvica", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 3, 2017.", 
    "company": "AbbVie Inc.", 
    "indication": "Hepatitis C virus (HCV)", 
    "name": "Glecaprevir/Pibrentasvir (G/P) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced May 29, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Uterine Fibroids", 
    "name": "Elagolix", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced July 24, 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "Endometriosis", 
    "name": "Elagolix ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 23, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Migraine", 
    "name": "Ubrogepant", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 16, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Rheumatoid arthritis", 
    "name": "ABT-494 upadacitinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be stopped due to shorted overall survival following recommendation from Independent Data Monitoring Committee (IDMC) December 5, 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "Second-line Small Cell Lung Cancer ", 
    "name": "Rova-T (TAHOE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial demonstrated no survival benefit at interim analysis - October 29, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "First-line Small Cell Lung Cancer ", 
    "name": "Rova-T (MERU)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced January 28, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL)", 
    "name": "Imbruvica and Gazyva - iLLUMINATE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 27, 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "Waldenström’s Macroglobulinemia", 
    "name": "IMBRUVICA (ibrutinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - noted July 11, 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "IMBRUVICA (ibrutinib)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced November 21, 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "First line unfit AML", 
    "name": "Venclexta", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b data released October 22, 2018 - primary endpoint met. Phase 3 trial initiation announced October 2018.", 
    "company": "AbbVie Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "Upadacitinib - U-ACHIEVE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "FDA approval announced May 15, 2019. ", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic Lymphocytic Leukemia", 
    "name": "Venetoclax and obinutuzumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint not met (PFS/OS).", 
    "company": "AbbVie Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "Ibrutinib (Imbruvica)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met.", 
    "company": "AbbVie Inc.", 
    "indication": "Multiple myeloma", 
    "name": "Venclexta BELLINI", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 24, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Lower limb spasticity", 
    "name": "Botox", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 21, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Upper limb spasticity", 
    "name": "Botox", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing announced June 4, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic lymphocytic leukemia ", 
    "name": "Venetoclax and obinutuzumab", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced September 3, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Mid-Face Injection Via Cannula", 
    "name": "JuvÃ©derm VOLUMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 presentation at ESMO 28 September 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Veliparib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data presented at EADV October 10, 2019.", 
    "company": "AbbVie Inc.", 
    "indication": "Psoriasis", 
    "name": "Risankizumab ( LIMMITLESS )", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced April 21, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).", 
    "name": "IMBRUVICA (ibrutinib) and rituximab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - January 14, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Plaque psoriasis", 
    "name": "Risankizumab vs secukinumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint -  February 28, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Treatment-naÃ¯ve Acute Myeloid Leukemia", 
    "name": "Venetoclax - Viale-C", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA filing announced June 1, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Psoriatic arthritis", 
    "name": "Upadacitinib", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Crohnâ€™s Disease", 
    "name": "Risankizumab MOTIVATE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Psoriatic Arthritis", 
    "name": "Risankizumab KEEPSAKE2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Psoriasis", 
    "name": "Risankizumab vs secukinumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met co-primary endpoints - June 18, 2020. Second Phase 3 trial also met primary endpoint - July 21, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "Upadacitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met dual primary endpoints of overall survival and composite complete remission rate - March 23, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "Venclexta (VIALE-A)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma", 
    "name": "Imbruvica + Venclexta (CAPTIVATE)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Chronic Graft Versus Host Disease", 
    "name": "Ibrutinib in combination with prednisone", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "AbbVie Inc.", 
    "indication": "Parkinson's disease", 
    "name": "ABBV-951", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated. ", 
    "company": "AbbVie Inc.", 
    "indication": "COVID-19", 
    "name": "Ibrutinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced June 15, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Augmentation of the chin region", 
    "name": "JUVÃ‰DERM VOLUMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA filing accepted June 22, 2020. PDUFA date 1Q 2021.", 
    "company": "AbbVie Inc.", 
    "indication": "Neurogenic Detrusor Overactivity", 
    "name": "Botox", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced August 3, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "COVID-19 (severe)", 
    "name": "Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "sNDA filing announced August 25, 2020.", 
    "company": "AbbVie Inc.", 
    "indication": "Active Ankylosing Spondylitis", 
    "name": "RINVOQ (upadacitinib)", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 presentation at WORLDSymposium February 12, 2020 noted trial has been well-tolerated to date, with no treatment-related severe adverse events.", 
    "company": "Abeona Therapeutics Inc.", 
    "indication": "Sanfilippo syndrome type B (MPS IIIB)", 
    "name": "ABO-101", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be completed early-2021.", 
    "company": "Abeona Therapeutics Inc.", 
    "indication": "Recessive dystrophic epidermolysis bullosa (RDEB)", 
    "name": "EB-101", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 enrollment to be completed by end of 2020.", 
    "company": "Abeona Therapeutics Inc.", 
    "indication": "Sanfilippo syndrome type A (MPS IIIA)", 
    "name": "ABO-102", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial planned. ", 
    "company": "Abeona Therapeutics Inc.", 
    "indication": "CLN1 disease (Infantile Batten disease)", 
    "name": "ABO-202", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in 2021 subject to financing.", 
    "company": "ARCA biopharma Inc.", 
    "indication": "Chronic Heart Failure", 
    "name": "Gencaro", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "ARCA biopharma Inc.", 
    "indication": "COVID-19", 
    "name": "AB201", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Program to be discontinued - February 10, 2020.", 
    "company": "Arbutus Biopharma Corporation", 
    "indication": "Hepatitis B ", 
    "name": "AB-452", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development to be discontinued - noted October 3, 2019.", 
    "company": "Arbutus Biopharma Corporation", 
    "indication": "Hepatitis B (HBV)", 
    "name": "AB-506", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1a/b multiple dose cohort data expected in 2H 2020", 
    "company": "Arbutus Biopharma Corporation", 
    "indication": "Hepatitis B (HBV)", 
    "name": "AB-729", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 20, 2020.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Adjunctive Treatment in Patients With Major Depressive Disorder", 
    "name": "Pimavanserin -  CLARITY-2 and CLARITY-3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiated 3Q 2020.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Adjunctive treatment in patients with negative symptoms of schizophrenia", 
    "name": "Pimavanserin - Advance-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - July 22, 2019.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Adjunctive treatment of schizophrenia", 
    "name": "Pimavanserin - Enhance", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Announced October 4, 2017 that trial will be discontinued.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Alzheimerâ€™s disease agitation", 
    "name": "Pimavanserin - SERENE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved April 29 2016. Additional dose approval announced June 29, 2018.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Parkinsonâ€™s disease psychosis (PDP)", 
    "name": "Pimavanserin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date April 3, 2021.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Alzheimerâ€™s disease psychosis", 
    "name": "Pimavanserin - Harmony", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Rett Syndrome", 
    "name": "Trofinetide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2021.", 
    "company": "ACADIA Pharmaceuticals Inc.", 
    "indication": "Pain", 
    "name": "ACP-044", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL issued June 25, 2019.", 
    "company": "Acer Therapeutics Inc.", 
    "indication": "Vascular Ehlers-Danlos Syndrome", 
    "name": "EDSIVO", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet primary endpoint - October 28, 2016.", 
    "company": "Acer Therapeutics Inc.", 
    "indication": "Secondary Progressive MS (SPMS)", 
    "name": "Tovaxin (Tcelna)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "NDA filing due 1H 2021.", 
    "company": "Acer Therapeutics Inc.", 
    "indication": "Urea cycle disorder (UCD)", 
    "name": "ACER-001", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 1H 2021.", 
    "company": "Acer Therapeutics Inc.", 
    "indication": "induced Vasomotor Symptoms (iVMS)", 
    "name": "Osanetant", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2/3 trial to be initiated 1H 2021.", 
    "company": "Acer Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "Emetine", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2020.", 
    "company": "Achieve Life Sciences Inc.", 
    "indication": "Smoking cessation", 
    "name": "Cytisine - ORCA-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Crenezumab - CREAD 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 2H 2020.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Semorinemab (Anti-Tau RO7105705)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b presentation at AAIC July 29, 2020.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimer's disease-like characteristics in individuals with Down syndrome", 
    "name": "ACI-24 (anti-Abeta vaccine)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Crenezumab - CREAD 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced February 20, 2019.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "MTAU9937A", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "ACI-3024", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b/2 interim analysis 2H 2020. Initiation of the second highest dosing group announced July 16, 2020.", 
    "company": "AC Immune SA", 
    "indication": "Alzheimerâ€™s Disease", 
    "name": "ACI-35.030", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 12-month analysis due 2H 2020.", 
    "company": "AC Immune SA", 
    "indication": " Alzheimerâ€™s disease (AD)", 
    "name": "ACI-24", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Decision on Inter Partes Review (IPR) released March 10, 2017 - patents upheld.", 
    "company": "Acorda Therapeutics Inc.", 
    "indication": "Improve walking in patients with multiple sclerosis", 
    "name": "Ampyra", 
    "stage": ""
  }, 
  {
    "newstxt": "Noted November 15, 2017 seven cases of sepsis, five of which were fatal. Company noted November 20, 2017 that program will be discontinued. ", 
    "company": "Acorda Therapeutics Inc.", 
    "indication": "Parkinsonâ€™s disease (PD)", 
    "name": "Tozadenant", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released November 21, 2016 - failed to show efficacy, development to be discontinued.", 
    "company": "Acorda Therapeutics Inc.", 
    "indication": "Post stroke deficits", 
    "name": "Dalfampridine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced December 22, 2018.", 
    "company": "Acorda Therapeutics Inc.", 
    "indication": "OFF episodes of Parkinsonâ€™s disease (PD)", 
    "name": "INBRIJA (CVT-301)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data did not meet primary endpoint - June 26, 2019.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Alopecia areata", 
    "name": "ATI-502 (ATI-50002-AA-201) - dose ranging", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued - noted August 8, 2019.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Vitiligo", 
    "name": "ATI-502 (VITI-201 Topical)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint and some secondary endpoints - July 30, 2019. Partner required for further development.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Alopecia areata", 
    "name": "ATI-501 (AUAT-201 Oral)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval announced December 15, 2017.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Seborrheic keratosis (SK)", 
    "name": "ESKATA (hydrogen peroxide)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data met all endpoints - September 16, 2019 and October 24, 2019.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Common warts (verruca vulgaris)", 
    "name": "A-101 THWART-1 and THWART-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Partner required to further development.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Androgenetic alopecia (AGA) - Hair loss", 
    "name": "ATI-502", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a data due 1H 2021.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Rheumatoid arthritis (RA)", 
    "name": "ATI-450", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 2H 2020.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "ATI-1777", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2a dosing commenced August 2020.", 
    "company": "Aclaris Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "ATI-450", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data released August 15 2016", 
    "company": "AcelRx Pharmaceuticals Inc.", 
    "indication": "Patients who presented to emergency departments with moderate-to-severe acute pain associated with trauma or injury", 
    "name": "ARX-04 (SAP302)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced November 2, 2018.", 
    "company": "AcelRx Pharmaceuticals Inc.", 
    "indication": "Moderate-to-severe acute pain following a surgical procedure", 
    "name": "DSUVIA (ARX-04)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL Jul 26 2014. NDA resubmission planned.", 
    "company": "AcelRx Pharmaceuticals Inc.", 
    "indication": "Post-operative pain following open abdominal surgery and hip or knee replacement surgery", 
    "name": "Zalviso", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 TRILOGY 1 data did not meet primary endpoint - January 13, 2020. TRILOGY 2 data due on OR about August 31, 2020,", 
    "company": "Acasti Pharma Inc.", 
    "indication": "Hypertriglyceridemia", 
    "name": "CaPre (TRILOGY 1 and 2)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 durability and translational data from patients with synovial sarcoma due at a medical conference 2H 2020.", 
    "company": "Adaptimmune Therapeutics plc", 
    "indication": "Solid tumors", 
    "name": "MAGE-A4 (ADP-A2M4)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 presentation at ILC August 27-29, 2020.", 
    "company": "Adaptimmune Therapeutics plc", 
    "indication": "Hepatocellular carcinoma", 
    "name": "AFP (ADP-A2AFP) (ILC)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 enrolment completed 2019.", 
    "company": "Adaptimmune Therapeutics plc", 
    "indication": "Non-Small Cell Lung Cancer (NSCLC)", 
    "name": "MAGE-A10 (ADP-A2M10)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 enrolment to be completed 1H 2021.", 
    "company": "Adaptimmune Therapeutics plc", 
    "indication": "Synovial sarcoma or myxoid/round cell liposarcoma (MRCLS)", 
    "name": "MAGE-A4 (SPEARHEADâ€‘1)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 dose update due 2H 2020. Phase 2 trial to be initiated 1H 2021.", 
    "company": "Adaptimmune Therapeutics plc", 
    "indication": "Solid tumors", 
    "name": "MAGE-A4 (ADP-A2M4CD8 - SURPASS)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 interim data due 1H 2021.", 
    "company": "ADC Therapeutics SA", 
    "indication": "Hodgkin lymphoma (HL)", 
    "name": "Camidanlumab tesirine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data June 12, 2020 noted overall response rate of 48.3%, a complete response rate of 24.1%.", 
    "company": "ADC Therapeutics SA", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "Loncastuximab tesirine and Ibrutinib - LOTIS 2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Initiation of dosing in pivotal portion of Phase 1/2 trial announced July 17, 2020. BLA filing due 2H 2020.", 
    "company": "ADC Therapeutics SA", 
    "indication": "Diffuse Large B-Cell Lymphoma / Mantle Cell Lymphoma", 
    "name": "Loncastuximab Tesirine and Ibrutinib", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 initiation announced February 6, 2020 with data due in 2021. Data from second Phase 3 trial for U.S. required endpoint due 2023.", 
    "company": "Adial Pharmaceuticals Inc", 
    "indication": "Alcohol use disorder", 
    "name": "AD04", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced April 1, 2019.", 
    "company": "ADMA Biologics Inc", 
    "indication": "Primary Immune Deficiency Diseases", 
    "name": "ASCENIV (RI-002)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Response to Complete Response Letter submitted January 7, 2019.", 
    "company": "ADMA Biologics Inc", 
    "indication": "Primary humoral immunodeficiency", 
    "name": "BIVIGAM", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL issued March 27 2015. CRL issued again June 6, 2016. Approval announced June 15, 2017 following third submission.", 
    "company": "Adamis Pharmaceuticals Corporation", 
    "indication": "Emergency treatment of anaphylaxis.", 
    "name": "Epinephrine Pre-filled Syringe (PFS) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 development on hold - noted May 9, 2019.", 
    "company": "Adamis Pharmaceuticals Corporation", 
    "indication": "Asthma/COPD", 
    "name": "APC-1000", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced September 27, 2018.", 
    "company": "Adamis Pharmaceuticals Corporation", 
    "indication": "Anaphylaxis", 
    "name": "Symjepi - low dose", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL announced November 25, 2019. NDA resubmitted with new PDUFA date of November 15, 2020.", 
    "company": "Adamis Pharmaceuticals Corporation", 
    "indication": "Opioid overdose", 
    "name": "ZIMHI (naloxone HCI Injection)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Refusal to file letter received February 26, 2019.", 
    "company": "Adamis Pharmaceuticals Corporation", 
    "indication": "Erectile dysfunction", 
    "name": "APC-8000 (sublingual tadalafil)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint at one of two doses. Secondary endpoint in walking impairment not met. Second trial will not be initiated as a result of data - December 17, 2019. Findings were confirmed June 17, 2020.", 
    "company": "Adamas Pharmaceuticals Inc.", 
    "indication": "Multiple sclerosis (MS)", 
    "name": "GOCOVRI (amantadine)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved December, 24 2014.", 
    "company": "Adamas Pharmaceuticals Inc.", 
    "indication": "Moderate to severe dementia of the Alzheimer's type.", 
    "name": "Namzaric", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 24, 2017. PDUFA date February 1, 2021 for sNDA to include treatment of OFF episodes in PD patients receiving levodopa.", 
    "company": "Adamas Pharmaceuticals Inc.", 
    "indication": "Levodopa-Induced Dyskinesia + Parkinson's disease patients receiving levodopa and experiencing OFF episodes", 
    "name": "GOCOVRI (ADS-5102)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 open-label data released April 19, 2018.", 
    "company": "Adamas Pharmaceuticals Inc.", 
    "indication": "Dyskinesia patients with Parkinson's disease", 
    "name": "GOCOVRI (amantadine)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial to be discontinued - noted December 17, 2019.", 
    "company": "Aduro Biotech Inc.", 
    "indication": "Solid tumors or lymphomas", 
    "name": "ADU-S100 and Spartalizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 enrolment to be terminated - noted December 17, 2019.", 
    "company": "Aduro Biotech Inc.", 
    "indication": "Melanoma", 
    "name": "ADU-S100 and ipilimumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 1H 2021 in IgA Nephropathy patients. ", 
    "company": "Aduro Biotech Inc.", 
    "indication": "IgA Nephropathy", 
    "name": "BION-1301", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Aduro Biotech Inc.", 
    "indication": "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
    "name": "ADU-S100 and pembrolizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated - noted February 6, 2020.", 
    "company": "Aduro Biotech Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "MK-5890 and pembrolizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 2H 2020 might be delayed.", 
    "company": "Aduro Biotech Inc.", 
    "indication": "Non-muscle invasive bladder cancer", 
    "name": "ADU-S100", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial planned.", 
    "company": "ADiTx Therapeutics Inc.", 
    "indication": "Psoriasis ", 
    "name": "ADi", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Development to be discontinued - noted November 1, 2018.", 
    "company": "Adverum Biotechnologies Inc.", 
    "indication": "Alpha-1 Antitrypsin (A1AT) Deficiency", 
    "name": "ADVM-043", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2a negative data released June 2015 (met primary endpoint but increase in retinal thickness). As a result Phase 2b development will not proceed.", 
    "company": "Adverum Biotechnologies Inc.", 
    "indication": "Wet age-related macular degeneration (Wet-AMD)", 
    "name": "AVA-101", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 updated data from all four cohorts was well tolerated. Pivotal trial to commence mid-2021.", 
    "company": "Adverum Biotechnologies Inc.", 
    "indication": "Wet age-related macular degeneration (Wet-AMD)", 
    "name": "ADVM-022 (OPTIC)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 randomization of first patient announced July 13, 2020 with data due 2H 2021.", 
    "company": "Adverum Biotechnologies Inc.", 
    "indication": "Diabetic macular edema", 
    "name": "ADVM-022 - INFINITY", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Enrollment to be terminated - noted November 2, 2018.", 
    "company": "Advaxis Inc.", 
    "indication": "Recurrent or refractory HPV-associated cervical cancer and head & neck cancer", 
    "name": "Axalimogene filolisbac + durvalumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 presentation at ASCO Genitourinary Cancers Symposium February 13, 2020 noted median overall survival (95% CI) of 33.7 months.", 
    "company": "Advaxis Inc.", 
    "indication": "Castrate-resistant prostate cancer", 
    "name": "ADXS-PSA and Keytruda - KEYNOTE-046", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial closed - noted June 27, 2019.", 
    "company": "Advaxis Inc.", 
    "indication": "High-risk, locally advanced cervical cancer", 
    "name": "Axalimogene filolisbac - AIM2CERV Trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Decided not to proceed to the expansion phase of the trial - noted in 10K December 21, 2017.", 
    "company": "Advaxis Inc.", 
    "indication": "HER2-driven malignancies - cancer", 
    "name": "ADXS-HER2 ", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Noted in 10-K December 21, 2017 that it will not initiate the Stage 2 portion of the trial in order to focus its resources on other clinical priorities.", 
    "company": "Advaxis Inc.", 
    "indication": "Anal cancer (FAWCETT)", 
    "name": "Axalimogene filolisbac", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 safety and immunogenicity data presented at AACR March 2019", 
    "company": "Advaxis Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "ADXS-NEO", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data noted 50% (3 of 6) of evaluable patients from monotherapy arm and 1/1 patients on combo arm (Keytruda) showed stable disease - February 20, 2020.", 
    "company": "Advaxis Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "ADXS-HOT 503", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced March 12, 2019.", 
    "company": "Aerie Pharmaceuticals Inc.", 
    "indication": "Glaucoma", 
    "name": "Roclatan", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date February 28, 2018. Approved ahead of schedule - December 18, 2017.", 
    "company": "Aerie Pharmaceuticals Inc.", 
    "indication": "Glaucoma", 
    "name": "Rhopressa", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiation announced August 20, 2019.", 
    "company": "Aerie Pharmaceuticals Inc.", 
    "indication": "Neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)", 
    "name": "AR-13503", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 top-line data July 27, 2020 noted treatment was well tolerated with no unexpected safety findings with sustained treatment effects.", 
    "company": "Aerie Pharmaceuticals Inc.", 
    "indication": "Macular edema due to RVO (retinal vein occlusion)", 
    "name": "AR-1105", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due late-3Q 2020.", 
    "company": "Aerie Pharmaceuticals Inc.", 
    "indication": "Open Angle Glaucoma", 
    "name": "Roclatan - Mercury 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated late-2020.", 
    "company": "Aerie Pharmaceuticals Inc.", 
    "indication": "Dry eye disease", 
    "name": "AR-15512 (AVX-012)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "CRL issued November 2014. Approval announced following resubmission December 20, 2017.", 
    "company": "Aeterna Zentaris Inc.", 
    "indication": "Adult Growth Deficiency", 
    "name": "Macimorelin Acetate - Macrilen", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - May 1, 2017.", 
    "company": "Aeterna Zentaris Inc.", 
    "indication": "Endometrial cancer", 
    "name": "Zoptrex", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Pharmacokinetics and pharmacodynamics data to be presented at ECE September 5-9, 2020. Safety and efficacy study expected to commence in 1Q 2021.", 
    "company": "Aeterna Zentaris Inc.", 
    "indication": "Paediatric patients with suspected growth hormone deficiency (GHD)", 
    "name": "Macimorelin acetate (AEZS-130)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b updated data at ICML June 22, 2019 noted ORR of 88% at highest dose, CR rates of 42%-46%.", 
    "company": "Affimed N.V.", 
    "indication": "Hodgkin Lymphoma - Cancer", 
    "name": "AFM13 with Keytruda", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2a ongoing.", 
    "company": "Affimed N.V.", 
    "indication": "Hodgkin Lymphoma - Cancer", 
    "name": "AFM13", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 interim analysis due mid-2021.", 
    "company": "Affimed N.V.", 
    "indication": "CD30-positive peripheral T cell lymphoma (PTCL)", 
    "name": "AFM13", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 program terminated - noted May 22, 2019.", 
    "company": "Affimed N.V.", 
    "indication": "Non-Hodgkin lymphoma (NHL) and acute lymphoblastic leukemia (ALL)", 
    "name": "AFM11", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2a completion of first cohort announced June 17, 2020. Noted no efficacy yet was observed, however, efficacy was not expected at this dose level.", 
    "company": "Affimed N.V.", 
    "indication": "EGFR-expressing solid tumors", 
    "name": "AFM24", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data to be presented at ESMO September 18, 2020.", 
    "company": "Agenus Inc.", 
    "indication": "Cervical cancer", 
    "name": "Balstilimab (anti-PD-1) and zalifrelimab (anti-CTLA-4)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 expansion trial underway - noted August 6, 2020.", 
    "company": "Agenus Inc.", 
    "indication": "Solid cancers", 
    "name": "Zalifrelimab - AGEN1884 (anti-CTLA-4)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Approval announced October 20, 2017.", 
    "company": "Agenus Inc.", 
    "indication": "Shingles", 
    "name": "Shingrix ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA filing due 2020.", 
    "company": "Agenus Inc.", 
    "indication": "Cervical cancer", 
    "name": "Balstilimab (AGEN2034) anti-PD-1", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 1 data presented at Investor Day February 20, 2020.", 
    "company": "Agenus Inc.", 
    "indication": "Advanced cancer", 
    "name": "AGEN1181 - 2nd gen CTLA", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 updated data at EHA June 12, 2020. Primary endpoint defined as a â‰¥1.0 g/dL increase in Hb concentration from baseline at 1 or more assessments between week 4 and week 12 was met by 12 of 13 (92.3%) patients.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Thalassemia", 
    "name": "AG-348 - Mitapivat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced July 20, 2018.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "IDH1m Relapsed/Refractory AML - cancer", 
    "name": "Ivosidenib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due between the end of 2020 and mid-2021.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Pyruvate kinase deficiency", 
    "name": "AG-348 (ACTIVATE-T)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2021.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Frontline Acute myeloid leukemia (AML) harboring an IDH1 mutation - cancer", 
    "name": "AG-120 and VIDAZA - AGILE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced August 1, 2017.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Advanced hematologic malignancies with an IDH2 mutation", 
    "name": "IDHIFA (enasidenib) - AG-221", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 mature overall survival data due 3Q 2020.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "IDH1 mutant positive cholangiocarcinoma - cancer", 
    "name": "AG-120 Ivosidenib (ClarIDHy)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 updated data February 25, 2019 noted ORR of 78%, 57% CR rate, and 12-month Survival Rate of 82%.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Frontline AML with IDH1 or IDH2 mutation", 
    "name": "Enasidenib or ivosidenib with VIDAZA", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 enrolment has slowed due to COVID-19. A go/no-go decision is expected no later than 2022.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "AG-270", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 enrolment has slowed as a result of COVID-19.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Glioma", 
    "name": "Vorasidenib (AG-881)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 2, 2019.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Frontline AML with IDH1 mutation", 
    "name": "Ivosidenib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 presentation at ASCO May 29, 2020. Median Progression-free Survival of 31.4 months.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "IDHm low-grade glioma", 
    "name": "Vorasidenib (AG-881)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 updated data at ASCO June 3, 2019. 30% CR rate.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": " IDH1 mutant newly diagnosed AML ineligible for standard therapies", 
    "name": "Ivosidenib", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 updated data at ASH December 9, 2019 noted complete response (CR) rate of 61% and a CR + CR with partial hematologic recovery (CRh) rate of 70%.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Newly diagnosed AML with an IDH1 mutation", 
    "name": "Ivosidenib and azacitidine ( Vidaza)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due between the end of 2020 and mid-2021.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Pyruvate Kinase Deficiency", 
    "name": "AG-348 - Mitapivat (ACTIVATE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due at ASH December 2020.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Sickle cell disease.", 
    "name": "AG-348 - Mitapivat (ASH)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 3Q 2020.", 
    "company": "Agios Pharmaceuticals Inc.", 
    "indication": "Healthy volunteers", 
    "name": "AG-946", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due 1Q 2021. ", 
    "company": "Aeglea BioTherapeutics Inc.", 
    "indication": "Arginase I deficiency", 
    "name": "Pegzilarginase (AEB1102)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "Aeglea BioTherapeutics Inc.", 
    "indication": "Small cell lung cancer (SCLC)", 
    "name": "Pegzilarginase (AEB1102) + KEYTRUDA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiated June 2020.", 
    "company": "Aeglea BioTherapeutics Inc.", 
    "indication": "Homocystinuria", 
    "name": "ACN00177", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced February 14, 2020.", 
    "company": "Agile Therapeutics Inc.", 
    "indication": "Contraceptive patch ", 
    "name": "Twirla", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due 2H 2020.", 
    "company": "Applied Genetic Technologies Corporation", 
    "indication": "Achromatopsia", 
    "name": "AAV Gene Therapy", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 interim data released December 12, 2018. No signs of clinical activity.", 
    "company": "Applied Genetic Technologies Corporation", 
    "indication": "X-linked retinoschisis (XLRS)", 
    "name": "rAAV-hRS1", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 further data due 2H 2020.", 
    "company": "Applied Genetic Technologies Corporation", 
    "indication": "X-linked Retinitis Pigmentosa (XLRP)", 
    "name": "AGTC-501", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "CRL February 4, 2013.", 
    "company": "AIM ImmunoTech Inc.", 
    "indication": "CFS", 
    "name": "Ampligen", 
    "stage": "crl"
  }, 
  {
    "newstxt": "All patients have been treated or are near completion of treatment - August 2020.", 
    "company": "AIM ImmunoTech Inc.", 
    "indication": "Triple-Negative Breast Cancer", 
    "name": "Ampligen, Intron A, celecoxib and pembrolizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "AIM ImmunoTech Inc.", 
    "indication": "Colorectal cancer", 
    "name": "Ampligen, Intron A, and celecoxib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial is enrolling - noted August 2020.", 
    "company": "AIM ImmunoTech Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Ampligen, cisplatin and pembrolizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated - noted August 2020.", 
    "company": "AIM ImmunoTech Inc.", 
    "indication": "Prostate Cancer", 
    "name": "Ampligen, Intron A", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 interim data to be presented 2020.", 
    "company": "AIM ImmunoTech Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Ampligen plus Intron A", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA approval announced January 31, 2020.", 
    "company": "Aimmune Therapeutics Inc.", 
    "indication": "Peanut Allergy", 
    "name": "PALFORZIA - AR101", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Aimmune Therapeutics Inc.", 
    "indication": "Egg Allergy", 
    "name": "AR 201", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced October 15, 2018. Ongoing as of July 30, 2020.", 
    "company": "Aimmune Therapeutics Inc.", 
    "indication": "Peanut Allergy", 
    "name": "AR101 with adjunctive dupilumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Aimmune Therapeutics Inc.", 
    "indication": "Peanut Allergy", 
    "name": "AR101 POSEIDON", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved Sept 5, 2014.", 
    "company": "Akebia Therapeutics Inc.", 
    "indication": "Hyperphosphatemia", 
    "name": "Auryxia", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoints - May 5, 2020.", 
    "company": "Akebia Therapeutics Inc.", 
    "indication": "Anemia related to chronic kidney disease who are undergoing dialysis (DD-CKD)", 
    "name": "Vadadustat - INNO2VATE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due early-September 2020.", 
    "company": "Akebia Therapeutics Inc.", 
    "indication": "Non-dialysis patients with anemia related to CKD (NDD-CKD)", 
    "name": "Vadadustat - PRO2TECT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA FDA Approval announced November 7, 2017.", 
    "company": "Akebia Therapeutics Inc.", 
    "indication": "Iron deficiency anemia in non-dialysis dependent CKD patients", 
    "name": "Auryxia", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 initiation announced July 14, 2020.", 
    "company": "Akebia Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "Vadadustat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data to be presented at ESC Congress August 29, 2020.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "Non-alcoholic fatty liver disease (NAFLD), Hypertriglyceridemia and Type 2 Diabetes Mellitus", 
    "name": "AKCEA-ANGPTL3-LRx", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data to be presented at ESC Congress August 29, 2020. Phase 3 trial to be initiated 2020.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "Hyperlipoproteinemia and established cardiovascular disease", 
    "name": "AKCEA-APOCIII-LRx", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2024.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "Hyperlipoproteinemia(a) and established cardiovascular disease", 
    "name": "AKCEA-APO(a)-LRx", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 5, 2018,", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "NEURO-TTR - familial amyloid polyneuropathy (FAP).", 
    "name": "Inotersen (IONIS-TTRRx)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued August 27, 2018. To be refiled 2020.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "Familial chylomicronemia syndrome (FCS)", 
    "name": "Volanesorsen - APPROACH", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - August 6, 2019.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "Familial partial lipodystrophy (FPL)", 
    "name": "Volanesorsen", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced November 25, 2019. Data due 2023.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "hATTR Amyloidosis", 
    "name": "AKCEA-TTR-LRx (NEURO-TTRansform)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced January 10, 2020. Data due 2023.", 
    "company": "Akcea Therapeutics Inc.", 
    "indication": "ATTR cardiomyopathy", 
    "name": "AKCEA-TTR-LRx - CARDIO-TTRansform", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Pre-clinical trials are planned with clinical trials to be potentially initiated after.", 
    "company": "Akers Biosciences Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "VLP vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a Cohort C (F4) readout and Phase 2b/3 initiation 1H 2021.", 
    "company": "Akero Therapeutics Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "AKR-001", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 interim data January 10, 2020 noted all patients achieved the primary endpoint of transfusion independence. ", 
    "company": "Akari Therapeutics Plc", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)", 
    "name": "Nomacopan - CAPSTONE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 enrolment has paused due to COVID-19. Interim update due mid-2020.", 
    "company": "Akari Therapeutics Plc", 
    "indication": "Atopic keratoconjunctivitis", 
    "name": "Nomacopan", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial met primary endpoint - May 1, 2020. Phase 3 trial to commence 1H 2021.", 
    "company": "Akari Therapeutics Plc", 
    "indication": "Bullous Pemphigoid", 
    "name": "Nomacopan (Coversin)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced December 23, 2019.", 
    "company": "Akari Therapeutics Plc", 
    "indication": "Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)", 
    "name": "Nomacopan", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence in 2021.", 
    "company": "Akouos Inc.", 
    "indication": "Hearing loss", 
    "name": "AK-OTOF", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data due mid-2020.", 
    "company": "Albireo Pharma Inc.", 
    "indication": "Progressive familial intrahepatic cholestasis (PFIC)", 
    "name": "Odevixibat (A4250) - PEDFIC- 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial met primary endpoint. However, development in NASH will not continue - August 18, 2020.", 
    "company": "Albireo Pharma Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Elobixibat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced July 14, 2020.", 
    "company": "Albireo Pharma Inc.", 
    "indication": "Biliary atresia", 
    "name": "Odevixibat (A4250)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to commence by the end of 2020.", 
    "company": "Albireo Pharma Inc.", 
    "indication": "Alagille syndrome", 
    "name": "Odevixibat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 (Part 1) data December 3, 2019 noted one co-primary endpoint was met while the other missed. Top-line results from the first of the RASP trials are expected by the end of 2020.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Dry eye syndrome", 
    "name": "ADX-102 - Reproxalap", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Allergic conjunctivitis", 
    "name": "Reproxalap (ADX-102) - INVIGORATE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet endpoints - June 25, 2019.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Noninfectious anterior uveitis", 
    "name": "ADX-102 reproxalap", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Development placed on hold - noted March 12, 2020.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "SjÃ¶gren-Larsson Syndrome (SLS)", 
    "name": "Reproxalap (ADX-102)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Development placed on hold - noted March 12, 2020.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Post-transplant lymphoproliferative disorder", 
    "name": "ADX-1612 (ganetespib)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment delayed due to COVID-19.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Proliferative vitreoretinopathy (PVR)", 
    "name": "ADX-2191", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial planned for 4Q 2020.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Psoriasis and atopic asthma", 
    "name": "ADX-629", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Update due by the end of 2020.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "ADX-629", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 enrolment to be completed in June 2020.", 
    "company": "Aldeyra Therapeutics Inc.", 
    "indication": "Ovarian cancer", 
    "name": "ADX-1612", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 commencement of dosing announced July 24, 2020.", 
    "company": "Alector Inc.", 
    "indication": "Frontotemporal Dementia", 
    "name": "AL001", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Alector Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "AL002", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial ongoing.", 
    "company": "Alector Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "AL003", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced January 6, 2020.", 
    "company": "Alector Inc.", 
    "indication": "Healthy volunteers", 
    "name": "AL101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014", 
    "company": "Alimera Sciences Inc.", 
    "indication": "Diabetic macular edema", 
    "name": "Iluvien", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced July 2, 2018.", 
    "company": "Alkermes plc", 
    "indication": "Schizophrenia", 
    "name": "Aripiprazole Lauroxil NanoCrystal Dispersion (ALNCD)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Advisory Committee Meeting October 9, 2020. PDUFA date November 15, 2020.", 
    "company": "Alkermes plc", 
    "indication": "Schizophrenia, bipolar", 
    "name": "ALKS 3831", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "CRL received March 15, 2010.", 
    "company": "Alkermes plc", 
    "indication": "Type 2 diabetes", 
    "name": "BYDUREON", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved October 5 2015. sNDA filed for 2-month option with approval announced June 6, 2017.", 
    "company": "Alkermes plc", 
    "indication": "Schizophrenia", 
    "name": "Aristada", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 30, 2019.", 
    "company": "Alkermes plc", 
    "indication": "Multiple sclerosis (MS)", 
    "name": "Diroximel fumarate (BIIB098)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL announced February 1, 2019.  ", 
    "company": "Alkermes plc", 
    "indication": "Major depressive disorder", 
    "name": "ALKS 5461", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 preliminary data released June 30, 2017. Primary endpoint met - adverse events included weight gain.", 
    "company": "Alkermes plc", 
    "indication": "Schizophrenia", 
    "name": "ALKS 3831 - ENLIGHTEN-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data at SITC November 2019 - 8/14 SD for monotherapy, 12/18 for combo (incl. 2 PRs).", 
    "company": "Alkermes plc", 
    "indication": "Solid tumors", 
    "name": "ALKS 4230 ARTISTRY-1", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data released April 9, 2019 - primary endpoint met.", 
    "company": "Alkermes plc", 
    "indication": "Schizophrenia", 
    "name": "Aristada and Invega Sustenna", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data presented at SITC November 8, 2019.", 
    "company": "Alkermes plc", 
    "indication": "Solid tumors", 
    "name": "ALKS 4230 + Keytruda - ARTISTRY-2", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 top-line data met primary endpoint - July 30, 2019.", 
    "company": "Alkermes plc", 
    "indication": "Relapsing Remitting Multiple Sclerosis (RRMS)", 
    "name": "Diroximel fumarate (BIIB098) - Head-to-head trial versus Tecfidera -", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced August 18, 2020.", 
    "company": "Alkermes plc", 
    "indication": "Solid Tumors", 
    "name": "ALKS 4230 (ARTISTRY-3)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b presentation at ASCRS May 16, 2020.", 
    "company": "Allakos Inc.", 
    "indication": "Severe Allergic Conjunctivitis", 
    "name": "AK002", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 data released February 19, 2019.", 
    "company": "Allakos Inc.", 
    "indication": "Indolent Systemic Mastocytosis", 
    "name": "AK002", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 additional data released February 11, 2019. 9% UAS7 complete responder rate.", 
    "company": "Allakos Inc.", 
    "indication": "Chronic Urticaria", 
    "name": "AK002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2H 2021.", 
    "company": "Allakos Inc.", 
    "indication": "Eosinophilic Gastritis", 
    "name": "Antolimab (AK002)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 top-line data due 2H 2021.", 
    "company": "Allakos Inc.", 
    "indication": "Eosinophilic esophagitis", 
    "name": "Antolimab (AK002)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Allakos Inc.", 
    "indication": "Healthy Volunteers", 
    "name": "Antolimab (subcutaneous)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Allogene Therapeutics Inc.", 
    "indication": "Acute lymphoblastic leukemia (ALL)", 
    "name": "UCART19 (PALL)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Allogene Therapeutics Inc.", 
    "indication": "Refractory B-cell Acute Lymphoblastic Leukaemia", 
    "name": "UCART19 - CALM", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 data due 4Q 2020.", 
    "company": "Allogene Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "ALLO-715 - UNIVERSAL", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 further data due late 2020 or early 2021.", 
    "company": "Allogene Therapeutics Inc.", 
    "indication": "Non-Hodgkin lymphoma (NHL) ", 
    "name": "ALLO-501 - ALPHA", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 2H 2020.", 
    "company": "Allogene Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "ALLO-715 with nirogacestat", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiated 2Q 2020.", 
    "company": "Allogene Therapeutics Inc.", 
    "indication": "Large B-cell lymphoma", 
    "name": "ALLO-501A (ALPHA2)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint, key secondary endpoint missed - November 7, 2019. ", 
    "company": "Allena Pharmaceuticals Inc.", 
    "indication": "Enteric Hyperoxaluria", 
    "name": "Reloxaliase ALLN-177 (URIROX-1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 presentation at ASN November 8, 2019.", 
    "company": "Allena Pharmaceuticals Inc.", 
    "indication": "Primary hyperoxaluria", 
    "name": "Reloxaliase ALLN-177  (Study 206)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 1Q 2022 and top-line data 3Q 2022.", 
    "company": "Allena Pharmaceuticals Inc.", 
    "indication": "Enteric Hyperoxaluria", 
    "name": "Reloxaliase ALLN-177 (URIROX-2)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 initial data due 4Q 2020.", 
    "company": "Allena Pharmaceuticals Inc.", 
    "indication": "Hyperuricemia", 
    "name": "ALLN-346", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA approval announced November 20, 2019.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Acute hepatic porphyrias", 
    "name": "Givosiran", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date December 2020.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Hyperlipidemia", 
    "name": "Inclisiran", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 preliminary antiviral activity and safety data to be presented at EASL August 28, 2020.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Chronic hepatitis B virus (HBV)", 
    "name": "VIR-2218", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date under priority review  December 3, 2020.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Primary Hyperoxaluria Type 1 (PH1)", 
    "name": "Lumasiran (ALN-GO1)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "FDA Approval announced August 10, 2018.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR", 
    "name": "Patisiran ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 2021.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "IgA nephropathy", 
    "name": "ALN-CC5 (cemdisiran)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Hemophilia A/B", 
    "name": "Fitusiran (ATLAS)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "ATTR amyloidosis", 
    "name": "Vutrisiran - HELIOS-A", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 initial data released.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "alpha-1 anti-trypsin deficiency-associated liver disease", 
    "name": "ALN-AAT02", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data due mid-2020.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Primary Hyperoxaluria Type 1", 
    "name": "Lumasiran (ALN-GO1) ILLUMINATE-B", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed in 2021.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Wild-type ATTR amyloidosis patients with cardiomyopathy", 
    "name": "Patisiran APOLLO-B", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial data due likely 2021.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Impaired renal function", 
    "name": "Lumasiran (ALN-GO1) ILLUMINATE-C", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "Hypertension", 
    "name": "ALN-AGT", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial has been initiated - noted November 22, 2019.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "ATTR amyloidosis with cardiomyopathy", 
    "name": "ALN-TTRsc02 (vutrisiran) - HELIOS-B", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Human trials to commence around the end of 2020.", 
    "company": "Alnylam Pharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "VIR-2703", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data released February 24, 2017 - primary endpoint not met.", 
    "company": "Alpine Immune Sciences Inc.", 
    "indication": "Cystic Fibrosis - one copy of the F508del mutation and a second mutation that results in a gating defect in the CFTR protein", 
    "name": "N91115", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 presentation at ASH December 8, 2019.", 
    "company": "Alpine Immune Sciences Inc.", 
    "indication": "Healthy volunteers", 
    "name": "ALPN-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced June 24, 2020.", 
    "company": "Alpine Immune Sciences Inc.", 
    "indication": "Advanced Malignancies", 
    "name": "ALPN-202", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b/2 trial is open for enrolment - noted March 30, 2020.", 
    "company": "Alpine Immune Sciences Inc.", 
    "indication": "Graft Vs Host Disease", 
    "name": "ALPN-101", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Noted that development to be discontinued - no pivotal trial.", 
    "company": "Aileron Therapeutics Inc.", 
    "indication": "Peripheral T-cell lymphoma (PTCL)", 
    "name": "ALRN-6924", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1/1b trial ongoing.", 
    "company": "Aileron Therapeutics Inc.", 
    "indication": "Acute myeloid leukemia (AML); Myelodysplastic syndrome (MDS)", 
    "name": "ALRN-6924 and Cytarabine (Ara-C)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2a final data due 2H 2020. Does not intend to further development.", 
    "company": "Aileron Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "ALRN-6924 and IBRANCE (palbociclib)", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 has been initiated.", 
    "company": "Aileron Therapeutics Inc.", 
    "indication": "Breast cancer", 
    "name": "ALRN-6924 and Paclitaxel", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b/2 top-line data from the schedule optimization and final data from the dose optimization parts of the trial due 4Q 2020.", 
    "company": "Aileron Therapeutics Inc.", 
    "indication": "Small Cell Lung Cancer (SCLC)", 
    "name": "ALRN-6924", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 4Q 2020.", 
    "company": "Altimmune Inc.", 
    "indication": "Hepatitis B", 
    "name": "HepTCell", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 additional data released March 19, 2019 noted all patients remained seroprotected. ", 
    "company": "Altimmune Inc.", 
    "indication": "Flu vaccine", 
    "name": "NasoVAX", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data due 4Q 2020.", 
    "company": "Altimmune Inc.", 
    "indication": "Anthrax", 
    "name": "NASOSHIELD", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated in 4Q 2020.", 
    "company": "Altimmune Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "ALT-801", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 4Q 2020.", 
    "company": "Altimmune Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "Intranasal COVID-19 Vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence July 2020 with data due 4Q 2020.", 
    "company": "Altimmune Inc.", 
    "indication": "COVID-19", 
    "name": "T-COVID", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 4Q 2020.", 
    "company": "AlloVir Inc.", 
    "indication": "Hematopoietic stem cell transplantation", 
    "name": "ALVR106", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "IND has been submitted. Proof of concept trial to be initiated in 2020.", 
    "company": "AlloVir Inc.", 
    "indication": "COVID-19", 
    "name": "ALVR109", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "AlloVir Inc.", 
    "indication": "BK virus", 
    "name": "Viralym-M (ALVR105)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "AlloVir Inc.", 
    "indication": "Cytomegalovirus (CMV)", 
    "name": "Viralym-M (ALVR105)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "AlloVir Inc.", 
    "indication": "Prevention of Multi-Virus Infections (BKV, CMV, AdV, EBV, HHV-6, and JCV)", 
    "name": "Viralym-M (ALVR105)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "AlloVir Inc.", 
    "indication": "Aleution disease virus (ADV)", 
    "name": "Viralym-M (ALVR105)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "AlloVir Inc.", 
    "indication": "Cytomegalovirus (CMV)", 
    "name": "Viralym-M (ALVR105)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 4Q 2020.", 
    "company": "AlloVir Inc.", 
    "indication": "Virus-associated hemorrhagic cystitis", 
    "name": "Viralym-M (ALVR105)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "None", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "", 
    "name": "", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "FDA Approval announced June 27, 2019.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)", 
    "name": "Eculizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 18, 2019.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "atypical Hemolytic Uremic Syndrome (aHUS)", 
    "name": "ULTOMIRIS (ravulizumab-cwvz)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced December 21, 2018.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)", 
    "name": "ULTOMIRIS (ravulizumab-cwvz)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced October 23, 2017.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Refractory generalized myasthenia gravis (gMG)", 
    "name": "Eculizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval noted June 23, 2017.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Venous thromboembolism (VTE) Prevention", 
    "name": "Bevyxxa (betrixaban)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2a data presented at ASH December 9, 2019. ORR 48%; 76% in combo cohort.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Refractory non-Hodgkin lymphoma and chronic lymphocytic leukemia - cancer", 
    "name": "Cerdulatinib (PRT2070)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Prior Approval Supplement (PAS) FDA Approval announced December 31, 2018.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Factor Xa inhibitor reversal agent", 
    "name": "Andexxa", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated by the end of 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)", 
    "name": "ALXN2040 (Danicopan/ACH-4471)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial is underway - noted May 5, 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)", 
    "name": "ALXN2050 (ACH-5228)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 2H 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "ATTR-PN", 
    "name": "AG10 / BBP-265", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Wilson disease", 
    "name": "ALXN1840 (WTX101)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Generalized myasthenia gravis (gMG)", 
    "name": "ULTOMIRIS (ravulizumab-cwvz)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial to be initiated in 2021.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Warm autoimmune hemolytic anemia (WAIHA)", 
    "name": "ALXN1830", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - June 24, 2020. Regulatory filing due 3Q 2021.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH) and atypical Hemolytic Uremic Syndrome (aHUS)", 
    "name": "ULTOMIRIS (ravulizumab-cwvz) subcutaneous", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint. ", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Leberâ€™s hereditary optic neuropathy (LHON)", 
    "name": "Elamipretide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - December 20, 2019.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Primary mitochondrial myopathy", 
    "name": "Elamipretide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": " Limited dose-ranging studies to commence 2H 2020, followed by Phase 3 trials in 2021.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Hematopoietic stem cell transplant-related thrombotic microangiopathy (HSCT-TMA)", 
    "name": "ULTOMIRIS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial has commenced - noted October 23, 2019.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Generalized myasthenia gravis (gMG) - children", 
    "name": "Eculizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to commence 2H 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Neuromyelitis Optica Spectrum Disorder (NMOSD) - children", 
    "name": "Eculizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiated March 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "ULTOMIRIS (ravulizumab) - CHAMPION-ALS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 open-label, randomized, controlled trial is underway - noted July 30, 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "COVID-19 Coronavirus", 
    "name": "ULTOMIRIS (ravulizumab-cwvz)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Development discontinued - noted July 29, 2020.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": "C3 Glomerulopathy (C3G)", 
    "name": "ALXN2040", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial underway.", 
    "company": "Alexion Pharmaceuticals Inc.", 
    "indication": " Neuromyelitis Optica Spectrum Disorder (NMOSD)", 
    "name": "ULTOMIRIS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 trial to be initiated 2H 2020.", 
    "company": "ALX Oncology Holdings Inc.", 
    "indication": "Myelodysplastic syndromes (MDS)", 
    "name": "ALX148 and azacitidine", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2021.", 
    "company": "ALX Oncology Holdings Inc.", 
    "indication": "Head and neck squamous cell carcinoma (HNSCC)", 
    "name": "ALX148 and Keytruda", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2021. ", 
    "company": "ALX Oncology Holdings Inc.", 
    "indication": "Gastric/Gastroesophageal Junction Cancer", 
    "name": "ALX148 and trastuzumab (Herceptin)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 trial stopped due to low likelihood of efficacy - August 6, 2020.", 
    "company": "AMAG Pharmaceuticals Inc.", 
    "indication": "Severe preeclampsia in pregnant women", 
    "name": "AMAG-423 / Digoxin immune fab (DIF)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "FDA approval announced June 21, 2019.", 
    "company": "AMAG Pharmaceuticals Inc.", 
    "indication": "Female sexual dysfunction (FSD)", 
    "name": "Vyleesi (Bremelanotide)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval for sNDA filing announced February 5, 2018.", 
    "company": "AMAG Pharmaceuticals Inc.", 
    "indication": "Adults with iron deficiency anemia (IDA)", 
    "name": "Feraheme", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced February 14, 2018.", 
    "company": "AMAG Pharmaceuticals Inc.", 
    "indication": "Reduce the risk of preterm birth in women with a singleton pregnancy", 
    "name": "Makena - auto injector", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Advisory Committee voted 9-7 recommending withdrawal from market - October 29, 2019.", 
    "company": "AMAG Pharmaceuticals Inc.", 
    "indication": "Preterm birth ", 
    "name": "Makena", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial planned.", 
    "company": "AMAG Pharmaceuticals Inc.", 
    "indication": "Anticoagulated reversal agent / Healthy volunteers", 
    "name": "Ciraparantag", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due late-2020.", 
    "company": "Amgen Inc.", 
    "indication": "Asthma", 
    "name": "Tezepelumab - NAVIGATOR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced May 21, 2018.", 
    "company": "Amgen Inc.", 
    "indication": "Glucocorticoid-induced osteoporosis (GIOP)", 
    "name": "Prolia (denosumab) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA approval announced June 11, 2018.", 
    "company": "Amgen Inc.", 
    "indication": "Relapsed Multiple Myeloma", 
    "name": "KYPROLIS (ASPIRE)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA approval announced June 29, 2017.", 
    "company": "Amgen Inc.", 
    "indication": "Wild-Type RAS Metastatic Colorectal Cancer", 
    "name": "Vectibix (Panitumumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 14, 2017.", 
    "company": "Amgen Inc.", 
    "indication": "Biosimilar candidate to Avastin (bevacizumab)", 
    "name": "MVASITM (bevacizumab-awwb)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approved April 15, 2015.", 
    "company": "Amgen Inc.", 
    "indication": "Chronic Heart Failure", 
    "name": "Corlanor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 17, 2018.", 
    "company": "Amgen Inc.", 
    "indication": "Migraine", 
    "name": "Erenumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced April 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Scalp Psoriasis", 
    "name": "OTEZLA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 - primary endpoint met.", 
    "company": "Amgen Inc.", 
    "indication": "Psoriatic Arthritis", 
    "name": "OTEZLA - PSA-006", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 19, 2019.", 
    "company": "Amgen Inc.", 
    "indication": "Behçet’s Disease", 
    "name": "OTEZLA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 1, 2017.", 
    "company": "Amgen Inc.", 
    "indication": "Cardiovascular disease", 
    "name": "Repatha", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA approval announced January 5, 2017.", 
    "company": "Amgen Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "XGEVA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 1, 2018.", 
    "company": "Amgen Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "KYPROLIS (ARROW)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA approved January 17, 2018.", 
    "company": "Amgen Inc.", 
    "indication": "Relapsed Multiple Myeloma", 
    "name": "KYPROLIS (ENDEAVOR)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date under priority review August 14, 2017. Approval announced July 11, 2017.", 
    "company": "Amgen Inc.", 
    "indication": "Ph+ R/R ALL", 
    "name": "BLINCYTO", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA (biosimilar) date December 19, 2020.", 
    "company": "Amgen Inc.", 
    "indication": "RITUXAN biosimilar - non-Hodgkin lymphoma", 
    "name": "ABP 798", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA approval announced June 13, 2019.", 
    "company": "Amgen Inc.", 
    "indication": "Herceptin biosimilar", 
    "name": "ABP 980 (Kanjinti; trastuzumab-anns)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "FDA Approval announced December 6, 2019.", 
    "company": "Amgen Inc.", 
    "indication": "REMICADE biosimilar -  rheumatoid arthritis", 
    "name": "ABP 710", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved February 7, 2017.", 
    "company": "Amgen Inc.", 
    "indication": "Secondary hyperparathyroidism (SHPT)", 
    "name": "Parsabiv", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 9, 2019.", 
    "company": "Amgen Inc.", 
    "indication": "Osteoporosis", 
    "name": "EVENITY (Romosozumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Acute heart failure", 
    "name": "Omecamtiv mecarbil GALACTIC-HF", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be completed early 2021.", 
    "company": "Amgen Inc.", 
    "indication": "Acute heart failure", 
    "name": "Omecamtiv mecarbil METEORIC-HF", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data ASCO June 2, 2019. Overall response rate 70% (7/10) in high dose, 13/42 response across all cohorts.", 
    "company": "Amgen Inc.", 
    "indication": "Relapsed. Refractory (R/R) Multiple Myeloma (MM)", 
    "name": "AMG 420", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA approval announced December 14, 2018.", 
    "company": "Amgen Inc.", 
    "indication": "Immune Thrombocytopenia (Pediatric)", 
    "name": "Nplate (Romiplostim) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 18, 2019.", 
    "company": "Amgen Inc.", 
    "indication": "Immune thrombocytopenia (ITP) ", 
    "name": "Nplate (Romiplostim)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - May 6, 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Psoriasis", 
    "name": "OTEZLA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial is complete. Considering next steps.", 
    "company": "Amgen Inc.", 
    "indication": "Healthy volunteers", 
    "name": "AMG 594", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 update at ASCO May 29, 2020. Objective response rate (ORR) was 12% (3/25) in 960 mg once-daily target dose cohort.", 
    "company": "Amgen Inc.", 
    "indication": "Solid tumors", 
    "name": "AMG 510", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial discontinued due to lack of efficacy. ", 
    "company": "Amgen Inc.", 
    "indication": "Alzheimerâ€™s Disease", 
    "name": "CNP520", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 enrolment terminated due to treatment benefit over chemo. Primary endpoint of event-free survival met.", 
    "company": "Amgen Inc.", 
    "indication": "Acute lymphoblastic leukemia (ALL) - pediatric", 
    "name": "BLINCYTO", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial is enrolling.", 
    "company": "Amgen Inc.", 
    "indication": "Systemic Lupus Erythematosus (SLE)", 
    "name": "AMG 570", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial is enrolling.", 
    "company": "Amgen Inc.", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Tezepelumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 monotherapy data due 2H 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "AMG 510", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial is enrolling.", 
    "company": "Amgen Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "AMG 510 CodeBreaK 200", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial has commenced - noted July 28, 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Cardiovascular disease / Elevated Lipoprotein", 
    "name": "AMG 890", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b/2 trial is enrolling - noted July 28, 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Systemic Lupus Erythematosus", 
    "name": "AMG 592", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b/2 trial is enrolling - noted July 28, 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Chronic Graft Versus Host Disease", 
    "name": "AMG 592", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Castration-resistant Prostate Cancer", 
    "name": "AMG 160", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Amgen Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "AMG 701", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Amgen Inc.", 
    "indication": " Small Cell Lung Cancer", 
    "name": "AMG 757", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced August 3, 2020.", 
    "company": "Amgen Inc.", 
    "indication": "COVID-19 (severe)", 
    "name": "Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment has been suspended - noted March 24, 2020.", 
    "company": "Ampio Pharmaceuticals Inc.", 
    "indication": "Osteoarthritis of the Knee", 
    "name": "Ampion", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data released May 2015 did not meet endpoints", 
    "company": "Ampio Pharmaceuticals Inc.", 
    "indication": "Diabetic Macula Edema", 
    "name": "Optina", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 commencement of enrolment announced July 23, 2020.", 
    "company": "Ampio Pharmaceuticals Inc.", 
    "indication": "COVID-19 ", 
    "name": "IV Ampion", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "CRL announced February 21, 2017.", 
    "company": "Amphastar Pharmaceuticals Inc.", 
    "indication": "Opioid overdose ", 
    "name": "Naloxone Intranasal", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL issued December 27, 2016.", 
    "company": "Amphastar Pharmaceuticals Inc.", 
    "indication": "Asthma", 
    "name": "Primatene Mist (epinephrine inhalation aerosol)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "FDA Approval announced December 13, 2019.", 
    "company": "Amarin Corporation plc", 
    "indication": "High Triglycerides With Mixed Dyslipidemia", 
    "name": "Vascepa", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "Amneal Pharmaceuticals Inc. Class A", 
    "indication": "Parkinson's disease", 
    "name": "IPX203", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing planned.", 
    "company": "Amneal Pharmaceuticals Inc. Class A", 
    "indication": "Myasthenia Gravis", 
    "name": "K127", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Applied Molecular Transport Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "AMT-101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned for 2020.", 
    "company": "Applied Molecular Transport Inc.", 
    "indication": "Pouchitis", 
    "name": "AMT-101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data failed to meet primary endpoint - November 8, 2019.", 
    "company": "AnaptysBio Inc.", 
    "indication": "Moderate-to-severe adult atopic dermatitis", 
    "name": "ANB020 - etokimab", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b trial initiation postponed.", 
    "company": "AnaptysBio Inc.", 
    "indication": "Severe adult eosinophilic asthma", 
    "name": "ANB020 - etokimab", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 data due 1Q 2021.", 
    "company": "AnaptysBio Inc.", 
    "indication": "Palmo-plantar pustular psoriasis", 
    "name": "ANB019 - POPLAR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 further data due 4Q 2020.", 
    "company": "AnaptysBio Inc.", 
    "indication": "Generalized pustular psoriasis", 
    "name": "ANB019", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data failed to meet primary endpoints after 8 weeks. 16 week data due by the end of 2020.", 
    "company": "AnaptysBio Inc.", 
    "indication": "Nasal polyps", 
    "name": "ANB020 - etokimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued due to lack of efficacy - November 15, 2019.", 
    "company": "Anchiano Therapeutics Ltd.", 
    "indication": "Non-muscle invasive bladder cancer (NMIBC)", 
    "name": "Inodiftagene - Codex", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 planned for 4Q 2019 or 1Q 2020.", 
    "company": "Anchiano Therapeutics Ltd.", 
    "indication": "Non-muscle invasive bladder cancer (NMIBC)", 
    "name": "Inodiftagene with BCG - Leo", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - June 19, 2018. Further trial to be initiated depending on COVID-19.", 
    "company": "Anika Therapeutics Inc.", 
    "indication": "Osteoarthritis", 
    "name": "Cingal", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved Feb 2014", 
    "company": "Anika Therapeutics Inc.", 
    "indication": "Osteoarthritis", 
    "name": "Monovisc", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 completion of enrolment to be delayed due to COVID-19.", 
    "company": "Anika Therapeutics Inc.", 
    "indication": "Cartilage defects of the knee", 
    "name": "HYALOFAST", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Refusal to File (RTF) letter announced April 29, 2020. sNDA to be refiled 1Q 2021.", 
    "company": "ANI Pharmaceuticals Inc.", 
    "indication": "", 
    "name": "Purified Cortrophin Gel", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "", 
    "company": "Anixa Biosciences Inc.", 
    "indication": "", 
    "name": "Breast cancer vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial to be initiated early 2021 with data due 1H 2023.", 
    "company": "Annexon Inc.", 
    "indication": "Guillain-BarrÃ© Syndrome", 
    "name": "ANX005", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated with data due 2H 2021.", 
    "company": "Annexon Inc.", 
    "indication": "Warm autoimmune hemolytic anemia (WAIHA)", 
    "name": "ANX005", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a trial to be initiated with data due 1H 2021.", 
    "company": "Annexon Inc.", 
    "indication": "Huntingtonâ€™s disease", 
    "name": "ANX005", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial be be initiated with data due 2H 2021.", 
    "company": "Annexon Inc.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "ANX005", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2021.", 
    "company": "Annexon Inc.", 
    "indication": "Geographic atrophy", 
    "name": "ANX007", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a data due in 2021.", 
    "company": "Annovis Bio Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "ANVS401", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 initial data due early 2021.", 
    "company": "Annovis Bio Inc.", 
    "indication": "Alzheimer’s disease (AD) and Parkinson’s disease (PD)", 
    "name": "ANVS401", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial plan update due 3Q 2020.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "Cold agglutinin disease (CAD)", 
    "name": "APL-2 subcutaneous", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 3Q 2021.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "Geographic atrophy (GA) associated with age-related macular degeneration (AMD)", 
    "name": "APL-2 OAKS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing due 2H 2020.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "Paroxysmal Nocturnal Hemoglobinuria (PNH)", 
    "name": "Pegcetacoplan (APL-2) PEGASUS", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 initial data presented at ASN November 8, 2019.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "Complement-dependent Nephropathies (CDN)", 
    "name": "APL-2 subcutaneous", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "Paroxysmal Nocturnal Hemoglobinuria (PNH)", 
    "name": "APL-2  PRINCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 3Q 2021.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "Geographic atrophy (GA)", 
    "name": "APL-2 (pegcetacoplan) - DERBY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced May 28, 2020. Enrolling patients in the randomized, double-blind, controlled part of the trial - noted July 31, 2020.", 
    "company": "Apellis Pharmaceuticals Inc.", 
    "indication": "COVID-19 / Acute respiratory distress syndrome (ARDS)", 
    "name": "APL-9", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2021.", 
    "company": "Applied Therapeutics Inc.", 
    "indication": "Diabetic cardiomyopathy (DbCM)", 
    "name": "AT-001 (ARISE-HF)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data January 8, 2019 noted significant plasma galactitol reduction of ~50% (p<0.01).", 
    "company": "Applied Therapeutics Inc.", 
    "indication": "Galactosemia", 
    "name": "AT-007", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data presented at EULAR June 8, 2020 - well tolerated and exhibited pharmacodynamic activity, enabling Phase 2 development.", 
    "company": "Applied Therapeutics Inc.", 
    "indication": "Healthy Volunteers", 
    "name": "ALPN-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 top-line data due by the end of 2020.", 
    "company": "Aprea Therapeutics Inc.", 
    "indication": "TP53 mutant Myelodysplastic syndromes (MDS)", 
    "name": "APR-246 (eprenetapopt) and azacitidine", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 enrollment to be completed 3Q 2020.", 
    "company": "Aprea Therapeutics Inc.", 
    "indication": "TP53 mutated myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) - post transplant", 
    "name": "APR-246 and azacitidine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial initiated 1Q 2020.", 
    "company": "Aprea Therapeutics Inc.", 
    "indication": "TP53 mutant AML", 
    "name": "APR-246 / venetoclax and azacitidine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 enrolment to commence 2H 2020.", 
    "company": "Aprea Therapeutics Inc.", 
    "indication": "Chronic lymphoid leukemia (CLL) and Mantle cell lymphoma (MCL)", 
    "name": "APR-246 and venetoclax and rituximab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 enrollment commenced August 2020.", 
    "company": "Aprea Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "APR-246", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b data noted favorable safety profile - December 7, 2019.", 
    "company": "Aptose Biosciences Inc.", 
    "indication": "Acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)", 
    "name": "APTO-253", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 presentation at ASCO May 29, 2020.", 
    "company": "Aptose Biosciences Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL/SLL) or non-Hodgkin lymphomas (NHL)", 
    "name": "CG-806", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1a/b trial to commence 2H 2020.", 
    "company": "Aptose Biosciences Inc.", 
    "indication": "Acute myeloid leukemia", 
    "name": "CG-806", 
    "stage": "phase1a"
  }, 
  {
    "newstxt": "Phase 2 enrolment has been suspended due to COVID-19.", 
    "company": "Aptinyx Inc.", 
    "indication": "Parkinsonâ€™s Disease Cognitive Impairment (healthy volunteers)", 
    "name": "NYX-458", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrollment to recommence September 2020.", 
    "company": "Aptinyx Inc.", 
    "indication": "Fibromyalgia", 
    "name": "NYX-2925", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrollment to recommence late-2020/early-2021. ", 
    "company": "Aptinyx Inc.", 
    "indication": "Neuropathic Pain Associated with Diabetic Peripheral Neuropathy", 
    "name": "NYX-2925", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Aptinyx Inc.", 
    "indication": "Post-traumatic stress disorder (PTSD)", 
    "name": "NYX-783", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development terminated - noted November 14, 2018.", 
    "company": "Aptevo Therapeutics Inc.", 
    "indication": "Castration-resistant prostate cancer", 
    "name": "APVO414", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development terminated - noted November 14, 2018.", 
    "company": "Aptevo Therapeutics Inc.", 
    "indication": "Relapsed or refractory peripheral T-cell lymphoma", 
    "name": "Otlertuzumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Aptevo Therapeutics Inc.", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "APVO436", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development terminated - noted October 3, 2019.", 
    "company": "Aptevo Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "APVO210", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "PDUFA date March 2, 2021.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "ADHD", 
    "name": "KP415", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA Approval announced November 22, 2019.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "Amyotrophic Lateral Sclerosis", 
    "name": "Exservan (riluzole) Oral Film", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Tentative approval issued August 31, 2018. Full approval issued November 2, 2018.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "Lennox-Gastaut Syndrome", 
    "name": "Sympazan", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date September 27, 2020.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "Epileptic seizures", 
    "name": "Libervant - AQST-203", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "CRL issued November 16, 2018.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "Erectile dysfunction", 
    "name": "AQST-119", 
    "stage": "crl"
  }, 
  {
    "newstxt": "FDA approval announced May 21, 2020.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "Parkinsonâ€™s Disease with motor fluctuations", 
    "name": "APL-130277", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 Pharmacokinetic (PK) trial initiation announced August 20, 2020. Data due 4Q 2020.", 
    "company": "Aquestive Therapeutics Inc.", 
    "indication": "Anaphylaxis", 
    "name": "AQST-108", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 top-line data released September 21, 2017 - primary endpoint not met.", 
    "company": "Aravive Inc.", 
    "indication": "Growth hormone deficiency, or GHD - pediatric", 
    "name": "VRS-317 VELOCITY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b interim analysis due 2021.", 
    "company": "Aravive Inc.", 
    "indication": "Ovarian cancer", 
    "name": "AVB-500 and paclitaxel", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b/2 trial to be initiated in 2020.", 
    "company": "Aravive Inc.", 
    "indication": "Clear Cell Renal Cell Carcinoma (ccRCC)", 
    "name": "AVB-500", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2a trial initiation announced December 20, 2019. Trial on hold due to COVID-19.", 
    "company": "Aravive Inc.", 
    "indication": "IgA Nephropathy / kidney fibrosis", 
    "name": "AVB-500", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiation announced November 12, 2019.", 
    "company": "Aravive Inc.", 
    "indication": "Ovarian cancer", 
    "name": "AVB-500 and Durvalumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced March 24, 2020.", 
    "company": "Aravive Inc.", 
    "indication": "Urothelial Carcinoma", 
    "name": "AVB-500 and avelumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initiation announced August 11, 2020 with initial data due 4Q 2020.", 
    "company": "Arcturus Therapeutics Holdings Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "LUNAR-COV19", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 4Q 2020.", 
    "company": "Arcturus Therapeutics Holdings Inc.", 
    "indication": "Ornithine Transcarbamylase (OTC) deficiency", 
    "name": "ARCT-810", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 interim data due 2H 2020 with top-line data due 2H 2021.", 
    "company": "Aridis Pharmaceuticals Inc.", 
    "indication": "ventilator associated pneumonia (VAP) / Staphylococcus aureus", 
    "name": "AR-301 (Salvecin)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not met primary endpoint - September 3, 2019.", 
    "company": "Aridis Pharmaceuticals Inc.", 
    "indication": "Pseudomonas aeruginosa", 
    "name": "AR-105 (Aerucin)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a data due 2H 2021.", 
    "company": "Aridis Pharmaceuticals Inc.", 
    "indication": "Chronic bacterial lung infections in patients with cystic fibrosis (CF)", 
    "name": "AR-501", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "FDA approval announced September 12, 2019.", 
    "company": "Ardelyx Inc.", 
    "indication": "Constipation-predominant irritable bowel syndrome (IBS-C) ", 
    "name": "Tenapanor (T3MPO-2)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Onset of action trial data released November 21, 2017 - noted significantly reduced serum potassium in patients. Development to be discontinued.", 
    "company": "Ardelyx Inc.", 
    "indication": "Hyperkalemia", 
    "name": "RDX7675", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "NDA filing announced June 30, 2020.", 
    "company": "Ardelyx Inc.", 
    "indication": "Serum phosphorus - chronic kidney disease (CKD) on dialysis", 
    "name": "Tenapanor", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data released May 12, 2017. Primary endpoint met - however, competitive concerns raised.", 
    "company": "Ardelyx Inc.", 
    "indication": "Constipation-predominant irritable bowel syndrome (IBS-C) ", 
    "name": "Tenapanor (T3MPO-1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint.", 
    "company": "Ardelyx Inc.", 
    "indication": "Hyperphosphatemia - adjunctive therapy to phosphate binders", 
    "name": "Tenapanor - AMPLIFY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to commence 2H 2020.", 
    "company": "argenx SE", 
    "indication": "Pemphigus vulgaris (PV)", 
    "name": "Efgartigimod (ARGX-113)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data due early 2021.", 
    "company": "argenx SE", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "Cusatuzumab (ARGX-110)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial initiated December 2019. ", 
    "company": "argenx SE", 
    "indication": "Immune thrombocytopenia (ITP)", 
    "name": "Efgartigimod (ARGX-113)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - May 26, 2020. BLA filing due by end of 2020.", 
    "company": "argenx SE", 
    "indication": "Myasthenia gravis (MG)", 
    "name": "Efgartigimod (ARGX-113)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 3Q 2020.", 
    "company": "argenx SE", 
    "indication": "Autoimmune diseases", 
    "name": "ARGX-117", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated - noted January 9, 2020. Decision to expand trial up to 130 patients expected in 2021.", 
    "company": "argenx SE", 
    "indication": "Chronic inflammatory demyelinating polyneuropathy", 
    "name": "Efgartigimod (ARGX-113) and Enhanze (ADHERE)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Trials to be initiated in 2020.", 
    "company": "Armata Pharmaceuticals Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "AP-PA02", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b/2 trial to be initiated in 2021.", 
    "company": "Armata Pharmaceuticals Inc.", 
    "indication": "Staphylococcus aureus", 
    "name": "AP-SA02", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Approved June 27, 2012.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Obesity", 
    "name": "Lorcaserin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b data due 1Q 2021.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Irritable Bowel Syndrome", 
    "name": "Olorinab", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 data due year-end 2021.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "Etrasimod", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Atopic dermatitis (AD)", 
    "name": "Etrasimod", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial ongoing. Considering options to help facilitate availability of top-line data in 2021", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Crohn's disease", 
    "name": "Etrasimod", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated in 2H 2020 dependent on COVID situation.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Eosinophilic esophagitis (EoE) ", 
    "name": "Etrasimod", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2H 2020 dependent on COVID situation.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Alopecia areata (AA)", 
    "name": "Etrasimod", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 top-line data due 4Q 2020.", 
    "company": "Arena Pharmaceuticals Inc.", 
    "indication": "Acute heart failure (AHF)", 
    "name": "APD418", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Aerpio Pharmaceuticals Inc.", 
    "indication": "Ulcerative Colitis", 
    "name": "AKB-4924 (GB004) - SHIFT-UC", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released March 18, 2019 did not meet primary endpoint.", 
    "company": "Aerpio Pharmaceuticals Inc.", 
    "indication": "Non-Proliferative Diabetic Retinopathy", 
    "name": "AKB-9778 - TIME 2B", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 4Q 2020.", 
    "company": "Aerpio Pharmaceuticals Inc.", 
    "indication": "Open-angle glaucoma (OAG)", 
    "name": "Razuprotafib (AKB-9778)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be completed 1Q 2021.", 
    "company": "Aerpio Pharmaceuticals Inc.", 
    "indication": "Acute Respiratory Distress Syndrome (ARDS) in COVID-19 patients", 
    "name": "Razuprotafib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Plaque psoriasis", 
    "name": "ARQ-151", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated 2H 2020 with data due 2H 2021.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "ARQ-151", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data due early-4Q 2020.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Seborrheic dermatitis", 
    "name": "ARQ-154", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 4Q 2020.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Scalp psoriasis", 
    "name": "ARQ-154", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b portion has been initiated - noted July 13, 2020. Top-line data 2H 2021.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Chronic Hand Eczema", 
    "name": "ARQ-252", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 long-term safety top-line data due 1H 2021.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Plaque psoriasis", 
    "name": "ARQ-151", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2H 2020.", 
    "company": "Arcutis Biotherapeutics Inc.", 
    "indication": "Vitiligo", 
    "name": "ARQ-252", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 update due 4Q 2020.", 
    "company": "Arvinas Inc.", 
    "indication": "Castration-resistant prostate cancer (CRPC)", 
    "name": "ARV-110", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data presented October 23, 2019. Further data due 4Q 2020.", 
    "company": "Arvinas Inc.", 
    "indication": "ER+ positive / HER2- negative breast cancer", 
    "name": "ARV-471", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b initiation announced August 28, 2019. Results in sustained hepatitis B surface antigen suppression to be presented at EASL August 28, 2020 at 13:30 CEST.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Hepatitis B (HBV)", 
    "name": "ARO-HBV / JNJ-3989", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2/3 trial ongoing.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Alpha-1 Liver Disease", 
    "name": "ARO-AAT", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 data released February 5, 2020. Hypercholesterolemia - mean maximum reductions in ANGPTL3 of 79-88%; Hypertriglyceridemia - mean maximum reductions in ANGPTL3 of 83%.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Dyslipidemia", 
    "name": "ARO-ANG3", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Presentation at ESC Congress August 31, 2020 at 10:50 CEST.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Familial chylomicronemia syndrome (FCS) / Hypertriglyceridemia", 
    "name": "AROAPOC31001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 open label data due 2H 2020.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "AATD-associated liver disease", 
    "name": "AROAAT2002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b trial initiation announced August 18, 2020.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Clear Cell Renal Cell Carcinoma", 
    "name": "ARO-HIF2", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced March 3, 2020.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "AROHSD1001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial has commenced - noted July 28, 2020.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Cardiovascular disease / Elevated Lipoprotein", 
    "name": "AMG 890", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2021.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Non-alcoholic Steatohepatitis (NASH)", 
    "name": "ARO-HSD", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced August 11, 2020.", 
    "company": "Arrowhead Pharmaceuticals Inc.", 
    "indication": "Cystic Fibrosis", 
    "name": "ARO-ENaC - AROENaC1001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - November 11, 2019.", 
    "company": "ASLAN Pharmaceuticals Limited", 
    "indication": "Biliary tract cancer", 
    "name": "Varlitinib - TREETOPP", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - January 13, 2019.", 
    "company": "ASLAN Pharmaceuticals Limited", 
    "indication": "Gastric cancer", 
    "name": "Varlitinib", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Evaluating next steps - noted August 2019.", 
    "company": "ASLAN Pharmaceuticals Limited", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "ASLAN003", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 new data presented at at ASCO Gastrointestinal Cancers Symposium January 2019.", 
    "company": "ASLAN Pharmaceuticals Limited", 
    "indication": "Biliary tract cancer", 
    "name": "Varlitinib +  gemcitabine and cisplatin", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Recommencement of enrollment announced August 24, 2020 with interim due 4Q 2020.", 
    "company": "ASLAN Pharmaceuticals Limited", 
    "indication": "Atopic dermatitis", 
    "name": "ASLAN004", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 presentation at ESMO September 28, 2019.", 
    "company": "ASLAN Pharmaceuticals Limited", 
    "indication": "Solid tumors", 
    "name": "Varlitinib + mFOLFIRI", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data from second trial did not meet primary endpoint - Feb 2014. Will not pursue future development", 
    "company": "Assembly Biosciences Inc.", 
    "indication": "Anal fissures", 
    "name": "VEN 307  (diltiazem cream)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 additional interim analyses due at EASL August 27-29, 2020.", 
    "company": "Assembly Biosciences Inc.", 
    "indication": "Hepatitis B virus (HBV)", 
    "name": "ABI-H0731", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b higher dose cohort data due at EASL August 27-29, 2020. Phase 2 trial initiation announced June 25, 2020.", 
    "company": "Assembly Biosciences Inc.", 
    "indication": "Hepatitis B virus (HBV)", 
    "name": "ABI-H2158", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b initiation of dosing announced June 27, 2019. Ongoing as of May 2020.", 
    "company": "Assembly Biosciences Inc.", 
    "indication": "Ulcerative Colitis", 
    "name": "ABI-M201", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1a trial ongoing.", 
    "company": "Assembly Biosciences Inc.", 
    "indication": "Hepatitis B virus (HBV)", 
    "name": "ABI-H3733", 
    "stage": "phase1a"
  }, 
  {
    "newstxt": "BLA filing announced June 26, 2020.", 
    "company": "Ascendis Pharma A/S", 
    "indication": "Growth hormone deficiency in children", 
    "name": "TransCon hGH", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 six-month data from the open-label extension portion due 3Q 2020. Phase 3 trial to commence 4Q 2020.", 
    "company": "Ascendis Pharma A/S", 
    "indication": "Hypoparathyroidism", 
    "name": "TransCon", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated.", 
    "company": "Ascendis Pharma A/S", 
    "indication": "Achondroplasia", 
    "name": "TransCon CNP - ACcomplisH", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved January 28, 2011.", 
    "company": "Assertio Holdings Inc.", 
    "indication": "Postherpetic neuralgia - shingles", 
    "name": "GRALISE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued May 31, 2013.", 
    "company": "Assertio Holdings Inc.", 
    "indication": "Hot flashes", 
    "name": "SEFELSA", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL announced October 21, 2019.", 
    "company": "Assertio Holdings Inc.", 
    "indication": "Adrenocortical insufficiency screening", 
    "name": "Cosyntropin depot", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Alterity Therapeutics Limited", 
    "indication": "Multiple System Atrophy (MSA)", 
    "name": "ATH434", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 MASTERS-2 trial initiation announced July 31, 2018.", 
    "company": "Athersys Inc.", 
    "indication": "Ischemic stroke", 
    "name": "Multistem", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 enrollment continues but reported May 2018 that enrollment is slower than expected.", 
    "company": "Athersys Inc.", 
    "indication": "Acute myocardial infarction", 
    "name": "Multistem", 
    "stage": "phase2"
  }, 
  {
    "newstxt": " Phase 2 enrollment to be completed 4Q 2020.", 
    "company": "Athersys Inc.", 
    "indication": "Acute Respiratory Distress Syndrome", 
    "name": "Multistem", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 enrolment has commenced - noted May 5, 2020.", 
    "company": "Athersys Inc.", 
    "indication": "COVID-19 induced Acute respiratory distress syndrome (ARDS)", 
    "name": "MultiStem - MACOVIA", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 initiation announced April 15, 2020.", 
    "company": "Athersys Inc.", 
    "indication": "Trauma patients following hospitalization", 
    "name": "MultiStem", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned, to be followed by pivotal trial.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Myelodysplastic syndrome (MDS)", 
    "name": "Actimab-MDS", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data presented at TAT April 2, 2019.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "Actimab-A", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2020.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Acute myeloid leukemia (AML) ", 
    "name": "Iomab-B", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 ongoing.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Refractory multiple myeloma", 
    "name": "Actimab-M", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 third cohort to be completed mid-2020.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Relapsed or refractory acute myeloid leukemia (AML)", 
    "name": "Actimab-A in combination with CLAG-M", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiation announced February 5, 2019.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Relapsed or refractory acute myeloid leukemia (AML)", 
    "name": "Actimab-A and Venetoclax", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initiation announced February 26, 2020.", 
    "company": "Actinium Pharmaceuticals Inc. (Delaware)", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "Actimab-A in combination with chemotherapy regimen 7+3", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b poster at ESMO September 29, 2019.", 
    "company": "Athenex Inc.", 
    "indication": "Gastric cancer", 
    "name": "Oraxol and CYRAMZA (Ramucirumab)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "PDUFA date December 30, 2020.", 
    "company": "Athenex Inc.", 
    "indication": "Actinic keratosis", 
    "name": "Tirbanibulin ointment", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "NDA to be filed in 2020.", 
    "company": "Athenex Inc.", 
    "indication": "Metastatic breast cancer", 
    "name": "Oraxol", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 presentation at ASCO May 29, 2020. Complete responses (CR) were observed in 27.3% of patients (6/22), partial responses (PR) were observed in 22.7% of patients (5/22),", 
    "company": "Athenex Inc.", 
    "indication": "Angiosarcoma", 
    "name": "Oraxol (Oral Paclitaxel)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint - June 27, 2019. High dropout rate noted.", 
    "company": "Atossa Therapeutics Inc.", 
    "indication": "Mammographic breast density (MBD)", 
    "name": "Endoxifen", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing - noted December 28, 2017.", 
    "company": "Atossa Therapeutics Inc.", 
    "indication": "Cuctal carcinoma in situ(DCIS) - invasive breast cancer", 
    "name": "Fulvestrant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 preliminary data September 13, 2018 noted drug met safety and tolerability objectives. Final data January 9, 2019 confirmed objectives met. Program will not be advanced in 2020.", 
    "company": "Atossa Therapeutics Inc.", 
    "indication": "Male breast cancer and Gynecomastia", 
    "name": "Endoxifen", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 interim data released May 7, 2020.", 
    "company": "Atossa Therapeutics Inc.", 
    "indication": "Breast cancer - window of opportunity setting", 
    "name": "Endoxifen", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation due in 2020 (Sweden).", 
    "company": "Atossa Therapeutics Inc.", 
    "indication": "Mammographic breast density (MBD)", 
    "name": "Endoxifen", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced August 17, 2020.", 
    "company": "Atossa Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "AT-301 Nasal Spray", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b commencement of enrolment announced June 17, 2020.", 
    "company": "Atara Biotherapeutics Inc.", 
    "indication": "Multiple sclerosis", 
    "name": "ATA188", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 3Q 2020.", 
    "company": "Atara Biotherapeutics Inc.", 
    "indication": "Epstein-Barr virus (EBV-PTLD) after solid organ transplant (SOT)", 
    "name": "ATA 129 (tab-cel) - ALLELE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 portion of the trial will note be initiated.", 
    "company": "Atara Biotherapeutics Inc.", 
    "indication": "Nasopharyngeal carcinoma (NPC)", 
    "name": "ATA129 and KEYTRUDA", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 endpoint not met December 2015", 
    "company": "Atara Biotherapeutics Inc.", 
    "indication": "Protein-energy wasting", 
    "name": "PINTA 745", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Atara Biotherapeutics Inc.", 
    "indication": "Epstein-Barr virus + other various cancers", 
    "name": "ATA 129", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved December 8, 2011.", 
    "company": "Antares Pharma Inc.", 
    "indication": "Overactive bladder", 
    "name": "Anturol", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved Oct 14, 2013.", 
    "company": "Antares Pharma Inc.", 
    "indication": "Rheumatoid arthritis (RA)", 
    "name": "OTREXUP", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced February 14, 2018.", 
    "company": "Antares Pharma Inc.", 
    "indication": "Reduce the risk of preterm birth in women with a singleton pregnancy", 
    "name": "Makena - auto injector", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 1, 2018.", 
    "company": "Antares Pharma Inc.", 
    "indication": "Testosterone deficiency", 
    "name": "XYOSTED (testosterone enanthate)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial planned for 2020.", 
    "company": "Antares Pharma Inc.", 
    "indication": "Acute myocardial infarction (AMI)", 
    "name": "Selatogrel and QuickShot", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "PDUFA date October 10, 2020.", 
    "company": "Avenue Therapeutics Inc.", 
    "indication": "Postoperative pain following bunionectomy surgery", 
    "name": "Intravenous (IV) tramadol", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2/3 data due 4Q 2020.", 
    "company": "Aurinia Pharmaceuticals Inc", 
    "indication": "Dry eye syndrome", 
    "name": "Voclosporin ophthalmic solution (VOS) - AUDREY", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "Aurinia Pharmaceuticals Inc", 
    "indication": "Focal segmental glomerulosclerosis (FSGS) and minimal change disease (MCD)", 
    "name": "Voclosporin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date under priority review of January 22, 2021", 
    "company": "Aurinia Pharmaceuticals Inc", 
    "indication": "Lupus", 
    "name": "Voclosporin - AURORA", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 2 trial enrollment has commenced - noted June 25, 2018.", 
    "company": "Aurinia Pharmaceuticals Inc", 
    "indication": "Lupus", 
    "name": "Voclosporin - AURORA 2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 interim data due 1H 2021.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "T-cell lymphoma", 
    "name": "AUTO4", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 updated data due at ESMO September 19-22, 2020.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "Relapsed or refractory diffuse large B-celllymphoma (DLBCL)", 
    "name": "AUTO3 - (ALEXANDER)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data presented at ASH December 8, 2019.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "Relapsed or refractory multiple myeloma", 
    "name": "AUTO2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 update at EHA June 2020. Event Free Survival (EFS) and Overall Survival (OS) at 6 months are 62% and 72% respectively in all patients. Full data due by the end of 2021.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "Acute lymphoblastic leukemia (ALL)", 
    "name": "AUTO1", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial for TRBC2-positive T-cell lymphoma to be initiated pending positive AUTO4 data.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "T-cell lymphoma", 
    "name": "AUTO5", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data presented at ASH December 2019.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "Acute Lymphoblastic Leukemia", 
    "name": "AUTO3 - (AMELIA)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 2H 2020.", 
    "company": "Autolus Therapeutics plc", 
    "indication": "Neuroblastoma", 
    "name": "AUTO6", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approved June 3, 2013.", 
    "company": "Avadel Pharmaceuticals plc", 
    "indication": "Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery", 
    "name": "Bloxiverz (neostigmine methylsulfate)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Announced approval May 2 2016", 
    "company": "Avadel Pharmaceuticals plc", 
    "indication": "Hypotension", 
    "name": "Akovaz", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met co-primary endpoints - April 27, 2020.", 
    "company": "Avadel Pharmaceuticals plc", 
    "indication": "Excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy", 
    "name": "FT 218", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved June 30 2014.", 
    "company": "Avadel Pharmaceuticals plc", 
    "indication": "Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia", 
    "name": "VAZCULEP (phenylephrine hydrochloride)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved Jun 3 2013", 
    "company": "Avadel Pharmaceuticals plc", 
    "indication": "Reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery", 
    "name": "Bloxiverz (neostigmine methylsulfate)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 16, 2019.", 
    "company": "Avadel Pharmaceuticals plc", 
    "indication": "Neonate Patients Requiring Total Parental Nutrition (TPN)", 
    "name": "AV001", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "Head and neck squamous cell carcinoma (HNSCC)", 
    "name": "Ficlatuzumab and cetuximab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 final data presented at ESMO 2019.", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "Renal cell cancer (RCC)", 
    "name": "Tivozanib + Opdivo", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Announced September 12, 2016 that its Phase 2 trial has been discontinued ", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "EGFR-mutated Non-small cell lung cancer (NSCLC)", 
    "name": "Ficlatuzumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date March 31, 2021.", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "Third line treatment of patients with renal cell cancer", 
    "name": "Tivozanib", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued due to COVID-19.", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "Ficlatuzumab and cytarabine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial has moved to Phase 2 part of trial - May 29, 2020.", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "Hepatocellular carcinoma (HCC)", 
    "name": "FOTIVDA (Tivozanib) and IMFINZI (Durvalumab)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b data noted 29% partial response (PR) rate - January 27, 2020.", 
    "company": "AVEO Pharmaceuticals Inc.", 
    "indication": "Pancreatic ductal adenocarcinoma (PDAC)", 
    "name": "Ficlatuzumab and nab-paclitaxel", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 updated data presented at American Society of Gene & Cell Therapy (ASGCT) May 13, 2020.", 
    "company": "AVROBIO Inc.", 
    "indication": "Cystinosis", 
    "name": "AVR-RD-04 (ASGCT)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 dosing commenced July 2020.", 
    "company": "AVROBIO Inc.", 
    "indication": "Gaucher disease", 
    "name": "AVR-RD-02", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "AVROBIO Inc.", 
    "indication": "Fabry disease", 
    "name": "AVR-RD-01 (FAB-201)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 4Q 2020.", 
    "company": "Anavex Life Sciences Corp.", 
    "indication": "Rett syndrome", 
    "name": "ANAVEX 2-73 - U.S. RS-001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b enrolment has reached 50% - noted December 16, 2019.", 
    "company": "Anavex Life Sciences Corp.", 
    "indication": "Mild to moderate Alzheimerâ€™s disease", 
    "name": "ANAVEX 2-73", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data due mid-2020.", 
    "company": "Anavex Life Sciences Corp.", 
    "indication": "Parkinsonâ€™s Disease Dementia (PDD)", 
    "name": "ANAVEX 2-73", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced June 6, 2019. Update due 2020.", 
    "company": "Anavex Life Sciences Corp.", 
    "indication": "Rett syndrome", 
    "name": "ANAVEX 2-73 - AVATAR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation of dosing announced July 1, 2020.", 
    "company": "Anavex Life Sciences Corp.", 
    "indication": "Rett syndrome ", 
    "name": "ANAVEX 2-73-RS-003 EXCELLENCE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 initiation of enrolment announced July 6, 2020. Top-line data due 1H 2021.", 
    "company": "Anavex Life Sciences Corp.", 
    "indication": "Healthy volunteers", 
    "name": "ANAVEX 3-71 (AF710B)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 preliminary report of trial data due 2Q 2022.", 
    "company": "Axogen Inc.", 
    "indication": "Severed peripheral nerves", 
    "name": "Avance Nerve Graf", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 6-month data from second dose cohort due 4Q 2020", 
    "company": "Axovant Gene Therapies Ltd.", 
    "indication": "Parkinson's disease", 
    "name": "AXO-Lenti-PD - SUNRISE-PD", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data presented October 23, 2019.", 
    "company": "Axovant Gene Therapies Ltd.", 
    "indication": "GM2 gangliosidosis", 
    "name": "AXO-AAV-GM2", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 six-month data from low dose cohort due 4Q 2020.", 
    "company": "Axovant Gene Therapies Ltd.", 
    "indication": "GM1 gangliosidosis", 
    "name": "AXO-AAV-GM1", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2021.", 
    "company": "Axcella Health Inc.", 
    "indication": "Hepatic encephalopathy", 
    "name": "AXA1665", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial planned for 1H 2021. Data from AXA1125-003 trial of AXA1125 and AXA1957 in non-alcoholic fatty liver disease (NAFLD) due at EASL August 28, 2020.", 
    "company": "Axcella Health Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH) / non-alcoholic fatty liver disease (NAFLD)", 
    "name": "AXA1125", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 top-line data met primary endpoint - April 15, 2019.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Smoking cessation", 
    "name": "AXS-05", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 top-line met primary endpoint - April 27, 2020. Second Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Agitation in patients with Alzheimerâ€™s disease (AD)", 
    "name": "AXS-05 ADVANCE-1", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 interim efficacy analysis January 9, 2017 recommended trial to discontinue due to futility.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Complex regional pain syndrome (CRPS)", 
    "name": "AXS-02 CREATE-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint. Secondary endpoints met. Second Phase 3 trial to commence 3Q 2020.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Treatment resistant depression", 
    "name": "AXS-05 STRIDE-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing due 4Q 2020.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Migraine", 
    "name": "AXS-07", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "NDA filing due 4Q 2020.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Major Depressive Disorder", 
    "name": "AXS-05 -GEMINI", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Narcolepsy", 
    "name": "AXS-12", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoints.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Fibromyalgia", 
    "name": "Esreboxetine (AXS-14)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 open-label trial data (3) due 4Q 2020.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Treatment resistant MDD / Antidepressant unresponsive MDD / suicidal ideation", 
    "name": "AXS-05 - COME-TRD/AU/SI", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 1H 2021.", 
    "company": "Axsome Therapeutics Inc.", 
    "indication": "Treatment resistant depression", 
    "name": "AXS-05 - MERIT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 updated data due at ESMO September 18, 2020, 03:55 CEST.", 
    "company": "Ayala Pharmaceuticals Inc.", 
    "indication": "Adenoid cystic carcinoma", 
    "name": "AL101 (ACCURACY)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Ayala Pharmaceuticals Inc.", 
    "indication": "Desmoid tumors", 
    "name": "AL102", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Ayala Pharmaceuticals Inc.", 
    "indication": "Triple negative breast cancer", 
    "name": "AL101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Ayala Pharmaceuticals Inc.", 
    "indication": "T-cell acute lymphoblastic leukemia", 
    "name": "AL101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due late-2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Asthma", 
    "name": "Tezepelumab - NAVIGATOR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Expanded approval announced August 28, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Monotherapy for expanded use in women with HR+, HER2- advanced breast cancer", 
    "name": "Faslodex (fulvestrant)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date December 20, 2020. ", 
    "company": "Astrazeneca PLC", 
    "indication": "Anaemia in Chronic Kidney Disease", 
    "name": "Roxadustat", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to overwhelming efficacy.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic Kidney Disease", 
    "name": "Farxiga (Dapa-CKD)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 21, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Heart failure in patients with type-2 diabetes", 
    "name": "Farxiga - DECLARE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "HPV-associated squamous cell carcinoma of the head & neck (SCCHN)", 
    "name": "MEDI0457", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data released November 1, 2017 - primary endpoint not met.", 
    "company": "Astrazeneca PLC", 
    "indication": "Severe, uncontrolled asthma", 
    "name": "Tralokinumab (STRATOS2)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 5, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Heart failure", 
    "name": "Farxiga (Dapa-HF)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released May 30, 2018. Primary endpoint not met.", 
    "company": "Astrazeneca PLC", 
    "indication": "COPD", 
    "name": "Benralizumab - TERRANOVA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Myelodysplastic syndromes (MDS)", 
    "name": "Roxadustat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced March 31, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC)", 
    "name": "Tagrisso", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Crohn's disease", 
    "name": "Brazikumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+", 
    "company": "Astrazeneca PLC", 
    "indication": "Adjuvant Non-small cell lung cancer (NSCLC)", 
    "name": "Durvalumab (ADJUVANT)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - May 10, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Severe, uncontrolled asthma", 
    "name": "Tralokinumab (STRATOS1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - noted July 26, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Thyroid cancer", 
    "name": "Selumetinib - ASTRA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced July 24, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Breztri - (ETHOS)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced September 13, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Cancer - leukaemia", 
    "name": "Moxetumomab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 19, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "First-line ovarian cancer following platinum-based chemotherapy", 
    "name": "Lynparza - SOLO 1", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 17, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Second-line ovarian cancer", 
    "name": "Lynparza - SOLO 2", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Breast cancer", 
    "name": "Lynparza", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released July 27, 2017 - primary endpoint (PFS) not met. Overall survival data also did not meet primary endpoint - November 16, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Lung cancer ", 
    "name": "Durvalumab +/- tremelimumab (MYSTIC)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released August 21, 2019 did not meet primary endpoint.", 
    "company": "Astrazeneca PLC", 
    "indication": "Lung cancer ", 
    "name": "Durvalumab +/- tremelimumab (NEPTUNE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Head & neck cancer ", 
    "name": "Durvalumab +/- tremelimumab (KESTREL)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released March 6, 2020 did not meet primary endpoint.", 
    "company": "Astrazeneca PLC", 
    "indication": "Bladder cancer ", 
    "name": "Durvalumab +/- tremelimumab (DANUBE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released December 7, 2018 - primary endpoints not met.", 
    "company": "Astrazeneca PLC", 
    "indication": "Head & neck cancer ", 
    "name": "Durvalumab +/- tremelimumab (EAGLE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released April 24, 2018 - primary endpoints not met.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Durvalumab +/- tremelimumab (ARCTIC)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced February 19, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Lung cancer ", 
    "name": "Durvalumab (PACIFIC)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 Cardiovascular Outcome trial data released September 14, 2017 - primary efficacy objective of a superior reduction in MACE missed statistical significance (p=0.061).", 
    "company": "Astrazeneca PLC", 
    "indication": "Type 2 Diabetes ", 
    "name": "Bydureon ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced June 1, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Type 2 Diabetes / coronary artery disease (CAD)", 
    "name": "Brilinta (THEMIS)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 TULIP 1 data released August 31, 2018. Primary endpoint not met. TULIP 2 data released August 29, 2019 did meet primary endpoint.", 
    "company": "Astrazeneca PLC", 
    "indication": "Lupus", 
    "name": "Anifrolumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Priority Review announced August 2, 2017. Approval announced October 31, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Relapsed or Refractory Mantle Cell Lymphoma", 
    "name": "Acalabrutinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA acceptance announced December 9, 2017. PDUFA under priority review. Approval announced May 1, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Bladder cancer ", 
    "name": "Urothelial carcinoma - Bladder cancer", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Second CRL issued March 17, 2017. Approval announced May 18, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Hyperkalaemia", 
    "name": "Lokelma (ZS-9)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced February 28, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Type-2 diabetes", 
    "name": "Saxagliptin and dapagliflozin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced November 14, 2017.", 
    "company": "Astrazeneca PLC", 
    "indication": "Severe, uncontrolled asthma", 
    "name": "Benralizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Announced discontinuation of trial due to futility - June 12, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Early Alzheimer's disease", 
    "name": "Lanabecestat (AZD3293) - AMARANTH", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary and secondary endpoints. ORR; 72.2% vs 51.4% for chemotherapy. PFS 13.4 months vs 9.2 months for chemo arm (HR 0.62).", 
    "company": "Astrazeneca PLC", 
    "indication": "Third-line ovarian cancer", 
    "name": "Lynparza - SOLO 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced December 30, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Pancreatic cancer", 
    "name": "Lynparza (POLO)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 PFS data met primary endpoint. OS data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Imfinzi + tremelimumab  (POSEIDON)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced March 30, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Small cell lung cancer (SCLC)", 
    "name": "Imfinzi + tremelimumab (CASPIAN)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "HER2-negative breast cancer", 
    "name": "Lynparza - OlympiA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - noted May 11, 2018.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Fasenra (benralizumab) - GALATHEA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 19, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Castration-Resistant Prostate Cancer", 
    "name": "Lynparza", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 21, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic lymphocytic leukaemia", 
    "name": "Calquence", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 8, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "First-line ovarian cancer", 
    "name": "Lynparza + Avastin- PAOLA-1", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2/3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Ulcerative colitis", 
    "name": "Brazikumab", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1b/2 data due 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Refractory head and neck cancer", 
    "name": "Durvalumab Plus Danvatirsen", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 final OS data released August 9, 2019. Endpoint met. Presentation at ESMO September 2019 noted OS of 38.6 months versus 31.8 months for comparator arm; PFS HR 0.48.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tagrisso - FLAURA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review 4Q 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Acute ischaemic stroke", 
    "name": "Brilinta (THALES)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 trial to be discontinued due to low likelihood of demonstrating a benefit - January 13, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Hypertriglyceridaemia CVOT", 
    "name": "Epanova", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Nasal polyps", 
    "name": "Fasenra OSTRO", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Neoadjuvant Non-small cell lung cancer (NSCLC)", 
    "name": "Imfinzi - AEGEAN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "HER low breast cancer", 
    "name": "Trastuzumab deruxtecan - DESTINY-Breast04", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Second line HER2+ breast cancer", 
    "name": "Trastuzumab deruxtecan - DESTINY-Breast03", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Third line HER2+ breast cancer", 
    "name": "Trastuzumab deruxtecan DESTINY-Breast02", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced December 20, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Third line HER2+ breast cancer", 
    "name": "Enhertu (trastuzumab deruxtecan)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Asthma", 
    "name": "Fasenra", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic Heart Failure (CHF), preserved ejection fraction (HFpEF)", 
    "name": "Farxiga (Deliver)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 positive interim data released May 7, 2019. Trial to be stopped early.", 
    "company": "Astrazeneca PLC", 
    "indication": "Relapsed/refractory chronic lymphocytic leukaemia", 
    "name": "Calquence", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced May 3, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Type 2 diabetes", 
    "name": "Qternmet XR (dapagliflozin, saxagliptin and metformin hydrochloride)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued for sNDA announced July 15, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Type 1 diabetes", 
    "name": "Farxiga (Depict)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Asthma", 
    "name": "PT027", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Imfinzi - PACIFIC-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data trial met primary endpoint.", 
    "company": "Astrazeneca PLC", 
    "indication": "Gastric cancer", 
    "name": "Trastuzumab deruxtecan - DESTINY-Gastric01", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL announced October 1, 2019.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "PT010", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - March 12, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Ovarian cancer", 
    "name": "Lynparza + cediranib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Imfinzi (PEARL)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Imfinzi (PACIFIC-5)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Bladder cancer", 
    "name": "Imfinzi + tremelimumab  (NILE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Hepatocellular carcinoma (HCC) ", 
    "name": "Imfinzi + tremelimumab  - HIMALAYA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Locoregional Hepatocellular carcinoma (HCC)", 
    "name": "Durvalumab - EMERALD-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Small cell lung cancer (SCLC) limited disease", 
    "name": "Durvalumab - ADRIATIC", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Castration-resistant prostate cancer -first line", 
    "name": "Lynparza - PROpel", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced April 13, 2020.", 
    "company": "Astrazeneca PLC", 
    "indication": "Neurofibromatosis type 1 plexiform neurofibromas", 
    "name": "Selumetinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released May 28, 2020 noted a reduction in the risk of disease recurrence or death by 83%. ", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-small Cell Lung Carcinoma", 
    "name": "Tagrisso (ADAURA)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Non-muscle invasive bladder cancer", 
    "name": "Imfinzi", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Muscle-invasive bladder cancer", 
    "name": "Imfinzi", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Locoregional Hepatocellular carcinoma (HCC)", 
    "name": "Imfinzi", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Cervical cancer", 
    "name": "Imfinzi CALLA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Astrazeneca PLC", 
    "indication": "Biliary-tract cancer", 
    "name": "Imfinzi TOPAZ-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Ovarian cancer", 
    "name": "Imfinzi DuO-O", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Eosinophilic granulomatosis with polyangiitis", 
    "name": "Fasenra MANDARA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD) and peripheral blood eosinophils", 
    "name": "Fasenra", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "hypereosinophilic syndrome (HES)", 
    "name": "Fasenra", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Astrazeneca PLC", 
    "indication": "Eosinophilic oesophagitis", 
    "name": "Fasenra MESSINA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data July 20, 2020 noted neutralising activity was seen in 91% of participants one month and in 100% of participants who received a second dose. Phase 3 data from non-U.S. trials due 3Q 2020.  Phase 3 U.S. trial to start soon.", 
    "company": "Astrazeneca PLC", 
    "indication": "COVID-19 vaccine", 
    "name": "AZD1222 (ChAdOx1 nCoV-19)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b top line data due in 1Q 2021.", 
    "company": "AzurRx BioPharma Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "MS1819 - OPTION 2", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 top line data due 2Q 2021.", 
    "company": "AzurRx BioPharma Inc.", 
    "indication": "Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency", 
    "name": "MS1819 Combination", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 Japanese trial met all primary and secondary efficacy endpoints - June 15, 2020. U.S. Phase 3 trial to be initiated in 4Q 2020.", 
    "company": "Brickell Biotech, Inc.", 
    "indication": "Axillary hyperhidrosis", 
    "name": "Sofpironium Bromide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 1H 2021 with top-line data due 1H 2022.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "ATTR-CM", 
    "name": "Acoramidis (AG10) - ATTRibute-CM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 2H 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "ATTR-PN", 
    "name": "AG10 / BBP-265", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 pivotal trial data due 2H 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Cholangiocarcinoma", 
    "name": "BBP-831 (infigratinib)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initial data due YE 2021.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Achondroplasia", 
    "name": "Low-dose infigratinib (PROPEL2)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 completion of enrolment announced December 2, 2019.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Gorlin syndrome", 
    "name": "BBP-009/Patidegib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced January 8, 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "High-Frequency Basal Cell Carcinoma", 
    "name": "BBP-009/Patidegib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Rolling NDA initiation announced December 3, 2019. To be completed in 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Molybdenum cofactor deficiency type A", 
    "name": "Fosdenopterin (BBP-870/ORGN001)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 data due 2021.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Epidermolysis bullosa", 
    "name": "BBP-589", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced March 12, 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Urothelial Carcinoma ", 
    "name": "Infigratinib (PROOF 302)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced March 12, 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Solid tumors", 
    "name": "Infigratinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial has been initiated - noted June 11, 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Healthy volunteers", 
    "name": "BBP-418", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 0/2 trial initiation announced July 28, 2020.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Recurrent Glioblastoma", 
    "name": "Infigratinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2020 with data due 2021.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Autosomal Dominant Hypocalcemia Type 1 (ADH1)", 
    "name": "Encaleret", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated and report initial data in 2021.", 
    "company": "BridgeBio Pharma Inc.", 
    "indication": "Congenital adrenal hyperplasia (CAH", 
    "name": "BBP-631", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial to continue as planned following DSMB review March 31, 2020. Next review 4Q 2020", 
    "company": "BioCardia Inc.", 
    "indication": "Heart Failure", 
    "name": "CardiAMP  (BCDA-01)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2Q 2020.", 
    "company": "BioCardia Inc.", 
    "indication": "Chronic Myocardial Ischemia", 
    "name": "CardiAMP (BCDA-02)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b initiation of dosing announced February 13, 2020. Initial safety data due late-2020 or early-2021.", 
    "company": "Atreca Inc.", 
    "indication": "Solid tumors", 
    "name": "ATRC-101", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 top-line data due by the end of November 2020.", 
    "company": "Brainstorm Cell Therapeutics Inc.", 
    "indication": "Amytrophic lateral sclerosis (ALS)", 
    "name": "NurOwn", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 dosing to be completed 4Q 2020.", 
    "company": "Brainstorm Cell Therapeutics Inc.", 
    "indication": "Progressive Multiple Sclerosis", 
    "name": "NurOwn", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Brainstorm Cell Therapeutics Inc.", 
    "indication": "Prodromal to mild Alzheimer's disease", 
    "name": "NurOwn", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved September 21, 2017.", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "Acute uncomplicated influenza to pediatric patients", 
    "name": "RAPIVAB (peramivir injection)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date December 3, 2020\n", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "Reduce or eliminate attacks in HAE patients ", 
    "name": "Berotralstat BCX7353", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2b data released February 2016 - primary endpoint not met", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "Hereditary angioedema", 
    "name": "BCX4161 - OPuS-2", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Approved Dec 22 2014", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "INFLUENZA ACUTE", 
    "name": "RAPIVAB (peramivir)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 trial completion announced May 9, 2019. Generally safe and well tolerated.", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "Healthy volunteers", 
    "name": "Galidesivir", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 3Q 2020.", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH)", 
    "name": "BCX9930", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "Fibrodysplasia ossificans progressiva (FOP)", 
    "name": "BCX9250", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Information from Part 1 of the trial are due 3Q 2020.", 
    "company": "BioCryst Pharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "Galidesivir", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 safety and tolerability data released July 1, 2019.", 
    "company": "Bicycle Therapeutics plc", 
    "indication": "Diabetic Macular Edema", 
    "name": "THR-149", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a trial to commence 2020.", 
    "company": "Bicycle Therapeutics plc", 
    "indication": "Solid tumors", 
    "name": "BT1718", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - noted May 5, 2020.", 
    "company": "Bicycle Therapeutics plc", 
    "indication": "Solid tumors", 
    "name": "BT5528 and Nivolumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated in 2020.", 
    "company": "Bicycle Therapeutics plc", 
    "indication": "Solid tumors", 
    "name": "BT8009", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2b data released December 13, 2016 - primary endpoints not met.", 
    "company": "BioDelivery Sciences International Inc.", 
    "indication": "Painful diabetic neuropathy (PDN)", 
    "name": "Clonidine gel", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Approved June 6, 2014.", 
    "company": "BioDelivery Sciences International Inc.", 
    "indication": "Opioid dependence", 
    "name": "BEMA Buprenorphine/Naloxone (BNX) - BUNAVAIL", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved October 26, 2015.", 
    "company": "BioDelivery Sciences International Inc.", 
    "indication": "Pain", 
    "name": "BEMA Buprenorphine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 part of trial to be completed 1H 2021.", 
    "company": "Black Diamond Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "BDTX-189", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due not before 2021.", 
    "company": "Biofrontera AG", 
    "indication": "Basal cell carcinoma", 
    "name": "Ameluz", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 planned.", 
    "company": "Biofrontera AG", 
    "indication": "Acne", 
    "name": "Ameluz", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - March 20, 2019. Additional trials required with patient recruitment to commence 2H 2020.", 
    "company": "Biofrontera AG", 
    "indication": "Actinic keratosis", 
    "name": "Ameluz", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 planned.", 
    "company": "Biofrontera AG", 
    "indication": "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
    "name": "Ameluz", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment completed.", 
    "company": "BeiGene Ltd.", 
    "indication": "Hepatocellular carcinoma (HCC)", 
    "name": "Tislelizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data to be presented at ESMO September 19-22, 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "Ovarian Cancers or Triple-Negative Breast Cancer", 
    "name": "Pamiparib (BGB-290)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2H 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "First-line chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", 
    "name": "Zanubrutinib (BGB-3111) - SEQUOIA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced November 14, 2019.", 
    "company": "BeiGene Ltd.", 
    "indication": "Relapsed or refractory mantle cell lymphoma (MCL)", 
    "name": "Zanubrutinib (BGB-3111)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 top-line data did not meet primary endpoint - December 16, 2019.", 
    "company": "BeiGene Ltd.", 
    "indication": "Waldenström’s macroglobulinemia", 
    "name": "Zanubrutinib (BGB-3111) - ASPEN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due in 2020 or early 2021.", 
    "company": "BeiGene Ltd.", 
    "indication": "Esophageal Squamous Cell Carcinoma (ESCC)", 
    "name": "Tislelizumab - BGB-A317", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 regulatory discussions to take place in 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "Hepatocellular carcinoma (HCC) - second-line", 
    "name": "Tislelizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced July 24, 2018.", 
    "company": "BeiGene Ltd.", 
    "indication": "Gastric Cancer", 
    "name": "Pamiparib (BGB-290)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2020 or 1H 2021.", 
    "company": "BeiGene Ltd.", 
    "indication": "Maintenance Therapy Ovarian Cancer", 
    "name": "Pamiparib (BGB-290)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due in 2020 or early 2021.", 
    "company": "BeiGene Ltd.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tislelizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint of PFS at interim analyses - January 21, 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "Squamous non-small cell lung cancer (NSCLC)", 
    "name": "Tislelizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be completed 2H 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "Refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)", 
    "name": "Zanubrutinib (BGB-3111) vs Ibrutinib - ALPINE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 additional data due in 2021.", 
    "company": "BeiGene Ltd.", 
    "indication": "Hepatocellular Carcinoma (HCC) / Gastric/Gastroesophageal Junction Cancer", 
    "name": "Sitravatinib and tislelizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced December 17, 2018.", 
    "company": "BeiGene Ltd.", 
    "indication": "Gastric Cancer", 
    "name": "Tislelizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 updated data at EHA 2020 noted overall response rate (ORR) was 80%, with a complete response (CR) rate of 15% and a partial response (PR) rate of 65%.", 
    "company": "BeiGene Ltd.", 
    "indication": "Waldenström’s macroglobulinemia", 
    "name": "Zanubrutinib (BGB-3111)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial enrolment has been completed - noted March 2, 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "Marginal Zone Lymphoma", 
    "name": "Zanubrutinib (BGB-3111) - MAGNOLIA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "BeiGene Ltd.", 
    "indication": "Nasopharyngeal cancer", 
    "name": "Tislelizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "BeiGene Ltd.", 
    "indication": "Mantle cell lymphoma (MCL) - front-line", 
    "name": "Zanubrutinib plus rituximab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data due 2021.", 
    "company": "BeiGene Ltd.", 
    "indication": "Solid tumors", 
    "name": "BGB-3245", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data to be presented at ESMO September 19-22, 2020.", 
    "company": "BeiGene Ltd.", 
    "indication": "Non-squamous non-small cell lung cancer (NSCLC)", 
    "name": "Tislelizumab and chemotherapy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced May 7, 2018.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Bowel cleansing", 
    "name": "Plenvu (NER1006)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced November 2, 2017.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Open angle glaucoma (OAG) or ocular hypertension (OHT)", 
    "name": "Latanoprostene bunod", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced February 25, 2019.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Ocular Inflammation", 
    "name": "Loteprednol Gel 0.38%", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 22, 2017.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Eye Brightener", 
    "name": "LUMIFY (brimonidine tartrate ophthalmic solution 0.025%)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 24, 2018.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Acne", 
    "name": "IDP-121 ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Tentative FDA Approval announced October 8, 2018. Final approval expected November 2018 pending the expiration of exclusivity for a related product.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Psoriasis", 
    "name": "IDP-122 ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Acne", 
    "name": "IDP-120", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced April 25, 2019.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Psoriasis", 
    "name": "DUOBRII (halobetasol propionate and tazarotene)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 19, 2019.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Acne", 
    "name": "IDP-123", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved February 15, 2017.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Psoriasis", 
    "name": "Brodalumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL received October 18, 2019. To resubmit 1H 2021.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Macular edema associated with non-infectious uveitis", 
    "name": "XIPERE (Suprachoroidal CLS-TA)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Approval announced March 2, 2018.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Contact lens", 
    "name": "ULTRA - 7 days", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date August 10, 2020 extended to September 15, 2020.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Allergic conjunctivitis", 
    "name": "EM-100", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint - March 31, 2020.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Overt hepatic encephalopathy", 
    "name": "Rifaximin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Atopic Dermatitis", 
    "name": "IDP-124", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial to commence 3Q 2021.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Crohn's disease", 
    "name": "Rifaximin", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Small intestinal bacterial overgrowth (SIBO)", 
    "name": "Rifaximin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "Acne", 
    "name": "IDP-126", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Bausch Health Companies Inc.", 
    "indication": "", 
    "name": "Amiselimod S1P6 Modulator", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 top-line data did not meet primary endpoint - June 24, 2020. Two further trials to be initiated in 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Obsessive compulsive disorder (OCD)", 
    "name": "TRORILUZOLE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "CRL issued July 19, 2019.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "Nurtec (riluzole) (BHV-0223)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "sNDA filing due 4Q 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Migraine - preventative", 
    "name": "Nurtec (Rimegepant)", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced February 27, 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Acute treatment of migraine", 
    "name": "Rimegepant Zydis ODT", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2/3 top-line data due 1Q 2021.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "TRORILUZOLE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 10, 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Generalized anxiety disorder (GAD)", 
    "name": "TRORILUZOLE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2021.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Multiple system atrophy (MSA)", 
    "name": "Verdiperstat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due late-2021.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Spinocerebellar Ataxia (SCA)", 
    "name": "TRORILUZOLE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial continues to enrol as of August 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Refractory trigeminal neuralgia", 
    "name": "Rimegepant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned. IND submission announced April 9, 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "COVID-19 Coronavirus associated pulmonary complications", 
    "name": "Vazegepant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 initiation announced August 3, 2020.", 
    "company": "Biohaven Pharmaceutical Holding Company Ltd.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "Verdiperstat (HEALEY ALS Platform Trial)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2/3 data due 1H 2021.", 
    "company": "Biogen Inc.", 
    "indication": "X-linked Retinitis Pigmentosa", 
    "name": "BIIB112", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Choroideremia", 
    "name": "BIIB111", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Parkinson's disease", 
    "name": "BIIB054", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint not met - noted April 2020.", 
    "company": "Biogen Inc.", 
    "indication": "Epilepsy", 
    "name": "Natalizumab - OPUS", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due by end of 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Large hemispheric infarction", 
    "name": "BIIB093", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - December 13, 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Progressive supranuclear palsy (PSP)", 
    "name": "BIIB092 - Anti Tau", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to unfavorable risk-benefit ratio.", 
    "company": "Biogen Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Elenbecestat (E2609) - (MissionAD2)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review March 7, 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Aducanumab", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to unfavorable risk-benefit ratio.", 
    "company": "Biogen Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Elenbecestat (E2609) - (MissionAD1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data due 2H 2020.", 
    "company": "Biogen Inc.", 
    "indication": "Multiple sclerosis (MS)", 
    "name": "Opicinumab (AFFINITY)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to futility - unlikely to meet primary endpoint upon completion - March 21, 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Alzheimer’s disease", 
    "name": "Aducanumab (Aβ mAb) - ENGAGE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data released February 8, 2018 - primary endpoint not met.", 
    "company": "Biogen Inc.", 
    "indication": "Acute ischemic stroke", 
    "name": "Natalizumab (Î±4-integrin inhibitor)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data released September 2018 - primary endpoint not met.", 
    "company": "Biogen Inc.", 
    "indication": "Painful Lumbosacral Radiculopathy (PLSR)", 
    "name": "Raxatrigine - BIIB074 (Nav1.7 inhibitor)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint - December 3, 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Lupus", 
    "name": "BIIB059 (anti-BDCA2)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data released October 23, 2018 - primary endpoint not met.", 
    "company": "Biogen Inc.", 
    "indication": "Lupus", 
    "name": "Dapirolizumab pegol (anti-CD40L)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 initiation announced March 22. 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "BAN2401", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial discontinued August 2019 due to safety concerns.", 
    "company": "Biogen Inc.", 
    "indication": "Idiopathic pulmonary fibrosis (IPF)", 
    "name": "BG00011 (STX-100)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "FDA Approval announced October 30, 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Multiple sclerosis (MS)", 
    "name": "Diroximel fumarate (BIIB098)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "Tofersen", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3b trial initiation announced January 3, 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Multiple sclerosis (MS)", 
    "name": "Natalizumab - NOVA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data due 2H 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Cognitive Impairment Associated With Schizophrenia (CIAS)", 
    "name": "BIIB104", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Acute ischemic stroke", 
    "name": "TMS-007", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Biogen Inc.", 
    "indication": "Small Fibre Neuropathy", 
    "name": "BIIB074 (Nav1.7 inhibitor)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 initiation announced September 18, 2019.", 
    "company": "Biogen Inc.", 
    "indication": "Spinal muscular atrophy (SMA)", 
    "name": "SPINRAZA - DEVOTE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2/3 commencement of dosing announced April 2, 2020.", 
    "company": "Biogen Inc.", 
    "indication": "Spinal muscular atrophy (SMA)", 
    "name": "SPINRAZA (nusinersen) - high dose", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 pediatric top-line data met primary endpoint of event free survival - July 8, 2019.", 
    "company": "Bellicum Pharmaceuticals Inc.", 
    "indication": "Adjunct T-cell therapy administered after allogeneic HSCT - (hematopoietic stem cell transplantation) - cancer", 
    "name": "BPX-501 Rivo-cel", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 Cohort 5C data due 4Q 2020.", 
    "company": "Bellicum Pharmaceuticals Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "BPX-601", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2/3 trial on hold pending partnership.", 
    "company": "Bellicum Pharmaceuticals Inc.", 
    "indication": "Acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS)", 
    "name": "Rivo-cel -THRIVE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated later in 2020.", 
    "company": "Bellicum Pharmaceuticals Inc.", 
    "indication": "HER2+ Solid Tumors", 
    "name": "BPX-603", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 initiation due 2H 2020.", 
    "company": "Bellerophon Therapeutics Inc.", 
    "indication": "Pulmonary Hypertension associated with Pulmonary Fibrosis (PH-PF)", 
    "name": "INOpulse delivery device", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial stopped due to futility - August 7, 2018.", 
    "company": "Bellerophon Therapeutics Inc.", 
    "indication": "Pulmonary Arterial Hypertension (PAH)", 
    "name": "INOpulse delivery device", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data noted statistically and clinically significant improvements in hemodynamic parameters - February 18, 2020.", 
    "company": "Bellerophon Therapeutics Inc.", 
    "indication": "Pulmonary hypertension associated with Pulmonary Fibrosis or Sarcoidosis (PH-Sarcoidosis)", 
    "name": "INOpulse delivery device", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 treatment of first patient announced July 13, 2020.", 
    "company": "Bellerophon Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "INOpulse Inhaled Nitric Oxide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 PFS and OS data due 2H 2020.", 
    "company": "BioLineRx Ltd.", 
    "indication": "Pancreatic cancer", 
    "name": "BL-8040 in combination with KEYTRUDA - COMBAT trial", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b interim data due 2H 2020.", 
    "company": "BioLineRx Ltd.", 
    "indication": "Consolidation treatment for AML cancer patients", 
    "name": "Motixafortide (BL-8040) - BLAST", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 2H 2020 with top-line data due 1H 2021.", 
    "company": "BioLineRx Ltd.", 
    "indication": "Stem-cell mobilization for autologous transplantation", 
    "name": "BL-8040 GENESIS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data due 2H 2021. ", 
    "company": "BioLineRx Ltd.", 
    "indication": "Solid tumors", 
    "name": "AGI-134", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2a data presented at ESMO December 13, 2019.", 
    "company": "BioLineRx Ltd.", 
    "indication": "Pancreatic cancer", 
    "name": "BL-8040 in combination with KEYTRUDA", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - July 6, 2020. Phase 2b trial planned 4Q 2020.", 
    "company": "BELLUS Health Inc.", 
    "indication": "Chronic cough", 
    "name": "BLU-5937", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020 with top-line data due 2021.", 
    "company": "BELLUS Health Inc.", 
    "indication": "Chronic pruritus associated with atopic dermatitis", 
    "name": "BLU-5937", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 1H 2020.", 
    "company": "bluebird bio Inc.", 
    "indication": "Sickle Cell Disease (SCD)", 
    "name": "LentiGlobin - HGB-210", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 updated data at EHA June 12, 2020. Six of eight evaluable patients achieved transfusion independence,", 
    "company": "bluebird bio Inc.", 
    "indication": "TDT and the β0/β0genotype", 
    "name": "LentiGlobin - HGB-212 Northstar-3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Refusal-to-file letter received May 13, 2020. BLA refiled July 29, 2020.", 
    "company": "bluebird bio Inc.", 
    "indication": "Relapsed/refractory multiple myeloma", 
    "name": "ide-cel bb2121 - KarMMa", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 updated data at EHA June 12, 2020 noted 89% of evaluable patients (17/19) achieved transfusion independence with 11.9 g/dL median weighted average total hemoglobin (Hb) level.", 
    "company": "bluebird bio Inc.", 
    "indication": "non-β0/β0 transfusion-dependent thalassemia (TDT)", 
    "name": "LentiGlobin - HGB-207 Northstar-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 data to be presented at EBMT meeting, August 29 - September 1, 2020.", 
    "company": "bluebird bio Inc.", 
    "indication": "Childhood cerebral adrenoleukodystrophy (CCALD)", 
    "name": "Lenti-D - ALD-102", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "BLA filing to be completed mid-2021.", 
    "company": "bluebird bio Inc.", 
    "indication": "Î²-Thalassemia", 
    "name": "LentiGlobin", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 updated data due by the end of 2020.", 
    "company": "bluebird bio Inc.", 
    "indication": "Sickle cell disease", 
    "name": "LentiGlobin - HGB-206", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data at ASH December 9, 2019 - 83% complete response.", 
    "company": "bluebird bio Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "bb21217", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2020.", 
    "company": "bluebird bio Inc.", 
    "indication": "Sickle Cell Disease (SCD)", 
    "name": "LentiGlobin - HGB-211", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data to be presented at EBMT 2020, taking place virtually from August 29 - September 1, 2020.", 
    "company": "bluebird bio Inc.", 
    "indication": "Cerebral Adrenoleukodystrophy (CALD)", 
    "name": "Lenti-D - ALD-104", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 52-week data due 1Q 2021.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Hemophilia A", 
    "name": "Valoctocogene roxaparvovec (BMN 270) - GENEr8-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing announced August 20, 2020.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Achondroplasia", 
    "name": "Vosoritide", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Approval announced May 24, 2018.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "Palynziq (Pegvaliase)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved February 14, 2014.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "(MPS IVA) Morquio A Syndrome", 
    "name": "Vimizim (GALNS)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date extended by three months to April 27 2017. Approval announced April 27, 2017.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Batten Disease", 
    "name": "Cerliponase alfa", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued January 14, 2016.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Duchenne Muscular Dystrophy (DMD)", 
    "name": "Kyndrisa", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL announced August 19, 2020.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Hemophilia A", 
    "name": "Valoctocogene roxaparvovec (BMN 270)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence dosing 2H 2020.", 
    "company": "BioMarin Pharmaceutical Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "BMN 307", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met - August 11, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Gastric cancer", 
    "name": "CM-649 â€“ Opdivo+ Yervoy or Chemo", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data April 25, 2019 did not meet primary endpoints.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Head and Neck Cancer", 
    "name": "CM-714 Opdivo + Yervoy", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate. Further data due 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers", 
    "name": "NKTR-214 + OPDIVO (nivolumab) - PIVOT-2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 2022+.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line, lower-risk Myelodysplastic syndromes (MDS)", 
    "name": "Luspatercept - COMMANDS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment has reached target enrolment. Top-line data due 2H 2021.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Ovarian Cancer - First-line maintenance treatment", 
    "name": "Opdivo and Rubraca ATHENA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced March 6, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "", 
    "name": "Opdivo -  4 week applications", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced November 10, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Philadelphia Chromosome-Positive Chronic Phase Chronic Myeloid Leukemia", 
    "name": "Sprycel (dasatinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced July 6, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Psoriatic Arthritis (PsA)", 
    "name": "ORENCIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced March 11, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Previously Treated Hepatocellular Carcinoma", 
    "name": "Opdivo and Yervoy", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to commence by end of 2020 or early-2021.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Myelofibrosis", 
    "name": "Luspatercept - INDEPENDENCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced August 1, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)", 
    "name": "CM-142 â€“ Opdivo ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing announced August 24, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line renal cell carcinoma", 
    "name": "CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 3 enrollment complete - noted April 27, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Multiple Myeloma - Maintenance Post-VMP induction", 
    "name": "REVLIMID - MM-026 ARUMM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 ongoing.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsed or Refractory Indolent Lymphoma", 
    "name": "REVLIMID - MAGNIFY NHL-008", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 28, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsed or Refractory Follicular Lymphoma", 
    "name": "REVLIMID - AUGMENT", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - June 2, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Ulcerative Colitis", 
    "name": "Ozanimod - TRUE NORTH", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced April 3, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Myelodysplastic syndromes (MDS) cancer", 
    "name": "Luspatercept", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date under priority review September 3, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "AML Maintenance", 
    "name": "CC-486-AML-001", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 ongoing.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Adjuvant Therapy in Surgically Resected Pancreatic Cancer", 
    "name": "ABRAXANE - PANC-003 apact", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released June 2017 - met the endpoint of a pre-planned interim futility analysis.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line late stage Squamous Non-small cell lung cancer (NSCLC) ", 
    "name": "ABRAXANE - NSCL-003 abound.sqm", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced March 26, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsing Multiple Sclerosis", 
    "name": "ZEPOSIA (Ozanimod)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved February 22, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Multiple myeloma (MM) - autologous stem cell transplant (ASCT)", 
    "name": "REVLIMID", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Head and Neck Cancer", 
    "name": "CM-651 â€“ Opdivo + Yervoy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - June 24, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Hepatocellular carcinoma (HCC) - cancer", 
    "name": "CM-459 â€“ Opdivo", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 ongoing.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Melanoma", 
    "name": "CM-511 â€“ Opdivo + Yervoy ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - November 26, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Small cell lung cancer (SCLC)", 
    "name": "CM-451 â€“ Opdivo + Yervoy ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released October 12, 2018 - primary endpoint not met.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Second-line Small cell lung cancer (SCLC)", 
    "name": "CM-331â€“ Opdivo ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 interim data released June 6, 2017 - primary endpoint met. Data presented at ESMO September 10, 2017 - HR 0.65 compared to Yervoy. FDA Approval announced December 20, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Melanoma", 
    "name": "CM-238 â€“ Opdivo (Adjuvant)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved April 16, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Renal cell carcinoma (RCC)", 
    "name": "CM-214 â€“ Opdivo + Yervoy", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 15, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Non-small cell lung cancer (NSCLC)", 
    "name": "CM-227 â€“ Opdivo + Yervoy", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Urothelial Carcinoma - Bladder cancer", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Bladder cancer", 
    "name": "Opdivo (nivolumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Refusal-to-file letter received May 13, 2020. BLA refiled July 29, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsed/refractory multiple myeloma", 
    "name": "ide-cel bb2121 - KarMMa", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "PDUFA date under priority review extended by three months to November 16, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsed or refractory (R/R) large B-cell lymphoma", 
    "name": "liso-cel (JCAR017) - TRANSCEND NHL-001", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet OS primary endpoint - August 25, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Refractory Acute myeloid leukemia (AML) - cancer", 
    "name": "Enasidenib - IDHENTIFY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced August 1, 2017.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Advanced hematologic malignancies with an IDH2 mutation", 
    "name": "IDHIFA (enasidenib) - AG-221", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due released Feb 17, 2017 - primary endpoint met, disability endpoint not met. Full data released October 27, 2017 at ECTRIMS meeting.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsing Multiple Sclerosis", 
    "name": "Ozanimod - SUNBEAM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced July 11, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "(dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (CRC)", 
    "name": "CM-142 â€“ Opdivo ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2021+.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Crohn's disease", 
    "name": "Ozanimod", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced August 17, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Small cell lung cancer (SCLC)", 
    "name": "CM-32 - Opdivo+chemo", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 updated data at ASH December 8, 2019. 45.5% CR; 81.5% ORR.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Chronic Lymphocytic Leukemia (CLL)", 
    "name": "Liso-cel (JCAR017) - TRANSCEND CLL-004", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 clinical hold lifted June 1, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Multiple Myeloma", 
    "name": "CM-602 â€“ Opdivo +  pomalidomide and dexamethasone", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced November 6, 2018.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsed/refractory multiple myeloma ", 
    "name": "Empliciti (elotuzumab) - ELOQUENT-3", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced January 2, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", 
    "name": "Sprycel (dasatinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 data at ASH December 9, 2019 - 83% complete response.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Multiple Myeloma", 
    "name": "bb21217", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data interim analysis due by end of 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Urothelial cancer", 
    "name": "IPI-549 + Nivolumab (MARIO-275)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced March 8, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Triple-negative breast cancer", 
    "name": "TECENTRIQ (atezolizumab) plus Abraxane", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Esophageal Cancer", 
    "name": "CM-648 Opdivo + Yervoy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Urothelial Cancer", 
    "name": "CM-901 Opdivo + Yervoy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Bladder cancer", 
    "name": "CM-274 Opdivo (nivolumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - August 11, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Esophageal cancer", 
    "name": "CM-577 - Opdivo", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 met overall survival endpoint at interim analysis - April 20, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Mesothelioma", 
    "name": "CM-743 Opdivo + Yervoy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet co-primary endpoint of recurrence-free survival (RFS). Trial to continue to assess RFS in the all-comer (intent-to-treat) endpoint. Data 2H 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Melanoma", 
    "name": "Opdivo (nivolumab) and Ipilimumab (Yervoy) CM-915", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet PFS endpoint. Trial to continue to allow OS endpoint to mature - September 5, 2019. Data due 2021.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Glioblastoma (GBM) cancer", 
    "name": "CM-548 - Opdivo", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Renal Cell Carcinoma", 
    "name": "CM-914 Opdivo in combination with Yervoy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 26, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "First-line Non-small cell lung cancer (NSCLC)", 
    "name": "CM-9LA Opdivo + Yervoy", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released May 9, 2019 did not meet primary endpoint.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Phase 3 data due 2H 2019.", 
    "name": "CM-498 Opdivo", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced August 16, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Myelofibrosis", 
    "name": "Fedratinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Renal Cell Carcinoma", 
    "name": "Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 15, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Kaposiâ€™s sarcoma", 
    "name": "POMALYST (pomalidomide)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 8, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Beta-thalassemia", 
    "name": "Luspatercept", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 presentation at EHA June 15, 2019.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Relapsed/Refractory Classical Hodgkin Lymphoma", 
    "name": "ADCETRIS and Opdivo CM-744", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 data due 2H 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Melanoma", 
    "name": "Relatlimab and Nivolumab (CA224-047)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Non-Small Cell Lung Cancer (NSCLC)", 
    "name": "Nivolumab Plus Ipilimumab (CM 816)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b ORR 19% (cabozantinib and nivolumab) /29% (cabozantinib, nivolumab and ipilimumab) - January 24, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Hepatocellular cancer", 
    "name": "Cabozantinib /nivolumab and ipilimumab (CM-040)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet progression-free survival primary endpoint - March 9, 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Multiple Myeloma", 
    "name": "Lenalidomide and Dexamethasone and Elotuzumab (ELOQUENT - 1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Bristol-Myers Squibb Company", 
    "indication": "Psoriasis", 
    "name": "BMS-986165 (TYK2i)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Announced late February 2016 plans to discontinue development", 
    "company": "Benitec Biopharma Inc.", 
    "indication": "Hepatitis C", 
    "name": "TT-034", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated in 2019.", 
    "company": "Benitec Biopharma Inc.", 
    "indication": "Oculopharyngeal muscular dystrophy (OPMD)", 
    "name": "BB-301", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b data released at SITC November 8, 2019.", 
    "company": "BioNTech SE", 
    "indication": "Melanoma, Lung Cancer or Bladder Cancer", 
    "name": "NEO-PV-01 + nivolumab NT-001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data update 2H 2020.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT131", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial has resumed - noted March 31, 2020.", 
    "company": "BioNTech SE", 
    "indication": "Pancreatic cancer", 
    "name": "BNT321", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 data update 2H 2020.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT311 / GEN1046", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data noted ORR of 8% - June 22, 2020.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT122", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 interim data due 2H 2021.", 
    "company": "BioNTech SE", 
    "indication": "Melanoma", 
    "name": "BNT122", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data update due 2H 2020.", 
    "company": "BioNTech SE", 
    "indication": "Triple negative breast cancer", 
    "name": "BNT114", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "BioNTech SE", 
    "indication": "Head and Neck Cancer / HPV", 
    "name": "BNT113", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "BioNTech SE", 
    "indication": "Melanoma", 
    "name": "BNT111 and Libtayo", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence 2H 2020.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT211", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiated December 2019.", 
    "company": "BioNTech SE", 
    "indication": "Prostate cancer", 
    "name": "BNT112", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 1H 2021.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT151", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced July 27, 2020. Data due October 2020. On track to seek regulatory review in October 2020.", 
    "company": "BioNTech SE", 
    "indication": "COVID-19 vaccine", 
    "name": "BNT162b2", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "BioNTech SE", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "BNT121", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2a dosing commenced July 8, 2020.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors ", 
    "name": "BNT411", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial in multiple solid tumors is now expected in 1H 2021.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT141", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 1H 2021.", 
    "company": "BioNTech SE", 
    "indication": "Solid tumors", 
    "name": "BNT142", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Initiation of clinical testing due 1H 2021.", 
    "company": "BioNTech SE", 
    "indication": "Influenza", 
    "name": "BNT161", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 enrolment in Part 2 of the trial has commenced - noted July 30, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Indolent and smoldering systemic mastocytosis (SM)", 
    "name": "Avapritinib BLU-285 - PIONEER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced January 9, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "PDGFRA exon 18 mutant Gastrointestinal stromal tumors (GIST)", 
    "name": "Avapritinib BLU-285", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 updated data at ASCO May 29, 2020. ORR 61% in patients who previously received platinum-based chemotherapy.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "RET-altered solid tumors", 
    "name": "Pralsetinib BLU-667 - ARROW", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data due 3Q 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Advanced Systemic mastocytosis (SM)", 
    "name": "Avapritinib BLU-285 - PATHFINDER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 top-line data due 3Q 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Advanced Systemic mastocytosis (SM)", 
    "name": "Avapritinib - EXPLORER", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - April 28, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Gastrointestinal stromal tumors (GIST)", 
    "name": "Avapritinib - Voyager", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced January 13, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "First-line RET-fusion non-small cell lung cancer (NSCLC)", 
    "name": "Pralsetinib (BLU-667) - AcceleRET", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review November 23, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "First-line RET-fusion non-small cell lung cancer (NSCLC)", 
    "name": "Pralsetinib (BLU-667)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 1b/2 trial initiation announced January 6, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Hepatocellular Carcinoma", 
    "name": "Fisogatinib and CS1001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "NDA filing announced July 1, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "RET-mutant medullary thyroid cancer", 
    "name": "Pralsetinib (BLU-667)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "CRL issued May 15, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Fourth-line GIST ", 
    "name": "Avapritinib", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced June 6, 2020.", 
    "company": "Blueprint Medicines Corporation", 
    "indication": "Healthy volunteers", 
    "name": "BLU-263", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence in 2H 2020.", 
    "company": "Bio-Path Holdings Inc.", 
    "indication": "Solid tumors", 
    "name": "Prexigebersen", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 commencement of Stage 2 dosing announced August 13, 2020.", 
    "company": "Bio-Path Holdings Inc.", 
    "indication": "Acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)", 
    "name": "Prexigebersen - BP1001 + Decitabine + Venetoclax", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Bio-Path Holdings Inc.", 
    "indication": "Refractory/relapsed lymphoma and chronic lymphocytic leukemia", 
    "name": "BP1002", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced May 11, 2020.", 
    "company": "Bio-Path Holdings Inc.", 
    "indication": "COVID-19", 
    "name": "INOpulse Inhaled Nitric Oxide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 update provided August 4, 2020.", 
    "company": "BioSig Technologies Inc.", 
    "indication": "COVID-19", 
    "name": "Merimepodib and remdesivir", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 topline data released June 2016 - endpoints met", 
    "company": "BioSpecifics Technologies Corp", 
    "indication": "Human lipomas", 
    "name": "XIAFLEX", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced July 6, 2020.", 
    "company": "BioSpecifics Technologies Corp", 
    "indication": "Edematous fibrosclerotic panniculopathy (“cellulite”)", 
    "name": "QWO", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet endpoint. Endo is currently performing a commercial assessment.", 
    "company": "BioSpecifics Technologies Corp", 
    "indication": "Adhesive Capsulitis (“Frozen Shoulder syndrome”)", 
    "name": "XIAFLEX", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 data released March 2019.", 
    "company": "BioSpecifics Technologies Corp", 
    "indication": "Uterine fibroids", 
    "name": "XIAFLEX", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data met primary and secondary endpoints - July 20, 2020. NDA filing due 1Q 2021.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Schizophrenia - Agitation", 
    "name": "BXCL501 (SERENITY I)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 initiation announced April 28, 2020 with interim data due 4Q 2020.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Neuroendocrine Prostate Cancer (tNEPC)", 
    "name": "BXCL701 and Keytruda", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial planned.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "BXCL701, bempegaldesleukin and BAVENCIO", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data due 4Q 2020.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Agitation associated with dementia", 
    "name": "BXCL501 (TRANQUILITY)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 open label basket trial initial data due later in 2020.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Advanced solid tumors", 
    "name": "BXCL701 and pembrolizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data met primary and secondary endpoints - July 20, 2020.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Bipolar disorder - agitation", 
    "name": "BXCL501 (SERENITY II)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 top-line data due 1Q 2021.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Opioid Withdrawal Symptoms", 
    "name": "BXCL501 - RELEASE", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated later in 2020.", 
    "company": "BioXcel Therapeutics Inc.", 
    "indication": "Agitation associated with delirium (incl ICU patients with or without COVID-19)", 
    "name": "BXCL501", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due late September to the end of October 2020.", 
    "company": "BiondVax Pharmaceuticals Ltd.", 
    "indication": "Universal flu vaccine", 
    "name": "M-001", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data met both primary endpoints - June 10, 2020.", 
    "company": "BiondVax Pharmaceuticals Ltd.", 
    "indication": "Universal flu vaccine", 
    "name": "M-001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced February 20, 2020.", 
    "company": "Baudax Bio Inc.", 
    "indication": "Acute pain following bunionectomy surgery", 
    "name": "Intravenous (IV) meloxicam", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 final data due 2H 2020.", 
    "company": "BeyondSpring Inc.", 
    "indication": "Chemotherapy-induced neutropenia (CIN)", 
    "name": "Plinabulin (Trial 105)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 final data due 2H 2020.", 
    "company": "BeyondSpring Inc.", 
    "indication": "Non small cell lung cancer - refractory", 
    "name": "Plinabulin (Trial 103)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 interim top-line data due met primary endpoint - June 15, 2020. Final analysis expected in 2H 2020", 
    "company": "BeyondSpring Inc.", 
    "indication": "Chemotherapy-induced neutropenia (CIN)", 
    "name": "Plinabulin + TAC (Trial 106)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced October 4, 2018.", 
    "company": "BeyondSpring Inc.", 
    "indication": "Small-cell lung cancer (SCLC)", 
    "name": "Plinabulin + Opdivo +Yervoy ", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 safety data from the first cohort due 1H 2021.", 
    "company": "Cabaletta Bio Inc.", 
    "indication": "Pemphigus vulgaris", 
    "name": "DSG3-CAART", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data at ESMO 2019 noted HR 0.64. PFS 3.8 months.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Clear cell renal cell carcinoma", 
    "name": "CB-839 + AFINITOR (everolimus)â€Ž - ENTRATA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due late-4Q 2020 or early-1Q 2021.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Renal cell carcinoma", 
    "name": "CB-839 + Cabozantinib (CANTATA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiation announced March 26, 2019. Enrolment paused due to COVID-19. Set to resume 3Q 2020.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Triple negative breast cancer", 
    "name": "Telaglenastat (CB-839) plus talazoparib", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data at ESMO 2019 noted - 7% PR rate.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Solid tumors", 
    "name": "INCB001158", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b initiation of dosing announced July 13, 2020.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "CB-280", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 dose escalation has been completed and dose expansion cohorts are enrolling.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "KRAS-mutated colorectal cancer (CRC) and KRAS-mutated non-small cell lung cancer (NSCLC)", 
    "name": "Telaglenastat (CB-839) + palbociclib", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data presented at ASH December 2019.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Myelodysplastic Syndrome", 
    "name": "Telaglenastat (CB-839) and azacitidine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrolment to commence 3Q 2020 with interim data due 2021.", 
    "company": "Calithera Biosciences Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC) patients with genetic mutation NRF2/KEAP1", 
    "name": "Telaglenastat - Keapsake", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2020.", 
    "company": "Calliditas Therapeutics AB", 
    "indication": "IgA nephropathy", 
    "name": "Nefecon (NefIgArd)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 failed to meet endpoint - July 2016", 
    "company": "Can-Fite Biopharma Ltd Sponsored ADR (Israel)", 
    "indication": "Glaucoma", 
    "name": "Piclidenoson (CF101)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data did not meet primary endpoint - March 27, 2019. Phase 3 trial planned.", 
    "company": "Can-Fite Biopharma Ltd Sponsored ADR (Israel)", 
    "indication": "Cancer - advanced liver cancer second line", 
    "name": "Namodenoson (CF102)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 4Q 2020.", 
    "company": "Can-Fite Biopharma Ltd Sponsored ADR (Israel)", 
    "indication": "Rheumatoid arthritis", 
    "name": "Piclidenoson (CF101)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial did not meet primary endpoint late March 2015. Additional Phase 3 trial initiated with interim data due 4Q 2020.", 
    "company": "Can-Fite Biopharma Ltd Sponsored ADR (Israel)", 
    "indication": "Psoriasis", 
    "name": "Piclidenoson (CF101)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 endpoints met - April 7, 2020.", 
    "company": "Can-Fite Biopharma Ltd Sponsored ADR (Israel)", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Namodenoson (CF102)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned. ", 
    "company": "Can-Fite Biopharma Ltd Sponsored ADR (Israel)", 
    "indication": "COVID-19", 
    "name": "Piclidenoson", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released May 13, 2020.", 
    "company": "Capricor Therapeutics Inc.", 
    "indication": "Duchenne Muscular Dystrophy (DMD)", 
    "name": "CAP-1002 HOPE-2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released May 12, 2017 - primary endpoint unlikely to be met.", 
    "company": "Capricor Therapeutics Inc.", 
    "indication": "Myocardial infarction (heart attack)", 
    "name": "CAP-1002 ALLSTAR ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 completed. Waiting on data from additional study to determine future", 
    "company": "Capricor Therapeutics Inc.", 
    "indication": "Ambulatory heart failure", 
    "name": "Cenderitide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 IND submission has been filed.", 
    "company": "Capricor Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "CAP-1002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data released June 27, 2018. Company noted primary endpoint met but data mixed.", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Acute pain", 
    "name": "IV CR845", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data released June 29, 2017 - trial failed.", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Osteoarthritis (OA) ", 
    "name": "CR845 ", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Chronic Liver Disease-Associated Pruritus", 
    "name": "KORSUVA (CR845/difelikefalin) oral", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - May 29, 2019. ", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus", 
    "name": "KORSUVA (CR845/difelikefalin) injection - KALM-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - April 21, 2020. NDA filing due 4Q 2020.", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Chronic kidney disease (CKD) on hemodialysis (HD) with Moderate-to Severe Pruritus", 
    "name": "KORSUVA (CR845/difelikefalin) injection", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint but secondary missed - December 3, 2019. Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Stage 3-4 Chronic Kidney Disease-Associated Pruritus", 
    "name": "KORSUVA (CR845/difelikefalin) oral", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrollment to be completed 4Q 2020 with data due 1H 2021.", 
    "company": "Cara Therapeutics Inc.", 
    "indication": "Atopic dermatitis patients with moderate-to-severe pruritus", 
    "name": "KORSUVA (CR845/difelikefalin) oral", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 1Q 2021.", 
    "company": "CASI Pharmaceuticals Inc.", 
    "indication": "Multiple myeloma", 
    "name": "CID-103", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be completed 1Q 2021", 
    "company": "CASI Pharmaceuticals Inc.", 
    "indication": "Non-Hodgkin Lymphoma (NHL) / Acute lymphoblastic leukemia (ALL)", 
    "name": "CNCT19", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020. ", 
    "company": "Catabasis Pharmaceuticals Inc.", 
    "indication": "Duchenne muscular dystrophy (DMD)", 
    "name": "Edasalonexent (CAT-1004)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a did not meet primary endpoint - June 2016", 
    "company": "Catabasis Pharmaceuticals Inc.", 
    "indication": "Hypercholesterolemia", 
    "name": "CAT-2054 ", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 planned - to be initiated by Kowa Pharmaceuticals.", 
    "company": "CymaBay Therapeutics Inc.", 
    "indication": "Gout", 
    "name": "Arhalofenate", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 open-label data to be presented at EASL August 27, 2020.", 
    "company": "CymaBay Therapeutics Inc.", 
    "indication": "Primary biliary cholangitis (PBC)", 
    "name": "Seladelpar", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Clinical hold released July 23, 2020.", 
    "company": "CymaBay Therapeutics Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Seladelpar", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 trial to commence late-2020.", 
    "company": "Catalyst Biosciences Inc.", 
    "indication": "Hemophilia", 
    "name": "Marzeptacog alfa", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data presented at the virtual World Foundation of Hemophilia Virtual Summit, June 15, 2020 - 28 days of daily SQ dosing of DalcA achieved protective target FIX levels of >12% in all participants.", 
    "company": "Catalyst Biosciences Inc.", 
    "indication": "Hemophilia B", 
    "name": "Dalcinonacog alfa â€“ DalcA", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 extension trial ongoing.", 
    "company": "Cleveland BioLabs Inc.", 
    "indication": "Solid tumors", 
    "name": "ENTOLIMOD", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - May 18, 2020.", 
    "company": "ChemoCentryx Inc.", 
    "indication": "Focal Segmental Glomerulosclerosis", 
    "name": "CCX140 - LUMINA-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "NDA filing announced July 9, 2020.", 
    "company": "ChemoCentryx Inc.", 
    "indication": "Associated vasculitis (AAV)", 
    "name": "Avacopan - CCX168 (ADVOCATE)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2b data due early-4Q 2020.", 
    "company": "ChemoCentryx Inc.", 
    "indication": "Hidradenitis Suppurativa (HS)", 
    "name": "Avacopan  -AURORA", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data due year-end 2020.", 
    "company": "ChemoCentryx Inc.", 
    "indication": "C3 glomerulopathy (C3G)", 
    "name": "Avacopan - CCX168", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "ChemoCentryx Inc.", 
    "indication": "Focal Segmental Glomerulosclerosis and Nephrotic Syndrome", 
    "name": "CCX140 - LUMINA-2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 timeline for data release uncertain due to COVID-19 - noted May 13, 2020.", 
    "company": "Cidara Therapeutics Inc.", 
    "indication": "Candidemia", 
    "name": "Rezafungin (CD101) ReSTORE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released February 21, 2017 - efficacy not evident, Development to be discontinued.", 
    "company": "Cidara Therapeutics Inc.", 
    "indication": "Vulvovaginal candidiasis (VVC)", 
    "name": "CD101 Topical - RADIANT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 dosing of first patient announced May 20, 2020.", 
    "company": "Cidara Therapeutics Inc.", 
    "indication": "Prophylaxis", 
    "name": "Rezafungin (CD101) ReSPECT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released July 29, 2019 - noted all objectives met.", 
    "company": "Cidara Therapeutics Inc.", 
    "indication": "Candidemia", 
    "name": "Rezafungin (CD101) STRIVE B", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial met endpoints - November 8, 2018.", 
    "company": "Codexis Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "CDX-6114", 
    "stage": "phase1a"
  }, 
  {
    "newstxt": "Phase 1b initial data due 1Q 2021.", 
    "company": "Cerecor Inc.", 
    "indication": "Pediatric onset Crohn's disease", 
    "name": "CERC-002 (AEVI-002)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 top-line data released December 5, 2016 - endpoint not met.", 
    "company": "Cerecor Inc.", 
    "indication": "Smoking cessation", 
    "name": "CERC-501", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data released November 29, 2016 failed to meet primary endpoint.", 
    "company": "Cerecor Inc.", 
    "indication": "Major depressive disorder (MDD)", 
    "name": "CERC-301", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Pivotal trial expected start 4Q 2020, top line data expected 4Q 2021.", 
    "company": "Cerecor Inc.", 
    "indication": "Phosphoglucomutase 1 (PGM1) deficiency", 
    "name": "CERC 801", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Pivotal trial expected start 4Q 2020, top line data expected 3Q 2021.", 
    "company": "Cerecor Inc.", 
    "indication": "", 
    "name": "CERC-802", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 initial data in multiple myeloma due 1Q 2021 and top-line data in 2Q 2021. Initial data in adult onset Stillâ€™s Disease due by 2Q 2021.", 
    "company": "Cerecor Inc.", 
    "indication": "Adult Onset Still's Disease (AOSD) and Multiple Myeloma (MM)", 
    "name": "CERC-007", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data due 2Q 2021.", 
    "company": "Cerecor Inc.", 
    "indication": "Lymphatic Malformations", 
    "name": "CERC-006", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced July 21, 2020 with data due 4Q 2020.", 
    "company": "Cerecor Inc.", 
    "indication": "COVID-19 induced Acute Respiratory Distress Syndrome (ARDS)", 
    "name": "CERC-002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b resumption announced August 26, 2020 with top-line data due 1Q 2021.", 
    "company": "Cerecor Inc.", 
    "indication": "Crohnâ€™s disease (adults)", 
    "name": "CERC-002", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial met endpoints - January 23, 2018. CE mark submission due 2H 2018.", 
    "company": "Cerus Corporation", 
    "indication": "Chronic anemia in thalassemia patients", 
    "name": "INTERCEPT ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PMA approved Dec 18 2014", 
    "company": "Cerus Corporation", 
    "indication": "Platelets", 
    "name": "INTERCEPT ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PMA approved Dec 16 2014. Two COVID-19 patients were transfused with INTERCEPT treated coronavirus convalescent plasma (CCP) - noted April 2, 2020.", 
    "company": "Cerus Corporation", 
    "indication": "Plasma / COVID-19", 
    "name": "INTERCEPT", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 initiation announced December 19, 2018.", 
    "company": "Cerus Corporation", 
    "indication": "Patients undergoing complex cardiac surgery procedures", 
    "name": "INTERCEPT (ReCePI)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initiation of dosing announced January 10, 2020. Continues to enroll as of August 2020.", 
    "company": "ContraFect Corporation", 
    "indication": "Serious infections caused byStaph aureus including MRSA", 
    "name": "CF-301 exebacase", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 presentation at AACR April 27, 2020 noted disease control rates of 69% (11/16) for monotherapy and 75% (9/12) for combination arm. Initial data from monotherapy expansion cohort due 1H 2021.", 
    "company": "Compugen Ltd.", 
    "indication": "Solid tumors", 
    "name": "COM701 and Opdivo", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiated September 2018.", 
    "company": "Compugen Ltd.", 
    "indication": "Solid tumors", 
    "name": "BAY 1905254", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 2021.", 
    "company": "Compugen Ltd.", 
    "indication": "Advanced cancer", 
    "name": "COM902", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence 2H 2020.", 
    "company": "Compugen Ltd.", 
    "indication": "", 
    "name": "COM701, Opdivo and BMS-986207", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA approval announced June 26, 2020.", 
    "company": "Chiasma Inc.", 
    "indication": "Acromegaly", 
    "name": "Mycapssa - OPTIMAL", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL April 15 2016", 
    "company": "Chiasma Inc.", 
    "indication": "Acromegaly", 
    "name": "Mycapssa", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Chiasma Inc.", 
    "indication": "Maintenance treatment of adult acromegaly", 
    "name": "Mycapssa - MPOWERED", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released January 2016. Endpoints met. However, commercialization not possible in US before 2029 due to patent issues", 
    "company": "Coherus BioSciences Inc.", 
    "indication": "Rheumatoid arthritis  ", 
    "name": "CHS-0214", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "BLA filing due in 4Q 2020.", 
    "company": "Coherus BioSciences Inc.", 
    "indication": "Psoriasis", 
    "name": "CHS-1420", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 trial met endpoint November 2015. However, commercialization not possible in US before 2029 due to patent issues", 
    "company": "Coherus BioSciences Inc.", 
    "indication": "Psoriasis", 
    "name": "CHS-0214", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced November 2, 2018.", 
    "company": "Coherus BioSciences Inc.", 
    "indication": "Pegfilgrastim biosimilar", 
    "name": "CHS-1701", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA submission withdrawn due to request for additional manufacturing data - February 5, 2020. To be refiled 2H 2020.", 
    "company": "Coherus BioSciences Inc.", 
    "indication": "Biosimilar", 
    "name": "Lucentis Biosimilar", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "BLA filing due 2021.", 
    "company": "Coherus BioSciences Inc.", 
    "indication": "", 
    "name": "Avastin (bevacizumab) biosimilar", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "Checkpoint Therapeutics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "CK-101", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 additional data due at ESMO September 19-21, 2020 with full top-line data due 2021.", 
    "company": "Checkpoint Therapeutics Inc.", 
    "indication": "Cutaneous squamous cell carcinoma (CSCC)", 
    "name": "Cosibelimab (CK-301)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 top-line data did not meet primary endpoint - February 13, 2019.", 
    "company": "Caladrius Biosciences Inc.", 
    "indication": "Type 1 diabetes", 
    "name": "CLBS03 (The Sanford Project T-Rex Study)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Announced January 2016 that Phase 3 trial has been discontinued", 
    "company": "Caladrius Biosciences Inc.", 
    "indication": "Metastatic melanoma", 
    "name": "CLBS20 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated by late-2020.", 
    "company": "Caladrius Biosciences Inc.", 
    "indication": "Coronary microvascular dysfunction (CMD)", 
    "name": "CLBS16", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial will not be initiated until funding determined.", 
    "company": "Caladrius Biosciences Inc.", 
    "indication": "Angina", 
    "name": "CLBS14-NORDA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2021.", 
    "company": "Caladrius Biosciences Inc.", 
    "indication": "Critical Limb Ischemia (CLI)", 
    "name": "CLBS12", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to commence September 2020.", 
    "company": "Caladrius Biosciences Inc.", 
    "indication": "COVID-19 Induced Pulmonary Damage", 
    "name": "CLBS119", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued - noted August 6, 2020.", 
    "company": "Celldex Therapeutics Inc.", 
    "indication": "Recurrent/metastatic head and neck squamous cell cancer", 
    "name": "CDX-3379", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Trial discontinued early March 2016 as unlikely to meet primary endpoint", 
    "company": "Celldex Therapeutics Inc.", 
    "indication": "Cancer- glioblastoma multiforme (GBM) front line", 
    "name": "CDX-110 rindopepimut - ACT IV", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data released April 16, 2018 - primary endpoint not met.", 
    "company": "Celldex Therapeutics Inc.", 
    "indication": "Metastatic triple negative breast cancers that overexpress gpNMB", 
    "name": "Glembatumumab vedotin", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 data to be presented fall of 2020.", 
    "company": "Celldex Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "CDX-1140", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b trial to be initiated by the end of 2020, with data from the CIndU and CSU due 1Q 2021 and 2H 2021, respectively", 
    "company": "Celldex Therapeutics Inc.", 
    "indication": "Chronic spontaneous urticaria (CSU) / Chronic inducible urticaria (CINDU)", 
    "name": "CDX-0159", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced August 24, 2020.", 
    "company": "Celldex Therapeutics Inc.", 
    "indication": "Solid Tumors", 
    "name": "CDX-527", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Cellectis S.A.", 
    "indication": "Acute lymphoblastic leukemia (ALL)", 
    "name": "UCART19 (PALL)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing in dose expansion trial announced January 15, 2020. Update due by end of 2020.", 
    "company": "Cellectis S.A.", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "UCART123 - AMELI-01", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Cellectis S.A.", 
    "indication": "Refractory B-cell Acute Lymphoblastic Leukaemia", 
    "name": "UCART19 - CALM", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 clinical hold announced July 6, 2020 due to patient death.", 
    "company": "Cellectis S.A.", 
    "indication": "Multiple Myeloma", 
    "name": "UCARTCS1A -  MELANI01", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 commencement of enrolment announced December 2, 2019. Update due by end of 2020.", 
    "company": "Cellectis S.A.", 
    "indication": "Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)", 
    "name": "UCART22 -  BALLI-01", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data update February 19, 2020. Non-Hodgkinâ€™s lymphoma (NHL) - 42% ORR.", 
    "company": "Cellectar Biosciences Inc.", 
    "indication": "Various lymphoma", 
    "name": "CLR 131 - CLOVER-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial has been completed - February 19, 2020. ", 
    "company": "Cellectar Biosciences Inc.", 
    "indication": "Multiple myeloma", 
    "name": "CLR 131", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 presentation at the International Symposium on Pediatric Neuro-Oncology (ISPNO) annual meeting December 13-16, 2020.", 
    "company": "Cellectar Biosciences Inc.", 
    "indication": "Solid tumors", 
    "name": "CLR 131 (CLOVER-2)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data released May 31, 2018 - mixed data. 12.3 ETDRS letters compared to 13.5 ETDRS letters in control arm.", 
    "company": "Clearside Biomedical Inc.", 
    "indication": "Diabetic Macular Edema (DME)", 
    "name": "Suprachoroidal CLS-TA - TYBEE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data released November 5, 2018 did not meet primary endpoint.", 
    "company": "Clearside Biomedical Inc.", 
    "indication": "Macular edema associated with retinal vein occlusion (RVO)", 
    "name": "Suprachoroidal CLS-TA - SAPPHIRE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL received October 18, 2019. To resubmit 1H 2021.", 
    "company": "Clearside Biomedical Inc.", 
    "indication": "Macular edema associated with non-infectious uveitis", 
    "name": "XIPERE (Suprachoroidal CLS-TA)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial to commence enrollment 3Q 2020 with interim data from first cohort due by the end of 2020.", 
    "company": "Clearside Biomedical Inc.", 
    "indication": "Wet AMD using using subretinal delivery", 
    "name": "RGX-314", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020 with interim data due in 2021.", 
    "company": "Clearside Biomedical Inc.", 
    "indication": "Diabetic retinopathy ", 
    "name": "RGX-314 - ALTITUDE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2a trial to be initiated by the end of 2020 with initial safety data from the first cohort expected in mid-2021.", 
    "company": "Clearside Biomedical Inc.", 
    "indication": "Wet age-related macular degeneration", 
    "name": "CLS-AX", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 second analysis July 13, 2020 recommends trial be stopped due to futility.", 
    "company": "Celsion Corporation", 
    "indication": "Hepatocellular carcinoma - liver cancer", 
    "name": "ThermoDox - OPTIMA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 completion of enrollment due 2Q 2021. Patient data and trends due in 2021. PFS data to be reported 12 months following full patient enrollment.", 
    "company": "Celsion Corporation", 
    "indication": "Ovarian cancer", 
    "name": "GEN-1 OVATION 2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Final data released December 2015", 
    "company": "Celsion Corporation", 
    "indication": "Recurrent Chest Wall Breast Cancer (RCWBC)", 
    "name": "ThermoDox - Dignity", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b PFS data released October 24, 2018 - PFS of 17.1 months in ITT population.", 
    "company": "Celsion Corporation", 
    "indication": "Ovarian cancer", 
    "name": "GEN-1 OVATION 1", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "FDA Approval announced May 15, 2020.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Castrate-resistant prostate cancer (mCRPC)", 
    "name": "Rubraca (rucaparib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrolment has reached target enrolment. Top-line data due 2H 2021.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Ovarian Cancer - First-line maintenance treatment", 
    "name": "Opdivo and Rubraca ATHENA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced April 6, 2018.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Ovarian cancer patients with a BRCA-like mutation", 
    "name": "Rucaparib ARIEL3 ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date was June 28, 2016. Company expect CRL. Phase 3 TIGER-3 also terminated.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Mutant EGFR T790M-positive lung cancer", 
    "name": "Rociletinib ", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approved December 19, 2016. Original PDUFA date under priority review was February 23, 2017. ", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Cancer - ovarian second line", 
    "name": "Rucaparib ARIEL2", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial to be discontinued due to lack of efficacy - April 12, 2019.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Urothelial carcinoma", 
    "name": "Rucaparib - ATLAS", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 confirmatory trial is enrolling.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Relapsed ovarian cancer patients with BRCA mutations", 
    "name": "Rucaparib ARIEL4", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data presented at AACR April 2019. PFS 9.1 months.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Platinum-sensitive pancreatic cancer", 
    "name": "Rucaparib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b initial data to be presented at ESMO September 19-21, 2020. Phase 2 commencement of enrollment announced August 5, 2020.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "Lucitanib with Opdivo (LIO-1)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial update due fall of 2020.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Lucitanib with Rubraca (SEASTAR)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial initiated 4Q 2019.", 
    "company": "Clovis Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "Rucaparib - LODESTAR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b trial noted ORR of 28% - June 1, 2020.", 
    "company": "Checkmate Pharmaceuticals Inc.", 
    "indication": "Melanoma", 
    "name": "CMP-001 and pembrolizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 trial is ongoing. Interim data noted pathological Complete Response, or pCR, rate of 62%.", 
    "company": "Checkmate Pharmaceuticals Inc.", 
    "indication": "Melanoma", 
    "name": "CMP-001 and nivolumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Trial planned.", 
    "company": "Checkmate Pharmaceuticals Inc.", 
    "indication": "Head and neck squamous cell carcinoma (HNSCC)", 
    "name": "CMP-001 and pembrolizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Rolling NDA to be completed mid-2020.", 
    "company": "Chimerix Inc.", 
    "indication": "Smallpox", 
    "name": "Oral Brincidofovir", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued - May 9, 2019.", 
    "company": "Chimerix Inc.", 
    "indication": "Adult allo-HCT recipients with Adenovirus", 
    "name": "IV Brincidofovir", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued - May 9, 2019.", 
    "company": "Chimerix Inc.", 
    "indication": "Allogeneic hematopoietic stem cell transplant (HCT) recipients with adenovirus (AdV)", 
    "name": "Oral Brincidofovir - AdAPT Study", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim analysis released May 2016. Final data released February 22, 2017.", 
    "company": "Chimerix Inc.", 
    "indication": "Adenovirus Infection", 
    "name": "Brincidofovir - Advise trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 discontinued following poor data from SUPPRESS trial", 
    "company": "Chimerix Inc.", 
    "indication": "Cytomegalovirus (CMV) infection", 
    "name": "Brincidofovir - SURPASS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 endpoints not met December 2015", 
    "company": "Chimerix Inc.", 
    "indication": "Cytomegalovirus (CMV) infection following an allogeneic hematopoietic stem cell transplant (HSCT)", 
    "name": "Brincidofovir - SUPPRESS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 discontinued following poor data from SUPPRESS trial", 
    "company": "Chimerix Inc.", 
    "indication": "Cytomegalovirus (CMV) infection", 
    "name": "Brincidofovir - SUSTAIN ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation delayed due to COVID-19.", 
    "company": "Chimerix Inc.", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "DSTAT (CX-01)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced April 29, 2020. Data from the first safety cohort from the Phase 2 portion due 2H 2020.", 
    "company": "Chimerix Inc.", 
    "indication": "COVID-19", 
    "name": "DSTAT", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Concert Pharmaceuticals Inc.", 
    "indication": "Alopecia areata", 
    "name": "CTP-543", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - September 27, 2019.", 
    "company": "Concert Pharmaceuticals Inc.", 
    "indication": "Agitation in patients with Alzheimer's disease", 
    "name": "AVP-786", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 enrollment to be completed by end of 2020 with data due in 2021.", 
    "company": "Concert Pharmaceuticals Inc.", 
    "indication": "Schizophrenia", 
    "name": "CTP-692", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned for early 2021.", 
    "company": "CNS Pharmaceuticals Inc.", 
    "indication": "Glioblastoma", 
    "name": "Berubicin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Further Phase 2 data due later in 2020. Phase 3 trial to commence 2H 2020.", 
    "company": "Constellation Pharmaceuticals Inc.", 
    "indication": "Myelofibrosis", 
    "name": "CPI-0610 and ruxolitinib - Manifest-1/2", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial initiated.", 
    "company": "Constellation Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "CPI-1205 ORIOn-E", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data did not demonstrate the definitive signal of activity necessary to advance the program into pivotal studies - June 11, 2020.", 
    "company": "Constellation Pharmaceuticals Inc.", 
    "indication": "Castration-resistant prostate cancer", 
    "name": "CPI-1205 - ProSTAR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 recommended dose to be known 2H 2020.", 
    "company": "Constellation Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "CPI-0209", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2a updated data presented AASLD November 10, 2019.", 
    "company": "Cocrystal Pharma Inc.", 
    "indication": "Hepatitis C", 
    "name": "CC-31244", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2021.", 
    "company": "Cocrystal Pharma Inc.", 
    "indication": "Influenza", 
    "name": "CC-42344", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approval announced November 7, 2017.", 
    "company": "Collegium Pharmaceutical Inc.", 
    "indication": "Severe pain", 
    "name": "Xtampza ER (oxycodone)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved April 26 2016", 
    "company": "Collegium Pharmaceutical Inc.", 
    "indication": "Severe pain", 
    "name": "Xtampza ER (oxycodone) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved February 17, 2012.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Cushing's Syndrome", 
    "name": "Corlux - Korlym", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced November 19, 2018. NDA planned for 2Q 2022.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Cushingâ€™s syndrome", 
    "name": "Relacorilant (GRACE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Ovarian cancer", 
    "name": "Relacorilant plus Abraxane", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Miricorilant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 dose finding to be completed by end of 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Castration-resistant prostate cancer (CRPC)", 
    "name": "Exicorilant plus Enzalutamide", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 3Q 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Long-standing antipsychotic-induced weight gain (APIWG)", 
    "name": "Miricorilant (GRATITUDE 2)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 initiation announced June 30, 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Pancreatic cancer", 
    "name": "Relacorilant plus nab-paclitaxel (RELIANT)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 (GRATITUDE) trial enrolling.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Antipsychotic-induced weight gain (APIWG)", 
    "name": "Miricorilant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 initiation announced July 28, 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Cushingâ€™s syndrome", 
    "name": "Relacorilant (GRADIENT)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b 900 mg cohort data released May 4, 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Healthy volunteers", 
    "name": "Miricorilant", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial to be initiated 3Q 2020.", 
    "company": "Corcept Therapeutics Incorporated", 
    "indication": "Adrenocortical cancer", 
    "name": "Relacorilant plus Keytruda", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "CRL announced December 24, 2019.", 
    "company": "Correvio Pharma Corp.", 
    "indication": "Atrial fibrillation (AF)", 
    "name": "Brinavess", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2 trial has been completed.", 
    "company": "Cumberland Pharmaceuticals Inc.", 
    "indication": "Hepatorenal syndrome", 
    "name": "Ifetroban", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial has been completed.", 
    "company": "Cumberland Pharmaceuticals Inc.", 
    "indication": "Portal hypertension", 
    "name": "Ifetroban", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 additional trial ongoing.", 
    "company": "Cumberland Pharmaceuticals Inc.", 
    "indication": "Asthma", 
    "name": "Ifetroban", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Cumberland Pharmaceuticals Inc.", 
    "indication": "Cardiomyopathy associated with Duchenne Muscular Dystrophy", 
    "name": "Ifetroban", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due before the end of 2020.", 
    "company": "Catalyst Pharmaceuticals Inc.", 
    "indication": "Spinal Muscular Atrophy (SMA) Type 3", 
    "name": "Firdapse", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - August 10, 2020.", 
    "company": "Catalyst Pharmaceuticals Inc.", 
    "indication": "MuSK-antibody positive myasthenia gravis (MuSK-MG)", 
    "name": "Firdapse", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - October 30, 2019.", 
    "company": "Catalyst Pharmaceuticals Inc.", 
    "indication": "Congenital Myasthenic Syndromes (CMS)", 
    "name": "Firdapse", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced November 28, 2018.", 
    "company": "Catalyst Pharmaceuticals Inc.", 
    "indication": "Lambert-Easton Myasthenic Syndrome (LEMS)", 
    "name": "Firdapse", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b data due 3Q 2020.", 
    "company": "Corbus Pharmaceuticals Holdings Inc.", 
    "indication": "Cystic Fibrosis", 
    "name": "Lenabasum", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 enrollment to be completed late-2020 / early-2021.", 
    "company": "Corbus Pharmaceuticals Holdings Inc.", 
    "indication": "Systemic lupus erythematosus (SLE)", 
    "name": "Anabasum (Resunab)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2021.", 
    "company": "Corbus Pharmaceuticals Holdings Inc.", 
    "indication": "Dermatomyositis", 
    "name": "Lenabasum (resunab) - DETERMINE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due summer 2020.", 
    "company": "Corbus Pharmaceuticals Holdings Inc.", 
    "indication": "Systemic Sclerosis", 
    "name": "Resunab - RESOLVE-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial to commence in 2021.", 
    "company": "Corbus Pharmaceuticals Holdings Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "CRB-4001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 efficacy data presented at EHA June 2020. Of the 21 patients evaluable for efficacy in the completed Phase 1b dose escalation study, 7 (33%) achieved an objective response.", 
    "company": "Cardiff Oncology Inc.", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "Onvansertib (PCM-075)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 biomarker data were to be presented at AACR April 24-29, 2020. Postponed due to COVID-19.", 
    "company": "Cardiff Oncology Inc.", 
    "indication": "Prostate cancer", 
    "name": "Onvansertib (PCM-075) and Zytiga", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b/2 released April 28, 2020 - 3/7 partial responses. Further presentation at ASCO May 29, 2020 noted 4/9 ORR.", 
    "company": "Cardiff Oncology Inc.", 
    "indication": "KRAS-Mutated Colorectal Cancer", 
    "name": "Onvansertib, Folfiri and Avastin (bevacizumab)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data due later in 2020.", 
    "company": "Curis Inc.", 
    "indication": "Relapsed or Refractory Non-Hodgkin Lymphoma", 
    "name": "CA-4948", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approved January 30, 2012.", 
    "company": "Curis Inc.", 
    "indication": "Basal Cell Carcinoma", 
    "name": "Vismodegib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Development to be discontinued - noted March 19, 2020.", 
    "company": "Curis Inc.", 
    "indication": "Diffuse-large B-cell lymphoma (DLBCL)", 
    "name": "Fimepinostat (CUDC-907) and venetoclax", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1a/1b trial to be initiated 2H 2020.", 
    "company": "Curis Inc.", 
    "indication": "Solid tumors", 
    "name": "CI-8993", 
    "stage": "phase1a"
  }, 
  {
    "newstxt": "Phase 1 commencement of dosing announced July 7, 2020 with initial data due 4Q 2020.", 
    "company": "Curis Inc.", 
    "indication": "Acute Myeloid Leukemia / Myelodysplastic Syndromes", 
    "name": "CA-4948", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2H 2020.", 
    "company": "Curis Inc.", 
    "indication": "Non-Hodgkin Lymphoma (NHL)", 
    "name": "CA-4948 and ibrutinib", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "NDA filing announced July 8, 2020.", 
    "company": "CorMedix Inc.", 
    "indication": "Hemodialysis patients with central venous catheters", 
    "name": "Neutrolin - LOCK-IT 100", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 to be initiated pending funding.", 
    "company": "CorMedix Inc.", 
    "indication": "Oncology patients on Total Parental Nutrition (TPN)", 
    "name": "Neutrolin - LOCK-IT 200", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Crinetics Pharmaceuticals Inc.", 
    "indication": "Acromegaly", 
    "name": "CRN00808 - ACROBAT EVOLVE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 4Q 2020.", 
    "company": "Crinetics Pharmaceuticals Inc.", 
    "indication": "Acromegaly", 
    "name": "CRN00808 Paltusotine (ACROBAT EDGE)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data presented at EHA June 12, 2020. Patient was free of vaso-occlusive crises at 9 months after CTX001 infusion. Further data due 2H 2020.", 
    "company": "CRISPR Therapeutics AG", 
    "indication": "Sickle cell disease", 
    "name": "CTX001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data presented at EHA June 12, 2020. Two patients are transfusion independent at 5 and 15 months after infusion. Further data due 2H 2020.", 
    "company": "CRISPR Therapeutics AG", 
    "indication": "Beta-thalassemia", 
    "name": "CTX001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 top-line data due at the end of 2020.", 
    "company": "CRISPR Therapeutics AG", 
    "indication": "CD19+ malignancies", 
    "name": "CTX110", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 enrolment has commenced - noted February 12, 2020.", 
    "company": "CRISPR Therapeutics AG", 
    "indication": "Relapsed or refractory multiple myeloma", 
    "name": "CTX120", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 interim analysis to occur 4Q 2020. Final data due 4Q 2021.", 
    "company": "Cortexyme Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "COR388 - GAIN", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1b/2 initial data from the RCC cohort at ASCO May 29, 2020. AdenoSig positive group -ORR of 17%. AdenoSig negative group - no partial responses.", 
    "company": "Corvus Pharmaceuticals Inc.", 
    "indication": "Solid tumors - cancer", 
    "name": "CPI-444", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/1b updated data due at SITC November 10-14, 2020", 
    "company": "Corvus Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "CPI-006", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/1b updated data due at ASH December 5-8, 2020.", 
    "company": "Corvus Pharmaceuticals Inc.", 
    "indication": "Peripheral T-cell lymphoma (PTCL), cutaneous T-cell lymphoma (CTCL)", 
    "name": "CPI-818 (ASH)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation announced July 7, 2020. Data due later in 2020.", 
    "company": "Corvus Pharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "CPI-006", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data released July 9. 2018. Primary endpoint not met.", 
    "company": "CTI BioPharma Corp.", 
    "indication": "B-cell non-Hodgkin lymphoma", 
    "name": "PIXUVRI - PIX306 Trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 Spleen Volume Reduction (SVR) data due 2H 2021.", 
    "company": "CTI BioPharma Corp.", 
    "indication": "Myelofibrosis", 
    "name": "Pacritinib - PACIFICA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 - noted July 2016 that unlikely to have survival benefit", 
    "company": "CTI BioPharma Corp.", 
    "indication": "Ovarian cancer", 
    "name": "OPAXIO", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment of first patient announced June 1, 2020. Data due by end of 2020.", 
    "company": "CTI BioPharma Corp.", 
    "indication": "COVID-19", 
    "name": "Pacritinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial has been terminated - March 30, 2020.", 
    "company": "CytomX Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "PROCLAIM-CX-072-002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data presented at ASCO May 29, 2020 - generally well tolerated.", 
    "company": "CytomX Therapeutics Inc.", 
    "indication": "Solid Tumors or Lymphomas", 
    "name": "BMS-986249 and nivolumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2021. Enrolment has been paused due to COVID-19.", 
    "company": "CytomX Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "CX-2009 - PROCLAIM", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 presentation at ASCO May 29, 2020. 3/17 partial reponses.", 
    "company": "CytomX Therapeutics Inc.", 
    "indication": "Solid tumors / diffuse large B-cell lymphoma (DLBCL)", 
    "name": "PROCLAIM-CX-2029", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2a trial ongoing.", 
    "company": "CytomX Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "BMS-986288 and nivolumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 2H 2020.", 
    "company": "Citius Pharmaceuticals Inc.", 
    "indication": "Catheter related blood stream infection", 
    "name": "Mino-Lok", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial planned for 2H 2020.", 
    "company": "Citius Pharmaceuticals Inc.", 
    "indication": "Hemorrhoids", 
    "name": "CITI-002", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 trial cohort 5 initiation of dosing announced July 28, 2020.", 
    "company": "Cue Biopharma Inc.", 
    "indication": "HPV+ head and neck squamous cell carcinoma (HNSCC)", 
    "name": "CUE-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 2H 2020.", 
    "company": "Cue Biopharma Inc.", 
    "indication": "HPV16+ head and neck cancer", 
    "name": "CUE-101 and Keytruda - KEYNOTE-A78", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 ongoing.", 
    "company": "CureVac N.V.", 
    "indication": "Solid tumors", 
    "name": "CV8102", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "CureVac N.V.", 
    "indication": "Rabies", 
    "name": "CV7202", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 4Q 2020.", 
    "company": "CureVac N.V.", 
    "indication": "COVID-19", 
    "name": "COVID-19 vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "CureVac N.V.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "BI 1361849 (CV9202)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial has reached the required number of events to evaluate data - May 4, 2020.  Final analysis due following database lock. ", 
    "company": "Cel-Sci Corporation", 
    "indication": "Head and Neck cancer", 
    "name": "Multikine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b commencement of dosing announced August 24, 2020 with top-line data due 1Q 2021.", 
    "company": "CohBar Inc.", 
    "indication": "Nonalcoholic Fatty Liver Disease /  Obesity / Nonalcoholic steatohepatitis", 
    "name": "CB4211", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint", 
    "company": "Celyad SA", 
    "indication": "Chronic Heart Failure secondary to ischemic cardiomyopathy", 
    "name": "C-Cure - Chart 1 trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 expansion data due 2H 2020.", 
    "company": "Celyad SA", 
    "indication": "Various cancers - solid and hematologic cancers", 
    "name": "CYAD-01 - THINK", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 expansion cohort to begin enrollment 4Q 2020.", 
    "company": "Celyad SA", 
    "indication": "Colorectal cancer", 
    "name": "CYAD-101 - alloSHRINK", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data presented at SITC November 8, 2019.", 
    "company": "Celyad SA", 
    "indication": "Colorectal cancer", 
    "name": "CYAD-01 and FOLFOX - SHRINK", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dose escalation data due 2H 2020.", 
    "company": "Celyad SA", 
    "indication": "AML or myelodysplastic syndrome (MDS)", 
    "name": "CYAD-01 and chemotherapy (DEPLETHINK)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Celyad SA", 
    "indication": "Relapsed/refractory Acute myeloid leukemia (AML) and Myelodysplastic Syndrome (MDS)", 
    "name": "CYAD-02 CYCLE-1", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Noted mid-Dec 2014 that interim analysis suggests that trial will fail. Top-line data released February 23, 2017 that primary endpoint was not met. Complete remission (CR) improvement noted - secondary endpoint.", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "Acute myeloid leukemia - cancer", 
    "name": "Sapacitabine (SEAMLESS)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 updated data due 2020/2021.", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "Advanced cancers", 
    "name": "Fadraciclib CYC065", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial proof of concept data due 2020/2021.", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL)", 
    "name": "Fadraciclib and venetoclax", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b/2 initial data due 2020/2021.", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "BRCA mutant breast cancer", 
    "name": "Sapacitabine in combination with olaparib", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2020/2021.", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "Leukemias", 
    "name": "CYC140", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data at AACR April 1, 2019. 2/20 partial responses (PRs).", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "BRCA mutant breast cancer", 
    "name": "Sapacitabine and seliciclib", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 initial data due 2020/2021.", 
    "company": "Cyclacel Pharmaceuticals Inc.", 
    "indication": "Relapsed or refractory Acute myeloid leukemia or myelodysplastic syndrome (MDS)", 
    "name": "Sapacitabine and Venetoclax", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data due late-3Q 2020.", 
    "company": "Cyclerion Therapeutics Inc.", 
    "indication": "Sickle Cell disease", 
    "name": "Olinciguat (IW-1701) - STRONG-SCD", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - October 30, 2019.", 
    "company": "Cyclerion Therapeutics Inc.", 
    "indication": "Diabetic nephropathy", 
    "name": "IW-1973 (Praliciguat)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - October 30, 2019.", 
    "company": "Cyclerion Therapeutics Inc.", 
    "indication": "Heart failure HFpEF", 
    "name": "IW-1973 (Praliciguat)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 translational pharmacology top-line data due September 2020.", 
    "company": "Cyclerion Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "IW-6463", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2H 2020.", 
    "company": "Cyclerion Therapeutics Inc.", 
    "indication": "Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like Episodes (MELAS)", 
    "name": "IW-6463", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated early 2021.", 
    "company": "Cyclerion Therapeutics Inc.", 
    "indication": "Alzheimer's disease with vascular features (ADv)", 
    "name": "IW-6463", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Refusal to file letter announced July 13, 2020.", 
    "company": "CytoDyn Inc", 
    "indication": "HIV", 
    "name": "Leronlimab (PRO 140)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 initiation announced June 11, 2020.", 
    "company": "CytoDyn Inc", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Leronlimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to continue as planned following DSMB safety review. Interim analysis likely due 2H 2020.", 
    "company": "CytoDyn Inc", 
    "indication": "COVID-19 (critically ill)", 
    "name": "Leronlimab", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data released August 11, 2020 did not report primary endpoint data (TCSS at Day 14). Day 3 subgroup showed clinical improvement but not mentioned to be statistically significant. Secondary NEWS2 was met. No data on other secondary endpoints.", 
    "company": "CytoDyn Inc", 
    "indication": "COVID-19 (Mild to Moderate)", 
    "name": "Leronlimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.\n", 
    "company": "CytoDyn Inc", 
    "indication": "Triple Negative Breast Cancer", 
    "name": "Leronlimab (PRO 140)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "Reldesemtiv", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2020.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Acute heart failure", 
    "name": "Omecamtiv mecarbil GALACTIC-HF", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released November 21, 2017 - primary endpoint not met.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "Tirasemtiv - VITALITY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data did not meet endpoints - October 5, 2018.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Reldesemtiv (CK-2127107)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be completed early 2021.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Acute heart failure", 
    "name": "Omecamtiv mecarbil METEORIC-HF", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Hypertrophic cardiomyopathy (HCM)", 
    "name": "CK-3773274 - Redwood-HCM", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial is complete. Considering next steps.", 
    "company": "Cytokinetics Incorporated", 
    "indication": "Healthy volunteers", 
    "name": "AMG 594", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b data due 2021.", 
    "company": "Dare Bioscience Inc.", 
    "indication": "Female Sexual Arousal Disorder (FSAD)", 
    "name": "Sildenafil Cream, 3.6%", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Pivotal trial to commence 2H 2020 with data due in 2022.", 
    "company": "Dare Bioscience Inc.", 
    "indication": "Contraception", 
    "name": "Ovaprene", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due by the end of 2020.", 
    "company": "Dare Bioscience Inc.", 
    "indication": "Bacterial Vaginosis", 
    "name": "DARE-BV1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 initiation announced July 27, 2020. Data due 2021.", 
    "company": "Dare Bioscience Inc.", 
    "indication": "Hormone replacement therapy", 
    "name": "DARE-HRT1", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 data released February 2018.", 
    "company": "DBV Technologies S.A.", 
    "indication": "Cowâ€™s milk protein allergy (CMPA)", 
    "name": "Viaskin Milk", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "CRL issued August 4, 2020", 
    "company": "DBV Technologies S.A.", 
    "indication": "Peanut allergy - ages 4 to 11 years", 
    "name": "Viaskin Peanut", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 (Part B) enrolment expectations due 2H 2020.", 
    "company": "DBV Technologies S.A.", 
    "indication": "Peanut allergy - ages 1 to 3 years", 
    "name": "Viaskin Peanut (EPITOPE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 update due 4Q 2020.", 
    "company": "Deciphera Pharmaceuticals Inc.", 
    "indication": "Solid tumors or hematological malignancies", 
    "name": "DCC-3014", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced May 15, 2020.", 
    "company": "Deciphera Pharmaceuticals Inc.", 
    "indication": "Gastrointestinal Stromal Tumors (GIST) - fourth-line", 
    "name": "Ripretinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 4Q 2020.", 
    "company": "Deciphera Pharmaceuticals Inc.", 
    "indication": "Gastrointestinal Stromal Tumors (GIST) - second-line", 
    "name": "DCC-2618 - INTRIGUE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 data from ovarian cancer cohort to be presented at ESMO September 19-21, 2020.", 
    "company": "Deciphera Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "Rebastinib and paclitaxel", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b/2 data to be presented at ESMO September 19-22, 2020.", 
    "company": "Deciphera Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "Rebastinib and carboplatin", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data to be presented at ESMO September 19-22, 2020.", 
    "company": "Deciphera Pharmaceuticals Inc.", 
    "indication": "Gastrointestinal Stromal Tumors (GIST) - second-fourth line", 
    "name": "Ripretinib DCC-2618", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 top-line data due YE 2020 / Early 2021.", 
    "company": "Delcath Systems Inc.", 
    "indication": "Liver-dominant ocular melanoma", 
    "name": "Melphalan/HDS - FOCUS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial has been initiated.", 
    "company": "Delcath Systems Inc.", 
    "indication": "Intrahepatic Cholangiocarcinoma", 
    "name": "Melphalan/HDS - ALIGN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment in the randomization portion is contingent upon entering into a strategic partnership.", 
    "company": "Diffusion Pharmaceuticals Inc.", 
    "indication": "Glioblastoma (GBM)", 
    "name": "Trans sodium crocetinate (TSC)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Company noted March 24, 2020 that it expects delays in enrolment due to COVID-19. Previous guidance for data release was for 2022. ", 
    "company": "Diffusion Pharmaceuticals Inc.", 
    "indication": "Ischemic or hemorrhagic stroke", 
    "name": "Trans sodium crocetinate (TSC) - PHAST-TSC", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1a/b dosing to commence August 2020 with first data due early-4Q 2020. ", 
    "company": "Diffusion Pharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "Trans sodium crocetinate (TSC)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 primary safety and tolerability endpoints met - May 13, 2020.", 
    "company": "DiaMedica Therapeutics Inc.", 
    "indication": "Acute ischaemic stroke", 
    "name": "DM199 - Remedy", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation announced December 17, 2019. Enrollment has been slower than expected.", 
    "company": "DiaMedica Therapeutics Inc.", 
    "indication": "Chronic Kidney Disease (African Americans) ", 
    "name": "DM199", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "DiaMedica Therapeutics Inc.", 
    "indication": "Lupus", 
    "name": "DM199", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 trial planned for 2021.", 
    "company": "Denali Therapeutics Inc.", 
    "indication": "Parkinsonâ€™s disease", 
    "name": "DNL151", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated in 2021.", 
    "company": "Denali Therapeutics Inc.", 
    "indication": "Hunter syndrome", 
    "name": "DNL310", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 enrolment has been paused due to COVID-19.", 
    "company": "Denali Therapeutics Inc.", 
    "indication": "Healthy Volunteers", 
    "name": "DNL343", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Trials to commence in late-2020.", 
    "company": "Denali Therapeutics Inc.", 
    "indication": "Neurological indications", 
    "name": "DNL788", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b trial initiation announced July 29, 2020.", 
    "company": "Denali Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "DNL758 (SAR443122)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Development discontinued September 2016.", 
    "company": "Dicerna Pharmaceuticals Inc.", 
    "indication": "Hepatocellular carcinoma (HCC) - cancer", 
    "name": "DCR-MYC", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2/3 enrollment to be completed 4Q 2020. Last patient to complete the trial in 1H 2021. NDA filing due 3Q 2021.", 
    "company": "Dicerna Pharmaceuticals Inc.", 
    "indication": "Primary hyperoxaluria (PH)", 
    "name": "DCR-PHXC - PHYOX2", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 data released August 6, 2020.", 
    "company": "Dicerna Pharmaceuticals Inc.", 
    "indication": "Hepatitis B virus (HBV)", 
    "name": "RG6346 (DCR-HBVS)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 dosing to commence 1Q 2021.", 
    "company": "Dicerna Pharmaceuticals Inc.", 
    "indication": "Alpha-1 antitrypsin (A1AT) deficiency-associated liver disease", 
    "name": "DCR-A1AT", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 multi-dose data presented March 31, 2020. More detailed data due August 2020.", 
    "company": "Dicerna Pharmaceuticals Inc.", 
    "indication": "Primary hyperoxaluria (PH)", 
    "name": "DCR-PHXC - PHYOX3", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced July 27, 2018.", 
    "company": "DURECT Corporation", 
    "indication": "Schizophrenia", 
    "name": "RBP-7000", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 top-line data did not meet endpoints - January 2, 2020.", 
    "company": "DURECT Corporation", 
    "indication": "Psoriasis", 
    "name": "DUR-928", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "CRL issued February 12, 2014.", 
    "company": "DURECT Corporation", 
    "indication": "Post-operative pain relief ", 
    "name": "Posidur", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL Feb 12 2014. Advisory Committee meeting voted 6-6 January 16, 2020 regarding approval. PDUFA date of December 27, 2019 was not met due to the meeting. No guidance announced regarding new timeline.", 
    "company": "DURECT Corporation", 
    "indication": "Post-operative pain relief", 
    "name": "POSIMIR", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 1b top-line data released May 26, 2020.", 
    "company": "DURECT Corporation", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "DUR-928", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2b trial to commence 2H 2020.", 
    "company": "DURECT Corporation", 
    "indication": "Alcoholic hepatitis (AH)", 
    "name": "DUR-928", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 initiation announced July 1, 2020.", 
    "company": "DURECT Corporation", 
    "indication": "COVID-19 Patients with Acute Liver or Kidney Injury", 
    "name": "DUR-928", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 updated data due 4Q 2020.", 
    "company": "Precision BioSciences Inc.", 
    "indication": "Relapsed or refractory B-cell precursor acute lymphoblastic leukemia and R/R non-hodgkin lymphoma", 
    "name": "PBCAR0191", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 initiation of dosing announced April 7, 2020.", 
    "company": "Precision BioSciences Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL)", 
    "name": "PBCAR20A", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 dosing of first patient announced June 8, 2020.", 
    "company": "Precision BioSciences Inc.", 
    "indication": "Multiple myeloma", 
    "name": "PBCAR269A", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "CRL February 25, 2013 and November 14, 2016. Advisory Committee Meeting July 28, 2017 voted 21 -1 in favor of recommending approval. Final approval announced November 9, 2017.", 
    "company": "Dynavax Technologies Corporation", 
    "indication": "Hepatitis B", 
    "name": "HEPLISAV-B ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2a trial did not meet primary endpoint - November 29, 2018.", 
    "company": "Dynavax Technologies Corporation", 
    "indication": "Asthma", 
    "name": "AZD1419", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 completion of enrolment announced June 9, 2020 with final immunogenicity data due 4Q 2020.", 
    "company": "Dynavax Technologies Corporation", 
    "indication": "End Stage Renal Disease on Dialysis undergoing hemodialysis", 
    "name": "HEPLISAV-B", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation announced June 19, 2020 with preliminary safety and immunogenicity data due September 2020.", 
    "company": "Dynavax Technologies Corporation", 
    "indication": "COVID-19 vaccine", 
    "name": "SCB-2019 + adjuvant system (Clover)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 preliminary safety and immunogenicity results are expected in October 2020.", 
    "company": "Dynavax Technologies Corporation", 
    "indication": "COVID-19 vaccine", 
    "name": "CpG 1018 and Medicago candidate", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Open label safety trial data released April 24, 2017 and May 9, 2017.", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Acute inner ear tinnitus", 
    "name": "Keyzilen (AM-101) - AMPACT open-label", 
    "stage": ""
  }, 
  {
    "newstxt": "Phase 3 HEALOS trial did not meet primary endpoint - November 28, 2017. ", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Acute inner ear hearing loss", 
    "name": "AM-111 HEALOS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released March 13, 2018 - primary endpoint not met. Noted April 25, 2019 that it intends to discuss a new Phase 2/3 trial with the FDA.", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Acute inner ear tinnitus", 
    "name": "Keyzilen (AM-101)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 ASSENT trial terminated - November 28, 2017.", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Acute inner ear hearing loss", 
    "name": "AM-111 ASSENT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial (REACH) enrollment pending funding.", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Surgery-induced hearing loss", 
    "name": "AM-111 REACH", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoints", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Acute inner ear tinnitus", 
    "name": "AM-101 (Keyzilen) - TACTT2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 interim analysis due 3Q 2020.", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Vertigo", 
    "name": "AM-125", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data released May 26, 2020. Phase 2 trial planned.", 
    "company": "Auris Medical Holding Ltd.", 
    "indication": "Healthy volunteers", 
    "name": "AM-201", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial to commence in 2020.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "Influenza A", 
    "name": "FLU-IGIV", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved May 17, 2012.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "Anthrax Vaccine", 
    "name": "BioThrax", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved November 24, 2015.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "Anthrax Vaccine Adsorbed", 
    "name": "BioThrax ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved March 25, 2015.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "Anthrax", 
    "name": "Anthrax Immune Globulin Intravenous (Human) [AIGIV] ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 data released November 19, 2018 - primary endpoint met with favorable safety profile.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "Zika vaccine", 
    "name": "VLA1601", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in 2021.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "Chikungunya virus", 
    "name": "CHIKV-VLP", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 IND filing announced August 10, 2020.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "COVID-19 Vaccine", 
    "name": "Covid-19 vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 3Q 2020.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "COVID-19", 
    "name": "COVID-HIG", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 3Q 2020.", 
    "company": "Emergent Biosolutions Inc.", 
    "indication": "COVID-19", 
    "name": "COVID-EIG", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved November 9 2015", 
    "company": "EDAP TMS S.A.", 
    "indication": "Cancer - Low risk, localized prostate cancer", 
    "name": "Ablatherm-HIFU (High Intensity Focused Ultrasound) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial to commence in France September 2020.", 
    "company": "EDAP TMS S.A.", 
    "indication": "Rectal endometriosis", 
    "name": "Focal One HIFU", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 commencement of dosing announced March 4, 2020.", 
    "company": "Editas Medicine Inc.", 
    "indication": "Leber Congenital Amaurosis type 10 (LCA10).", 
    "name": "AGN-151587 (EDIT-101)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "IND filing due by the end of 2020.", 
    "company": "Editas Medicine Inc.", 
    "indication": "Sickle Cell Disease", 
    "name": "EDIT-301", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b trial ongoing.", 
    "company": "Edesa Biotech Inc.", 
    "indication": "Allergic contact dermatitis (ACD)", 
    "name": "EB01", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Proof of concept trial to be initiated in 2020.", 
    "company": "Edesa Biotech Inc.", 
    "indication": "Hemorrhoids disease (HD)", 
    "name": "EB01", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial to be initiated (Canada). IND also filed with U.S. July 30, 2020.", 
    "company": "Edesa Biotech Inc.", 
    "indication": "COVID-19 ", 
    "name": "EB05", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Pivotal trial planned for 2020.", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Breast cancer", 
    "name": "Fulvestrant", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Tentative approval announced October 27, 2017. Full approval pending patent litigation with Eli Lilly.", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Nonsquamous Non-Small Cell Lung Cancer (NSCLC) and Mesothelioma", 
    "name": "PEMFEXY,", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL announced August 10, 2020.", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Exertional heat stroke (EHS)", 
    "name": "Ryanodex", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Tentative approval July 2 2014. Teva has also received orphan drug and related pediatric exclusivity expiring in September 2015 and May 2016 for the CLL and NHL indications, respectively. ", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Chronic lymphocytic leukemia; Indolent non-Hodgkin's lymphoma - cancer", 
    "name": "EP-3101 (bendamustine RTD) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL March 18 2016. FDA requested further characterization of bivalirudin-related substances in the drug product", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Percutaneous Coronary Intervention (PCI) and Percutaneous Transluminal Coronary Angioplasty (PTCA)", 
    "name": "KANGIO (bivalirudin injection)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approved December 24, 2015.", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Breast, non-small cell lung, prostate gastric adenocarcinoma, and head and neck cancer", 
    "name": "Docetaxel Injection", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved July 22, 2014 under priority review.", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Malignant hyperthermia - cancer", 
    "name": "Ryanodex", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing due 2H 2020.", 
    "company": "Eagle Pharmaceuticals Inc.", 
    "indication": "Nerve agent (NA) exposure", 
    "name": "Ryanodex", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 1H 2021 with top-line data due 1H 2022.", 
    "company": "Eidos Therapeutics Inc.", 
    "indication": "ATTR-CM", 
    "name": "Acoramidis (AG10) - ATTRibute-CM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 2H 2020.", 
    "company": "Eidos Therapeutics Inc.", 
    "indication": "ATTR-PN", 
    "name": "AG10 / BBP-265", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released October 16, 2018 - endpoints met. Data presented at ENDO March 25, 2019.", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Post-Bariatric Hypoglycemia (PBH)", 
    "name": "Avexitide (Exendin 9-39)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be completed in 2021. ", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Chronic hepatitis delta virus (HDV)", 
    "name": "Lonafarnib - D-LIVR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet endpoints - January 16, 2018.", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "Ubenimex - LIBERTY ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released October 16, 2018 did not meet endpoints.", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Secondary lymphedema", 
    "name": "Ubenimex - ULTRA ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b negative data released April 2015. Formerly CLDN pre-merger", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Ischemic or dilated cardiomyopathy", 
    "name": "MYDICAR - CUPID 2 Trial", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 additional data expected at EASL August 27â€“29, 2020", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Hepatitis delta virus (HDV)", 
    "name": "Pegylated interferon lambda + ritonavir (RTV)-boosted lonafarnib (LNF) - LIFT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date under priority review November 20, 2020.", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "Hutchinson-Gilford Progeria Syndrome (HGPS)", 
    "name": "Lonafarnib", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 2 commencement of dosing announced April 30, 2020.", 
    "company": "Eiger BioPharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "Peginterferon lambda (Lambda)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrollment has resumed following pause due to the COVID-19 pandemic.", 
    "company": "Eloxx Pharmaceuticals Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "ELX-02", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released January 14, 2020.", 
    "company": "Eloxx Pharmaceuticals Inc.", 
    "indication": "Cystinosis", 
    "name": "ELX-02", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Advisory Committee Meeting March 14, 2017 voted 18 to eight that the benefits of reformulated OPANA ER  no longer outweigh its risks.\n", 
    "company": "Endo International plc", 
    "indication": "Management of pain", 
    "name": "OPANA ER", 
    "stage": ""
  }, 
  {
    "newstxt": "Approved October 26, 2015.", 
    "company": "Endo International plc", 
    "indication": "Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment for which alternative treatment options are inadequate", 
    "name": "BEMA Buprenorphine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued May 30 2013. Approved March 6 2014.", 
    "company": "Endo International plc", 
    "indication": "Men diagnosed with hypogonadism", 
    "name": "AVEED (testosterone undecanoate) intramuscular injection", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced July 6, 2020.", 
    "company": "Endo International plc", 
    "indication": "Edematous fibrosclerotic panniculopathy (“cellulite”)", 
    "name": "QWO", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2Q 2021.", 
    "company": "Enlivex Therapeutics Ltd.", 
    "indication": "GvHD - steroid refractory", 
    "name": "Allocetra", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated 4Q 2020.", 
    "company": "Enlivex Therapeutics Ltd.", 
    "indication": "Prevention of cytokine storms in Sepsis", 
    "name": "Allocetra", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2/3 trial to be initiated 1Q 2020.", 
    "company": "Enlivex Therapeutics Ltd.", 
    "indication": "Prevention of GvHD & Transplant Complications", 
    "name": "Allocetra", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 initiation of dosing announced August 10, 2020.", 
    "company": "Enlivex Therapeutics Ltd.", 
    "indication": "COVID-19", 
    "name": "Allocetra", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 3Q 2021.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Respiratory Syncytial Virus", 
    "name": "EDP-938", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b trial dosing is ongoing.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "EDP-305 ARGON-2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data did not meet primary endpoint - May 6, 2020.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Primary biliary cholangitis (PBC)", 
    "name": "EDP-305 INTREPID", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval announced August 3, 2017.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Hepatitis C virus (HCV)", 
    "name": "Glecaprevir/Pibrentasvir (G/P) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved December 19, 2014.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "HCV - genotype 1", 
    "name": "VIEKIRA PAK", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved July 25, 2017.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "HCV - genotype", 
    "name": "VIEKIRA PAK - once-daily, fixed-dose formulation through Abbvie", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 new data to be presented at EASL August 29, 2020. Phase 1b initial data due 1H 2021.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Hepatitis B virus (HBV)", 
    "name": "EDP-514", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 3Q 2020 with data due 2Q 2021.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "EDP-297", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b top-line data due 2Q 2021.", 
    "company": "Enanta Pharmaceuticals Inc.", 
    "indication": "Hepatitis B - NUC-Suppressed", 
    "name": "EDP-514", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 biomarker data from the higher dose groups due 1Q 2021 with full 6-month data due 2Q 2021.", 
    "company": "Entera Bio Ltd.", 
    "indication": "Osteoporosis", 
    "name": "EB613", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b or Phase 3 trial to be initiated in 2021. ", 
    "company": "Entera Bio Ltd.", 
    "indication": "Hypoparathyroidism", 
    "name": "EB612", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "FDA Approval announced February 1, 2019.", 
    "company": "Evolus Inc.", 
    "indication": "Glabellar lines", 
    "name": "DWP-450", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced July 15, 2020.", 
    "company": "ESSA Pharma Inc.", 
    "indication": "Castrate resistant prostate cancer", 
    "name": "EPI-7386", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 dosing commenced August 2016. Noted April 23, 2018 that all Tazemetostat trials have been placed on partial clinical hold. ", 
    "company": "Epizyme Inc.", 
    "indication": "Adult patients with mesothelioma characterized by BAP1 loss-of-function", 
    "name": "Tazemetostat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced June 18, 2020.", 
    "company": "Epizyme Inc.", 
    "indication": "Follicular lymphoma", 
    "name": "Tazemetostat", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced January 23, 2020.", 
    "company": "Epizyme Inc.", 
    "indication": "Epithelioid Sarcoma", 
    "name": "Tazemetostat", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1b enrollment complete.", 
    "company": "Epizyme Inc.", 
    "indication": "Relapsed or refractory diffuse large B-cell lymphoma (DLBCL)", 
    "name": "Tazemetostat + Atezolizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b data released August 10, 2020. Across the first two dose cohorts 71% of patients achieved a CR by Day 29", 
    "company": "Equillium Inc.", 
    "indication": "Acute graft-versus-host disease", 
    "name": "EQ001 - itolizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b enrolment has resumed following paused due to COVID-19 - July 13, 2020.", 
    "company": "Equillium Inc.", 
    "indication": "Asthma", 
    "name": "EQ001 - itolizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b enrolment has resumed following pause due to COVID-19 - July 13, 2020.", 
    "company": "Equillium Inc.", 
    "indication": "Systemic lupus erythematosus (SLE) and lupus nephritis (LN)", 
    "name": "EQ001 - itolizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 trial completed.", 
    "company": "Erytech Pharma S.A.", 
    "indication": "Hemorrhoids", 
    "name": "Hydro-Lido", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 interim superiority analysis expected around end of 2020; final analysis due 2H 2021.", 
    "company": "Erytech Pharma S.A.", 
    "indication": "Pancreatic cancer", 
    "name": "Eryaspase (Trybeca-1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 interim update noted eryaspase achieved the target level and duration of asparaginase activity - June 9, 2020. Full data 4Q 2020.", 
    "company": "Erytech Pharma S.A.", 
    "indication": "Acute lymphoblastic leukemia (ALL)", 
    "name": "Eryaspase (NOR-GRASPALL-2016)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Erytech Pharma S.A.", 
    "indication": "Triple-Negative Breast Cancer (TNBC)", 
    "name": "Eryaspase (GRASPA) - TRYbeCA2", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 enrolment to commence 2H 2020.", 
    "company": "Erytech Pharma S.A.", 
    "indication": "Pancreatic cancer", 
    "name": "Eryaspase in combination with FOLFIRINOX", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA approval announced February 26, 2020.", 
    "company": "Esperion Therapeutics Inc.", 
    "indication": "Hypercholesterolemia", 
    "name": "Bempedoic Acid/ Ezetimibe", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced February 21, 2020.", 
    "company": "Esperion Therapeutics Inc.", 
    "indication": "Hypercholesterolemia ", 
    "name": "Bempedoic acid", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial met primary endpoint - August 29, 2019.", 
    "company": "Esperion Therapeutics Inc.", 
    "indication": "LDL-C and type 2 diabetes", 
    "name": "Bempedoic Acid/ Ezetimibe (1002-058)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 completion of enrolment announced September 5, 2019. Trial to be completed in 2H 2022.", 
    "company": "Esperion Therapeutics Inc.", 
    "indication": "Cardiovascular Diseases", 
    "name": "Bempedoic Acid (ETC-1002) CLEAR Outcomes", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 3Q 2020.", 
    "company": "89bio Inc.", 
    "indication": "Severe hypertriglyceridemia", 
    "name": "BIO89-100", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b/2 trial top-line data late-3Q to early-4Q 2020.", 
    "company": "89bio Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "BIO89-100", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "PDUFA date August 10, 2020 extended to September 15, 2020.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Allergic conjunctivitis", 
    "name": "EM-100", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Rolling NDA filing announced March 14, 2019. However, third-party has been granted five years of market exclusivity.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Nutritional deficiencies", 
    "name": "DS-200", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "aNDA filed. GDUFA target action date in October 2020. Paragraph IV litigation likely to delay the productâ€™s final approval.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Nutritional deficiencies", 
    "name": "DS-300", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA Approval announced October 22, 2019.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Injectable hospital product", 
    "name": "ET-202", 
    "stage": "approved"
  }, 
  {
    "newstxt": "NDA filing to be resubmitted 2H 2020.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Injectable hospital product", 
    "name": "ET-203", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "NDA filing announced July 30, 2020.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Neurological indication", 
    "name": "ET-104", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "CRL issued March 17, 2020. Additional trial required.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Lennox-Gastaut syndrome, epilepsy", 
    "name": "EM-105", 
    "stage": "crl"
  }, 
  {
    "newstxt": "NDA filing due 2H 2020.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Oral solution of topiramate", 
    "name": "ET-101", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "NDA filing announced July 27, 2020.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Methanol poisoning", 
    "name": "DS-100", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "PDUFA date September 29, 2020.", 
    "company": "Eton Pharmaceuticals Inc.", 
    "indication": "Pediatric adrenal insufficiency (AI) ", 
    "name": "Alkindi Sprinkle", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 top-line data timeline unsure due to COVID-19.", 
    "company": "Entasis Therapeutics Holdings Inc.", 
    "indication": "Complicated urinary tract infections (cUTI)", 
    "name": "ETX0282CPDP", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 top-line data timeline unsure due to COVID-19.", 
    "company": "Entasis Therapeutics Holdings Inc.", 
    "indication": "Acinetobacter baumannii infections", 
    "name": "ETX2514SUL (ATTACK)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Entasis Therapeutics Holdings Inc.", 
    "indication": "Uncomplicated gonorrhea", 
    "name": "Zoliflodacin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data met primary endpoint - December 2, 2019.", 
    "company": "Evofem Biosciences Inc.", 
    "indication": "Prevention of urogenital Chlamydia trachomatis infection in women", 
    "name": "Amphora - AMPREVENCE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "FDA Approval announced May 22, 2020.", 
    "company": "Evofem Biosciences Inc.", 
    "indication": "contraceptive vaginal gel", 
    "name": "Amphora - AMPOWER", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to commence 4Q 2020 with data due in 2022.", 
    "company": "Evofem Biosciences Inc.", 
    "indication": "Chlamydia and gonorrhea", 
    "name": "EVO100", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Development to be discontinued - noted February 13, 2020.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "Psoriasis or atopic dermatitis", 
    "name": "EDP1066", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a trial ongoing - no longer providing guidance as to timing of data.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "Melanoma", 
    "name": "EDP1503 and KEYTRUDA (pembrolizumab)", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 3Q 2020 with data due mid-2021.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "Mild to moderate psoriasis", 
    "name": "EDP1815", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 initial data due 4Q 2020.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "Colorectal cancer; Triple-negative breast cancer", 
    "name": "EDP1503 and KEYTRUDA (pembrolizumab)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b data due 1Q 2021.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "EDP1815", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial to be initiated 1Q 2021.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "Asthma", 
    "name": "EDP1867", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2/3 interim data due 4Q 2020.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "COVID-19", 
    "name": "EDP1815 - TACTIC-E", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Evelo Biosciences Inc.", 
    "indication": "COVID-19", 
    "name": "EDP1815-205", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced June 19, 2020.", 
    "company": "Evoke Pharma Inc.", 
    "indication": "Diabetic gastroparesis", 
    "name": "Gimoti - EVK-001", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved August 2014", 
    "company": "Exact Sciences Corporation", 
    "indication": "Cancer - Colorectal DNA test", 
    "name": "Cologuard", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - June 20, 2019.", 
    "company": "Exelixis Inc.", 
    "indication": "First-line BRAF wild-type metastatic or unresectable locally advanced melanoma", 
    "name": "IMspire170 - cobimetinib and atezolizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released May 10, 2018. Primary endpoint not met.", 
    "company": "Exelixis Inc.", 
    "indication": "Third-line advanced or metastatic colorectal cancer", 
    "name": "IMblaze370 - cobimetinib and atezolizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA filing announced August 24, 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "First-line renal cell carcinoma", 
    "name": "CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Approved November 29, 2012.", 
    "company": "Exelixis Inc.", 
    "indication": "Medullary thyroid cancer", 
    "name": "Cabozantinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Late breaker at ESMO September 10, 2017 showed PFS 8.6 months versus 5.3 months for sunitinib. HR 0.48. PDUFA date under priority review for sNDA February 15, 2018. Approval announced December 19, 2017.", 
    "company": "Exelixis Inc.", 
    "indication": "First-Line RCC - cancer", 
    "name": "Cabozantinib - CABOSUN", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced January 14, 2019.", 
    "company": "Exelixis Inc.", 
    "indication": "Advanced hepatocellular cancer (HCC)", 
    "name": "Cabozantinib (CELESTIAL)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved April 25 2016.", 
    "company": "Exelixis Inc.", 
    "indication": "Metastatic renal cell cancer (RCC)", 
    "name": "CABOMETYX (cabozantinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved November 10, 2015.", 
    "company": "Exelixis Inc.", 
    "indication": "BRAF V600 Mutation-Positive Advanced Melanoma - Cancer", 
    "name": "Vemurafenib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 COMET-2 trial did not meet endpoint December 1 2014", 
    "company": "Exelixis Inc.", 
    "indication": "Cancer - Castration-Resistant Prostate Cancer", 
    "name": "Cabozantinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 2H 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "Thyroid Carcinoma", 
    "name": "Cabozantinib - COSMIC-311", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data due late-4Q 2020 or early-1Q 2021.", 
    "company": "Exelixis Inc.", 
    "indication": "Renal cell carcinoma", 
    "name": "CB-839 + Cabozantinib (CANTATA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced July 30, 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma", 
    "name": "IMspire150 - cobimetinib, atezolizumab and vemurafenib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced June 11, 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "Solid tumors", 
    "name": "Cabozantinib + atezolizumab (TECENTRIQ) CONTACT-01", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Exelixis Inc.", 
    "indication": "Hepatocellular Carcinoma", 
    "name": "CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Exelixis Inc.", 
    "indication": "Renal Cell Carcinoma", 
    "name": "Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 4 PFS data due 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "Medullary Thyroid Cancer", 
    "name": "Cabozantinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b ORR 19% (cabozantinib and nivolumab) /29% (cabozantinib, nivolumab and ipilimumab) - January 24, 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "Hepatocellular cancer", 
    "name": "Cabozantinib /nivolumab and ipilimumab (CM-040)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 initiation announced June 30, 2020.", 
    "company": "Exelixis Inc.", 
    "indication": "Castration-Resistant Prostate Cancer", 
    "name": "Cabozantinib and Atezolizumab - CONTACT-02", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial is enrolling.", 
    "company": "Exelixis Inc.", 
    "indication": "Renal Cell Carcinoma", 
    "name": "Cabozantinib and Atezolizumab (CONTACT-03)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data released February 5, 2018 - co-primary endpoints not met.", 
    "company": "Eyegate Pharmaceuticals Inc.", 
    "indication": "Ocular inflammation and pain post cataract surgery ", 
    "name": "EGP-437", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 data did not demonstrate non-inferiority - September 4, 2018.", 
    "company": "Eyegate Pharmaceuticals Inc.", 
    "indication": "Non-infectious anterior uveitis", 
    "name": "EGP-437", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PRK pivotal trial met primary endpoint - November 22, 2019.", 
    "company": "Eyegate Pharmaceuticals Inc.", 
    "indication": "Wound healing", 
    "name": "Ocular Bandage Gel", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Data from follow-on pilot trial released March 31, 2020.", 
    "company": "Eyegate Pharmaceuticals Inc.", 
    "indication": "Dry eye disease", 
    "name": "Ocular Bandage Gel eye drop", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 resumption of enrolment following COVID-19 announced June 30, 2020.", 
    "company": "Eyenovia Inc.", 
    "indication": "Myopia", 
    "name": "MicroPine - CHAPERONE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Development to be deferred - noted October 29, 2019.", 
    "company": "Eyenovia Inc.", 
    "indication": "Dry eye disease", 
    "name": "MicroTears", 
    "stage": ""
  }, 
  {
    "newstxt": "NDA filing due 2020.", 
    "company": "Eyenovia Inc.", 
    "indication": "Mydriasis - pupil dilation", 
    "name": "MicroStat", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Development to be deferred - noted October 29, 2019.", 
    "company": "Eyenovia Inc.", 
    "indication": "Chronic angle closure glaucoma (CACG)", 
    "name": "MicroProst", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in 2020.", 
    "company": "Eyenovia Inc.", 
    "indication": "Presbyopia", 
    "name": "MicroLine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL Nov 2011. Second CRL Oct 17 2013. Approved Sept 26 2014", 
    "company": "EyePoint Pharmaceuticals Inc.", 
    "indication": "Diabetic macular edema", 
    "name": "Iluvien", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 15, 2018.", 
    "company": "EyePoint Pharmaceuticals Inc.", 
    "indication": "Non-infectious uveitis", 
    "name": "YUTIQ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing planned.", 
    "company": "EyePoint Pharmaceuticals Inc.", 
    "indication": "Non-infectious uveitis", 
    "name": "Yutiq", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Fate Therapeutics Inc.", 
    "indication": "Acute graft-versus-host disease (GvHD) undergoing hematopoietic cell transplantation (HCT)", 
    "name": "ProTmune - PROTECT", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 dosing commenced February 2019. No dose-limiting toxicities related SAEs - noted December 7, 2019.", 
    "company": "Fate Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "FT500", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing. Noted complete neutrophil recovery observed in first AML patient - December 7, 2019.", 
    "company": "Fate Therapeutics Inc.", 
    "indication": "Acute Myelogenous Leukemia", 
    "name": "FT516", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - noted April 2, 2020.", 
    "company": "Fate Therapeutics Inc.", 
    "indication": "B-Cell Chronic Lymphoma, chronic lymphocytic leukemia", 
    "name": "FT596", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Fate Therapeutics Inc.", 
    "indication": "Acute myeloid leukemia (AML) / multiple myeloma.", 
    "name": "FT538", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated. IND acceptance announced July 9, 2020.", 
    "company": "Fate Therapeutics Inc.", 
    "indication": "B-cell Leukemias and Lymphomas", 
    "name": "FT819", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "CK-101", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 MBIO IND to be filed 4Q 2020.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Glioblastoma", 
    "name": "MB-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "None", 
    "company": "Fortress Biotech Inc.", 
    "indication": "", 
    "name": "", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data in adults due 2022.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Severe Traumatic Brain Injury", 
    "name": "CEVA101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data in children due 2H 2020.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Severe Traumatic Brain Injury", 
    "name": "CEVA101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Rolling NDA submission expected to start in 4Q 2020.\n", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Menkes disease", 
    "name": "CUTX-101", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "PDUFA date October 10, 2020.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Postoperative pain following bunionectomy surgery", 
    "name": "Intravenous (IV) tramadol", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 trial planned with top-line data due 2H 2022.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "X-linked Severe Combined Immunodeficiency (XSCID)", 
    "name": "MB-107", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due at ASH December 5-8, 2020.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)", 
    "name": "MB-106", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 1H 2020.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Cytomegalovirus (CMV)", 
    "name": "Triplex", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 first data due 1Q 2021.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Prostate cancer", 
    "name": "MB-105", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 commencement of dosing announced October 24, 2019.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Glioblastoma multiforme", 
    "name": "MB-108", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 IND to be filed 3Q 2020.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "X-linked severe combined immunodeficiency (XSCID)", 
    "name": "MB-207", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 additional data due at ESMO September 19-21, 2020 with full top-line data due 2021.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Cutaneous squamous cell carcinoma (CSCC)", 
    "name": "Cosibelimab (CK-301)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 first data due 2021.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "Multiple Myeloma ", 
    "name": "MB-104", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 first data due 2021.", 
    "company": "Fortress Biotech Inc.", 
    "indication": "GBM and Metastatic Breast Cancer to Brain", 
    "name": "MB-103", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "CRL announced August 10, 2020.", 
    "company": "Fennec Pharmaceuticals Inc.", 
    "indication": "Cisplatin-Induced Hearing Loss ", 
    "name": "Pedmark (sodium thiosulfate)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "PDUFA date December 20, 2020. ", 
    "company": "FibroGen Inc", 
    "indication": "Anaemia in Chronic Kidney Disease", 
    "name": "Roxadustat", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "FibroGen Inc", 
    "indication": "Myelodysplastic syndromes (MDS)", 
    "name": "Roxadustat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrollment announced August 10, 2020.", 
    "company": "FibroGen Inc", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "Pamrevlumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced July 22, 2019. Second Phase 3 trial to be initiated later in 2020.", 
    "company": "FibroGen Inc", 
    "indication": "Idiopathic pulmonary fibrosis", 
    "name": "Pamrevlumab (FG-3019) - ZEPHYRUS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initiation of dosing announced October 23, 2019.", 
    "company": "FibroGen Inc", 
    "indication": "Pancreatic cancer", 
    "name": "Pamrevlumab (LAPIS)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced September 26, 2019.", 
    "company": "FibroGen Inc", 
    "indication": "Chemotherapy-induced anemia (CIA)", 
    "name": "Roxadustat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 commencement of enrolment in Italy trial announced June 8, 2020.", 
    "company": "FibroGen Inc", 
    "indication": " COVID-19", 
    "name": "Pamrevlumab - Borea", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced June 23, 2020.", 
    "company": "FibroGen Inc", 
    "indication": "COVID-19", 
    "name": "Pamrevlumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 update due 3Q/4Q 2020.", 
    "company": "Homology Medicines Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "HMI-102", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued - noted November 7, 2019.", 
    "company": "Flexion Therapeutics Inc.", 
    "indication": "Osteoarthritis of the hip", 
    "name": "Zilretta", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced October 6, 2017.", 
    "company": "Flexion Therapeutics Inc.", 
    "indication": "Osteoarthritis of the knee ", 
    "name": "Zilretta - FX006", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 26, 2019. New label notes that efficacy and safety of repeat administration of ZILRETTA have not been demonstrated.", 
    "company": "Flexion Therapeutics Inc.", 
    "indication": "Osteoarthritis of the knee", 
    "name": "Zilretta - FX006 label update", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial has been suspended due to COVID-19.", 
    "company": "Flexion Therapeutics Inc.", 
    "indication": "Shoulder osteoarthritis (OA) and frozen shoulder", 
    "name": "Zilretta - FX006", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 enrollment has resumed following pause due to COVID-19.", 
    "company": "Flexion Therapeutics Inc.", 
    "indication": "Osteoarthritis (OA)", 
    "name": "FX201", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 additional data due 2H 2020.", 
    "company": "Forma Therapeutics Holdings Inc.", 
    "indication": "Sickle cell disease", 
    "name": "FT-4202", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 4Q 2020.", 
    "company": "Forma Therapeutics Holdings Inc.", 
    "indication": "Prostate cancer (CRPC)", 
    "name": "FT-7051", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "Forma Therapeutics Holdings Inc.", 
    "indication": "Acute myeloid leukemia", 
    "name": "FT-2102", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Forma Therapeutics Holdings Inc.", 
    "indication": "Glioma", 
    "name": "FT-2102", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced August 10, 2018.", 
    "company": "Amicus Therapeutics Inc.", 
    "indication": "Fabry Disease", 
    "name": "Migalastat", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 top-line data released September 13, 2017 - endpoints not met.", 
    "company": "Amicus Therapeutics Inc.", 
    "indication": "Epidermolysis Bullosa (EB)", 
    "name": "SD-101 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 additional data due at Child Neurology Society Annual Meeting in October 19 - 23, 2020.", 
    "company": "Amicus Therapeutics Inc.", 
    "indication": "Batten disease", 
    "name": "CLN6 Gene Therapy", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Rolling BLA filing to be submitted 2H 2020. To be completed with full data 1H 2021.", 
    "company": "Amicus Therapeutics Inc.", 
    "indication": "Pompe Disease", 
    "name": "AT-GAA - Propel", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 initial data due early 2021.", 
    "company": "Amicus Therapeutics Inc.", 
    "indication": "Batten disease", 
    "name": "AAV9-CLN3", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data due late-2020 or early-2021.", 
    "company": "Five Prime Therapeutics Inc.", 
    "indication": "Gastric and gastro-esophageal junction cancer", 
    "name": "FPA144 +  chemo (FIGHT)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 complete. Phase 3 development will not be pursued.", 
    "company": "Five Prime Therapeutics Inc.", 
    "indication": "Pigmented Villonodular Synovitis (PVNS)", 
    "name": "Cabiralizumab (FPA008)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b ovarian cancer data due mid-2020. No plans to independently advance the clinical development.", 
    "company": "Five Prime Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "FPA150", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - February 18, 2020.", 
    "company": "Five Prime Therapeutics Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "Cabiralizumab (FPA008) and Opdivo (nivolumab)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 early monotherapy efficacy data due by end of 2020", 
    "company": "Five Prime Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "FPT155", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a data due 2Q 2021.", 
    "company": "Frequency Therapeutics Inc.", 
    "indication": "Hearing loss", 
    "name": "FX-322", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing. Pivotal trial to be initiated in 2021.", 
    "company": "Freeline Therapeutics Holdings plc", 
    "indication": "Hemophilia B", 
    "name": "FLT180a", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 first patient dosed August 2019. ", 
    "company": "Freeline Therapeutics Holdings plc", 
    "indication": "Fabry disease", 
    "name": "FLT190 (MARVEL-1)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2b interim data did not show separation from placebo - August 11, 2020. Top-line data 1Q 2021.", 
    "company": "Fulcrum Therapeutics Inc.", 
    "indication": "Facioscapulohumeral muscular dystrophy (FSHD)", 
    "name": "Losmapimod", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 open-label trial has completed enrolment - noted March 5, 2020.", 
    "company": "Fulcrum Therapeutics Inc.", 
    "indication": "Facioscapulohumeral muscular dystrophy (FSHD)", 
    "name": "Losmapimod", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated by the end of 2020.", 
    "company": "Fulcrum Therapeutics Inc.", 
    "indication": "Sickle Cell Disease", 
    "name": "FTX-6058", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced June 24, 2020. Interim analysis due 4Q 2020 with top-line data due 1Q 2021.", 
    "company": "Fulcrum Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "Losmapimod", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 single-dose safety and imaging data due 4Q 2020.", 
    "company": "Fusion Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "FPI-1434", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b/3 commencement of enrolment announced June 30, 2020 with top-line data due 4Q 2022.", 
    "company": "Galectin Therapeutics Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH) with cirrhosis", 
    "name": "GR-MD-02", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1b data released September 20, 2018. ORR 50%.", 
    "company": "Galectin Therapeutics Inc.", 
    "indication": "Melanoma", 
    "name": "GR-MD-02 and pembrolizumab (KEYTRUDA)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2a interim data released May 2016", 
    "company": "Galectin Therapeutics Inc.", 
    "indication": "moderate-to-severe plaque psoriasis. ", 
    "name": "GR-MD-02 ", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2a discontinuation announced October 23, 2017 due to lack of efficacy.", 
    "company": "Global Blood Therapeutics Inc.", 
    "indication": "Hypoxemia in patients with idiopathic pulmonary fibrosis (IPF) who are on supplemental oxygen at rest", 
    "name": "GBT440", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "FDA Approval announced November 25, 2019.", 
    "company": "Global Blood Therapeutics Inc.", 
    "indication": "Sickle cell disease", 
    "name": "Voxelotor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data to be presented at ASH December 3, 2018 noted 55% (6 of 11) achieved a hemoglobin response >1 g/dL .", 
    "company": "Global Blood Therapeutics Inc.", 
    "indication": "Sickle cell disease - children age 6-17.", 
    "name": "GBT440 HOPE-KIDS 1", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2022.", 
    "company": "Geron Corporation", 
    "indication": "Myelodysplastic syndromes", 
    "name": "Imetelstat - IMerge Study", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to commence 1Q 2021 with interim analysis in 1H 2023 and final analysis in 1H 2024.", 
    "company": "Geron Corporation", 
    "indication": "Myelofibrosis", 
    "name": "Imetelstat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 11, 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Selonsertib (GS-4997) - STELLAR 4", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Sjogrenâ€™s syndrome", 
    "name": "Filgotinib and GS-9876", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2H 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Primary sclerosing cholangitis", 
    "name": "Cilofexor (GS-9674)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 3, 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Pre-exposure prophylaxis", 
    "name": "F/TAF (Descovy)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA filing due later in 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Indolent B-Cell Non-Hodgkin Lymphoma", 
    "name": "Axicabtagene ciloleucel - (ZUMA-5)", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 2b data due 2H 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Osteoarthritis", 
    "name": "GLPG1972 - ROCCELLA", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Cutaneous lupus erythematosus (CLE)", 
    "name": "Filgotinib and GS-9876", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated later in 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Ankylosing spondylitis", 
    "name": "Filgotinib - TORTUGA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment has been paused due to COVID-19,", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Psoriatic arthritis", 
    "name": "Filgotinib PENGUIN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved February 7, 2018.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "HIV", 
    "name": "Bictegravir/F/TAF", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data April 25, 2019 did not meet primary endpoint.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Selonsertib (GS-4997) - STELLAR 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced July 18, 2017.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Hepatitis C virus (HCV)", 
    "name": "Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b/3 data released May 20, 2020. 200mg dose met primary endpoint. 100mg did not meet clinical remission endpoint.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "Filgotinib - SELECTION", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed in 2021.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Crohnâ€™s disease", 
    "name": "Filgotinib - DIVERSITY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL announced August 18, 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Rheumatoid arthritis (RA)", 
    "name": "Filgotinib", 
    "stage": "crl"
  }, 
  {
    "newstxt": "FDA approval announced July 24, 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Relapsed or Refractory Mantle Cell Lymphoma (r/r MCL) - cancer", 
    "name": "Axicabtagene ciloleucel - (ZUMA-2)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 pivotal trial enrolment completed 3Q 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Adult patients with r/r ALL - cancer", 
    "name": "Axicabtagene ciloleucel - (ZUMA-3)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data released 2Q 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Pediatric and young adult patients with r/r ALL - cancer", 
    "name": "Axicabtagene ciloleucel - (ZUMA-4)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data due 2021.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL)", 
    "name": "Axicabtagene ciloleucel (ZUMA-8)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": " Registration-enabling trial initiated 1Q 2020 with interim data due 2H 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Diffuse Large B-Cell Lymphoma", 
    "name": "Magrolimab + rituximab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Refractory diffuse large B-cell lymphoma (DLBCL)", 
    "name": "Axicabtagene ciloleucel (ZUMA-7)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - December 16, 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Cilofexor (GS-9674) and firsocostat (GS-0976) - ATLAS", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial initiated 3Q 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Diabetic kidney disease", 
    "name": "Selonsertib (GS-4997)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "", 
    "name": "Axicabtagene ciloleucel - KTE-C19 and utomilumab (ZUMA-11)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial initiated 4Q 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Large B-cell Lymphoma", 
    "name": "Axicabtagene ciloleucel and rituximab/lenalidomide (ZUMA-14)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Diffuse Large B-Cell Lymphoma (DLBCL)", 
    "name": "Axicabtagene ciloleucel - (ZUMA-12)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2019.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Ulcerative Colitis", 
    "name": "GS-4875", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Higher risk-Myelodysplastic Syndrome (MDS)", 
    "name": "Magrolimab + Azacitidine", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "sNDA FDA Approval announced March 19, 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "Hepatitis C", 
    "name": "Epclusa (sofosbuvir /velpatasvir)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "NDA filing announced August 10, 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "COVID-19 Coronavirus", 
    "name": "Remdesivir", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "5-day treatment met primary endpoint. 10-day treatment did not meet primary endpoint.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "COVID-19 - moderate disease", 
    "name": "Remdesivir - SIMPLE-Moderate study", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced May 28, 2020.", 
    "company": "Gilead Sciences Inc.", 
    "indication": "COVID-19", 
    "name": "Actemra/RoActemra plus remdesivir", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "Glaukos Corporation", 
    "indication": "Presbyopia", 
    "name": "PiXL", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Glaukos Corporation", 
    "indication": "Progressive keratoconus", 
    "name": "Epi-on", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "Glaukos Corporation", 
    "indication": "Glaucoma", 
    "name": "iDose TR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initial data due 2H 2023.", 
    "company": "Galmed Pharmaceuticals Ltd.", 
    "indication": "Non-Alcoholic Steatohepatitis (NASH)", 
    "name": "Aramchol - ARMOR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data released February 14, 2018 did not meet primary endpoint.", 
    "company": "Galmed Pharmaceuticals Ltd.", 
    "indication": "HIV-associated lipodystrophy and nonalcoholic fatty liver disease (NAFLD)", 
    "name": "Aramchol - ARRIVE ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial enrolment has been paused due to COVID-19.", 
    "company": "Galapagos NV", 
    "indication": "Non-infectious uveitis", 
    "name": "Filgotinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 2H 2020.", 
    "company": "Galapagos NV", 
    "indication": "Osteoarthritis", 
    "name": "GLPG1972 - ROCCELLA", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint.", 
    "company": "Galapagos NV", 
    "indication": "Cutaneous lupus erythematosus (CLE)", 
    "name": "Filgotinib and GS-9876", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated later in 2020.", 
    "company": "Galapagos NV", 
    "indication": "Ankylosing spondylitis", 
    "name": "Filgotinib - TORTUGA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment has been paused due to COVID-19,", 
    "company": "Galapagos NV", 
    "indication": "Psoriatic arthritis", 
    "name": "Filgotinib PENGUIN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data released December 20, 2016.", 
    "company": "Galapagos NV", 
    "indication": "Cystic Fibrosis", 
    "name": "GLPG1837", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 futility analysis due 1H 2021.", 
    "company": "Galapagos NV", 
    "indication": "Idiopathic pulmonary fibrosis", 
    "name": "ISABELA  - GLPG1690", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b/3 data released May 20, 2020. 200mg dose met primary endpoint. 100mg did not meet clinical remission endpoint.", 
    "company": "Galapagos NV", 
    "indication": "Ulcerative colitis", 
    "name": "Filgotinib - SELECTION", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed in 2021.", 
    "company": "Galapagos NV", 
    "indication": "Crohnâ€™s disease", 
    "name": "Filgotinib - DIVERSITY", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL announced August 18, 2020.", 
    "company": "Galapagos NV", 
    "indication": "Rheumatoid arthritis (RA)", 
    "name": "Filgotinib", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2 trial halted due to futility - October 28, 2019.", 
    "company": "Galapagos NV", 
    "indication": "Atopic dermatitis", 
    "name": "MOR106 IGUANA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Galapagos NV", 
    "indication": "Idiopathic pulmonary fibrosis (IPF)", 
    "name": "GLPG1205 - PINTA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 2H 2020.", 
    "company": "Galapagos NV", 
    "indication": "Systemic sclerosis", 
    "name": "GLPG1690 -  NOVESA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced September 24, 2019.", 
    "company": "Galapagos NV", 
    "indication": "Psoriasis", 
    "name": "GLPG3970", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Galapagos NV", 
    "indication": "Inflammatory Bowel Disease", 
    "name": "Filgotinib (MANTA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2H 2021.", 
    "company": "GlycoMimetics Inc.", 
    "indication": "Acute myeloid leukemia (AML) newly diagnosed and refractory - cancer", 
    "name": "Uproleselan (GMI-1271)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data failed to meet endpoints - August 2, 2019. Biomarker data to be presented at FSCDR meeting September 23-25, 2020,", 
    "company": "GlycoMimetics Inc.", 
    "indication": "Vaso-occlusive crisis of sickle cell disease", 
    "name": "GMI-1070 (rivipansel)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b data due 4Q 2020 / 1Q 2021.", 
    "company": "GlycoMimetics Inc.", 
    "indication": "Hormone receptor positive metastatic breast cancer", 
    "name": "GMI-1359", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced April 23, 2019.", 
    "company": "GlycoMimetics Inc.", 
    "indication": "Acute myeloid leukemia (AML) ", 
    "name": "Uproleselan (GMI-1271) - NCI", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - May 28, 2020.", 
    "company": "Genmab A/S", 
    "indication": "Amyloidosis", 
    "name": "DARZALEX (Daratumumab) using ENHANZE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data noted 24% ORR with a median duration of response of 8.3 months.", 
    "company": "Genmab A/S", 
    "indication": "Cervical Cancer", 
    "name": "Tisotumab Vedotin (innovaTV 204 )", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced August 20, 2020.", 
    "company": "Genmab A/S", 
    "indication": "Relapsing multiple sclerosis", 
    "name": "OMB157 (ofatumumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.", 
    "company": "Genmab A/S", 
    "indication": "Relapsed or refractory multiple myeloma", 
    "name": "DARZALEX (Daratumumab) +  pomalidomide and dexamethasone", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 dosing has commenced - noted July 12, 2018.", 
    "company": "Genmab A/S", 
    "indication": "Solid tumors", 
    "name": "Tisotumab Vedotin (innovaTV 207)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 updated data presented at ESMO October 20. 2018.", 
    "company": "Genmab A/S", 
    "indication": "Recurrent Cervical Cancer", 
    "name": "Tisotumab Vedotin (innovaTV 201)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced June 28, 2019.", 
    "company": "Genmab A/S", 
    "indication": "Newly Diagnosed Multiple Myeloma (NDMM)", 
    "name": "Daratumumab - MAIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 1, 2020.", 
    "company": "Genmab A/S", 
    "indication": "Multiple myeloma", 
    "name": "DARZALEX (Daratumumab) using ENHANZE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 20, 2020.", 
    "company": "Genmab A/S", 
    "indication": "Multiple Myeloma", 
    "name": "Darzalex (daratumumab) and Kyprolis (carfilzomib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced September 26, 2019.", 
    "company": "Genmab A/S", 
    "indication": "Multiple myeloma - candidates for autologous stem cell transplant (ASCT)", 
    "name": "Daratumumab + VTD", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 initial data presented at IASLC 2019 WCLC September 8, 2019.", 
    "company": "Genmab A/S", 
    "indication": "Solid tumors", 
    "name": "Enapotamab vedotin", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "Genmab A/S", 
    "indication": "Solid tumors", 
    "name": "HexaBody-DR5/DR5", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data presented at ASCO May 29, 2020.", 
    "company": "Genmab A/S", 
    "indication": "B-cell Lymphoma", 
    "name": "Epcoritamab (DuoBody-CD3xCD20)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data update 2H 2020.", 
    "company": "Genmab A/S", 
    "indication": "Solid tumors", 
    "name": "BNT311 / GEN1046", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 updated data due 4Q 2020.", 
    "company": "Gamida Cell Ltd.", 
    "indication": "Non-Hodgkin lymphoma; Multiple myeloma", 
    "name": "NAM-NK (GDA-201)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 data due 4Q 2020.", 
    "company": "Gamida Cell Ltd.", 
    "indication": "Severe aplastic anemia", 
    "name": "NiCord (omidubicel)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "BLA filing 4Q 2020.", 
    "company": "Gamida Cell Ltd.", 
    "indication": "Acute myeloid leukemia", 
    "name": "NiCord (omidubicel)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Announced September 25, 2017 that development will be ceased.", 
    "company": "Genocea Biosciences Inc.", 
    "indication": "Genital herpes", 
    "name": "GEN-003", 
    "stage": ""
  }, 
  {
    "newstxt": "Topline data did not meet endpoints - September 2015", 
    "company": "Genocea Biosciences Inc.", 
    "indication": "Universal vaccine candidate against pneumococcus", 
    "name": "GEN-004", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 Part B initial data noted 3/5 responses - July 30, 2020.", 
    "company": "Genocea Biosciences Inc.", 
    "indication": "Various cancers", 
    "name": "GEN-009", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 IND placed on clinical hold - July 20, 2020.", 
    "company": "Genocea Biosciences Inc.", 
    "indication": "Various tumors", 
    "name": "GEN-011", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - May 11, 2020.", 
    "company": "GENFIT S.A.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Elafibranor - RESOLVE-IT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation put on hold due to COVID-19.", 
    "company": "GENFIT S.A.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Elafibranor +  SGLT2 inhibitor", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 launch announced June 4, 2019. Enrolment put on hold due to COVID-19.", 
    "company": "GENFIT S.A.", 
    "indication": "Non-Alcoholic Fatty Liver Disease (NAFLD)", 
    "name": "Elafibranor", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 initiation put on hold due to COVID-19.", 
    "company": "GENFIT S.A.", 
    "indication": "Primary biliary cholangitis (PBC)", 
    "name": "Elafibranor", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial on hold due to COVID-19.", 
    "company": "GENFIT S.A.", 
    "indication": "NASH Fibrosis", 
    "name": "Nitazoxanide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrolment will not be re-opened - noted February 5, 2020.", 
    "company": "Genprex Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Oncoprex With Tarceva", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated mid-2020.", 
    "company": "Genprex Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Oncoprex in combination with osimertinib", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Gossamer Bio Inc.", 
    "indication": "Ulcerative Colitis", 
    "name": "AKB-4924 (GB004) - SHIFT-UC", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data due 2H 2020.", 
    "company": "Gossamer Bio Inc.", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "GB002", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Gossamer Bio Inc.", 
    "indication": "Nasal polyps / Chronic spontaneous urticaria", 
    "name": "GB001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b top-line data 2H 2020.", 
    "company": "Gossamer Bio Inc.", 
    "indication": "Eosinophilic asthma", 
    "name": "GB001", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1/2 further data due 4Q 2020.", 
    "company": "Gossamer Bio Inc.", 
    "indication": "Solid tumors", 
    "name": "GB1275", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020 with data due 2H 2021. Additional Phase 1 data due 2H 2020.", 
    "company": "Gritstone Oncology Inc.", 
    "indication": "Colorectal Cancer / Gastric Cancer", 
    "name": "GRANITE-001 (GO-004)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020 with data due 1H 2021.", 
    "company": "Gritstone Oncology Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "SLATE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a dosing of first patient announced January 7, 2020.", 
    "company": "Galera Therapeutics Inc.", 
    "indication": "Esophagitis", 
    "name": "GC4419", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1b/2a trial to be initiated 2H 2020.", 
    "company": "Galera Therapeutics Inc.", 
    "indication": "Non-Small Cell Lung Cancer (NSCLC)", 
    "name": "GC4711", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b/2a data due 2H 2020.", 
    "company": "Galera Therapeutics Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "GC4419", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021. ", 
    "company": "Galera Therapeutics Inc.", 
    "indication": "Oral mucositis", 
    "name": "GC4419 ROMAN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 23, 2018.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Malaria", 
    "name": "Tafenoquine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced April 24, 2018 for expanded label.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Trelegy Ellipta (FF/UMEC/VI)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 12, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Eosinophilic Granulomatosis with Polyangiitis (EGPA)", 
    "name": "Mepolizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA under priority review. No date provided. Estimate September 26, 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Severe hypereosinophilic syndrome (HES)", 
    "name": "Mepolizumab", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Approval announced January 11, 2018.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Influenza A - children 6-35 months of age.", 
    "name": "Fluarix Quadrivalent (Influenza Vaccine)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 29, 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Ovarian cancer", 
    "name": "Niraparib - PRIMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced September 18, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Trelegy Ellipta (FF/UMEC/VI)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced November 21, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Dolutegravir + rilpivirine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Advisory Committee July 25, 2018 voted 3-16 against recommending approval. CRL issued September 7, 2018.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype", 
    "name": "Mepolizumab", 
    "stage": "crl"
  }, 
  {
    "newstxt": "FDA approval announced April 8, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Dolutegravir + lamivudine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 top-line data from cardiovascular outcome study due 2022. Pharmaceuticals and Medicines Device Agency decision due by end of 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Anemia", 
    "name": "Daprodustat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Development discontinued due to lack of efficacy.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Danirixin", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Approval announced October 20, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Shingles", 
    "name": "Shingrix ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced July 21, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Systemic lupus erythematosus (SLE)", 
    "name": "Benlysta (belimumab) - subcutaneous", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing announced October 2, 2019. Estimate August 2, 2020 using 10-month timeline. However, Advisory Committee meeting was postponed due to COVID, resulting in a likely extension. Estimate 2H 2020. ", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Asthma", 
    "name": "Closed Triple - CAPTAIN", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approval announced September 19, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "COPD", 
    "name": "Closed Triple", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL January 11 2017. FDA Approval announced October 25, 2017 following resubmission.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients", 
    "name": "Rolapitant - intravenous (IV)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date under priority review was June 30, 2017. Approved March 27, 2017.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Cancer - ovarian", 
    "name": "Niraparib - NOVA (Niraparib Ovarian) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 23, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Ovarian cancer", 
    "name": "Niraparib - (QUADRA trial)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 2, 2015.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Prevention of chemotherapy induced nausea and vomiting, or CINV in HEC patients", 
    "name": "Rolapitant", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA filed 2H 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Endometrial cancer", 
    "name": "TSR-042 - GARNET", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Complete Response Letter issued December 21, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Dolutegravir + rilpivirine", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Systemic lupus erythematosus (SLE)", 
    "name": "Benlysta  (belimumab) and rituximab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 ContRAst trial initiation announced July 3, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Rheumatoid Arthritis", 
    "name": "Otilimab (MOR103/GSK3196165)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2021", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Solid tumors", 
    "name": "TSR-022 + TSR-042 AMBER", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Regulatory filing due 2H 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Nasal polyps", 
    "name": "Mepolizumab (NUCALA)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval granted August 5, 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Multiple myeloma", 
    "name": "GSKâ€™916 - belantamab mafodotin (BCMA)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 6, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Severe eosinophilic asthma - pediatric", 
    "name": "Mepolizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Castration-Resistant Prostate Cancer", 
    "name": "Niraparib (Galahad)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met - August 22, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Cabotegravir + rilpivirine - ATLAS2M", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced August 6, 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Dolutegravir + lamivudine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced September 12, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Severe eosinophilic asthma (6-11 yrs)", 
    "name": "Mepolizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced October 28, 2019. Data due 2H 2021.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Uncomplicated urinary tract infection (uUTI)", 
    "name": "Gepotidacin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data significantly reduced incidence of pulmonary tuberculosis disease - October 29, 2019.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Pulmonary tuberculosis", 
    "name": "M72/AS01E", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 pivotal data due 2H 2021.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Ovarian cancer", 
    "name": "Zejula and dostarlimab - MOONSTONE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced July 2, 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Fostemsavir", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - December 18, 2019. BLA filed 2Q 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Lupus Nephritis", 
    "name": "Benlysta  (belimumab)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Pivotal data due 1H 2021.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Biliary tract cancer", 
    "name": "Bintrafusp alfa", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2/3 trial to commence August 2020. Initial data due by end of 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "COVID-19 antibody", 
    "name": "VIR-7831", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence September 2020. Late-stage trial to commence late-2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "COVID-19 vaccine", 
    "name": "Adjuvanted COVID-19 vaccine", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to sufficient efficacy. ", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "HIV", 
    "name": "Cabotegravir HPTN 083", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 initiation announced June 19, 2020 with preliminary safety and immunogenicity data due September 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "COVID-19 vaccine", 
    "name": "SCB-2019 + adjuvant system (Clover)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "dMMR pan-tumor", 
    "name": "Dostarlimab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Endometrial Cancer", 
    "name": "Dostarlimab Plus Carboplatin-paclitaxel (RUBY)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2022.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "Multiple Myeloma", 
    "name": "Belantamab mafodotin (DREAMM-3)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a data due 1H 2021.", 
    "company": "GlaxoSmithKline PLC", 
    "indication": "COVID-19", 
    "name": "Otilimab", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 OS update 4Q 2020.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "Triple-negative breast cancer", 
    "name": "Trilaciclib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data presented at ESMO September 29, 2019.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "First-line small-cell lung cancer", 
    "name": "Trilaciclib plus Tecentriq", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data due at SABCS December 11, 2019 noted median PFS of 15 months. Further update due 3Q 2020.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "ER+ breast cancer", 
    "name": "Lerociclib (G1T38) plus Faslodex", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "PDUFA date under priority review February 15, 2021.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "Second/third-line small-cell lung cancer", 
    "name": "Trilaciclib", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 1/2 additional data due 4Q 2020.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "ER+, HER2- breast cancer", 
    "name": "Rintodestrant (G1T48) and Ibrance", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial to commence 4Q 2020.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "Colorectal cancer", 
    "name": "Trilaciclib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiated 2Q 2020.", 
    "company": "G1 Therapeutics Inc.", 
    "indication": "Neoadjuvant breast cancer", 
    "name": "Trilaciclib - I-SPY 2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 open-label trial underway - noted February 25, 2020.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Rett syndrome", 
    "name": "GWP42006 (CBDV)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet endpoint", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Type 2 diabetes", 
    "name": "GWP42004", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released February 21, 2018 - primary endpoint not met.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Epilepsy", 
    "name": "GWP42006 (CBDV)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial to commence 2H 2020.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Schizophrenia", 
    "name": "GWP42003", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval announced June 25, 2018.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Dravet Syndrome and Lennox-Gastaut syndrome", 
    "name": "Epidiolex", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 3, 2020.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Tuberous Sclerosis Complex", 
    "name": "Epidiolex", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trials planned for 2H 2020 and 1H 2021.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Spasticity due multiple sclerosis", 
    "name": "Sativex (Nabiximols)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to recommence 2H 2020.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Autism", 
    "name": "GWP42006 (CBDV)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to recommence 2H 2020 following pause due to COVID-19.", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Rett syndrome", 
    "name": "Epidiolex", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial to commence 1H 2021", 
    "company": "GW Pharmaceuticals Plc", 
    "indication": "Post-Traumatic Stress Disorder (PTSD)", 
    "name": "Nabiximols", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - May 28, 2020.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Amyloidosis", 
    "name": "DARZALEX (Daratumumab) using ENHANZE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced June 22, 2017.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Various blood cancers", 
    "name": "Subcutaneous rituximab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Discontinued August 2016", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "PEGPH20 in Combination with docetaxel", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 data November 4, 2019 did not meet primary endpoint.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "HALO-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved September 12, 2014.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Subcutaneous treatment for patients with primary immunodeficiency (PI)", 
    "name": "HYQVIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 29, 2020.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "HER2-positive early breast cancer", 
    "name": "Subcutaneous Pertuzumab And Trastuzumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1b trial ongoing. 42/70 patients have enrolled as of December 2018.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Cholangiocarcinoma", 
    "name": "PEGPH20 and atezolizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "FDA approval announced February 28, 2019.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Breast cancer", 
    "name": "Trastuzumab (Herceptin) using ENHANZE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 1, 2020.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "DARZALEX (Daratumumab) using ENHANZE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 3Q 2020.", 
    "company": "Halozyme Therapeutics Inc.", 
    "indication": "Autoimmune diseases", 
    "name": "ARGX-117", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2a data due 2H 2020.", 
    "company": "Harpoon Therapeutics Inc.", 
    "indication": "Ovarian cancer", 
    "name": "HPN536", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 preliminary data at ASCO May 29, 2020 - generally well-tolerated.", 
    "company": "Harpoon Therapeutics Inc.", 
    "indication": "Metastatic castration-resistant prostate cancer", 
    "name": "HPN424", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 initiation of dosing announced April 27, 2020.", 
    "company": "Harpoon Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "HPN217", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2a trial to be initiated 2H 2020.", 
    "company": "Harpoon Therapeutics Inc.", 
    "indication": "Small cell lung cancer", 
    "name": "HPN328", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/1b trial initiation announced October 4, 2019.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Indolent Non-Hodgkin lymphoma (NHL) ", 
    "name": "HMPL-523", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Rolling NDA to commence late-2020 / early-2021.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Neuroendocrine Tumors", 
    "name": "Surufatinib", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1/1b data be presented at ESMO 2019 noted ORR of 13.3% and DCR of 73.3%. Phase 2/3 trial to be initiated 1H 2020.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Pancreatic neuroendocrine tumors", 
    "name": "Surufatinib", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial to completed late-2021.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Colorectal cancer ", 
    "name": "Fruquintinib (FRESCO-2)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 full data from papillary renal cell carcinoma cohort presented at ASCO-GU 2020.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Renal cell carcinoma (RCC) ", 
    "name": "Savolitinib + Imfinzi (CALYPSO)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 interim analysis due 3Q 2020.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Savolitinib (SAVANNAH)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation announced January 13, 2020.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Solid Tumors", 
    "name": "Surufatinib and Tuoyi", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced March 31, 2020.", 
    "company": "Hutchison China MediTech Limited", 
    "indication": "Mesothelioma", 
    "name": "HMPL-453", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued - November 2017.", 
    "company": "Hepion Pharmaceuticals Inc.", 
    "indication": "Shingles", 
    "name": "Valnivudine - FV-100", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a commencement of dosing announced August 5, 2020 with data due by end of 2020.", 
    "company": "Hepion Pharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis", 
    "name": "CRV431 - AMBITION", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 safety and immunogenicity data was well tolerated - June 22, 2020. Efficacy data due 2H 2020.", 
    "company": "HOOKIPA Pharma Inc.", 
    "indication": "Cytomegalovirus (CMV)", 
    "name": "HB-101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiation announced December 30, 2019 with with preliminary safety and efficacy data expected in late 2020 or early 2021. ", 
    "company": "HOOKIPA Pharma Inc.", 
    "indication": "Treatment-refractory HPV16+ cancers", 
    "name": "HB-201 and HB-202 (alone and double)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Hoth Therapeutics Inc.", 
    "indication": "Atopic Dermatitis", 
    "name": "BioLexa", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2021.", 
    "company": "Harmony Biosciences Holdings Inc.", 
    "indication": "Excessive daytime sleepiness (EDS) and cataplexy", 
    "name": "WAKIX (pitolisant)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL previously received. NDA to be refiled 3Q 2020.", 
    "company": "Harmony Biosciences Holdings Inc.", 
    "indication": "Adult cataplexy", 
    "name": "WAKIX (pitolisant)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020 with data due 1H 2022.", 
    "company": "Harmony Biosciences Holdings Inc.", 
    "indication": "Excessive daytime sleepiness associated with Prader-Willi Syndrome", 
    "name": "WAKIX (pitolisant)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2021 with data due 2H 2022.", 
    "company": "Harmony Biosciences Holdings Inc.", 
    "indication": "Myotonic dystrophy", 
    "name": "WAKIX (pitolisant)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL announced June 29, 2020.", 
    "company": "Heron Therapeutics Inc.", 
    "indication": "Post operative pain", 
    "name": "HTX-011", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL Mar 28 2013. Approved August 10 2016.", 
    "company": "Heron Therapeutics Inc.", 
    "indication": "Prevention of acute- and delayed-onset chemotherapy-induced nausea and vomiting (CINV)", 
    "name": "APF530 - Sustol", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA additional approval allowing  IV injection in addition to current IV infusion.", 
    "company": "Heron Therapeutics Inc.", 
    "indication": "Prevention of chemotherapy-induced nausea and vomiting (CINV)", 
    "name": "CINVANTI (HTX-019)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3b data released October 3, 2019.", 
    "company": "Heron Therapeutics Inc.", 
    "indication": "Total knee arthroplasty", 
    "name": "HTX-011", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 trial initiation announced May 18, 2020.", 
    "company": "Heron Therapeutics Inc.", 
    "indication": "Postoperative Pain", 
    "name": "HTX-034", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 initiation announced July 16, 2020.", 
    "company": "Heron Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "CINVANTI (aprepitant) -  (GUARDS-1)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b/2 completion of enrolment announced July 14, 2020. Top-line data due 4Q 2020.", 
    "company": "Histogen Inc.", 
    "indication": "Androgenic Alopecia", 
    "name": "HST 001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data presented at ASCO May 29, 2020. Median overall survival (mOS) of 28.7 months.", 
    "company": "Heat Biologics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "HS-110 and nivolumab (Opdivo)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - November 30, 2016.", 
    "company": "Heat Biologics Inc.", 
    "indication": "Bladder cancer", 
    "name": "HS-410", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data released December 6, 2016.", 
    "company": "Heat Biologics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "HS-110", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced December 16, 2019. Initial data due 2020.", 
    "company": "Heat Biologics Inc.", 
    "indication": "Solid tumors", 
    "name": "HS-130", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced June 22, 2020.", 
    "company": "Heat Biologics Inc.", 
    "indication": "Solid tumors", 
    "name": "PTX-35", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Heat Biologics Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "COVID vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data released December 8, 2016 - primary endpoint not met.", 
    "company": "Horizon Therapeutics Public Limited Company", 
    "indication": "Friedreich's Ataxia (FA)", 
    "name": "ACTIMMUNE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 4 data due 2021.", 
    "company": "Horizon Therapeutics Public Limited Company", 
    "indication": "Gout", 
    "name": "Krystexxa with Methotrexate - MIRROR RCT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced January 21, 2020.", 
    "company": "Horizon Therapeutics Public Limited Company", 
    "indication": "Thyroid Eye Disease (TED)", 
    "name": "Teprotumumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 completion of enrolment announced January 29, 2020.", 
    "company": "Intercept Pharmaceuticals Inc.", 
    "indication": "NASH patients with compensated cirrhosis", 
    "name": "Ocaliva - Obeticholic acid (OCA) - REVERSE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint met - July 31, 2017. One patient death noted but DSMB noted unlikely to be related to OCA (company unsure).", 
    "company": "Intercept Pharmaceuticals Inc.", 
    "indication": "NASH patients taking statins", 
    "name": "Obeticholic acid (OCA)  - CONTROL", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved May 27 2016. Updated U.S. label for Ocaliva anticipated by early 2018", 
    "company": "Intercept Pharmaceuticals Inc.", 
    "indication": "Primary biliary cirrhosis (PBC) - POISE", 
    "name": "Obeticholic acid (Ocaliva)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL announced June 29, 2020. New Phase 3 analyses of the interim analysis data to be presented at EASL August 28, 2020.", 
    "company": "Intercept Pharmaceuticals Inc.", 
    "indication": "Adult nonalcoholic steatohepatitis (NASH) patients.", 
    "name": "Ocaliva (Obeticholic acid (OCA)) - REGENERATE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released July 31, 2017 - primary endpoint met. Late breaker at AASLD October 23, 2017.", 
    "company": "Intercept Pharmaceuticals Inc.", 
    "indication": "Primary Sclerosing Cholangitis (PSC)", 
    "name": "Obeticholic acid (OCA) AESOP", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 final data announced April 20, 2020 - Overall response rate of 22%;  Disease control rate of 71%.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Cancer - melanoma", 
    "name": "Tilsotolimod + ipilimumab - ILLUMINATE 204", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development suspended - September 2016.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Waldenström’s Macroglobulinemia", 
    "name": "IMO-8400", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Development suspended - September 2016.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Diffuse Large B-cell Lymphoma (DLBCL)", 
    "name": "IMO-8400", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data released June 12, 2018 - primary endpoint not met.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Dermatomyositis", 
    "name": "IMO-8400", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data at AACR April 2019 noted 45% disease control rate.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "Tilsotolimod - ILLUMINATE 101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due 1Q 2021.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Melanoma", 
    "name": "Tilsotolimod (IMO-2125) + ipilimumab - ILLUMINATE 301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2Q 2021.", 
    "company": "Idera Pharmaceuticals Inc.", 
    "indication": "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
    "name": "Tilsotolimod + nivolumab and ipilimumab  - ILLUMINATE 206", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 monotherapy interim data due 1H 2021.", 
    "company": "IDEAYA Biosciences Inc.", 
    "indication": "Solid tumors", 
    "name": "IDE196", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing - one complete response confirmed October 31, 2019.", 
    "company": "IDEAYA Biosciences Inc.", 
    "indication": "Uveal Melanoma", 
    "name": "IDE196", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dosing of first patient announced July 9, 2020. Interim data due late 2021-early 2022.", 
    "company": "IDEAYA Biosciences Inc.", 
    "indication": "Metastatic uveal melanoma (MUM)", 
    "name": "IDE196 and binimetinib", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b data June 5, 2019 did not meet primary endpoint.", 
    "company": "InflaRx N.V.", 
    "indication": "Hidradenitis Suppurativa", 
    "name": "IFX-1", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2a data from the higher dose groups are expected in 2021.", 
    "company": "InflaRx N.V.", 
    "indication": "Pyoderma Gangraenosum (PG)", 
    "name": "IFX-1", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 final data due 2021.", 
    "company": "InflaRx N.V.", 
    "indication": "ANCA-associated vasculitis (AAV)", 
    "name": "IFX-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in the coming months - noted July 21, 2020.", 
    "company": "InflaRx N.V.", 
    "indication": "COVID-19", 
    "name": "IFX-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 initial data due 4Q 2020.", 
    "company": "IGM Biosciences Inc.", 
    "indication": "Relapsed/refractory B cell Non-Hodgkinâ€™s lymphoma (NHL)", 
    "name": "IGM-2323", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "CRL announced March 27, 2020.", 
    "company": "Intelgenx Techs Corp", 
    "indication": "Migraine ", 
    "name": "RIZAPORT (RHB-103)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 ongoing.", 
    "company": "I-MAB", 
    "indication": "Multiple Myeloma (MM) - second line", 
    "name": "TJ202/MOR202", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 ongoing (China).", 
    "company": "I-MAB", 
    "indication": "Third-line multiple myeloma", 
    "name": "TJ202/MOR202", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b trial planned.", 
    "company": "I-MAB", 
    "indication": "Systemic lupus erythematosus", 
    "name": "TJ202/MOR202", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 IND to be filed 2020.", 
    "company": "I-MAB", 
    "indication": "Growth hormone deficiency", 
    "name": "Eftansomatropin (TJ101)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1Q 2021.", 
    "company": "I-MAB", 
    "indication": "Head and neck cancer", 
    "name": "Enoblituzumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 dose escalation data due 3Q 2020.", 
    "company": "I-MAB", 
    "indication": "Advanced cancers", 
    "name": "TJC4", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced May 13, 2020. Safety data due 2020.", 
    "company": "I-MAB", 
    "indication": "Advanced solid tumors", 
    "name": "TJD5", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b trial to commence 2Q 2020.", 
    "company": "I-MAB", 
    "indication": "Rheumatoid arthritis", 
    "name": "TJM2", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 interim data released May 27, 2020.", 
    "company": "I-MAB", 
    "indication": "COVID-19", 
    "name": "TJM2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Approved Feb 22 2013 - under priority review", 
    "company": "ImmunoGen Inc.", 
    "indication": "2nd-line HER2+ Metastatic Breast Cancer", 
    "name": "Kadcyla", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1b/2 data from platinum-sensitive triplet cohort due at ESMO September 19-21, 2020.", 
    "company": "ImmunoGen Inc.", 
    "indication": "Ovarian cancer and relapsed endometrial cancer", 
    "name": "Mirvetuximab soravtansine - FORWARD II", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial enrolling - February 14, 2020.", 
    "company": "ImmunoGen Inc.", 
    "indication": "Cancer - ovarian cancer and relapsed endometrial cancer", 
    "name": "Mirvetuximab - MIRASOL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet endpoints.", 
    "company": "ImmunoGen Inc.", 
    "indication": "HER2-positive breast cancer - neo-adjuvant setting", 
    "name": "Kadcyla KRISTINE trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Endpoint not met - October 2015", 
    "company": "ImmunoGen Inc.", 
    "indication": "Cancer - metastatic HER2+ gastric cancer", 
    "name": "Kadcyla GATSBY trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released Dec 18 2014. Met non-inferiority endpoint but did NOT significantly improve PFS compared to Herceptin and chemotherapy", 
    "company": "ImmunoGen Inc.", 
    "indication": "Cancer - 1st-line HER2+ Metastatic Breast Cancer", 
    "name": "Trastuzumab emtansine ( T-DM1, trastuzumab-DM1) - Kadcyla - MARIANNE trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 updated data at ASH December 9, 2019. AML ORR 54%; BPDCN 33%. Further data due at ASH December 5-8, 2020.", 
    "company": "ImmunoGen Inc.", 
    "indication": "Acute Myeloid Leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm (BPDCN)", 
    "name": "IMGN632 (ASH)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Further development to be discontinued - noted June 27, 2019.", 
    "company": "ImmunoGen Inc.", 
    "indication": "Relapsed/refractory acute myeloid leukemia (AML)", 
    "name": "IMGN779", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial data due mid-2021.", 
    "company": "ImmunoGen Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Mirvetuximab - SORAYA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b overall survival data due late-2020. 63% of patients were progression-free at 6 months compared with 54% on placebo (HR 0.93)", 
    "company": "Immutep Limited", 
    "indication": "Metastatic breast cancer (MBC) ", 
    "name": "Eftilagimod Alpha  - Active Immunotherapy PAClitaxel (AIPAC)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 final safety data due 2H 2020.", 
    "company": "Immutep Limited", 
    "indication": "Melanoma", 
    "name": "Eftilagimod alpha and Keytruda (TACTI-mel)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 presentation of new data at ESMO September 17, 2020, CEST.", 
    "company": "Immutep Limited", 
    "indication": "Non-small cell lung cancer; Head and neck cancer", 
    "name": "Eftilagimod alpha and Keytruda - TACTI-002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data to be presented at ESMO September 17, 2020.", 
    "company": "Immutep Limited", 
    "indication": "Solid tumors", 
    "name": "Eftilagimod alpha - INSIGHT-004", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be completed August 2022.", 
    "company": "Immutep Limited", 
    "indication": "Ulcerative Colitis", 
    "name": "GSK2831781", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data February 11, 2019 noted ORR 31% (14/45), with 2 CRs and 12 PRs. Presentation ASCO-GU February 15, 2019.", 
    "company": "Immunomedics Inc.", 
    "indication": "Urothelial cancer", 
    "name": "SACITUZUMAB GOVITECAN", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced April 22, 2020.", 
    "company": "Immunomedics Inc.", 
    "indication": "Triple-negative breast cancer", 
    "name": "SACTUZUMAB GOVITECAN (IMMU-132)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial terminated due to poor efficacy", 
    "company": "Immunomedics Inc.", 
    "indication": "Cancer - Pancreatic", 
    "name": "Clivatuzumab tetraxetan", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Endpoints not met July 2015", 
    "company": "Immunomedics Inc.", 
    "indication": "Lupus", 
    "name": "Epratuzumab (EMBODY 1 and 2)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment to resumed mid-May 2020.", 
    "company": "Immunomedics Inc.", 
    "indication": "HR+/HER2- metastatic breast cancer", 
    "name": "SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-02", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 final data to be presented at ESMO September 19-21, 2020.", 
    "company": "Immunomedics Inc.", 
    "indication": "Urothelial cancer", 
    "name": "SACITUZUMAB GOVITECAN - TROPHY U-01", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial update due fall of 2020.", 
    "company": "Immunomedics Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Lucitanib with Rubraca (SEASTAR)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 enrolling.", 
    "company": "Immunomedics Inc.", 
    "indication": "Solid tumors", 
    "name": "SACTUZUMAB GOVITECAN (IMMU-132) - TROPICS-03", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint. Presentation at ESMO September 19-22, 2020.", 
    "company": "Immunomedics Inc.", 
    "indication": "Cancer -  metastatic triple-negative breast cancer", 
    "name": "SACTUZUMAB GOVITECAN (IMMU-132) - ASCENT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a top-line data due 4Q 2020.", 
    "company": "IMARA Inc.", 
    "indication": "Sickle cell disease", 
    "name": "IMR-687", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2b trial initiated 2Q 2020 with interim data due 1H 2021.", 
    "company": "IMARA Inc.", 
    "indication": "b-thalassemia", 
    "name": "IMR-687", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1/2 commencement of enrollment announced January 31, 2018. ", 
    "company": "Immuron Limited", 
    "indication": "C. difficile infection", 
    "name": "IMM-529", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data released August 8, 2019. No significant reduction in MELD score.", 
    "company": "Immuron Limited", 
    "indication": "Alcoholic steatohepatitis (ASH) ", 
    "name": "IMM-124E", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 Interim analysis July 10, 2017 showed no statistical difference with placebo. However, company noted March 8, 2018 that top-line data were positive.", 
    "company": "Immuron Limited", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "IMM-124E", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "Immuron Limited", 
    "indication": "Nonalcoholic fatty liver disease (NAFLD) - pediatric", 
    "name": "IMM-124E", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial initiation postponed due to COVID-19. ", 
    "company": "Immuron Limited", 
    "indication": "Travelersâ€™ Diarrhea", 
    "name": "IMM-124E", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2021.", 
    "company": "Immunic Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "IMU-838", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released August 2, 2020 met secondary and primary endpoints.", 
    "company": "Immunic Inc.", 
    "indication": "Relapsing-remitting multiple sclerosis", 
    "name": "IMU-838", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence in 2020.", 
    "company": "Immunic Inc.", 
    "indication": "Crohnâ€™s disease", 
    "name": "IMU-838", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 commencement of dosing announced September 18, 2019.", 
    "company": "Immunic Inc.", 
    "indication": "Healthy volunteers", 
    "name": "IMU-935", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due early 2021.", 
    "company": "Immunic Inc.", 
    "indication": "Primary Sclerosing Cholangitis", 
    "name": "IMU-838", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced August 20, 2020.", 
    "company": "Immunic Inc.", 
    "indication": "Healthy Volunteers", 
    "name": "IMU-856", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 commencement of dosing announced June 15, 2020 with data due later in 2020.", 
    "company": "Immunic Inc.", 
    "indication": "COVID-19", 
    "name": "IMU-838 CALVID-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced July 27, 2020.", 
    "company": "Immunic Inc.", 
    "indication": "COVID-19", 
    "name": "IMU-838 and Oseltamivir (Tamiflu) - (IONIC)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 top-line data to be presented 2H 2020.", 
    "company": "IMV Inc.", 
    "indication": "Diffuse Large Cell Lymphoma", 
    "name": "DPX-Survivac and pembrolizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 updated data at ASCO May 29, 2020. 5/19 patients (26%) achieved a PR with tumor regression.", 
    "company": "IMV Inc.", 
    "indication": "Ovarian cancer", 
    "name": "DPX-Survivac and epacadostat (DeCidE1)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "IMV Inc.", 
    "indication": "Ovarian cancer", 
    "name": "DPX-Survivac and pembrolizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 updated data due 2H 2020.", 
    "company": "IMV Inc.", 
    "indication": "Solid tumors", 
    "name": "DPX-Survivac and KEYTRUDA (pembrolizumab) - basket trial", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - January 17, 2019.", 
    "company": "IMV Inc.", 
    "indication": "Ovarian cancer", 
    "name": "DPX-NEO - neoepitopes", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence summer 2020. Data due fall of 2020.", 
    "company": "IMV Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "DPX-COVID-19", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a initial data due 4Q 2020.", 
    "company": "Immunovant Inc.", 
    "indication": "Warm autoimmune hemolytic anemia", 
    "name": "IMVT-1401", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released August 25, 2020.", 
    "company": "Immunovant Inc.", 
    "indication": "Myasthenia Gravis (MG)", 
    "name": "IMVT-1401", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a initial data March 30, 2020 noted 65% mean reduction in total IgG.", 
    "company": "Immunovant Inc.", 
    "indication": "Graves Ophthalmopathy", 
    "name": "IMVT-1401", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2b top-line data due 1H 2021.", 
    "company": "Immunovant Inc.", 
    "indication": "Graves Ophthalmopathy / Thyroid Eye Disease (TED)", 
    "name": "IMVT-1401", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 single agent cohort data due 4Q 2020. Initial data from combination cohorts due 1H 2021. Initiation of registration-enabling trials in 2021.", 
    "company": "Inhibrx Inc.", 
    "indication": "Chondrosarcoma and mesothelioma", 
    "name": "INBRX-109", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 single agent dose escalation cohort data 4Q 2020. Escalation with Keytruda data 2H 2021.", 
    "company": "Inhibrx Inc.", 
    "indication": "Solid Tumors", 
    "name": "INBRX-106", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due dose escalation data due 1H 2021. Initial data from expansion cohorts 4Q 2021.", 
    "company": "Inhibrx Inc.", 
    "indication": "Solid Tumors", 
    "name": "INBRX-105", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dose escalation data due 2H 2021.", 
    "company": "Inhibrx Inc.", 
    "indication": "Alpha-1 Antitrypsin Deficiency", 
    "name": "INBRX-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 BREEZE-AD5 trial met primary endpoint - January 30, 2020. ", 
    "company": "Incyte Corporation", 
    "indication": "Atopic dermatitis", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced April 17, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Cholangiocarcinoma", 
    "name": "Pemigatinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 updated data due 2021.", 
    "company": "Incyte Corporation", 
    "indication": "Bladder cancer", 
    "name": "INCB54828 Pemigatinib (FIGHT-201)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved November 16, 2011.", 
    "company": "Incyte Corporation", 
    "indication": "Myelofibrosis", 
    "name": "Jakafi", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - January 2, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Treatment-naÃ¯ve acute GVHD", 
    "name": "Itacitinib - GRAVITAS-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be discontinued - noted June 21, 2018.", 
    "company": "Incyte Corporation", 
    "indication": "Diffuse large B cell lymphoma", 
    "name": "INCB50465  (CITADEL-202)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Recruitment has been discontinued - February 13, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Essential thrombocythemia", 
    "name": "Ruxolitinib  (RESET)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary and secondary endpoints - July 23, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Steroid-refractory chronic GVHD (Graft versus host disease)", 
    "name": "Ruxolitinib - REACH 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - October 16, 2019. Data to be presented at EBMT August 30-September 2, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Steroid-refractory acute GVHD (Graft versus host disease)", 
    "name": "Ruxolitinib - REACH 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.", 
    "company": "Incyte Corporation", 
    "indication": "Rheumatoid arthritis", 
    "name": "Baricitinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - noted April 6, 2018.", 
    "company": "Incyte Corporation", 
    "indication": "Cancer - first-line metastatic melanoma.", 
    "name": "Epacadostat with Keytruda - ECHO-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved December 4, 2014.", 
    "company": "Incyte Corporation", 
    "indication": "Polycythemia Vera", 
    "name": "Jakafi (ruxolitinib) (RESPONSE)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced May 24, 2019.", 
    "company": "Incyte Corporation", 
    "indication": "Graft versus host disease", 
    "name": "Ruxolitinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to lack of efficacy", 
    "company": "Incyte Corporation", 
    "indication": "Cancer - Pancreatic", 
    "name": "Ruxolitinib - JANUS 1 and JANUS 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial stopped January 2016 due to lack of efficacy", 
    "company": "Incyte Corporation", 
    "indication": "Colorectal cancer", 
    "name": "Ruxolitinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Endpoint not met, mid-2014", 
    "company": "Incyte Corporation", 
    "indication": "Disease-related symptoms in patients with Polycythemia Vera", 
    "name": "Jakafi (ruxolitinib) (RELIEF)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 6, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Non-small cell lung cancer", 
    "name": "Capmatinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be discontinued. ", 
    "company": "Incyte Corporation", 
    "indication": "Renal cancer", 
    "name": "Epacadostat with pembrolizumab (ECHO-302) ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 31, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Relapsed or refractory diffuse large B cell lymphoma", 
    "name": "Tafasitamab (MOR208/XmAb5574)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "NDA to be filed by end of 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Atopic dermatitis", 
    "name": "Ruxolitinib - TRuE-AD1", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Follicular lymphoma", 
    "name": "Parsaclisib INCB50465  (CITADEL-203)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initial data due 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Marginal zone lymphoma", 
    "name": "Parsaclisib INCB50465  (CITADEL-204)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initial data due 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Mantle cell lymphoma", 
    "name": "Parsaclisib INCB50465  (CITADEL-205)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Anal cancer", 
    "name": "Retifanlimab INCMGA0012", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 initial data due in 2021.", 
    "company": "Incyte Corporation", 
    "indication": "Vitiligo", 
    "name": "Ruxolitinib - TRuE-V", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data at ESMO 2019 noted - 7% PR rate.", 
    "company": "Incyte Corporation", 
    "indication": "Solid tumors", 
    "name": "INCB001158", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Incyte Corporation", 
    "indication": "Alopecia Areata", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Incyte Corporation", 
    "indication": "Systemic lupus erythematosus (SLE)", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Incyte Corporation", 
    "indication": "Chronic Graft-Versus-Host Disease", 
    "name": "Itacitinib - GRAVITAS-309", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initiation of dosing announced June 4, 2019.", 
    "company": "Incyte Corporation", 
    "indication": "Cholangiocarcinoma - first line", 
    "name": "Pemigatinib (FIGHT-302)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initiation announced April 17, 2020. Data due 2H 2020.", 
    "company": "Incyte Corporation", 
    "indication": "COVID-19 associated cytokine storm", 
    "name": "Ruxolitinib (Jakafi)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced August 26, 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Triple-negative breast cancer.", 
    "name": "Pelareorep and retifanlimab (INCMGA00012) - IRENE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2H 2020.", 
    "company": "Incyte Corporation", 
    "indication": "Solid Tumors", 
    "name": "INCB86550", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/1b translational data due 2H 2020.", 
    "company": "Infinity Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "IPI-549 + Nivolumab (MARIO-1)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data released June 2016 - short of expectations", 
    "company": "Infinity Pharmaceuticals Inc.", 
    "indication": "Indolent non-Hodgkin lymphoma", 
    "name": "Duvelisib (IPI-145) DYNAMO", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 failed to meet endpoint - Jan 2015", 
    "company": "Infinity Pharmaceuticals Inc.", 
    "indication": "Rheumatoid arthritis", 
    "name": "Duvelisib (IPI-145)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initiation announced September 4, 2019.", 
    "company": "Infinity Pharmaceuticals Inc.", 
    "indication": "Triple negative breast cancer (TNBC) and ovarian cancer", 
    "name": "AB298 + IPI-549 + Doxil", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data interim analysis due by end of 2020.", 
    "company": "Infinity Pharmaceuticals Inc.", 
    "indication": "Urothelial cancer", 
    "name": "IPI-549 + Nivolumab (MARIO-275)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrollment completion is expected in the RCC cohort by the end of 2020 and the TNBC cohort by the end of 1Q 2021. Initial data due 2H 2020.", 
    "company": "Infinity Pharmaceuticals Inc.", 
    "indication": "Front-line triple negative breast cancer (TNBC); Renal cell cancer (RCC)", 
    "name": "IPI-549 + Tecentriq and Abraxane and IPI-549 + Tecentriq and Avastin (MARIO-3)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated mid-2020.", 
    "company": "INmune Bio Inc.", 
    "indication": "HER2+ breast cancer", 
    "name": "INB03", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b interim data released July 13, 2020. Additional data due 2H 2020.", 
    "company": "INmune Bio Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "XPro1595", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated mid-2020.", 
    "company": "INmune Bio Inc.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "LIVNate", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 enrolment to commence 2H 2020.", 
    "company": "INmune Bio Inc.", 
    "indication": "Myelodysplastic syndromes (MDS)", 
    "name": "INKmune", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 enrolment to commence mid-2020.", 
    "company": "INmune Bio Inc.", 
    "indication": "Ovarian cancer", 
    "name": "INKmune", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "INmune Bio Inc.", 
    "indication": "Immune mediated complications from COVID-19", 
    "name": "Quello", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 planned.", 
    "company": "", 
    "indication": "Ulcerative colitis", 
    "name": "INN-108", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2021.", 
    "company": "", 
    "indication": "Celiac disease", 
    "name": "INN-202", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 to be initiated in 2019.", 
    "company": "", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Larazotide acetate", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 18-month data due 4Q 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Glioblastoma (GBM)", 
    "name": "INO-5401", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial discontinued - noted July 16, 2019.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Bladder cancer", 
    "name": "INO-5401 and atezolizumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b data at ESMO 2018 noted 86% of patients remained progression-free after 72 weeks.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Prostate cancer", 
    "name": "INO-5150", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "HPV-associated squamous cell carcinoma of the head & neck (SCCHN)", 
    "name": "MEDI0457", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Cervical dysplasia", 
    "name": "VGX-3100 - REVEAL-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data noted 50% showed clearance of HPV lesions and 75% showed a decrease in the number of lesions 6 months after the start of treatment - March 26, 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Human papilloma virus (HPV)-related anal dysplasia", 
    "name": "VGX-3100", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 interim data due 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "HIV", 
    "name": "PENNVAX-GP", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "MERS virus (Middle East Respiratory Syndrome)", 
    "name": "INO-4700 / GLS-5300", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 commencement of dosing announced December 4, 2018.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Human papilloma virus (HPV)", 
    "name": "MEDI0457", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 initiation announced March 4, 2019.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Cervical Dysplasia", 
    "name": "VGX-3100 - REVEAL-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial announced July 29, 2019.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Castration-resistant Prostate Cancer", 
    "name": "INO-5151", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 interim data due 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Zika virus", 
    "name": "INO-A002", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "Recurrent respiratory papillomatosis", 
    "name": "INO-3107", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 interim data released June 30, 2020. 94% of Phase 1 trial participants demonstrated overall immune responses at Week 6 but no data on how many patients produced antibodies. Phase 2/3 trial to commence July/August 2020.", 
    "company": "Inovio Pharmaceuticals Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "INO-4800", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2020.", 
    "company": "Insmed Inc.", 
    "indication": "Bronchiectasis", 
    "name": "Brensocatib (INS1007)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 ready.", 
    "company": "Insmed Inc.", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "INS1009", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 Euro data released 1 July 2013. Met endpoint but slighly inferior data to competition", 
    "company": "Insmed Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "ARIKAYCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced September 28, 2018.", 
    "company": "Insmed Inc.", 
    "indication": "Nontuberculous mycobacterial (NTM) lung disease", 
    "name": "ARIKAYCE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced April 24, 2018 for expanded label.", 
    "company": "Innoviva Inc.", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Trelegy Ellipta (FF/UMEC/VI)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced September 18, 2017.", 
    "company": "Innoviva Inc.", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Trelegy Ellipta (FF/UMEC/VI)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing announced October 2, 2019. Estimate August 2, 2020 using 10-month timeline. However, Advisory Committee meeting was postponed due to COVID, resulting in a likely extension. Estimate 2H 2020. ", 
    "company": "Innoviva Inc.", 
    "indication": "Asthma", 
    "name": "Closed Triple - CAPTAIN", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approval announced September 19, 2017.", 
    "company": "Innoviva Inc.", 
    "indication": "COPD", 
    "name": "Closed Triple", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 trial planned.", 
    "company": "Inozyme Pharma Inc.", 
    "indication": "ENPP1 deficiency", 
    "name": "INZ-701", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data to be presented at ESC Congress August 29, 2020. Phase 3 trial to be initiated 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Hyperlipoproteinemia and established cardiovascular disease", 
    "name": "AKCEA-APOCIII-LRx", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Huntington's Disease", 
    "name": "Tominersen (IONIS-HTT Rx)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2024.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Hyperlipoproteinemia(a) and established cardiovascular disease", 
    "name": "AKCEA-APO(a)-LRx", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 5, 2018,", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "NEURO-TTR - familial amyloid polyneuropathy (FAP).", 
    "name": "Inotersen (IONIS-TTRRx)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved December 23, 2016.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Spinal muscular atrophy (SMA)", 
    "name": "SPINRAZA - Nusinersen", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b data likely due 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "End-stage renal disease", 
    "name": "IONIS-FXIRx", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "CRL issued August 27, 2018. To be refiled 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Familial chylomicronemia syndrome (FCS)", 
    "name": "Volanesorsen - APPROACH", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "Tofersen", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 data due 2021.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Refractory head and neck cancer", 
    "name": "Durvalumab Plus Danvatirsen", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced November 25, 2019. Data due 2023.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "hATTR Amyloidosis", 
    "name": "AKCEA-TTR-LRx (NEURO-TTRansform)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Acromegaly", 
    "name": "IONIS-GHR-LRx", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 initiation announced September 18, 2019.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Spinal muscular atrophy (SMA)", 
    "name": "SPINRAZA - DEVOTE", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced January 10, 2020. Data due 2023.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "ATTR cardiomyopathy", 
    "name": "AKCEA-TTR-LRx - CARDIO-TTRansform", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Hereditary Angioedema", 
    "name": "IONIS-PKK-LRx", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Healthy volunteers", 
    "name": "IONIS-ENaC-2.5Rx", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 commencement of dosing announced April 2, 2020.", 
    "company": "Ionis Pharmaceuticals Inc.", 
    "indication": "Spinal muscular atrophy (SMA)", 
    "name": "SPINRAZA (nusinersen) - high dose", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "BLA filing due late-2020.", 
    "company": "Iovance Biotherapeutics Inc.", 
    "indication": "Refractory metastatic melanoma", 
    "name": "LN-144 - lifileucel", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 data released May 31, 2019 noted ORR 44%; CR 11%. Top-line data due 2020.", 
    "company": "Iovance Biotherapeutics Inc.", 
    "indication": "Cervical cancer", 
    "name": "LN-145", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data presented at AACR Virtual Annual Meeting April 28, 2020.", 
    "company": "Iovance Biotherapeutics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tumor infiltrating lymphocytes (TIL)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "Innate Pharma S.A.", 
    "indication": "Solid tumors", 
    "name": "Monalizumab and durvalumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 cohort 3 data due 2H 2020.", 
    "company": "Innate Pharma S.A.", 
    "indication": "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
    "name": "Monalizumab in combination with cetuximab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 expansion cohort initial data due 2H 2020.", 
    "company": "Innate Pharma S.A.", 
    "indication": "Non-small-cell lung cancer (NSCLC) and hepatocellular carcinoma (HCC)", 
    "name": "IPH5401 STELLAR-001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 partial clinical hold lifted - June 24, 2020. Mycosis fungoides data due in 2021. Sézary syndrome data due 2022.", 
    "company": "Innate Pharma S.A.", 
    "indication": "Mycosis Fungoides and Sézary syndrome", 
    "name": "IPH4102 - TELLOMAK", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced March 9, 2020.", 
    "company": "Innate Pharma S.A.", 
    "indication": "Solid tumors", 
    "name": "IPH5201", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approval announced August 21, 2017.", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Hyperuricemia associated with gout", 
    "name": "DUZALLO (LESINURAD AND ALLOPURINOL)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA approval announced January 26, 2017.", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Chronic idiopathic constipation (CIC)", 
    "name": "Linaclotide 72 mcg dose  for use in the treatment of adults", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3b data met all endpoints - June 18, 2019.", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Irritable Bowel Syndrome with Constipation (IBS-C)", 
    "name": "Linaclotide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a data released April 2016. Development to be discontinued due to disappointing data", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Gastroparesis", 
    "name": "IW-9179", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 4Q 2020. Top-line data due 1H 2021.", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Gastroesophageal reflux disease (GERD)", 
    "name": "IW-3718", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "No additional trials planned.", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Achalasia", 
    "name": "IW-1701", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - May 27, 2020.", 
    "company": "Ironwood Pharmaceuticals Inc.", 
    "indication": "Irritable Bowel Syndrome", 
    "name": "MD-7246", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 2H 2020.", 
    "company": "IVERIC bio Inc.", 
    "indication": "Autosomal Recessive Stargardt Disease", 
    "name": "Zimura", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2a top-line data released November 12, 2018 noted that treatment was generally well tolerated.", 
    "company": "IVERIC bio Inc.", 
    "indication": "Wet age-related macular degeneration (Wet-AMD)", 
    "name": "Zimura", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data released December 12, 2016 - primary endpoint not met. Data from third trial released August 14, 2017- primary endpoint not met. ", 
    "company": "IVERIC bio Inc.", 
    "indication": "Wet age-related macular degeneration (Wet-AMD)", 
    "name": "Fovista", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint. Initiation of second trial announced June 30, 2020.", 
    "company": "IVERIC bio Inc.", 
    "indication": "Geographic atrophy", 
    "name": "Zimura - GATHER2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 1H 2021.", 
    "company": "IVERIC bio Inc.", 
    "indication": "Rhodopsin-mediated autosomal dominant retinitis pigmentosa (RHO-adRP)", 
    "name": "IC-100", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated in 2021.", 
    "company": "IVERIC bio Inc.", 
    "indication": "BEST1 related retinal diseases", 
    "name": "IC-200", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 8, 2019.", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Bipolar depression", 
    "name": "ITI-007 - Monotherapy (Study 401)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 interim analysis December 18, 2018 noted trial to stop due to futility. ", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Agitation in patients with dementia", 
    "name": "ITI-007-201", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced December 23, 2019.", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Schizophrenia", 
    "name": "Lumateperone", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 top-line data due mid-September 2020.", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Bipolar depression", 
    "name": "Lumateperone ITI-007-402", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - July 8, 2019.", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Bipolar depression", 
    "name": "ITI-007 - Monotherapy (Study 404)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 top-line data released June 29, 2020 noted improved cardiac output by increasing heart contractility and decreasing vascular resistance.", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Heart failure", 
    "name": "ITI-214-105", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Intra-Cellular Therapies Inc.", 
    "indication": "Bipolar Depression", 
    "name": "Lumateperone ITI-007-403", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 initial expansion data due 1H 2021.", 
    "company": "iTeos Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "EOS-850", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2a data due 1H 2021.", 
    "company": "iTeos Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "EOS-448", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 3Q 2020.", 
    "company": "iTeos Therapeutics Inc.", 
    "indication": "PD-1-Resistant Melanoma", 
    "name": "EOS-850 in combination with pembrolizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 3Q 2020.", 
    "company": "iTeos Therapeutics Inc.", 
    "indication": "Castrate-R Prostate Cancer", 
    "name": "EOS-850 in combination with pembrolizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 3Q 2020.", 
    "company": "iTeos Therapeutics Inc.", 
    "indication": "Triple-negative breast cancer (TNBC)", 
    "name": "EOS-850 and chemotherapy", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data released June 29, 2020. One of two primary endpoints met.", 
    "company": "Iterum Therapeutics plc", 
    "indication": "Uncomplicated urinary tract infections (uUTI)", 
    "name": "Sulopenem", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - June 1, 2020.", 
    "company": "Iterum Therapeutics plc", 
    "indication": "Complicated urinary tract infections (cUTI) ", 
    "name": "Sulopenem", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data missed primary endpoint - December 10, 2019.", 
    "company": "Iterum Therapeutics plc", 
    "indication": "Complicated intra-abdominal infections (cIAI)", 
    "name": "Sulopenem", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Enrolment of first patient announced March 31, 2020.", 
    "company": "Iterum Therapeutics plc", 
    "indication": "COVID-19 Coronavirus", 
    "name": "IFX-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial met primary endpoint - June 2020. Phase 3 trial to be initiated following discussions with the FDA in 4Q 2020.", 
    "company": "Inventiva S.A.", 
    "indication": "Nonalcoholic steatohepatitis (NASH)", 
    "name": "Lanifibranor", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1/2 trial in pediatric population to be initiated 1H 2021.", 
    "company": "Inventiva S.A.", 
    "indication": "MPS VI", 
    "name": "Odiparcil", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 primary completion set for 4Q 2020.", 
    "company": "Inventiva S.A.", 
    "indication": "Psoriasis", 
    "name": "ABBV-157", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 final data due mid-2021.", 
    "company": "Jaguar Health Inc.", 
    "indication": "Cancer related diarrhea (CRD)", 
    "name": "Mytesi (crofelemer) HALT-D", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Protocol development for discussions with FDA.", 
    "company": "Jaguar Health Inc.", 
    "indication": "Inflammatory bowel disease (IBD)", 
    "name": "Mytesi (crofelemer)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Randomized, double-blind, placebo-controlled trial to commence 4Q 2020 with top-line data due 4Q 2021.", 
    "company": "Jaguar Health Inc.", 
    "indication": "Functional diarrhea", 
    "name": "Mytesi (crofelemer)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 4 full enrollment is expected to be reached by the end of 2020, and the study results are expected to be available by mid to late 2021.", 
    "company": "Jaguar Health Inc.", 
    "indication": "Chronic Idiopathic Diarrhea in Non-HIV Patients", 
    "name": "Crofelemer (Mytesi)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 22, 2020.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Cataplexy and Excessive Daytime Sleepiness in Narcolepsy", 
    "name": "Xywav", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL received October 11, 2010.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Fibromyalgia", 
    "name": "JZP-6", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 26, 2018.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Pediatric narcolepsy patients with cataplexy", 
    "name": "Xyrem", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released March 20, 2017 - primary endpoints met.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Excessive sleepiness associated with obstructive sleep apnea", 
    "name": "JZP-110", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced March 20, 2019.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Excessive sleepiness associated with narcolepsy", 
    "name": "Solriamfetol (JZP-110)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to lack of efficacy. ", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "VOD in high-risk patients following hematopoietic stem cell transplantation", 
    "name": "Defibrotide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced August 3, 2017.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Acute myeloid leukemia", 
    "name": "Vyxeos", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "acute Graft-versus-Host-Disease (aGvHD)", 
    "name": "Defibrotide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2H 2020.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Idiopathic Hypersomnia", 
    "name": "JZP-258", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b ongoing.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "First-line unfit Acute myeloid leukemia", 
    "name": "Vyxeos in combination with venetoclax", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "BLA filing due 4Q 2020.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Acute lymphoblastic leukemia (ALL)", 
    "name": "PF743 (JZP-458)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced October 10, 2019.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "CAR-T associated neurotoxicity in diffuse large B-cell lymphoma (DLBCL) patients", 
    "name": "Defibrotide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated early-2021.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Essential Tremor", 
    "name": "JZP-385", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced June 15, 2020.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Small cell lung cancer (SCLC)", 
    "name": "Lurbinectedin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to commence mid-2020.", 
    "company": "Jazz Pharmaceuticals plc", 
    "indication": "Excessive daytime sleepiness (EDS) in major depressive disorder", 
    "name": "Solriamfetol (JZP-110)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data to be presented at ASCO-SITC Clinical Immuno-Oncology Symposium Annual Meeting on February 6, 2020.", 
    "company": "Jounce Therapeutics Inc.", 
    "indication": "Solid tumors - Cancer", 
    "name": "Vopratelimab JTX-2011", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data due 2021. ", 
    "company": "Jounce Therapeutics Inc.", 
    "indication": "Second-line non-small cell lung cancer (NSCLC) patients", 
    "name": "Vopratelimab and JTX-4014 - SELECT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 interim analysis due early 2021.", 
    "company": "Jounce Therapeutics Inc.", 
    "indication": "Non-small cell lung cancer and bladder cancer", 
    "name": "Vopratelimab and Ipilimumab - EMERGE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated in 2020.", 
    "company": "Jounce Therapeutics Inc.", 
    "indication": "", 
    "name": "JTX-8064", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - May 28, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": "Amyloidosis", 
    "name": "DARZALEX (Daratumumab) using ENHANZE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 discontinuation announced October 17, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "Talacotuzumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced February 14, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Non-metastatic castration-resistant prostate cancer (CRPC)", 
    "name": "Apalutamide", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced July 17, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "HIV", 
    "name": "D/C/F/TAF", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 2, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Second-line Chronic graft-versus-host disease (GVHD)", 
    "name": "Imbruvica", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 14, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Reduce the Risk of Recurrent Venous Thromboembolism (VTE)", 
    "name": "XARELTO (rivaroxaban)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced October 23, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Hidradenitis Suppurativa (HS)", 
    "name": "Bermekimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to positive efficacy - February 8, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Coronary Artery Disease or Peripheral Artery Disease", 
    "name": "XARELTO (rivaroxaban)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 30, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Type 2 diabetes", 
    "name": "INVOKANA CANVAS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced September 30, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Diabetic Kidney Disease", 
    "name": "INVOKANA - CREDENCE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 7, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Frontline multiple myeloma (non-transplant)", 
    "name": "DARZALEX (Daratumumab) - ALCYONE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced March 5, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Treatment resistant depression ", 
    "name": "Esketamine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing announced September 26, 2017. Priority Review. Approved January 19, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Marginal zone lymphoma", 
    "name": "Imbruvica", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced October 13, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Plaque psoriasis", 
    "name": "STELARA (USTEKINUMAB)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced October 20, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Psoriatic arthritis (PsA)", 
    "name": "SIMPONI ARIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced October 20, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Ankylosing Spondylitis", 
    "name": "SIMPONI ARIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced July 13, 2017.", 
    "company": "Johnson & Johnson", 
    "indication": "Plaque psoriasis", 
    "name": "Guselkumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued September 22, 2017. Advisory Committee Meeting August 2, 2017 voted 12-1 against that safety data is adequate to support approval. 13-0 in favor of efficacy.", 
    "company": "Johnson & Johnson", 
    "indication": "Rheumatoid arthritis", 
    "name": "Sirukumab ", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approval announced June 16, 2017 - note: submitted by Janssen Biotech, Inc.", 
    "company": "Johnson & Johnson", 
    "indication": "Relapsed or refractory multiple myeloma", 
    "name": "DARZALEX (Daratumumab) +  pomalidomide and dexamethasone", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA approval announced February 8, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "metastatic hormone-naÃ¯ve prostate cancer (mHNPC)", 
    "name": "ZYTIGA (abiraterone acetate) - LATITUDE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 12, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Urothelial cancer", 
    "name": "Erdafitinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Complete Response Letter issued December 21, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "HIV", 
    "name": "Dolutegravir + rilpivirine", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced November 12, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Atopic Dermatitis (AD)", 
    "name": "Bermekimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Announced May 18, 2018 that dosing will be stopped.", 
    "company": "Johnson & Johnson", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Atabecestat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced August 27, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Waldenström’s Macroglobulinemia", 
    "name": "IMBRUVICA (ibrutinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced July 11, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Crohn's disease", 
    "name": "Guselkumab (GALAXI 1)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - noted July 11, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "IMBRUVICA (ibrutinib)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced November 19, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Hidradenitis Suppurativa", 
    "name": "Guselkumab (NOVA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced June 28, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Newly Diagnosed Multiple Myeloma (NDMM)", 
    "name": "Daratumumab - MAIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met - December 12, 2018.", 
    "company": "Johnson & Johnson", 
    "indication": "Psoriasis", 
    "name": "Guselkumab vs Cosentyx - ECLIPSE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 1, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": "Multiple myeloma", 
    "name": "DARZALEX (Daratumumab) using ENHANZE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2a initiation announced January 17, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Ulcerative colitis", 
    "name": "Guselkumab ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced October 21, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Ulcerative colitis", 
    "name": "STELARA (USTEKINUMAB)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 20, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": "Multiple Myeloma", 
    "name": "Darzalex (daratumumab) and Kyprolis (carfilzomib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced September 18, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Metastatic castration-sensitive prostate cancer (mCSPC).", 
    "name": "Apalutamide", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 initial data to be presented at ASCO GU February 14, 2019. ORR 40%.", 
    "company": "Johnson & Johnson", 
    "indication": "Castration-Resistant Prostate Cancer", 
    "name": "Niraparib (Galahad)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval announced February 27, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Plaque psoriasis", 
    "name": "Guselkumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced September 26, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Multiple myeloma - candidates for autologous stem cell transplant (ASCT)", 
    "name": "Daratumumab + VTD", 
    "stage": "approved"
  }, 
  {
    "newstxt": "NDA filing announced March 18, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": "Relapsing multiple sclerosis", 
    "name": "Ponesimod", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced July 14, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": " Psoriatic Arthritis", 
    "name": "Guselkumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced October 2, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Systemic Sclerosis", 
    "name": "Bermekimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced August 3, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": "Major depressive disorder (MDD)", 
    "name": "Esketamine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA filing announced October 7, 2019.", 
    "company": "Johnson & Johnson", 
    "indication": "Plaque psoriasis - pediatric", 
    "name": "STELARA (USTEKINUMAB)", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced April 21, 2020.", 
    "company": "Johnson & Johnson", 
    "indication": "Chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).", 
    "name": "IMBRUVICA (ibrutinib) and rituximab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 trial has been initiated, Initial Phase I data due second half of September, with a Phase 3 trial to start mid to end September.", 
    "company": "Johnson & Johnson", 
    "indication": "COVID-19 vaccine", 
    "name": "Ad26.COV2-S", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA approval announced August 23, 2018.", 
    "company": "Kala Pharmaceuticals Inc.", 
    "indication": "Postâ€‘operative inflammation and pain following cataract surgery", 
    "name": "INVELTYS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released January 5, 2017 - both primary symptom endpoints met. Primary sign endpoint missed.", 
    "company": "Kala Pharmaceuticals Inc.", 
    "indication": "Dry eye disease", 
    "name": "INVELTYS - STRIDE 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL issued August 8, 2019. NDA resubmitted with new PDUFA date of October 30, 2020.", 
    "company": "Kala Pharmaceuticals Inc.", 
    "indication": "Dry eye disease", 
    "name": "EYSUVIS (KPIâ€‘121) 0.25%", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - March 9, 2020.", 
    "company": "Kala Pharmaceuticals Inc.", 
    "indication": "Dry eye disease", 
    "name": "KPIâ€‘121 0.25% STRIDE 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data did not meet primary endpoint - December 9, 2019.", 
    "company": "KalVista Pharmaceuticals Inc.", 
    "indication": "Diabetic macular edema (DME)", 
    "name": "KVD001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "KalVista Pharmaceuticals Inc.", 
    "indication": "Hereditary Angioedema (HAE) ", 
    "name": "KVD900", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020. ", 
    "company": "KalVista Pharmaceuticals Inc.", 
    "indication": "Hereditary angioedema", 
    "name": "KVD824", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "NDA filing 4Q 2020.", 
    "company": "Kadmon Holdings Inc.", 
    "indication": "Chronic graft-versus-host disease (cGVHD)", 
    "name": "KD025 - ROCKstar (KD025-213)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 data released February 12, 2018. Open label - noted data were \"positive\".", 
    "company": "Kadmon Holdings Inc.", 
    "indication": "Idiopathic pulmonary fibrosis (IPF)", 
    "name": "KD025", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial enrolling.", 
    "company": "Kadmon Holdings Inc.", 
    "indication": "Systemic sclerosis (scleroderma)", 
    "name": "KD025", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Kadmon Holdings Inc.", 
    "indication": "Fibrosis (kidney/lung/liver)", 
    "name": "KD045", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dosing of first patient announced June 23, 2020.", 
    "company": "Kadmon Holdings Inc.", 
    "indication": "Advanced Solid Tumors", 
    "name": "KD033", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2021.\n", 
    "company": "Kaleido Biosciences Inc.", 
    "indication": "Urea cycle disorder (UCD)", 
    "name": "KB195 (UNLOCKED)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Top-line data due 4Q 2020. Non-IND trial.", 
    "company": "Kaleido Biosciences Inc.", 
    "indication": "Mild-to-moderate COVID-19", 
    "name": "KB109 (K031)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Top-line data due 1Q 2021. Non-IND trial.", 
    "company": "Kaleido Biosciences Inc.", 
    "indication": "Mild-to-Moderate COVID-19", 
    "name": "KB109 (K032)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 3Q 2020 with top-line data due mid-2021.", 
    "company": "Kaleido Biosciences Inc.", 
    "indication": "Ulcerative colitis (UC)", 
    "name": "KB295", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 2020.", 
    "company": "Kamada Ltd.", 
    "indication": "Prevention of lung transplant rejection", 
    "name": "Alpha-1 antitrypsin (AAT)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Approval announced August 25, 2017.", 
    "company": "Kamada Ltd.", 
    "indication": "Prophylaxis of rabies disease", 
    "name": "KamRAB", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced December 16, 2019.", 
    "company": "Kamada Ltd.", 
    "indication": "AATD - Alpha-1 Antitrypsin deficiency", 
    "name": "Inhaled formulation of AAT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released November 3, 2017. No significant treatment effect noted overall.", 
    "company": "Kamada Ltd.", 
    "indication": "Pediatric patients newly diagnosed with type 1 diabetes", 
    "name": "Alpha-1 Antitrypsin (AAT)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 interim data due 2020.", 
    "company": "Kamada Ltd.", 
    "indication": "Graft Versus Host Disease (GvHD)", 
    "name": "Alpha-1 antitrypsin (AAT)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1/2 commencement of enrollment in Israel announced August 10, 2020. IND required for U.S. trials.", 
    "company": "Kamada Ltd.", 
    "indication": "COVID-19", 
    "name": "Plasma-derived IgG product", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "PDUFA date March 2, 2021.", 
    "company": "KemPharm Inc.", 
    "indication": "ADHD", 
    "name": "KP415", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "CRL issued June 13, 2016. Resubmitted, and issued FDA Approval February 23, 2018.", 
    "company": "KemPharm Inc.", 
    "indication": "Acute pain", 
    "name": "Apadaz (KP201/APAP)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Pivotal data due in 2020.", 
    "company": "KemPharm Inc.", 
    "indication": "ADHD", 
    "name": "KP484", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sBLA filing due 2H 2020.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Pericarditis", 
    "name": "Rilonacept (RHAPSODY)", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Giant cell arteritis (GCA)", 
    "name": "Mavrilimumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data showed no meaningful benefit - August 12, 2019.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Atopic dermatitis", 
    "name": "KPL-716", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated 4Q 2020.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Prurigo nodularis", 
    "name": "Vixarelimab (KPL-716)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 interim data due released May 11, 2020.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Chronic Pruritus", 
    "name": "Vixarelimab (KPL-716)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Relapsed or Refractory Large B-Cell Lymphoma", 
    "name": "Mavrilimumab and Yescarta", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data due 4Q 2020.", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "Healthy volunteers", 
    "name": "KPL-404", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial potentially planned. Early clinical data from open-label treatment noted no deaths among 13 patients. ", 
    "company": "Kiniksa Pharmaceuticals Ltd.", 
    "indication": "COVID-19", 
    "name": "Mavrilimumab", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 pivotal trial top-line data due 2021.", 
    "company": "Kodiak Sciences Inc", 
    "indication": "Wet age-related macular degeneration (AMD)", 
    "name": "KSI-301 (DAZZLE)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 pivotal trial to commence September/October 2020.", 
    "company": "Kodiak Sciences Inc", 
    "indication": "Diabetic macular edema (DME) / wet AMD", 
    "name": "KSI-301", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in September/October 2020.", 
    "company": "Kodiak Sciences Inc", 
    "indication": "Retinal vein occlusion (RVO)", 
    "name": "KSI-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated.", 
    "company": "Kodiak Sciences Inc", 
    "indication": "Diabetic retinopathy", 
    "name": "KSI-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due in 2H 2020.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Dedifferentiated liposarcoma", 
    "name": "Selinexor - SEAL", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "FDA Approval announced July 3, 2019. ", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Quadruple Refractory Multiple Myeloma", 
    "name": "Selinexor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date estimate March 19, 2021.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "Selinexor", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA Approval announced June 22, 2020.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Diffuse Large B-Cell Lymphoma (DLBCL)", 
    "name": "Selinexor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Data Safety Monitoring Board (DSMB) noted March 2, 2017 that trial will not meet primary endpoint.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Cancer - Relapsed/Refractory Acute Myeloid Leukemia (AML)", 
    "name": "Selinexor SOPRA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial terminated.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Richter's transformation", 
    "name": "Selinexor - SIRRT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial terminated.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Cancer - hormone-refractory prostate cancer (HRPC)", 
    "name": "Selinexor - SHIP", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2020.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Endometrial cancer", 
    "name": "Selinexor - SIENDO", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data reported at ASCO-GU 2019.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "Eltanexor", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 ongoing.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Non-Hodgkin Lymphoma", 
    "name": "KPT-9274", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data noted unlikely to demonstrate efficacy benefit across entire patient population with benefit in a clearly defined subpopulation of patients. ", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "COVID-19 Coronavirus", 
    "name": "Selinexor", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 commencement of dosing announced June 9, 2020.", 
    "company": "Karyopharm Therapeutics Inc.", 
    "indication": "Glioblastoma", 
    "name": "Selinexor", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2H 2021.", 
    "company": "Keros Therapeutics Inc.", 
    "indication": "Osteoporosis", 
    "name": "KER-012", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned for 2021.", 
    "company": "Keros Therapeutics Inc.", 
    "indication": "Myelofibrosis", 
    "name": "KER-050", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned for 2H 2020.", 
    "company": "Keros Therapeutics Inc.", 
    "indication": "Myelodysplastic syndromes", 
    "name": "KER-050", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 completion of dosing announced August 4, 2020. Data due 2H 2020.", 
    "company": "Keros Therapeutics Inc.", 
    "indication": "Anemia ", 
    "name": "KER-047", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in 2020. Additional Phase 3 trial to be initiated 1H 2021.", 
    "company": "Karuna Therapeutics Inc.", 
    "indication": "Acute psychosis in patients with schizophrenia", 
    "name": "KarXT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data due by the end of 2020.", 
    "company": "Karuna Therapeutics Inc.", 
    "indication": "Healthy elderly volunteers / dementia-related psychosis", 
    "name": "KarXT", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b data released August 3, 2020. Insufficient evidence of an analgesic benefit compared to placebo. Development to be discontinued for pain indication.", 
    "company": "Karuna Therapeutics Inc.", 
    "indication": "Pain in healthy volunteers ", 
    "name": "KarXT", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced July 28, 2020. Top-line data due in 2021.", 
    "company": "Krystal Biotech Inc.", 
    "indication": "Epidermolysis Bullosa", 
    "name": "B-VEC (Beremagene Geperpavec)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrollment announced August 10, 2020.", 
    "company": "Krystal Biotech Inc.", 
    "indication": "Transglutaminase-1 Deficient Autosomal Recessive Congenital Ichthyosis", 
    "name": "KB105", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced August 25, 2020 with initial data due in 2021.", 
    "company": "Krystal Biotech Inc.", 
    "indication": "Wrinkles and acne scars ", 
    "name": "KB301 (PEARL-1)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approval announced May 31, 2018.", 
    "company": "Kitov Pharma Ltd.", 
    "indication": "Osteoarthritis and Hypertension", 
    "name": "KIT-302", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced July 9, 2020 with initial data due 2H 2021.", 
    "company": "Kitov Pharma Ltd.", 
    "indication": "Squamous cell carcinoma of the head & neck (SCCHN)", 
    "name": "NT-219", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence 2H 2020.", 
    "company": "Kitov Pharma Ltd.", 
    "indication": "Non-small cell lung cancer", 
    "name": "CM-24 and Opdivo", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 interim data noted PFS of 8.7 months. Top-line data due 3Q 2020.", 
    "company": "Kintara Therapeutics Inc.", 
    "indication": "MGMT-unmethylated newly diagnosed Glioblastoma Multiforme (GBM)", 
    "name": "VAL-083", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data noted overall survival of 7.1 months. Update due at Society for Neuro-Oncology Annual Scientific Meeting in November 19 - 22, 2020.", 
    "company": "Kintara Therapeutics Inc.", 
    "indication": "MGMT-unmethylated Recurrent Glioblastoma Multiforme (GBM)", 
    "name": "VAL-083", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Kura Oncology Inc.", 
    "indication": "Chronic myelomonocytic leukemia (CMML) - cancer", 
    "name": "Tipifarnib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Registration-directed trial to be initiated in 2H 2020.", 
    "company": "Kura Oncology Inc.", 
    "indication": "Relapsed or refractory peripheral T-cell lymphoma", 
    "name": "Tipifarnib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrolling.", 
    "company": "Kura Oncology Inc.", 
    "indication": "Head and neck squamous cell carcinomas (HNSCC)", 
    "name": "Tipifarnib - (AIM-HN/SEQ-HN)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 development terminated - May 4, 2020.", 
    "company": "Kura Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "KO-947", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 mature data presented at ASCO May 29, 2020 - Median OS of 15.4 months, median PFS of 5.9 months and ORR of 50% observed in recurrent/metastatic HRAS mutant HNSCC", 
    "company": "Kura Oncology Inc.", 
    "indication": "Head and neck squamous cell carcinomas (HNSCC) with HRAS Mutations", 
    "name": "Tipifarnib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial presentation at ASH December 5-8, 2020", 
    "company": "Kura Oncology Inc.", 
    "indication": "Relapsed or refractory acute myeloid leukemia (AML)", 
    "name": "KO-539", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Kura Oncology Inc.", 
    "indication": "HRAS Mutant Urothelial Carcinoma", 
    "name": "Tipifarnib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 1H 2021.", 
    "company": "Kymera Therapeutics Inc.", 
    "indication": "Hidradenitis suppurativa / atopic dermatitis", 
    "name": "KT-474", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 2H 2021.", 
    "company": "Kymera Therapeutics Inc.", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "IRAKIMiD program", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2H 2021.", 
    "company": "Kymera Therapeutics Inc.", 
    "indication": "Oncology", 
    "name": "STAT3 program", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 new interim data noted PFS of 8.5 months, compared with 5.3 months with temozolomide (standard of care). Overall survival 17.7 months, compared with 12.7 months for temozolomide. Further data due 2H 2020, and final data in 1H 2021.\n", 
    "company": "Kazia Therapeutics Limited", 
    "indication": "Glioblastoma multiforme", 
    "name": "GDC-0084", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 ORR 19% (1 complete response + 2 partial responses) June 22, 2020. Final data due 2H 2020.", 
    "company": "Kazia Therapeutics Limited", 
    "indication": "Ovarian cancer ", 
    "name": "Cantrixil", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "Kazia Therapeutics Limited", 
    "indication": "Breast cancer brain metastases", 
    "name": "GDC-0084", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial efficacy data due 2H 2020.", 
    "company": "Kazia Therapeutics Limited", 
    "indication": "Diffuse Intrinsic Pontine Glioma", 
    "name": "Paxalisib (GDC-0084)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial to be initiated 2H 2020.", 
    "company": "Kazia Therapeutics Limited", 
    "indication": "Glioblastoma", 
    "name": "GDC-0084", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 interim data due late-2021.", 
    "company": "Kezar Life Sciences Inc.", 
    "indication": "Lupus", 
    "name": "KZR-616 (MISSION)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial is enrolling.", 
    "company": "Kezar Life Sciences Inc.", 
    "indication": "Dermatomyositis and polymyositis", 
    "name": "KZR-616", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2H 2020.", 
    "company": "Lineage Cell Therapeutics, Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "VAC2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Intends to meet with FDA 2H 2020 regarding further development of program.", 
    "company": "Lineage Cell Therapeutics, Inc.", 
    "indication": "Cervical spinal cord injury", 
    "name": "AST-OPC1 SCiSTAR", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 updated data due at AAO meeting November 14-17, 2020.", 
    "company": "Lineage Cell Therapeutics, Inc.", 
    "indication": "Dry age-related macular degeneration (AMD)", 
    "name": "OpRegen", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 to be presented 2H 2020. BLA filing also due to be filed 2H 2020.", 
    "company": "Legend Biotech Corporation", 
    "indication": "Multiple myeloma", 
    "name": "LCAR-B38M/JNJ-4528 (CARTITUDE-1)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Legend Biotech Corporation", 
    "indication": "Relapsed and refractory B-cell lymphoma", 
    "name": "LB1909", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Legend Biotech Corporation", 
    "indication": "Acute myeloid leukemia (AML) ", 
    "name": "LB1910", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Legend Biotech Corporation", 
    "indication": "Gastric cancer ", 
    "name": "LB1904", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Legend Biotech Corporation", 
    "indication": "Pancreatic Cancer", 
    "name": "LB1904", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "sNDA approval announced June 11, 2018.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Relapsed Multiple Myeloma", 
    "name": "KYPROLIS (ASPIRE)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2a data released March 2, 2018.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis", 
    "name": "RPL554", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "FDA approval announced March 19, 2018.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Postpartum Depression - moderate", 
    "name": "Brexanolone - SAGE-547 (202C)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 1, 2018.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Multiple Myeloma", 
    "name": "KYPROLIS (ARROW)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA approved January 17, 2018.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Relapsed Multiple Myeloma", 
    "name": "KYPROLIS (ENDEAVOR)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 3Q 2020 with data due 1H 2022.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Refractory status epilepticus (RSE)", 
    "name": "Ganaxolone", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 negative data released July 23, 2019.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Postpartum depression", 
    "name": "Ganaxolone - Magnolia", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released June 2016. Primary endpoint not met but intends to advance development", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Fragile X Syndrome", 
    "name": "Ganaxolone", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1Q 2021.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Focal segmental glomerulosclerosis (FSGS)", 
    "name": "Sparsentan - DUPLEX", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b enrolment to be completed 1H 2021.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Non-alcoholic steatohepatitis (NASH) and fibrosis", 
    "name": "VK2809 VOYAGE", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Acute Hip Fracture", 
    "name": "VK5211", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 3Q 2020.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "CDKL5 Deficiency Disorder (CDD)", 
    "name": "Ganaxolone - Marigold", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - January 2, 2020. Additional Phase 3 trial to be initiated September 2020 with data due late-2Q 2021.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Molluscum", 
    "name": "SB206", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "IgA nephropathy", 
    "name": "Sparsentan", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "APVO436", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint - August 5, 2019.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Maintenance treatment of COPD", 
    "name": "RPL554 DPI formulation", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 top-line data met primary endpoint - July 10, 2019.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Contrast-induced Nephropathy", 
    "name": "Captisol-enabled (CE) Iohexol program", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b additional data to be presented at ESMO September 8, 2020. Phase 3 trial to be initiated 2H 2020.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Ensifentrine (RPL554) and tiotropium", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 MDI second part of trial initiation announced August 19, 2020 with data due 1H 2021.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Maintenance treatment of COPD", 
    "name": "Ensifentrine (RPL554) - Metered Dose Inhaler", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial has been initiated by partner CStone Pharmaceuticals.", 
    "company": "Ligand Pharmaceuticals Incorporated", 
    "indication": "Gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma.", 
    "name": "CS1001", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "aTyr Pharma Inc.", 
    "indication": "Pulmonary sarcoidosis", 
    "name": "ATYR1923", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 dosing of first patient announced June 15, 2020.", 
    "company": "aTyr Pharma Inc.", 
    "indication": "COVID-19", 
    "name": "ATYR1923", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued due to lack of efficacy - November 25, 2019.", 
    "company": "La Jolla Pharmaceutical Company", 
    "indication": "Beta thalassemia patients suffering from iron overload", 
    "name": "LJPC-401", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date under priority review scheduled for February 28, 2018. Approval announced December 21, 2017.", 
    "company": "La Jolla Pharmaceutical Company", 
    "indication": "Increase blood pressure in adults with septic or other distributive shock", 
    "name": "GiaprezaTM (angiotensin II)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 27, 2018.", 
    "company": "La Jolla Pharmaceutical Company", 
    "indication": "cIAI (complicated intra-abdominal infections)", 
    "name": "Eravacycline (TP-434) - IGNITE4", 
    "stage": "approved"
  }, 
  {
    "newstxt": "On May 29, 2020, La Jolla received tentative approved. La Jolla will not receive final approval until Amivasâ€™ 7-year market exclusivity has expired.", 
    "company": "La Jolla Pharmaceutical Company", 
    "indication": "Severe Malaria", 
    "name": "LJPC-0118", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint - June 6, 2019. ", 
    "company": "La Jolla Pharmaceutical Company", 
    "indication": "Hereditary Hemochromatosis", 
    "name": "LJPCâ€‘401", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 BREEZE-AD5 trial met primary endpoint - January 30, 2020. ", 
    "company": "Eli Lilly and Company", 
    "indication": "Atopic dermatitis", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced December 30, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Medullary thyroid cancer (MTC)", 
    "name": "LOXO-292", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval (label expansion) announced June 5, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "First-Line Nonsquamous Non-small cell lung cancer (NSCLC)", 
    "name": "KEYTRUDA + chemo (KEYNOTE-021)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced September 27, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Migraine prevention", 
    "name": "Galcanezumab - EVOLVE-1, EVOLVE-2 and REGAIN", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 11, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Migraine", 
    "name": "Lasmiditan", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA label expansion announced January 31, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)", 
    "name": "(MK-3475-189/KEYNOTE-189)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.", 
    "company": "Eli Lilly and Company", 
    "indication": "Chronic low back pain", 
    "name": "Tanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 15, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Diabetes", 
    "name": "Lyumjev ultra rapid insulin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date December 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Osteoarthritis", 
    "name": "Tanezumab", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Cancer pain", 
    "name": "Tanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 PFS data met primary endpoint but overall survival not improved. Will not seek regulatory approval.", 
    "company": "Eli Lilly and Company", 
    "indication": "First-line gastric cancer", 
    "name": "Ramucirumab - RAINFALL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 28, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Patients evaluated for Alzheimer's Disease", 
    "name": "Flortaucipir F 18 (Tau imaging agent)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - December 13, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Heart failure with preserved ejection fraction (HFpEF)", 
    "name": "Empagliflozin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - December 13, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Heart failure with reduced ejection fraction (HFrEF)", 
    "name": "Empagliflozin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced February 26, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "HR+, HER2-locoregionally recurrent or metastatic breast cancer (MBC)", 
    "name": "Abemaciclib - MONARCH 3", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved October 4, 2017.", 
    "company": "Eli Lilly and Company", 
    "indication": "Second-line hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer and HR+, HER2- breast cancer", 
    "name": "Abemaciclib - MONARCH 1 and 2", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released October 10, 2017 - primary endpoint not met.", 
    "company": "Eli Lilly and Company", 
    "indication": "Thrid line KRAS mutation positive Non-small cell lung cancer (NSCLC)", 
    "name": "Abemaciclib - JUNIPER", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced December 1, 2017.", 
    "company": "Eli Lilly and Company", 
    "indication": "Psoriatic Arthritis", 
    "name": "Taltz", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Rheumatoid arthritis", 
    "name": "Baricitinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 26, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Solid tumors that harbor a TRK fusion.", 
    "name": "Larotrectinib (LOXO-101)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced June 29, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Primary axillary hyperhidrosis", 
    "name": "Glycopyrronium tosylate", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL announced March 20, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Type 1 Diabetes", 
    "name": "Empagliflozin", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Announced discontinuation of trial due to futility - June 12, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Early Alzheimer's disease", 
    "name": "Lanabecestat (AZD3293) - AMARANTH", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced May 13, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Hepatocellular Carcinoma", 
    "name": "Ramucirumab REACH-2", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 29, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Non-small cell lung cancer", 
    "name": "CYRAMZA Ramucirumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 26, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Axial Spondyloarthritis", 
    "name": "Ixekizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - July 19, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Type 2 Diabetes", 
    "name": "Tradjenta (linagliptin) - CARMELINA CV outcomes", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced October 9, 2019. Top-line data due 2021.", 
    "company": "Eli Lilly and Company", 
    "indication": "Atopic Dermatitis", 
    "name": "Lebrikizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 4, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Cluster headache", 
    "name": "Galcanezumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due spring of 2021.", 
    "company": "Eli Lilly and Company", 
    "indication": "Ulcerative Colitis", 
    "name": "Mirikizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced February 21, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Type 2 diabetes", 
    "name": "Trulicity REWIND CV outcomes", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint of non-inferiority.", 
    "company": "Eli Lilly and Company", 
    "indication": "Type 2 Diabetes", 
    "name": "Tradjenta (linagliptin) - CAROLINA CV outcomes", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary and all key secondary endpoints vs placebo at Week 16 and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 and Week 52 - July 17, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Psoriasis", 
    "name": "Mirikizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Eli Lilly and Company", 
    "indication": "Alopecia Areata", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Eli Lilly and Company", 
    "indication": "Systemic lupus erythematosus (SLE)", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data did not meet primary endpoint - October 16, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Pancreatic ductal adenocarcinoma (PDAC)", 
    "name": "AM0010 (PEG-IL-10) - Sequoia", 
    "stage": "phase3"
  }, 
  {
    "newstxt": " CYPRESS-1 trial was closed early after the planned final analysis because the risk benefit ratio is unfavorable.", 
    "company": "Eli Lilly and Company", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Pegilodecakin (LY3500518) and Pembrolizumab - Cypress 1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 presentation at ASH December 8, 2019 noted CLL 77% ORR; MCL 50% ORR.", 
    "company": "Eli Lilly and Company", 
    "indication": "Refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), non-Hodgkinâ€™s lymphomas (NHL)", 
    "name": "LOXO-305", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data released January 18, 2018 did not meet primary endpoint. FDA had already awarded accelerated approval.", 
    "company": "Eli Lilly and Company", 
    "indication": "Soft tissue sarcoma (STS)", 
    "name": "LARTRUVO (olaratumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 1, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Non-radiographic axial spondyloarthritis", 
    "name": "Taltz (Ixekizumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Proof of concept initiation announced February 22, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Primary palmar hyperhidrosis", 
    "name": "QBREXZA (glycopyrronium)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due late-2020 (first of five trials).", 
    "company": "Eli Lilly and Company", 
    "indication": "Type 2 Diabetes", 
    "name": "Tirzepatide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Eli Lilly and Company", 
    "indication": "Crohn's disease", 
    "name": "Mirikizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced January 27, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Type 2 Diabetes", 
    "name": "Empagliflozin, linagliptin and metformin - triple combo", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary and key secondary endpoints - December 17, 2018.", 
    "company": "Eli Lilly and Company", 
    "indication": "Psoriatic Arthritis", 
    "name": "Taltz (Ixekizumab) and adalimumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 24, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Severe hypoglycemia in people with diabetes", 
    "name": "BAQSIMI (glucagon)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Eli Lilly and Company", 
    "indication": "Alzheimer's disease", 
    "name": "Zagotenemab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - August 5, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Chronic and episodic migraine", 
    "name": "Galcanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 10, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Inherited Alzheimer's disease", 
    "name": "Solanezumab", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced December 11, 2019.", 
    "company": "Eli Lilly and Company", 
    "indication": "Treatment-naÃ¯ve RET fusion-positive non-small cell lung cancer (NSCLC)", 
    "name": "Selpercatinib (LOXO-292)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - January 13, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Nonsquamous NSCLC", 
    "name": "Tyvyt and ALIMTA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 8, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Non-small cell lung cancer, medullary thyroid cancer and thyroid cancer. ", 
    "name": "Selpercatinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced March 30, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Pediatric Patients with Moderate to Severe Plaque Psoriasis", 
    "name": "Taltz (ixekizumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Inherited Alzheimers Disease", 
    "name": "Solanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 enrolling.", 
    "company": "Eli Lilly and Company", 
    "indication": "COVID-19", 
    "name": "LY3127804", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "COVID-19", 
    "name": "Baricitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 enrollment to be completed in September with initial data due soon thereafter and full data due 4Q 2020. Phase 3 trial initiation announced August 3, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "COVID-19 Antibody", 
    "name": "LY-CoV555 (BLAZE-1/2)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 commencement of dosing announced June 8, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "COVID-19 antibody", 
    "name": "JS016", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial met the primary endpoint of invasive disease-free survival (IDFS) - June 16, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "HR+ / HER2- breast cancer", 
    "name": "Abemaciclib - monarchE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - July 30, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Heart failure with reduced ejection fraction", 
    "name": "Empagliflozin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint August 5, 2020.", 
    "company": "Eli Lilly and Company", 
    "indication": "Heart failure with reduced ejection fraction", 
    "name": "EMPEROR-Reduced", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - December 23, 2019. NDA filing due 3Q 2020.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Prostate cancer", 
    "name": "PyL", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 trial to be completed 2H 2020.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Coronary artery disease (CAD)", 
    "name": "flurpiridaz F 18", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced July 30, 2018.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Pheochromocytoma", 
    "name": "Azedra", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met one of two co-primary endpoints.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Help visualize prostate cancer by targeting prostate specific membrane antigen (PSMA)", 
    "name": "1404", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved July 19 2016.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Chronic pain", 
    "name": "Oral RELISTOR", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 29, 2014.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Chronic pain", 
    "name": "Subcutaneous RELISTOR", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 enrolment has paused due to COVID-19.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Prostate Cancer", 
    "name": "1095", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 3, 2020.", 
    "company": "Lantheus Holdings Inc.", 
    "indication": "Left Ventricular Ejection Fraction", 
    "name": "DEFINITY (BENEFIT 1)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 enrollment to commence early 2021.", 
    "company": "LogicBio Therapeutics Inc.", 
    "indication": "Methylmalonic Acidemia (MMA)", 
    "name": "LB-001 - SUNRISE", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2b top-line data released September 2016. Seeking feedback from FDA regarding Phase 3 design.", 
    "company": "Lipocine Inc.", 
    "indication": "Oral testosterone product", 
    "name": "LPCN 1111", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "PDUFA date August 28, 2020", 
    "company": "Lipocine Inc.", 
    "indication": "Men with low testosterone (Low T)", 
    "name": "TLANDO - LPCN 1021", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Conduct food/fact effect study in preparation for Phase 3 trial.", 
    "company": "Lipocine Inc.", 
    "indication": "Prevention of preterm birth (\"PTB\").", 
    "name": "LPCN 1107", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 4Q 2020.", 
    "company": "Lipocine Inc.", 
    "indication": "Non-alcoholic fatty liver disease (NAFLD) / Non-alcoholic steatohepatitis (NASH)", 
    "name": "LPCN 1144", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020 or 1Q 2021.", 
    "company": "Lipocine Inc.", 
    "indication": "Liver cirrhosis", 
    "name": "LPCN 1148", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data August 6, 2019 noted 50% ORR.", 
    "company": "Leap Therapeutics Inc.", 
    "indication": "Esophagogastric adenocarcinoma", 
    "name": "DKN-01 + KEYTRUDA", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data released December 14, 2018 noted 21.3% PR rate.", 
    "company": "Leap Therapeutics Inc.", 
    "indication": "Biliary tract cancer (BTC)", 
    "name": "DKN-01", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data noted stable disease of 55% - April 23, 2020. ORR 10% in monotherapy arm.", 
    "company": "Leap Therapeutics Inc.", 
    "indication": "Endometrial Cancer", 
    "name": "DKN-01 and Paclitaxel", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "De-prioritizing further development - November 14, 2019", 
    "company": "Leap Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "TRX518", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trials planned for 2020.", 
    "company": "Liquidia Technologies Inc.", 
    "indication": "Post-operative pain", 
    "name": "LIQ865", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date November 24, 2020.", 
    "company": "Liquidia Technologies Inc.", 
    "indication": "Pulmonary arterial hypertension", 
    "name": "LIQ861 - INSPIRE", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 1 top-line data due 1H 2021.", 
    "company": "Larimar Therapeutics Inc.", 
    "indication": "Friedreichâ€™s ataxia (FA)", 
    "name": "CTI-1601", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced December 19, 2019.", 
    "company": "Lumos Pharma Inc.", 
    "indication": "Ebola", 
    "name": "ERVEBO (V920)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated by the end of 2020.", 
    "company": "Lumos Pharma Inc.", 
    "indication": "Pediatric Growth Hormone Deficiency (PGHD)", 
    "name": "LUM-201", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 data released September 9, 2016 met primary endpoint. Data from second trial released December 21, 2016 - primary endpoint met. Data from third trial also met primary endpoint - June 9, 2017.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Type 1 Diabetes", 
    "name": "Sotagliflozin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Type 1 Diabetes", 
    "name": "Sotagliflozin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL issued March 22, 2019. Appeal rejected by FDA - December 2, 2019.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Type 1 Diabetes", 
    "name": "Sotagliflozin", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approved February 28, 2017.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Carcinoid Syndrome", 
    "name": "Telotristat etiprate (XERMELO)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "SNY informed LXRX July 26, 2019 that it plans to terminate its agreement following insufficient efficacy across three Phase 3 trials. Four Phase 3 sotagliflozin trials (July 21, 2020) met their primary objectives.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Type 2 Diabetes", 
    "name": "Sotagliflozin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 dosing to commence 3Q 2020.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Neuropathic pain", 
    "name": "LX9211", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a PFS data due 4Q 2020.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Biliary tract cancer (BTC)", 
    "name": "Telotristat ethyl - TELE-ABC", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "Lexicon Pharmaceuticals Inc.", 
    "indication": "Post-herpetic neuralgia", 
    "name": "LX9211", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Lyra Therapeutics Inc.", 
    "indication": "Chronic rhinosinusitis / Chronic Sinusitis", 
    "name": "LYR-210 - LANTERN", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial termination announced November 7, 2018.", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "HER2 negative metastatic breast cancer", 
    "name": "MM-121 (SHERBOC)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released June 25, 2018 - endpoints not met.", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Cancer - front line pancreatic cancer", 
    "name": "MM-141 - CARRIE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued December 21, 2016 due to poor efficacy.", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Cancer - HER2-positive locally advanced or metastatic breast cancer", 
    "name": "MM-302 HERMIONE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved October 22, 2015.", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Cancer - second line pancreatic", 
    "name": "ONIVYDE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued due to futility - noted October 19, 2018.", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Cancer - Heregulin Positive Non-Small Cell Lung Cancer", 
    "name": "MM-121 SHERLOC", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Acquired by Ipsen", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Cancer - HER2-negative gastric cancer", 
    "name": "ONIVYDE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Acquired by Ipsen", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Cancer - front line pancreatic", 
    "name": "ONIVYDE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Announced April 4, 2019 discontinuation of development.", 
    "company": "Merrimack Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "MM-310", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial is enrolling - noted August 10, 2020.", 
    "company": "Mustang Bio Inc.", 
    "indication": "Acute myeloid leukemia", 
    "name": "MB-102", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 MBIO IND to be filed 4Q 2020.", 
    "company": "Mustang Bio Inc.", 
    "indication": "Glioblastoma", 
    "name": "MB-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned with top-line data due 2H 2022.", 
    "company": "Mustang Bio Inc.", 
    "indication": "X-linked Severe Combined Immunodeficiency (XSCID)", 
    "name": "MB-107", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due at ASH December 5-8, 2020.", 
    "company": "Mustang Bio Inc.", 
    "indication": "B-cell Non-Hodgkin Lymphoma & Chronic Lymphocytic Leukemia (CLL)", 
    "name": "MB-106", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 first data due 1Q 2021.", 
    "company": "Mustang Bio Inc.", 
    "indication": "Prostate cancer", 
    "name": "MB-105", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial opening announced October 9, 2019.", 
    "company": "Mustang Bio Inc.", 
    "indication": "Glioblastoma", 
    "name": "IL13Ralpha2-Targeted CAR-T and Nivolumab/ Ipilimumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 commencement of dosing announced October 24, 2019.", 
    "company": "Mustang Bio Inc.", 
    "indication": "Glioblastoma multiforme", 
    "name": "MB-108", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 IND to be filed 3Q 2020.", 
    "company": "Mustang Bio Inc.", 
    "indication": "X-linked severe combined immunodeficiency (XSCID)", 
    "name": "MB-207", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 first data due 2021.", 
    "company": "Mustang Bio Inc.", 
    "indication": "Multiple Myeloma ", 
    "name": "MB-104", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 first data due 2021.", 
    "company": "Mustang Bio Inc.", 
    "indication": "GBM and Metastatic Breast Cancer to Brain", 
    "name": "MB-103", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 interim data presented December 4, 2019.", 
    "company": "Moleculin Biotech Inc.", 
    "indication": "Acute myeloid leukemia (AML) - cancer", 
    "name": "Annamycin", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial initiated.", 
    "company": "Moleculin Biotech Inc.", 
    "indication": "Glioblastoma", 
    "name": "WP1066", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data demonstrated safety - November 19, 2019. ", 
    "company": "Moleculin Biotech Inc.", 
    "indication": "Cutaneous T-Cell Lymphoma (CTCL)", 
    "name": "WP1220", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - August 10, 2020.", 
    "company": "Seres Therapeutics Inc.", 
    "indication": "Recurrent C. Difficile infection", 
    "name": "SER-109 - ECOSPOR III", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b enrolment has slowed due to COVID-19. No updated timeline for data readout provided. Previous guidance was for data due 2H 2020. ", 
    "company": "Seres Therapeutics Inc.", 
    "indication": "Mild-to-Moderate Ulcerative Colitis", 
    "name": "SER-287", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1b data due 2H 2020.", 
    "company": "Seres Therapeutics Inc.", 
    "indication": "Melanoma", 
    "name": "SER-401", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial to be initiated later in 2020.", 
    "company": "Seres Therapeutics Inc.", 
    "indication": "Gastrointestinal infections, bacteremia and graft versus host disease (GvHD)", 
    "name": "SER-155", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 top-line data released February 8, 2018 - primary endpoint met.", 
    "company": "Madrigal Pharmaceuticals Inc.", 
    "indication": "Heterozygous familial hypercholesterolemia (HeFH)", 
    "name": "MGL-3196 ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced March 28, 2019. Data due 2021.", 
    "company": "Madrigal Pharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "MGL-3196 (resmetirom)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Data from open label 100 mg arm due by the end of 2020. MAESTRO-NASH completion of enrollment might be delayed beyond 2020.", 
    "company": "Madrigal Pharmaceuticals Inc.", 
    "indication": "Non-Alcoholic Fatty Liver Disease", 
    "name": "Resmetirom - MAESTRO-NAFLD-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "BLA filing announced June 30, 2020.", 
    "company": "MediWound Ltd.", 
    "indication": "Severe burns", 
    "name": "NexoBrid", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 interim assessment due 1H 2021.", 
    "company": "MediWound Ltd.", 
    "indication": "Venous leg ulcers (VLUâ€™s)", 
    "name": "EscharEx", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data presented at ASCO May 29, 2020.", 
    "company": "MEI Pharma Inc.", 
    "indication": "High-risk Myelodysplastic Syndrome (MDS)", 
    "name": "Pracinostat in combination with Vidaza", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrolment to be completed summer of 2020.", 
    "company": "MEI Pharma Inc.", 
    "indication": "Relapsed/refractory Follicular Lymphoma (FL) Non Hodgkin Lymphoma", 
    "name": "ME-401", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 final data presented at ASCO June 1, 2019 noted statistically significant biologic anti-tumor activity.", 
    "company": "MEI Pharma Inc.", 
    "indication": "HER2-negative Breast Cancer", 
    "name": "ME-344", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to lack of efficacy - July 2, 2020. ", 
    "company": "MEI Pharma Inc.", 
    "indication": "Acute Myeloid Leukemia", 
    "name": "Pracinostat in combination with Vidaza", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 update due 2020.", 
    "company": "MEI Pharma Inc.", 
    "indication": "B-Cell Malignancies", 
    "name": "Voruciclib", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b updated data presented at ASCO May 29, 2020.", 
    "company": "MEI Pharma Inc.", 
    "indication": "Relapsed/refractory Follicular Lymphoma/Chronic Lymphocytic Leukemia (CLL)", 
    "name": "ME-401", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Mesoblast Limited", 
    "indication": "Chronic low back pain", 
    "name": "Rexlemestrocel (MPC-06-ID)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review September 30, 2020. FDA Oncologic Drugs Advisory Committee meeting August 13, 2020 voted 8-2 supporting approval.", 
    "company": "Mesoblast Limited", 
    "indication": "acute graft versus host disease (aGVHD) in children", 
    "name": "Remestemcel-L (MSC-100-IV)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 2 data released August 2016. Partnership required for Phase 3 development.", 
    "company": "Mesoblast Limited", 
    "indication": "Rheumatoid arthritis", 
    "name": "MPC-300-IV", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Mesoblast Limited", 
    "indication": "Heart failure", 
    "name": "Rexlemestrocel", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet primary endpoint - November 11, 2018.", 
    "company": "Mesoblast Limited", 
    "indication": "End-Stage Heart Failure with LVADs", 
    "name": "MPC-150-IM", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due early September 2020.", 
    "company": "Mesoblast Limited", 
    "indication": "COVID-19", 
    "name": "Remestemcel-L", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data released October 16, 2019.", 
    "company": "Miragen Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "MRG-110", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data noted median survival time of 26 months compared with 7.4 months in historical cohort and PFS of 12.5 months compared with 5.4 months in historical cohort - January 30, 2020.", 
    "company": "Miragen Therapeutics Inc.", 
    "indication": "Chronic Lymphocytic Leukemia (CLL); Diffuse Large B-Cell Lymphoma (DLBCL); Cutaneous T-cell Lymphoma (CTCL); Adult T-Cell Leukemia/Lymphoma (ATLL)", 
    "name": "Cobomarsen MRG-106", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 interim data released December 11, 2019 - generally safe and well tolerated. Trial to continue through to primary endpoint.", 
    "company": "Miragen Therapeutics Inc.", 
    "indication": "Keloids", 
    "name": "MRG-201 Remlarsen", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 additional data due by the end of 2020.", 
    "company": "Miragen Therapeutics Inc.", 
    "indication": "Cutaneous T-Cell Lymphoma", 
    "name": "Cobomarsen - SOLAR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Updated data due 4Q 2020.", 
    "company": "MacroGenics Inc.", 
    "indication": "AML", 
    "name": "Flotetuzumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "PDUFA date December 18, 2020. FDA will not require an Oncologic Drugs Advisory Committee (ODAC) meeting.", 
    "company": "MacroGenics Inc.", 
    "indication": "Metastatic breast cancer", 
    "name": "Margetuximab", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "MacroGenics Inc.", 
    "indication": "Anal cancer", 
    "name": "Retifanlimab INCMGA0012", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 trial planned.", 
    "company": "MacroGenics Inc.", 
    "indication": "Solid tumors", 
    "name": "Enoblituzumab and MGA012", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 partial clinical hold lifted January 25, 2019.", 
    "company": "MacroGenics Inc.", 
    "indication": "Solid tumors", 
    "name": "MGD009", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data presented at ASCO May 29, 2020.", 
    "company": "MacroGenics Inc.", 
    "indication": "Solid tumors", 
    "name": "MGD013", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data to be presented at ESMO September 19-21, 2020.", 
    "company": "MacroGenics Inc.", 
    "indication": "Solid tumors", 
    "name": "MGD019", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 initial data due 2H 2020.", 
    "company": "MacroGenics Inc.", 
    "indication": "Gastric cancer", 
    "name": "Margetuximab and MGA012 (MAHOGANY)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1Q 2021.", 
    "company": "MacroGenics Inc.", 
    "indication": "Head and neck cancer", 
    "name": "Enoblituzumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 enrollment has been completed.", 
    "company": "Magenta Therapeutics Inc.", 
    "indication": "Acute Lymphoblastic Leukemia", 
    "name": "MGTA-456", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated.", 
    "company": "Magenta Therapeutics Inc.", 
    "indication": "Allogeneic and autologous transplant", 
    "name": "MGTA-145", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data due 2021.", 
    "company": "Magenta Therapeutics Inc.", 
    "indication": "Conditioning for stem cell transplant ", 
    "name": "MGTA-117", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 initial data due 2H 2020.", 
    "company": "MeiraGTx Holdings plc", 
    "indication": "Xerostomia", 
    "name": "AAV-AQP1", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Data presented at AAO October 12, 2019.", 
    "company": "MeiraGTx Holdings plc", 
    "indication": "RPE65-Deficiency", 
    "name": "AAV-RPE65", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing. Phase 3 trial planned.", 
    "company": "MeiraGTx Holdings plc", 
    "indication": "X-Linked Retinitis Pigmentosa", 
    "name": "AAV-RPGR", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiation announced August 7, 2019.", 
    "company": "MeiraGTx Holdings plc", 
    "indication": "Achromatopsia", 
    "name": "AAV-CNGA3", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "MeiraGTx Holdings plc", 
    "indication": "Achromatopsia", 
    "name": "AAV-CNGB3", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 presentation at ASCO May 29, 2020.", 
    "company": "MeiraGTx Holdings plc", 
    "indication": "Solid Tumors", 
    "name": "MGC018", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 ongoing.", 
    "company": "Mirum Pharmaceuticals Inc.", 
    "indication": "Progressive Familial Intrahepatic Cholestasis (PFIC)", 
    "name": "Maralixibat - MARCH", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Rolling NDA to be filed 3Q 2020. To be completed 1Q 2021.", 
    "company": "Mirum Pharmaceuticals Inc.", 
    "indication": "Alagille Syndrome (ALGS)", 
    "name": "Maralixibat", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Mirum Pharmaceuticals Inc.", 
    "indication": "Cholestatic liver diseases", 
    "name": "Volixiba", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 open-label data to be presented at EASL August 27-29, 2020.", 
    "company": "Mirum Pharmaceuticals Inc.", 
    "indication": "Progressive Familial Intrahepatic Cholestasis (PFIC)", 
    "name": "Maralixibat - INDIGO (EASL)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Milestone Pharmaceuticals Inc.", 
    "indication": "Angina", 
    "name": "Etripamil", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2020.", 
    "company": "Milestone Pharmaceuticals Inc.", 
    "indication": "Atrial fibrillation", 
    "name": "Etripamil", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 open label data due 1H 2021.", 
    "company": "Milestone Pharmaceuticals Inc.", 
    "indication": "Paroxysmal supraventricular tachycardia (PSVT)", 
    "name": "Etripamil - NODE-302", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data released March 23, 2020 did not meet primary endpoint.", 
    "company": "Milestone Pharmaceuticals Inc.", 
    "indication": "Paroxysmal supraventricular tachycardia (PSVT)", 
    "name": "Etripamil - NODE-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 open label commencement of dosing announced October 3, 2019.", 
    "company": "Milestone Pharmaceuticals Inc.", 
    "indication": "Paroxysmal supraventricular tachycardia (PSVT)", 
    "name": "Etripamil - NODE-303", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Data due late 2021/early 2022.", 
    "company": "Milestone Pharmaceuticals Inc.", 
    "indication": "Paroxysmal supraventricular tachycardia (PSVT)", 
    "name": "NODE-301B - RAPID", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b enrollment to be completed by end of 2020.", 
    "company": "Stealth BioTherapeutics Corp.", 
    "indication": "Geographic atrophy / Age-related macular degeneration (AMD)", 
    "name": "Elamipretide", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint. ", 
    "company": "Stealth BioTherapeutics Corp.", 
    "indication": "Leberâ€™s hereditary optic neuropathy (LHON)", 
    "name": "Elamipretide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 trial did not meet primary endpoint December 2018. Intends to meet with FDA mid-2020. NDA filing potentially by end of 2020.", 
    "company": "Stealth BioTherapeutics Corp.", 
    "indication": "Barth", 
    "name": "Elamipretide", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - December 20, 2019.", 
    "company": "Stealth BioTherapeutics Corp.", 
    "indication": "Primary mitochondrial myopathy", 
    "name": "Elamipretide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced January 21, 2020.", 
    "company": "Stealth BioTherapeutics Corp.", 
    "indication": "Rare neurodegenerative diseases", 
    "name": "SBT-272", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b data did not meet primary endpoint - April 6, 2020.", 
    "company": "Millendo Therapeutics Inc.", 
    "indication": "Prader-Willi syndrome (PWS)", 
    "name": "Livoletide", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b interim review completed. Development to be discontinued - June 23, 2020.", 
    "company": "Millendo Therapeutics Inc.", 
    "indication": "Congenital adrenal hyperplasia (CAH)", 
    "name": "Nevanimibe", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 3Q 2020.", 
    "company": "Millendo Therapeutics Inc.", 
    "indication": "Vasomotor symptoms (VMS)", 
    "name": "MLE-301", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "PDUFA date September 12, 2020. Advisory Committee Meeting July 15, 2020 voted 8-7 that the benefits outweigh the risks.", 
    "company": "Mallinckrodt plc", 
    "indication": "Hepatorenal syndrome (HRS) Type 1", 
    "name": "Terlipressin", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "CRL issued August 22, 2018.", 
    "company": "Mallinckrodt plc", 
    "indication": "Jaundice", 
    "name": "Stannsoporfin", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 enrolment to stop following interim analysis February 20, 2019.", 
    "company": "Mallinckrodt plc", 
    "indication": "Acute Graft Versus Host Disease", 
    "name": "UVADEX (methoxsalen) and Therakos ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved April 30, 2015.", 
    "company": "Mallinckrodt plc", 
    "indication": "Hemostasis", 
    "name": "RAPLIXA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date under priority review February 2, 2021.", 
    "company": "Mallinckrodt plc", 
    "indication": "Deep partial thickness severe burns - skin defects", 
    "name": "StrataGraft skin tissue", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 trial did not show a statistically significant separation from placebo.", 
    "company": "Mallinckrodt plc", 
    "indication": "Niemann-Pick Disease", 
    "name": "VTS-270", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL issued December 12, 2018.", 
    "company": "Mallinckrodt plc", 
    "indication": "Pain", 
    "name": "MNK-812", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 data released May 7, 2019 did not meet primary endpoint.", 
    "company": "Mallinckrodt plc", 
    "indication": "Familial Adenomatous Polyposis (FAP) ", 
    "name": "CPP-1X/sulindac", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial discontinued due to safety concerns - July 16, 2019.", 
    "company": "Mallinckrodt plc", 
    "indication": "Amyotrophic Lateral Sclerosis", 
    "name": "H.P. Acthar Gel", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 commencement of dosing announced August 12, 2019. ", 
    "company": "Mallinckrodt plc", 
    "indication": "Hepatic Cirrhosis and Chronic Hepatic Encephalopathy (HE)", 
    "name": "MNK-6106", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Approved June 27, 2014.", 
    "company": "MannKind Corporation", 
    "indication": "Type 1/2 diabetes", 
    "name": "AFREZZA ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 29, 2020.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Papulopustular rosacea", 
    "name": "FMX103", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 18, 2019.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Acne", 
    "name": "FMX101", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - April 6, 2020.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Pruritus associated with prurigo nodularis", 
    "name": "Serlopitant", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released October 8, 2018. Endpoints not met.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Refractory chronic cough", 
    "name": "Serlopitant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released April 9, 2018. Endpoints not met.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Pruritus associated with atopic dermatitis", 
    "name": "Serlopitant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - February 26, 2020.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Chronic pruritus of unknown origin", 
    "name": "Serlopitant", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released June 2, 2020.", 
    "company": "Menlo Therapeutics Inc.", 
    "indication": "Acne", 
    "name": "FCD105", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "MediciNova Inc.", 
    "indication": "Progressive multiple sclerosis (progressive MS)", 
    "name": "MN-166", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 abstract presented at EASL April 13, 2018. Noted April 2, 2018 that trial has been terminated early due meeting one of two primary endpoints (data from second endpoint of cholesterol efflux capacity not released).", 
    "company": "MediciNova Inc.", 
    "indication": "NASH (nonalcoholic steatohepatitis)", 
    "name": "MN-001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released March 29, 2018 - primary endpoint not met.", 
    "company": "MediciNova Inc.", 
    "indication": "Methamphetamine dependence", 
    "name": "MN-166", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b/3 trial launched - June 5, 2019. Enrolment to commence soon.", 
    "company": "MediciNova Inc.", 
    "indication": "Amyotrophic lateral sclerosis (ALS)", 
    "name": "MN-166", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced August 6, 2018.", 
    "company": "MediciNova Inc.", 
    "indication": "Degenerative cervical myelopathy (DCM)", 
    "name": "MN-166 (ibudilast)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 initiation announced January 8, 2019.", 
    "company": "MediciNova Inc.", 
    "indication": "Glioblastoma", 
    "name": "MN-166", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "MediciNova Inc.", 
    "indication": "Idiopathic pulmonary fibrosis (IPF)", 
    "name": "MN-001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Clinical trials planned. No timeline provided.", 
    "company": "MediciNova Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "COVID-19 vaccine using BC-PIV", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 enrolment to commence 2H 2020.", 
    "company": "Monopar Therapeutics Inc.", 
    "indication": "Soft tissue sarcoma", 
    "name": "Camsirubicin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b/3 planned for 2H 2020.", 
    "company": "Monopar Therapeutics Inc.", 
    "indication": "Oral mucositis", 
    "name": "Validive", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Filed 2007. Approved April 16 2015.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Multiple sclerosis", 
    "name": "Generic Copaxone", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 development discontinued due to poor efficacy shown", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Advanced metastatic pancreatic cancer", 
    "name": "Necuparanib (MOM-M402-103)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initiation 2020.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Healthy volunteers", 
    "name": "M230 (CSL730)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial met primary endpoint - June 15, 2020. Phase 3 trial to be initiated 1Q 2021.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "generalized myasthenia gravis (gMG)", 
    "name": "Nipocalimab (M281)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 due 2021.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Hemolytic disease of the fetus and newborn (HDFN)", 
    "name": "Nipocalimab (M281)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 additional data due 3Q 2020.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Immune Thrombocytopenic Purpura (ITP)", 
    "name": "M254", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to recommence enrollment 4Q 2020.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Warm Autoimmune Hemolytic Anemia (wAIHA)", 
    "name": "Nipocalimab (M281)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2021.", 
    "company": "Momenta Pharmaceuticals Inc.", 
    "indication": "Chronic inflammatory demyelinating polyneuropathy (CIDP)", 
    "name": "M254", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 ContRAst trial initiation announced July 3, 2019.", 
    "company": "MorphoSys AG", 
    "indication": "Rheumatoid Arthritis", 
    "name": "Otilimab (MOR103/GSK3196165)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial halted due to futility - October 28, 2019.", 
    "company": "MorphoSys AG", 
    "indication": "Atopic dermatitis", 
    "name": "MOR106 IGUANA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data presented at ASH December 7, 2019.", 
    "company": "MorphoSys AG", 
    "indication": "Chronic Lymphocytic Leukemia", 
    "name": "MOR208 + idelalisib (COSMOS)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 futility analysis passed November 18, 2019. Top-line data due 1Q 2022.", 
    "company": "MorphoSys AG", 
    "indication": "Relapsed or refractory diffuse large B cell lymphoma (r/r DLBCL)", 
    "name": "Bendamustine + MOR208 - B-MIND", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 31, 2020.", 
    "company": "MorphoSys AG", 
    "indication": "Relapsed or refractory diffuse large B cell lymphoma", 
    "name": "Tafasitamab (MOR208/XmAb5574)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrollment has commenced - noted June 14, 2018.", 
    "company": "MorphoSys AG", 
    "indication": "Early Alzheimer's disease", 
    "name": "Gantenerumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced July 11, 2018.", 
    "company": "MorphoSys AG", 
    "indication": "Crohn's disease", 
    "name": "Guselkumab (GALAXI 1)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced November 19, 2018.", 
    "company": "MorphoSys AG", 
    "indication": "Hidradenitis Suppurativa", 
    "name": "Guselkumab (NOVA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met - December 12, 2018.", 
    "company": "MorphoSys AG", 
    "indication": "Psoriasis", 
    "name": "Guselkumab vs Cosentyx - ECLIPSE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a initiation announced January 17, 2019.", 
    "company": "MorphoSys AG", 
    "indication": "Ulcerative colitis", 
    "name": "Guselkumab ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval announced February 27, 2019.", 
    "company": "MorphoSys AG", 
    "indication": "Plaque psoriasis", 
    "name": "Guselkumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1b initiation of dosing announced December 27, 2019.", 
    "company": "MorphoSys AG", 
    "indication": "Front-line diffuse large B cell lymphoma (DLBCL)", 
    "name": "MOR208 tafasitamab (First-MIND)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 trial is enrolling.", 
    "company": "MorphoSys AG", 
    "indication": "Membranous nephropathy", 
    "name": "MOR202 (M-PLACE)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced July 14, 2020.", 
    "company": "MorphoSys AG", 
    "indication": " Psoriatic Arthritis", 
    "name": "Guselkumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "IND filing due late-2020.", 
    "company": "Morphic Holding Inc.", 
    "indication": "Idiopathic pulmonary fibrosis", 
    "name": "MORF-720", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 3Q 2020.", 
    "company": "Morphic Holding Inc.", 
    "indication": "inflammatory bowel disease", 
    "name": "MORF-057", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Mereo BioPharma Group plc", 
    "indication": "Platinum-Resistant Ovarian Cancer", 
    "name": "Navicixizumab (OMP-305B83)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 ready.", 
    "company": "Mereo BioPharma Group plc", 
    "indication": "Acute Exacerbations of Chronic Obstructive Pulmonary Disease (AECOPD)", 
    "name": "Acumapimod", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 2H 2021.", 
    "company": "Mereo BioPharma Group plc", 
    "indication": "Severe alpha-1 antitrypsin deficiency", 
    "name": "Alvelestat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b trial to commence 4Q 2020.", 
    "company": "Mereo BioPharma Group plc", 
    "indication": "Solid tumors", 
    "name": "Etigilimab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial planned. Partnership required.", 
    "company": "Mereo BioPharma Group plc", 
    "indication": "Osteogenesis Imperfecta", 
    "name": "Setrusumab (BPS-804)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2 trial initiation announced August 25, 2020.", 
    "company": "Mereo BioPharma Group plc", 
    "indication": "COVID-19", 
    "name": "Alvelestat", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced February 19, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Melanoma", 
    "name": "KEYTRUDA - EORTC1325/KEYNOTE-054", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced June 13, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)", 
    "name": "Keytruda", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval (label expansion) announced June 5, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "First-Line Nonsquamous Non-small cell lung cancer (NSCLC)", 
    "name": "KEYTRUDA + chemo (KEYNOTE-021)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)", 
    "name": "KEYNOTE-040 KEYTRUDA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma", 
    "name": "Keytruda", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 MOSAIC initiation of dosing announced October 2, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Overgrowth Diseases", 
    "name": "ARQ 092", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Type 2 Diabetes", 
    "name": "Januvia (Sitagliptin)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approved March 1, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "House dust mite allergies", 
    "name": "Odactra (MK-8237)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved May 18, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "First and Second line locally advanced or metastatic urothelial cancer - bladder cancer", 
    "name": "KEYTRUDA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA label expansion announced January 31, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)", 
    "name": "(MK-3475-189/KEYNOTE-189)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 20, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Type 2 diabetes", 
    "name": "Ertugliflozin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Mild-to-moderate Alzheimer's", 
    "name": "MK-8931 (019) - Verubecestat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced November 9, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Cytomegalovirus (CMV) Infection", 
    "name": "Letermovir", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial stopped due to lack of efficacy - February 14, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Mild-to-moderate Alzheimer's", 
    "name": "MK-8931 (017) - Verubecestat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved May 10, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer ", 
    "name": "Keytruda", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released March 17, 2020. 45 mg arm met primary endpoint; 15 mg arm did not meet the primary efficacy endpoint.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Chronic cough", 
    "name": "MK-7264", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced March 14, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Relapsed or Refractory Classical Hodgkin Lymphoma", 
    "name": "KEYTRUDA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Microsatellite Instability-High Cancer", 
    "name": "KEYTRUDA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Biosimilar candidate of Remicade", 
    "name": "RENFLEXIS - SB2 (infliximab biosimilar)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 30, 2017.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "HIV-1", 
    "name": "ISENTRESS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 19, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "First-line ovarian cancer following platinum-based chemotherapy", 
    "name": "Lynparza - SOLO 1", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Breast cancer", 
    "name": "Lynparza", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - noted April 6, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Cancer - first-line metastatic melanoma.", 
    "name": "Epacadostat with Keytruda - ECHO-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced June 12, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Cervical cancer", 
    "name": "KEYTRUDA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 30, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Pancreatic cancer", 
    "name": "Lynparza (POLO)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrolment completed in January 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Urothelial cancer", 
    "name": "Enfortumab vedotin and Keytruda - EV-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced April 11, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Keytruda - KEYNOTE-042", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "HER2-negative breast cancer", 
    "name": "Lynparza - OlympiA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced October 30, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Squamous non-small cell lung cancer (sNSCLC)", 
    "name": "KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 presentation at ASH December 9, 2019. 89% ORR in CLL patients; 50% in Richterâ€™s Transformation.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "B-cell malignancies", 
    "name": "ARQ 531", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced May 19, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Castration-Resistant Prostate Cancer", 
    "name": "Lynparza", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced October 5, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Human Papilloma virus vaccine", 
    "name": "GARDASIL 9", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1b trial ongoing.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Solid tumors", 
    "name": "ARQ 751", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced May 8, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "First-line ovarian cancer", 
    "name": "Lynparza + Avastin- PAOLA-1", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released April 25, 2019 noted that monotherapy arm met noninferiority primary endpoint. Combo arm did not meet OS/PFS endpoints.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Gastric cancer", 
    "name": "Keytruda KN-062", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data February 19, 2019 did not meet primary endpoints.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Hepatocellular Carcinoma", 
    "name": "Keytruda KN-240", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data May 20, 2019 did not meet primary endpoint.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Triple negative breast cancer (TNBC)", 
    "name": "Keytruda KN-119", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 11, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Head and neck squamous cell carcinoma (HNSCC)", 
    "name": "Keytruda KN-048", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date March 29, 2021.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Triple negative breast cancer (TNBC)", 
    "name": "Keytruda KN-522", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA approval announced November 9, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Hepatocellular carcinoma (HCC)", 
    "name": "Keytruda - KEYNOTE-224", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 16, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Hepatocellular Carcinoma (HCC)", 
    "name": "LENVIMA (lenvatinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 19, 2018.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Merkel Cell Carcinoma", 
    "name": "Keytruda KN-17", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced June 3, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Hospital-acquired bacterial pneumonia (HABP)", 
    "name": "ZERBAXA(ceftolozane and tazobactam)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced April 22, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Renal cell carcinoma", 
    "name": "KEYTRUDA and Inlyta - KEYNOTE-426", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date under priority review January 20, 2021.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Heart Failure", 
    "name": "Vericiguat", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "PDUFA date under priority review November 28, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Triple negative breast cancer (TNBC)", 
    "name": "Keytruda KN-355", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "FDA Approval announced July 31, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Esophageal Cancer", 
    "name": "Keytruda KN-181", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 29, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Colorectal cancer (CRC)", 
    "name": "Keytruda KN-177", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data did not meet dual primary endpoints - June 9, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Bladder cancer", 
    "name": "Keytruda KN-361", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met PFS primary endpoint; overall survival primary endpoint not met - January 6, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Small cell lung cancer (SCLC)", 
    "name": "Keytruda KN-604", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Renal cell carcinoma (RCC) - cancer", 
    "name": "LENVIMA (lenvatinib) + Keytruda - KN-581", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced December 19, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Ebola", 
    "name": "ERVEBO (V920)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval for sNDA announced September 20, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "HIV", 
    "name": "DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Nasopharyngeal Carcinoma", 
    "name": "Keytruda KN-122", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced July 17, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)", 
    "name": "Imipenem/ cilastatin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 18, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Small cell lung cancer (SCLC)", 
    "name": "Keytruda - KN-158", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "HIV", 
    "name": "MK-8591", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL issued February 18, 2020. Resubmission announced April 23, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "6-week dosing for melanoma and other indications", 
    "name": "Keytruda", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data presented at ESMO September 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Malignant pleural mesothelioma (MPM)", 
    "name": "Pembrolizumab vs chemotherapy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced September 17, 2019.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Endometrial cancer", 
    "name": "Keytruda and Lenvima", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced January 27, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Clostridium difficile infections (CDI)", 
    "name": "DIFICID (fidaxomicin)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced January 8, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "NMIBC Bladder cancer", 
    "name": "Keytruda KN-057", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced June 4, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP)", 
    "name": "Recarbrio", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date October 30, 2020", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Classical Hodgkin lymphoma", 
    "name": "Keytruda - KEYNOTE-204", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA Approval June 17, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Solid tumors - TMB-H â‰¥10 mutations/megabase", 
    "name": "Keytruda", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 13, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Neurofibromatosis type 1 plexiform neurofibromas", 
    "name": "Selumetinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 trial has been completed - well-tolerated. Phase 2 trial is underway.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "COVID-19", 
    "name": "MK-4482 (EIDD-2801)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 3Q 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "COVID-19 vaccine", 
    "name": "V591 (Themis)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 2H 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "COVID-19 vaccine", 
    "name": "V590 (IAVI)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced June 12, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Prevention HPV-Related Head and Neck Cancers", 
    "name": "GARDASIL 9", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced June 24, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Cutaneous squamous cell carcinoma (cSCC)", 
    "name": "Keytruda", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued July 8, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Hepatocellular Carcinoma", 
    "name": "Keytruda and Lenvima", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 primary endpoints of overall survival (OS) and progression-free survival (PFS) met - August 19, 2020.", 
    "company": "Merck & Company Inc. (new)", 
    "indication": "Esophageal Cancer", 
    "name": "Keytruda + chemo (KEYNOTE-590)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 program to be discontinued due to lack of efficacy.", 
    "company": "Marker Therapeutics Inc.", 
    "indication": "Platinum-sensitive ovarian cancer", 
    "name": "TPIV200", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "Marker Therapeutics Inc.", 
    "indication": "Triple-negative breast cancer (TNBC)", 
    "name": "TPIV200", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "Marker Therapeutics Inc.", 
    "indication": "Lymphoma", 
    "name": "MultiTAA-Specific T Cells", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 clinical hold lifted - February 11, 2020. Replaced with partial hold.", 
    "company": "Marker Therapeutics Inc.", 
    "indication": "Acute Myeloid Leukemia", 
    "name": "MultiTAA-Specific T Cells", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data update at ASCO May 29, 2020. 4/13 overall responses.", 
    "company": "Marker Therapeutics Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "MultiTAA-Specific T Cells", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 completed.", 
    "company": "Moderna Inc.", 
    "indication": "Myocardial ischemia", 
    "name": "VEGF-A(AZD8601)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 presentation at AACR April 27, 2020.", 
    "company": "Moderna Inc.", 
    "indication": "Advanced malignancies", 
    "name": "mRNA-2416 and durvalumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated.", 
    "company": "Moderna Inc.", 
    "indication": "Personalized cancer vaccine", 
    "name": "mRNA-4157 (KEYNOTE-942)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 completed.", 
    "company": "Moderna Inc.", 
    "indication": "Chikungunya vaccine ", 
    "name": "mRNA-1388", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 completed.", 
    "company": "Moderna Inc.", 
    "indication": "Influenza vaccine", 
    "name": "mRNA-1851", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 completed.", 
    "company": "Moderna Inc.", 
    "indication": "Influenza vaccine", 
    "name": "mRNA-1440", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial presented at IDWeek October 5.", 
    "company": "Moderna Inc.", 
    "indication": "Human Metapneumovirus and Human Parainfluenza Infection (hMPV+PIV3 vaccine)", 
    "name": "mRNA-1653", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 first interim analysis is expected 3Q 2020", 
    "company": "Moderna Inc.", 
    "indication": "CMV vaccine (Cytomegalovirus Infection)", 
    "name": "mRNA-1647", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development has been paused - May 8, 2019.", 
    "company": "Moderna Inc.", 
    "indication": "RSV vaccine", 
    "name": "mRNA-1777", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 enrolment of first patient announced February 10, 2020.", 
    "company": "Moderna Inc.", 
    "indication": "Methylmalonic Acidemia (MMA)", 
    "name": "mRNA-3704", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - noted January 8, 2019.", 
    "company": "Moderna Inc.", 
    "indication": "Solid tumors, lymphoma", 
    "name": "mRNA-2752", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 enrolment has been paused due to COVID-19.", 
    "company": "Moderna Inc.", 
    "indication": "Chikungunya Virus Infection", 
    "name": "mRNA-1944", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data presented at ASCO June 1, 2019.", 
    "company": "Moderna Inc.", 
    "indication": "Autologous Cancer", 
    "name": "mRNA-4650", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - August 7, 2019.", 
    "company": "Moderna Inc.", 
    "indication": "RSV vaccine", 
    "name": "mRNA-1172", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - August 7, 2019.", 
    "company": "Moderna Inc.", 
    "indication": "KRAS cancer vaccine", 
    "name": "mRNA-5671", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 interim efficacy data due 3Q 2020. Phase 3 enrollment to be completed September 2020.", 
    "company": "Moderna Inc.", 
    "indication": "COVID-19 vaccine ", 
    "name": "mRNA-1273", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 3Q 2020 with data due 1H 2022.", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "Refractory status epilepticus (RSE)", 
    "name": "Ganaxolone", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 negative data released July 23, 2019.", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "Postpartum depression", 
    "name": "Ganaxolone - Magnolia", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released June 2016. Primary endpoint not met but intends to advance development", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "Fragile X Syndrome", 
    "name": "Ganaxolone", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data did not meet endpoints - June 2016", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "Focal onset seizures", 
    "name": "Ganaxolone", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 3Q 2020.", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "CDKL5 Deficiency Disorder (CDD)", 
    "name": "Ganaxolone - Marigold", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "PCDH19-related epilepsy", 
    "name": "Ganaxolone (Violet Study)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 1H 2021.", 
    "company": "Marinus Pharmaceuticals Inc.", 
    "indication": "Tuberous Sclerosis Complex", 
    "name": "Ganaxolone", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued - noted January 4, 2019.", 
    "company": "Mersana Therapeutics Inc.", 
    "indication": "HER2 - breast cancer", 
    "name": "XMT1522", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 interim dose expansion data May 27, 2020 noted 35% objective response rate, including 10% complete response rate. Further data due around year-end 2020. Incremental interim update due September 17, 2020.", 
    "company": "Mersana Therapeutics Inc.", 
    "indication": "Ovarian Cancer, Non Small Cell Lung Cancer", 
    "name": "XMT-1536", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced May 14, 2020.", 
    "company": "Mersana Therapeutics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC) adenocarcinoma and ovarian cancer", 
    "name": "XMT-1592", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 updated data due in 2021.", 
    "company": "Mirati Therapeutics Inc.", 
    "indication": "Renal cell carcinoma (RCC)", 
    "name": "Sitravatinib and Nivolumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim analysis 4Q 2021.", 
    "company": "Mirati Therapeutics Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Sitravatinib plus nivolumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 additional data due in 2021.", 
    "company": "Mirati Therapeutics Inc.", 
    "indication": "Hepatocellular Carcinoma (HCC) / Gastric/Gastroesophageal Junction Cancer", 
    "name": "Sitravatinib and tislelizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 updated data due at triple meeting in October 2020 (monotherapy NSCLC & CRC). Enrollment in registration-enabling monotherapy arm to be completed 3Q 2020.", 
    "company": "Mirati Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "MRTX849 - KRYSTAL", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 initial data presented at SITC November 9, 2019 noted 6/22 ORR, 21/22 SD. Additional data due in 2021.", 
    "company": "Mirati Therapeutics Inc.", 
    "indication": "Urothelial Carcinoma (Bladder)", 
    "name": "Sitravatinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Does not plan to initiate a Phase 3 trial.", 
    "company": "Merus N.V.", 
    "indication": "Breast cancer - HER2-positive MBC and ER+/HER2-low MBC", 
    "name": "MCLA-128", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due by end of 2020.", 
    "company": "Merus N.V.", 
    "indication": "Solid tumors - NRG1", 
    "name": "Zenocutuzumab (MCLA-128)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 interim data presented at EHA June 2020.", 
    "company": "Merus N.V.", 
    "indication": "Acute Myeloid Leukemia", 
    "name": "MCLA-117", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 update due by end of 2020.", 
    "company": "Merus N.V.", 
    "indication": "Colorectal cancer", 
    "name": "MCLA-158", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 dosing has commenced - May 9, 2019.", 
    "company": "Merus N.V.", 
    "indication": "Solid tumors", 
    "name": "MCLA-145", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)", 
    "name": "MT-3724 and chemotherapy", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development discontinued due to poor data - September 29, 2016.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Cancer - mutant EGFR-positive, T790M-negative advanced non-small cell lung cancer", 
    "name": "Tarloxotinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 endpoints not met", 
    "company": "Molecular Templates Inc.", 
    "indication": "Cancer - Pancreatic", 
    "name": "Evofosfamide MAESTRO", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 endpoints not met", 
    "company": "Molecular Templates Inc.", 
    "indication": "Cancer - soft tissue sarcoma (406 trial)", 
    "name": "Evofosfamide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Independent Data Safety Monitoring Board conducted unlikely to reach primary endpoint - trial closed", 
    "company": "Molecular Templates Inc.", 
    "indication": "Cancer - second line NSCLC", 
    "name": "Evofosfamide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development discontinued due to poor data - September 29, 2016.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Cancer - Recurrent or Metastatic Squamous Cell Carcinomas of the Head and Neck or Skin", 
    "name": "Tarloxotinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "MT-3724 and Revlimid", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)", 
    "name": "MT-3724", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 additional data from the dose escalation portion of the study due 4Q 2020.", 
    "company": "Molecular Templates Inc.", 
    "indication": "HER2-positive solid tumors", 
    "name": "MT-5111", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiated 4Q 2019.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Multiple myeloma", 
    "name": "TAK-169", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trials to be initiated 2H 2020.", 
    "company": "Molecular Templates Inc.", 
    "indication": "Follicular lymphoma and mantle cell lymphoma", 
    "name": "MT-3724", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 1Q 2021.", 
    "company": "Matinas Biopharma Holdings Inc.", 
    "indication": "Severe hypertriglyceridemia", 
    "name": "MAT9001 (ENHANCE-IT)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 announcement of progression from first cohort to the second cohort due 4Q 2020. Full data due 2H 2021. ", 
    "company": "Matinas Biopharma Holdings Inc.", 
    "indication": "Cryptococcal meningitis", 
    "name": "MAT2203 (EnACT)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Approval announced October 4, 2017.", 
    "company": "Mylan N.V.", 
    "indication": "Multiple sclerosis (MS)", 
    "name": "Glatiramer Acetate Injection - Generic for Copaxone", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced June 4, 2018.", 
    "company": "Mylan N.V.", 
    "indication": "Neulasta biosimilar", 
    "name": "MYL-1401H", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date originally set for September 3 extended by three months to December 3, 2017. Advisory Committee Meeting July 13, 2017 voted 16-0 recommending approval. Approval announced December 1, 2017.", 
    "company": "Mylan N.V.", 
    "indication": "Trastuzumab biosimilar", 
    "name": "Ogivri - trastuzumab biosimilar", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 9, 2018.", 
    "company": "Mylan N.V.", 
    "indication": "COPD", 
    "name": "Revefenacin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BsUFA date December, 27, 2020.", 
    "company": "Mylan N.V.", 
    "indication": "Avastin (bevacizumab) biosimilar", 
    "name": "MYL-1402O", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "BsUFA date November 16, 2020.", 
    "company": "Mylan N.V.", 
    "indication": "Multiple sclerosis - Tecfidera generic", 
    "name": "Dimethyl fumarate (generic)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA Approval announced July 9, 2020.", 
    "company": "Mylan N.V.", 
    "indication": "Humira biosimilar", 
    "name": "Hulio (adalimumab-fkjp)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data met endpoints - May 11, 2020. Data to be presented at ESC meeting August 29, 2020 at 6:30 CET. NDA filing due August 4, 2020.", 
    "company": "MyoKardia Inc.", 
    "indication": "Hypertrophic cardiomyopathy (HCM)", 
    "name": "Mavacamten (MYK-461) - EXPLORER-HCM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 updated data released November 11, 2019.", 
    "company": "MyoKardia Inc.", 
    "indication": "Non-obstructive Hypertrophic cardiomyopathy (HCM)", 
    "name": "Mavacamten (MYK-461) - PIONEER-OLE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 initiation of dosing announced August 3, 2020.", 
    "company": "MyoKardia Inc.", 
    "indication": "Hypertrophic cardiomyopathy (HCM)", 
    "name": "Mavacamten - VALOR-HCM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "MyoKardia Inc.", 
    "indication": "Dilated cardiomyopathy (DCM)", 
    "name": "Danicamtiv (MYK-491)", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 enrollment has resumed following pause due to COVID-19.", 
    "company": "MyoKardia Inc.", 
    "indication": "Hypertrophic cardiomyopathy (HCM)", 
    "name": "MYK-224", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data met co-primary endpoints June 23, 2020. ", 
    "company": "Myovant Sciences Ltd.", 
    "indication": "Endometriosis-associated pain", 
    "name": "Relugolix - SPIRIT 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met co-primary endpoints - April 22, 2020.", 
    "company": "Myovant Sciences Ltd.", 
    "indication": "Endometriosis-associated pain", 
    "name": "Relugolix - SPIRIT 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review December 20, 2020.", 
    "company": "Myovant Sciences Ltd.", 
    "indication": "Advanced prostate cancer", 
    "name": "Relugolix - HERO", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "PDUFA date June 1, 2020.", 
    "company": "Myovant Sciences Ltd.", 
    "indication": "Uterine fibroids", 
    "name": "Relugolix", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data due 1Q 2021.", 
    "company": "Myovant Sciences Ltd.", 
    "indication": "Endometriosis", 
    "name": "Relugolix - SPIRIT EXTENSION", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved March 13, 2013.", 
    "company": "Navidea Biopharmaceuticals Inc.", 
    "indication": "Lymphatic-tissue tracing agent", 
    "name": "Lymphoseek", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 - seeking partner to continue development", 
    "company": "Navidea Biopharmaceuticals Inc.", 
    "indication": "Predicting Progression to Alzheimer's Disease (AD) in Subjects With Mild Cognitive Impairment (MCI)", 
    "name": "NAV4694", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved June 13, 2014.", 
    "company": "Navidea Biopharmaceuticals Inc.", 
    "indication": "Head and Neck Cancer", 
    "name": "Lymphoseek", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b full enrolment announced June 15, 2020. Final patients to be screened and evaluated by end of 2020.", 
    "company": "Navidea Biopharmaceuticals Inc.", 
    "indication": "Rheumatoid arthritis", 
    "name": "NAV3-31 (TC99m-tilmanocept)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2a trial ongoing.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Congenital Adrenal Hyperplasia (CAH) - children", 
    "name": "Crinecerfont", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 2H 2020.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Congenital Adrenal Hyperplasia (CAH) - adults", 
    "name": "Crinecerfont (NBI-74788)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval for sNDA 80 mg capsules announced October 5, 2017.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Tardive dyskinesia", 
    "name": "INGREZZA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 27, 2020.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Parkinson's disease", 
    "name": "Opicapone", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 top-line data released December 12, 2018 did not meet primary endpoint.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Tourette syndrome - juvenile", 
    "name": "INGREZZA - T-Force GOLD", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data released January 18, 2017 did not meet primary endpoint.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Tourette syndrome - adults", 
    "name": "INGREZZA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced May 29, 2020.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Uterine Fibroids", 
    "name": "Elagolix", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced July 24, 2018.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Endometriosis", 
    "name": "Elagolix ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved April 11, 2017.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Tardive dyskinesia", 
    "name": "INGREZZA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)", 
    "name": "NBI-921352", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial initiated 3Q 2019.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Polycystic ovary syndrome (PCOS)", 
    "name": "Elagolix", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to resume enrollment in 2H 2020 (paused due to COVID).", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Huntington's disease", 
    "name": "Valbenazine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Pediatric epilepsy", 
    "name": "ACT-709478 (NBI-827104)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial is ongoing.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Negative symptoms of schizophrenia", 
    "name": "TAK-831", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Treatment-resistant depression", 
    "name": "TAK-653", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Anhedonia in depression", 
    "name": "TAK-041", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to re-enroll 2H 2020. Phase 3 trial to commence 1H 2021.", 
    "company": "Neurocrine Biosciences Inc.", 
    "indication": "Parkinson's Disease", 
    "name": "VY-AADC02 (RESTORE-1)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced August 19, 2019.", 
    "company": "Nabriva Therapeutics plc", 
    "indication": "Moderate to severe Community Acquired Bacterial Pneumonia (CABP)", 
    "name": "Lefamulin - Intravenous and Oral", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued April 30, 2019. Further CRL received June 19, 2020.", 
    "company": "Nabriva Therapeutics plc", 
    "indication": "Complicated urinary tract infections (cUTI)", 
    "name": "Contepo", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Data released August 2014. Endpoints not met", 
    "company": "NovaBay Pharmaceuticals Inc.", 
    "indication": "Viral conjunctivitis", 
    "name": "Auriclosene (NVC-422)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Failed to meet endpoint Nov 2013. Plans to reinitiate trial in 2014", 
    "company": "NovaBay Pharmaceuticals Inc.", 
    "indication": "Impetigo skin infection study", 
    "name": "Auriclosene (NVC-422)", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 trial has re-commenced enrollment - May 5, 2020.", 
    "company": "NuCana plc", 
    "indication": "Front-Line Treatment of Advanced Biliary Tract Cancer", 
    "name": "NUC-1031 (NuTide:121)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2020.", 
    "company": "NuCana plc", 
    "indication": "Solid tumors", 
    "name": "NUC-3373 (NuTide:301)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 enrolment suspended due to futility - August 20, 2019.", 
    "company": "NuCana plc", 
    "indication": "Pancreatic cancer", 
    "name": "NUC-1031 (Acelarin)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Part 2 portion of trial will not be initiated. ", 
    "company": "NuCana plc", 
    "indication": "Platinum-sensitive ovarian cancer", 
    "name": "NUC-1031 (Acelarin)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data to be presented at ESMO September 19-21, 2020.", 
    "company": "NuCana plc", 
    "indication": "Colorectal Cancer", 
    "name": "NUC-3373 (NuTide:302)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data to be presented at ESMO September 19-21, 2020.", 
    "company": "NuCana plc", 
    "indication": "Solid tumors", 
    "name": "NUC-7738 (NuTide:701)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approval announced September 15, 2017.", 
    "company": "Neos Therapeutics Inc.", 
    "indication": "Attention deficit hyperactivity disorder (ADHD)", 
    "name": "NT-0201", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved January 27, 2016.", 
    "company": "Neos Therapeutics Inc.", 
    "indication": "Attention deficit hyperactivity disorder (ADHD)", 
    "name": "Adzenys XR-ODT", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced June 19, 2017.", 
    "company": "Neos Therapeutics Inc.", 
    "indication": "Attention deficit hyperactivity disorder (ADHD)", 
    "name": "Cotempla XR-ODT", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 ascending dose trial initiation planned in 2H 2020.", 
    "company": "Neos Therapeutics Inc.", 
    "indication": "Sialorrhea", 
    "name": "NT0502", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b data noted quantitative advantage but no statistical separation between two arms. Company noted trial was not designed to detect statistical significance.", 
    "company": "Minerva Neurosciences Inc", 
    "indication": "Major Depressive Disorder", 
    "name": "MIN-202 (seltorexant) vs quetiapine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data May 13, 2019 noted p-value was 0.083.", 
    "company": "Minerva Neurosciences Inc", 
    "indication": "Major Depressive Disorder", 
    "name": "MIN-202 (seltorexant)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data failed to meet endpoints - December 18, 2019. Development to be discontinued in MDD.", 
    "company": "Minerva Neurosciences Inc", 
    "indication": "Major Depressive Disorder", 
    "name": "MIN-117", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - May 29, 2020.", 
    "company": "Minerva Neurosciences Inc", 
    "indication": "Schizophrenia", 
    "name": "Roluperidone (MIN-101)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b data June 24, 2019 met primary endpoint.", 
    "company": "Minerva Neurosciences Inc", 
    "indication": "Primary insomnia", 
    "name": "MIN-202 (seltorexant)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1a/1b trial initiation announced February 11, 2020.", 
    "company": "NGM Biopharmaceuticals Inc.", 
    "indication": "Cachexia syndrome", 
    "name": "NGM120", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 safety & tolerability data 2H 2020. Phase 2 initiation announced July 27, 2020.", 
    "company": "NGM Biopharmaceuticals Inc.", 
    "indication": "Geographic atrophy", 
    "name": "NGM621", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 preliminary top-line results from the 24-week cohort (Cohort 4) met primary endpoint - February 24, 2020. Detailed data to be presented August 29, 2020 at ILC meeting.", 
    "company": "NGM Biopharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Aldafermin (NGM282)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b top-line data due 1H 2021.", 
    "company": "NGM Biopharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "NGM282 - ALPINE 2/3", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "90% Disease Control with Median Overall Survival of 9.5 Months - noted - November 7, 2018.", 
    "company": "NantKwest Inc.", 
    "indication": "Pancreatic cancer vaccine", 
    "name": "haNK", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 ongoing.", 
    "company": "NantKwest Inc.", 
    "indication": "Pancreatic cancer vaccine", 
    "name": "haNK", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "80% Disease Control noted - November 7, 2018.", 
    "company": "NantKwest Inc.", 
    "indication": "Triple Negative Breast Cancer (TNBC)", 
    "name": "haNK", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "First dosing announced October, 2017.", 
    "company": "NantKwest Inc.", 
    "indication": "Solid tumors", 
    "name": "haNK", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 ongoing.", 
    "company": "NantKwest Inc.", 
    "indication": "Merkel cell carcinoma", 
    "name": "aNK", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 dosing of first patient announced March 19, 2020.", 
    "company": "NantKwest Inc.", 
    "indication": "Merkel cell carcinoma (MCC)", 
    "name": "haNK + avelumab + N-803 (QUILT-3.063)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data noted ORR 67% at SABCS December 13, 2019.", 
    "company": "NantKwest Inc.", 
    "indication": "Triple Negative Breast Cancer", 
    "name": "haNK + other vaccines (NANT vaccine)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "IND clearance announced June 5, 2019.", 
    "company": "NantKwest Inc.", 
    "indication": "B-cell lymphoma", 
    "name": "CD19-t-haNK", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b data at ASCO 2019 - ORR of 58%, CR rate of 33%.", 
    "company": "NantKwest Inc.", 
    "indication": "Epstein-Barr Virus Associated Lymphoma", 
    "name": "Nanatinostat (VRx-3996) and valganciclovir", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 preliminary data noted one complete response - January 14, 2020. Data from the full 11 metastatic pancreatic patients due in 2020.", 
    "company": "NantKwest Inc.", 
    "indication": "Solid tumors", 
    "name": "PD-L1 t-haNK", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated in 2020.", 
    "company": "NantKwest Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "t-haNK and N-803", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 updated data at SITC November 9, 2019 noted ORR was 53% (20/38) with 34% (13/38) complete response (CR) rate. Further data due 2020.", 
    "company": "Nektar Therapeutics", 
    "indication": "Urothelial carcinoma, Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers", 
    "name": "NKTR-214 + OPDIVO (nivolumab) - PIVOT-2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 initial NSCLC data due 4Q 2020.", 
    "company": "Nektar Therapeutics", 
    "indication": "Solid tumors - cancer", 
    "name": "NKTR-214 + TECENTRIQ + KEYTRUDA (PROPEL)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 second trial did not meet endpoint - April 5, 2017.", 
    "company": "Nektar Therapeutics", 
    "indication": "Bronchiectasis", 
    "name": "Cipro DPI ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Advisory Committee voted 27-0 against recommending approval - January 14, 2020.", 
    "company": "Nektar Therapeutics", 
    "indication": "Lower back pain", 
    "name": "NKTR-181", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data released November 24, 2017. Endpoints not met.", 
    "company": "Nektar Therapeutics", 
    "indication": "Gram-Negative Pneumonia (INHALE 1)", 
    "name": "Inhaled Amikacin Solution (BAY41-6551T)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 topline data mid March 2015 did not reach primary endpoint.", 
    "company": "Nektar Therapeutics", 
    "indication": "Cancer - Metastatic Breast Cancer", 
    "name": "Etirinotecan pegol NKTR-102 (BEACON)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved November 16, 2015.", 
    "company": "Nektar Therapeutics", 
    "indication": "Hemophilia A", 
    "name": "ADYNOVATE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 16, 2014.", 
    "company": "Nektar Therapeutics", 
    "indication": "Opioid-induced constipation (OIC)", 
    "name": "MOVANTIK (Naloxegol)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 initial data March 1, 2019 noted ORR 2/11 ( 18%) - maximum tolerated dose has not been reached. To be completed 2020.", 
    "company": "Nektar Therapeutics", 
    "indication": "Solid tumors", 
    "name": "NKTR-262 and NKTR-214 - REVEAL", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b data presented June 4, 2020 at EULAR - safe and well tolerated.", 
    "company": "Nektar Therapeutics", 
    "indication": "Systemic lupus erythematosus (SLE)", 
    "name": "NKTR-358", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial initiation announced October 7, 2019.", 
    "company": "Nektar Therapeutics", 
    "indication": "Atopic Dermatitis", 
    "name": "NKTR-358", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial initiation announced October 7, 2019.", 
    "company": "Nektar Therapeutics", 
    "indication": "Psoriasis", 
    "name": "NKTR-358", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 initiation announced October 16, 2019. First data due 2020/21.", 
    "company": "Nektar Therapeutics", 
    "indication": "Relapsed or Refractory Non-Hodgkin Lymphoma or Multiple Myeloma", 
    "name": "NKTR-255", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 initiation of dosing announced August 12, 2020.", 
    "company": "Nektar Therapeutics", 
    "indication": "Squamous Cell Carcinoma of the Head and Neck", 
    "name": "Bempegaldesleukin (NKTR-214)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial planned for 4Q 2020.", 
    "company": "Nkarta Inc.", 
    "indication": "Acute myeloid leukemia / myelodysplastic syndromes", 
    "name": "NKX101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due mid-2021 with top-line data due 2H 2021.", 
    "company": "9 Meters Biopharma Inc.", 
    "indication": "Celiac disease", 
    "name": "Larazotide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b/2a top-line data due 1Q 2021.", 
    "company": "9 Meters Biopharma Inc.", 
    "indication": "Short bowel syndrome ", 
    "name": "NM-002", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data released November 29, 2016. Primary endpoint met. ", 
    "company": "Novan Inc.", 
    "indication": "Human papillomavirus (HPV)", 
    "name": "SB206", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released April 12, 2017. Primary endpoint met.", 
    "company": "Novan Inc.", 
    "indication": "Fungal infections", 
    "name": "SB208", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in  NI-AC302 trial. Additional Phase 3 trial required.", 
    "company": "Novan Inc.", 
    "indication": "Acne vulgaris", 
    "name": "SB204 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - January 2, 2020. Additional Phase 3 trial to be initiated September 2020 with data due late-2Q 2021.", 
    "company": "Novan Inc.", 
    "indication": "Molluscum", 
    "name": "SB206", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2019.", 
    "company": "Novan Inc.", 
    "indication": "Atopic Dermatitis", 
    "name": "SB414", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2b primary endpoint met - June 28, 2018.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Severe Hypertriglyceridemia (SHTG)", 
    "name": "Gemcabene - INDIGO-1", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b data released June 28, 2017 - primary endpoint met.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Homozygous Familial Hypercholesterolemia (HoFH)", 
    "name": "Gemcabene - COBALT-1", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 top-line released June 26, 2019.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Familial Partial Lipodystrophy (FPL)", 
    "name": "Gemcabene", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 trial has been postponed due to COVID-19.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Diabetic neuropathic pain (DNP)", 
    "name": "NB-01", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Familial Partial Lipodystrophy (FPL)", 
    "name": "Gemcabene", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 1H 2021.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Dyslipidemia", 
    "name": "NB-02", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 partial clinical hold remains - May 26, 2020.", 
    "company": "NeuroBo Pharmaceuticals Inc.", 
    "indication": "Dyslipidemia", 
    "name": "Gemcabene", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Nurix Therapeutics Inc.", 
    "indication": "Non-Hodgkin lymphoma /chronic lymphocytic leukemia", 
    "name": "NX-2127", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data released July 22, 2019 did not meet primary endpoint.", 
    "company": "Intec Pharma Ltd.", 
    "indication": "Advanced Parkinson's Disease", 
    "name": "AP-CDLD", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 PK trial planned for 2020.", 
    "company": "Intec Pharma Ltd.", 
    "indication": "Various pain indications", 
    "name": "AP-THC", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to commence dosing 2H 2020.", 
    "company": "Intellia Therapeutics Inc.", 
    "indication": "transthyretin amyloidosis (ATTR)", 
    "name": "NTLA-2001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data released May 1, 2017 - primary endpoint not met.", 
    "company": "Neurotrope Inc.", 
    "indication": "Alzheimer's disease", 
    "name": "Bryostatin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - September 9, 2019.", 
    "company": "Neurotrope Inc.", 
    "indication": "Alzheimer's disease", 
    "name": "Bryostatin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 dosing to commence late-3Q or early-4Q 2020.", 
    "company": "Neurotrope Inc.", 
    "indication": "Alzheimer's disease", 
    "name": "Bryostatin-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data met primary endpoints - March 24, 2020.", 
    "company": "Novavax Inc.", 
    "indication": "Influenza", 
    "name": "NanoFlu vaccine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 released September 15, 2016 did not demonstrate efficacy.", 
    "company": "Novavax Inc.", 
    "indication": "Respiratory Syncytial Virus (RSV) in older adults", 
    "name": "RSV vaccine - Resolve trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data released March 28, 2019 - primary endpoint not met. Noted June 10, 2019 that a further Phase 3 trial is required.", 
    "company": "Novavax Inc.", 
    "indication": "Respiratory Syncytial Virus (RSV) in healthy pregnant women - protect infants via maternal immunization", 
    "name": "RSV vaccine - prepare trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation in U.S. and Australia announced August 24, 2020. Interim immunogenicity and safety data data due 4Q 2020.", 
    "company": "Novavax Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "NVX-CoV2373", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim data 2021. Final data 2023.", 
    "company": "NovoCure Limited", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tumor Treating Fields (TTFields) LUNAR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 interim analysis 2021 with final data due 2023.", 
    "company": "NovoCure Limited", 
    "indication": "Ovarian cancer", 
    "name": "Tumor Treating Fields (TTFields) - INNOVATE-3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 interim analysis 2021. Final data due 2023.", 
    "company": "NovoCure Limited", 
    "indication": "Pancreatic cancer", 
    "name": "Tumor Treating Fields (TTFields) -  PANOVA 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "NovoCure Limited", 
    "indication": "Brain Metastases Originating from Non-Small Cell Lung Cancer", 
    "name": "Tumor Treating Fields (TTFields) METIS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 abstract September 5, 2018 noted 6.1 months improvement in OS compared with control. ", 
    "company": "NovoCure Limited", 
    "indication": "Mesothelioma", 
    "name": "Tumor Treating Fields (TTFields) STELLAR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "NovoCure Limited", 
    "indication": "Liver cancer", 
    "name": "Tumor Treating Fields (TTFields) - HEPANOVA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "NovoCure Limited", 
    "indication": "Gastric cancer", 
    "name": "EF-31", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned for 2H 2020.", 
    "company": "NovoCure Limited", 
    "indication": "Non-Small Cell Lung Cancer", 
    "name": "Tumor Treating Fields and Keytruda", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due in 2022.", 
    "company": "NovoCure Limited", 
    "indication": "Recurrent glioblastoma ", 
    "name": "EF-33", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Pivotal trial enrolment commenced May 2019. Noted a total of five patients enrolled as of October 22, 2019.", 
    "company": "InVivo Therapeutics Holdings Corp.", 
    "indication": "Complete Thoracic AIS A Spinal Cord Injury", 
    "name": "Neuro-Spinal Scaffold: INSPIRE 2.0", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced September 20, 2019.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 2 diabetes", 
    "name": "Semaglutide - oral - PIONEER", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial has resumed - noted August 13, 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Hemophilia A", 
    "name": "Concizumab - Explorer 7", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced August 25, 2017.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 2 diabetes", 
    "name": "Victoza (liraglutide)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 29, 2017.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 1 and type 2 diabetes", 
    "name": "Fiasp (fast-acting insulin aspart)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial initiated 2Q 2019.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Growth Hormone Deficiency (GHD)", 
    "name": "Somapacitan (NN8640)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released 2Q 2019. ", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 1 diabetes", 
    "name": "Anti-IL 21 GLP-1 T1D (NNc)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approval announced December 5, 2017.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 2 diabetes", 
    "name": "Semaglutide", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 31, 2017.", 
    "company": "Novo Nordisk A/S", 
    "indication": "haemophilia B", 
    "name": "Nonacog beta pegol", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced February 19, 2019.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Hemophilia A", 
    "name": "N8-GP", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint met - June 18, 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Obesity", 
    "name": "AM833", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Diabetes", 
    "name": "Insulin icodec (LAI287)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial completed December 2019.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 2 diabetes", 
    "name": "LAIsema", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial completed 4Q 2019.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Obesity", 
    "name": "PYY 1562", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - May 13, 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Obesity", 
    "name": "Semaglutide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial completed in April 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "Semaglutide", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Type 2 Diabetes ", 
    "name": "Semaglutide (SUSTAIN FORTE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Novo Nordisk A/S", 
    "indication": "Chronic Kidney Diseases", 
    "name": "Ziltivekimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Head-to-head trial versus proposed biosimilar adalimumab initiated. Expected completion 2022.", 
    "company": "Novartis AG", 
    "indication": "Ankylosing spondylitis (AS)", 
    "name": "Cosentyx (secukinumab) - SURPASS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced April 30, 2018.", 
    "company": "Novartis AG", 
    "indication": "Melanoma with BRAF V600E or V600K mutations", 
    "name": "Tafinlar (dabrafenib) and Mekinist (trametinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Novartis AG", 
    "indication": "Metastatic castration-resistant prostate cancer (mCRPC)", 
    "name": "Lu-PSMA-617", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced May 11, 2018.", 
    "company": "Novartis AG", 
    "indication": "Multiple Sclerosis (MS)", 
    "name": "Fingolimod", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA filing 2021.", 
    "company": "Novartis AG", 
    "indication": "Spinal muscular atrophy (SMA) Type 2", 
    "name": "Zolgensma AVXS-101", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced June 22, 2017.", 
    "company": "Novartis AG", 
    "indication": "Non-small cell lung cancer (NSCLC) with BRAF V600E mutation", 
    "name": "Tafinlar (dabrafenib) and Mekinist (trametinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 1, 2018.", 
    "company": "Novartis AG", 
    "indication": "Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)", 
    "name": "Kymriah (CTL019 )- JULIET", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 overall survival data due 2021.", 
    "company": "Novartis AG", 
    "indication": "Breast cancer", 
    "name": "Kisqali - MONALEESA-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL issued May 2, 2018.", 
    "company": "Novartis AG", 
    "indication": "Various blood cancers, rheumatoid arthritis.", 
    "name": "Biosimilar rituximab", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Priority review granted February 22, 2017. Approval announced May 26, 2017.", 
    "company": "Novartis AG", 
    "indication": "First-line use in patients with ALK+ metastatic NSCLC", 
    "name": "Zykadia", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary and secondary endpoints - July 23, 2020.", 
    "company": "Novartis AG", 
    "indication": "Steroid-refractory chronic GVHD (Graft versus host disease)", 
    "name": "Ruxolitinib - REACH 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - October 16, 2019. Data to be presented at EBMT August 30-September 2, 2020.", 
    "company": "Novartis AG", 
    "indication": "Steroid-refractory acute GVHD (Graft versus host disease)", 
    "name": "Ruxolitinib - REACH 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL announced October 18, 2018.", 
    "company": "Novartis AG", 
    "indication": "CV risk reduction", 
    "name": "ACZ885 (canakinumab) ", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 data released March 22, 2017 - primary endpoints not met.", 
    "company": "Novartis AG", 
    "indication": "Acute heart failure", 
    "name": "RELAX-AHF-2 (RLX030)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 8, 2019.", 
    "company": "Novartis AG", 
    "indication": "Wet age-related macular degeneration (AMD) ", 
    "name": "RTH258 (brolucizumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - December 16, 2019.", 
    "company": "Novartis AG", 
    "indication": "Asthma", 
    "name": "QAW039 (fevipiprant) - LUSTER-1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced August 20, 2020.", 
    "company": "Novartis AG", 
    "indication": "Relapsing multiple sclerosis", 
    "name": "OMB157 (ofatumumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 29, 2019.", 
    "company": "Novartis AG", 
    "indication": "HF-pEF (heart failure with preserved ejection fraction)", 
    "name": "Entresto - PARAGON-HF", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 readout due 1H 2021.", 
    "company": "Novartis AG", 
    "indication": "AMI (acute myocardial infarction)", 
    "name": "Entresto - PARADISE-MI", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced early - August 30, 2017.", 
    "company": "Novartis AG", 
    "indication": "Relapsed/Refractory B-Cell Acute lymphoblastic leukemia", 
    "name": "Kymriah (CTL019)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 17, 2018.", 
    "company": "Novartis AG", 
    "indication": "Migraine", 
    "name": "Erenumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Priority review granted November 14, 2016. Approval announced April 28, 2017.", 
    "company": "Novartis AG", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "Rydapt (Midostaurin - PKC412)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Priority review granted November 1, 2016. Approval announced March 13, 2017.", 
    "company": "Novartis AG", 
    "indication": "HR+/HER2- advanced breast cancer", 
    "name": "LEE011", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 31, 2018.", 
    "company": "Novartis AG", 
    "indication": "Rheumatoid Arthritis", 
    "name": "Adalimumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date December 2020.", 
    "company": "Novartis AG", 
    "indication": "Hyperlipidemia", 
    "name": "Inclisiran", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approved January 26, 2018. Acquired from Advanced Accelerator Applications (NASDAQ: AAAP).", 
    "company": "Novartis AG", 
    "indication": "Inoperable progressive midgut NETs", 
    "name": "Lutathera", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 24, 2019.", 
    "company": "Novartis AG", 
    "indication": "Spinal muscular atrophy (SMA) Type 1", 
    "name": "Zolgensma AVXS-101", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved August 29, 2017.", 
    "company": "Novartis AG", 
    "indication": "Complicated urinary tract infections (cUTI)", 
    "name": "Meropenem-vaborbactam", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL April 30 2014. Approved June 22 2015", 
    "company": "Novartis AG", 
    "indication": "Reduction of thrombotic cardiovascular events including stent thrombosis in patients with coronary artery disease undergoing percutaneous coronary intervention (PCI)", 
    "name": "Cangrelor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved April 30, 2015.", 
    "company": "Novartis AG", 
    "indication": "Acute postoperative pain", 
    "name": "IONSYS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved August 6 2014 under priority review.", 
    "company": "Novartis AG", 
    "indication": "ABSSSI", 
    "name": "Oritavancin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data May 5, 2019 noted 11/22 patients who could sit without support for at least 30 seconds. To be completed in 2021.", 
    "company": "Novartis AG", 
    "indication": "Spinal muscular atrophy (SMA) Type 1", 
    "name": "Zolgensma AVXS-101 STR1VE EU", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial completed 2Q 2020.", 
    "company": "Novartis AG", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "LJN452", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced May 6, 2020.", 
    "company": "Novartis AG", 
    "indication": "Non-small cell lung cancer", 
    "name": "Capmatinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 24, 2019.", 
    "company": "Novartis AG", 
    "indication": "HR + Metastatic breast cancer (MBC)", 
    "name": "BYL719 +  fulvestrant", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced February 8, 2018.", 
    "company": "Novartis AG", 
    "indication": "Psoriasis", 
    "name": "Cosentyx", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data May 5, 2019 noted all patients (18/18) were alive and event-free. Completion 2021.", 
    "company": "Novartis AG", 
    "indication": "Pre-symptomatic patients with spinal muscular atrophy (SMA) Types 1, 2 and 3", 
    "name": "Zolgensma AVXS-101 SPRINT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA approval announced November 16, 2018.", 
    "company": "Novartis AG", 
    "indication": "Severe aplastic anemia (SAA)", 
    "name": "Promacta (eltrombopag)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced March 26, 2019.", 
    "company": "Novartis AG", 
    "indication": "Secondary progressive multiple sclerosis", 
    "name": "Mayzent (siponimod/BAF312)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Regulatory filing due 2H 2020.", 
    "company": "Novartis AG", 
    "indication": "Metastatic melanoma", 
    "name": "PDR001", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced November 15, 2019.", 
    "company": "Novartis AG", 
    "indication": "Sickle cell disease", 
    "name": "Crizanlizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 16, 2020.", 
    "company": "Novartis AG", 
    "indication": "Non-radiographic axial spondyloarthritis", 
    "name": "Cosentyx (secukinumab) - PREVENT", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced February 13, 2019.", 
    "company": "Novartis AG", 
    "indication": "Fascioliasis", 
    "name": "Egaten", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 5, 2019.", 
    "company": "Novartis AG", 
    "indication": "Pegfilgrastim biosimilar", 
    "name": "Biosimilar pegfilgrastim", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to be completed 2022.", 
    "company": "Novartis AG", 
    "indication": "Heart failure", 
    "name": "Entresto -  PERSPECTIVE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be completed 2H 2021.", 
    "company": "Novartis AG", 
    "indication": "Heart failure", 
    "name": "Entresto -  Panorama", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint.", 
    "company": "Novartis AG", 
    "indication": "Asthma", 
    "name": "QMF149", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial discontinued due to lack of efficacy. ", 
    "company": "Novartis AG", 
    "indication": "Alzheimerâ€™s Disease", 
    "name": "CNP520", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - noted October 22, 2019.", 
    "company": "Novartis AG", 
    "indication": "Asthma", 
    "name": "QAW039 (fevipiprant) - ZEAL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - October 31, 2019.", 
    "company": "Novartis AG", 
    "indication": "Psoriatic arthritis", 
    "name": "Cosentyx", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Novartis AG", 
    "indication": "Chronic myeloid leukemia", 
    "name": "Asciminib (ABL001)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Novartis AG", 
    "indication": "Diabetic macular edema (DME)", 
    "name": "Beovu (Brolucizumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Novartis AG", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Canakinumab (ACZ885)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Novartis AG", 
    "indication": "Chronic spontaneous urticaria ", 
    "name": "QGE031 - Pearl 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued July 2016 due to poor data", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Cancer - castration-resistant prostate cancer (CRPC)", 
    "name": "Galeterone - ARMOR3-SV", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Announced in August 2016 that Phase 2 trial enrollment has been discontinued. ", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Xtandi (enzalutamide) refractory metastatic castration-resistant prostate cancer (mCRPC)", 
    "name": "Galeterone - ARMOR2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data presented June 11, 2019, 1pm.", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "OP0201- C-002", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data released April 22, 2019. Safety and tolearbility objectives met.", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "OP0201 C-001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data released April 22, 2019. Safety and tolerability objectives met.", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Acute Otitis Media - adults", 
    "name": "OP0201", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a data did not meet primary endpoint - June 1, 2020.", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Acute Otitis Media - children", 
    "name": "OP0201 - C-006", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 data released April 22, 2019. Safety and tolerability objectives met.", 
    "company": "Novus Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "OP0201 - C-001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Noted July 13, 2020 that it does not plan to advance advance the NSCLC and ovarian cancer cohorts into the stage 2 portion of the Phase 2 trial. HNSCC and breast cancer cohorts continue to enrol. Clinical data update and additional biomarker data due 4Q 2020.", 
    "company": "NextCure Inc.", 
    "indication": "Solid tumors", 
    "name": "NC318", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 initiation announced July 7, 2020. Initial Phase 1 data due 1H 2021.", 
    "company": "NextCure Inc.", 
    "indication": "Solid Tumors", 
    "name": "NC410", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Data released February 2016 met endpoint", 
    "company": "Nymox Pharmaceutical Corporation", 
    "indication": "Low grade localized prostate cancer", 
    "name": "NX-1207 long-term NX03-0040 trial", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "NDA filing planned for late-3Q / early-4Q 2020.", 
    "company": "Nymox Pharmaceutical Corporation", 
    "indication": "BPH", 
    "name": "NX-1207 Fexapotide", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - December 9, 2019. Regulatory filing due 1H 2021.", 
    "company": "ObsEva SA", 
    "indication": "Uterine fibroids", 
    "name": "Linzagolix OBE2109 - PRIMROSE 2", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2a data due 4Q 2020.", 
    "company": "ObsEva SA", 
    "indication": "Pre-term labor", 
    "name": "OBE022 - PROLONG", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data released February 26,2018 - primary endpoint met. Improvement shown in ET D5 subgroup but not in ET D3. ", 
    "company": "ObsEva SA", 
    "indication": "IVF", 
    "name": "OBE001 - IMPLANT2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data trial met primary endpoint - July 6, 2020. Placebo adjusted rates lower than competition.", 
    "company": "ObsEva SA", 
    "indication": "Uterine fibroids", 
    "name": "Linzagolix OBE2109 - PRIMROSE 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - November 10, 2019.", 
    "company": "ObsEva SA", 
    "indication": "Improving IVF outcomes", 
    "name": "Nolasiban (OBE001) - IMPLANT 4", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initiation announced May 9, 2019. Enrollment has resumed following pause due to COVID-19.", 
    "company": "ObsEva SA", 
    "indication": "Endometriosis", 
    "name": "Linzagolix (OBE2109)- EDELWEISS 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 initiation announced May 9, 2019. Enrollment has resumed following pause due to COVID-19.", 
    "company": "ObsEva SA", 
    "indication": "Endometriosis", 
    "name": "Linzagolix (OBE2109) -  EDELWEISS 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to insufficient efficacy - June 1, 2020.", 
    "company": "Ocugen, Inc.", 
    "indication": "Graft Versus Host Disease", 
    "name": "OCU 300", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated in 2H 2021 with data due in 2022.", 
    "company": "Ocugen, Inc.", 
    "indication": " Retinitis Pigmentosa", 
    "name": "OCU400 (AAV-NR2E3)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval June 21, 2019.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Post-surgical ocular inflammation and pain", 
    "name": "DEXTENZA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - June 2016. Additional Phase 3 trial did meet primary endpoints - April 28, 2020. sNDA filing due 2020.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Allergic conjunctivitis", 
    "name": "DEXTENZA", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data May 20, 2019 did not meet primary endpoint.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Glaucoma and ocular hypertension", 
    "name": "OTX-TP", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced December 3, 2018.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Ocular inflammation and pain following cataract surgery", 
    "name": "DEXTENZA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 initial data released April and May 2019. Phase 2 trial to be initiated 1H 2021.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Glaucoma and ocular hypertension", 
    "name": "OTX-TIC", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 update due fall of 2020.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Wet Age-related Macular Degeneration (AMD)", 
    "name": "OTX-TKI", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial has been enrolled. Phase 2 trial to be initiated by end of 2020.", 
    "company": "Ocular Therapeutix Inc.", 
    "indication": "Dry eye disease (DED).", 
    "name": "OTX-CSI", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - August 24, 2020. Median PFS was 9.8 months for tesetaxel plus capecitabine vs 6.9 months capecitabine alone. High levels of neutropenia noted (71.2%). Overall survival data due in 2022.", 
    "company": "Odonate Therapeutics Inc.", 
    "indication": "Metastatic breast cancer (MBC)", 
    "name": "Tesetaxel - CONTESSA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced March 4, 2019.", 
    "company": "Odonate Therapeutics Inc.", 
    "indication": "Metastatic breast cancer (MBC)", 
    "name": "Tesetaxel - Contessa 2", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released April 15, 2020 did not meet primary endpoint.", 
    "company": "Oragenics Inc.", 
    "indication": "Oral mucositis (OM)", 
    "name": "AG013", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated in early 2021.", 
    "company": "Oragenics Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "TerraCoV2", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Rolling BLA filing to be completed 3Q 2020.", 
    "company": "Omeros Corporation", 
    "indication": "Hematopoietic stem cell-associated TMA (HSCT-TMA)", 
    "name": "OMS721", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Omeros Corporation", 
    "indication": "IgA nephropathy", 
    "name": "OMS721", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released October 2016.", 
    "company": "Omeros Corporation", 
    "indication": "Kidney disorders", 
    "name": "OMS721 ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved June 2, 2014.", 
    "company": "Omeros Corporation", 
    "indication": "Cataract surgery", 
    "name": "Omidria", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrollment has opened - noted March 16, 2017.", 
    "company": "Omeros Corporation", 
    "indication": "Atypical hemolytic uremic syndrome (aHUS)", 
    "name": "OMS721 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data September 16, 2019 noted treatment was safe and well-tolerated.", 
    "company": "Omeros Corporation", 
    "indication": "Nicotine Addiction", 
    "name": "OMS527", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "SITC presentation - November 10, 2017. Updated data showed 57% PFS rate at 15 months.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Melanoma", 
    "name": "ImmunoPulse IL-12", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2018.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Squamous Cell Carcinoma of the Head and Neck (SCCHN)", 
    "name": "ImmunoPulse IL-12", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 2H 2020.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Melanoma - cancer", 
    "name": "ImmunoPulse IL-12 - KEYNOTE-695", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 data to be presented December 6, 2018.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Triple Negative Breast Cancer (TNBC)", 
    "name": "TAVO", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 interim data at SABCS December 12, 2019 noted ORR 28.5%. Full data due 2020. Enrolment in second cohort (first-line) to commence 3Q 2020.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Triple negative breast cancer (TNBC)", 
    "name": "TAVO + KEYTRUDA KEYNOTE-890", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data to be presented November 2018 resulted in 47% of patients experiencing tumor regression in at least one untreated lesion.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Melanoma", 
    "name": "OMS-100", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation of dosing announced May 23, 2019.", 
    "company": "OncoSec Medical Incorporated", 
    "indication": "Head and Neck Squamous Cell Carcinoma", 
    "name": "TAVO + epacadostat + KEYTRUDA (TRIFECTA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b expansion cohort data due 4Q 2020.", 
    "company": "Oncternal Therapeutics Inc.", 
    "indication": "Relapsed or refractory Ewing sarcoma", 
    "name": "TK216 and vincristine", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b update due 1H 2021.", 
    "company": "Oncternal Therapeutics Inc.", 
    "indication": "Breast cancer", 
    "name": "Cirmtuzumab and paclitaxel", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 update 4Q 2020.", 
    "company": "Oncternal Therapeutics Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL)", 
    "name": "Cirmtuzumab and ibrutinib", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 interim data due at ASH December 5-8, 2020.", 
    "company": "Oncolytics Biotech Inc.", 
    "indication": "Multiple myeloma", 
    "name": "Pelareorep and Opdivo (ASH)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b final data due 2H 2020.", 
    "company": "Oncolytics Biotech Inc.", 
    "indication": "Breast cancer", 
    "name": "Pelareorep and Tecentriq - AWARE-1", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 final data due 1H 2021.", 
    "company": "Oncolytics Biotech Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "Pelareorep with Keytruda", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 interim data noted ORR 50% - May 29, 2020 at ASCO.", 
    "company": "Oncolytics Biotech Inc.", 
    "indication": "Multiple myeloma", 
    "name": "Pelareorep and Carfilzomib /Dexamethasone", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 dosing of first patient announced June 23, 2020.", 
    "company": "Oncolytics Biotech Inc.", 
    "indication": "HR+ / HER2- breast cancer", 
    "name": "Pelareorep, paclitaxel and avelumab - BRACELET-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced August 26, 2020.", 
    "company": "Oncolytics Biotech Inc.", 
    "indication": "Triple-negative breast cancer.", 
    "name": "Pelareorep and retifanlimab (INCMGA00012) - IRENE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 Special Protocol Assessment (SPA) submission announced January 2, 2019.", 
    "company": "Onconova Therapeutics Inc.", 
    "indication": "First-line HR-MDS (high risk myelodysplastic syndromes)", 
    "name": "Oral Rigosertib and azacitidine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - August 24, 2020.", 
    "company": "Onconova Therapeutics Inc.", 
    "indication": "2nd-line HR-MDS (high risk myelodysplastic syndromes)", 
    "name": "IV Rigosertib - INSPIRE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2a initiation announced June 22, 2020.", 
    "company": "Onconova Therapeutics Inc.", 
    "indication": "KRAS+ Lung Adenocarcinoma", 
    "name": "Rigosertib and Nivolumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2b top-line data March 21, 2019 met primary endpoint. Phase 3 trial planned.", 
    "company": "Opko Health Inc.", 
    "indication": "Obesity and diabetes", 
    "name": "OPK88003", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b trial suspension announced January 31, 2019.", 
    "company": "Opko Health Inc.", 
    "indication": "Benign Prostatic Hyperplasia (BPH)", 
    "name": "OPK88004", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 initial open label data noted trial was well tolerated - March 25, 2020. Final top-line data 1Q 2021.", 
    "company": "Opko Health Inc.", 
    "indication": "Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5", 
    "name": "RAYALDEE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data released December 30, 2016 - primary endpoint not met.", 
    "company": "Opko Health Inc.", 
    "indication": "Adults - growth hormone deficiency", 
    "name": "hGH-CTP", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "BLA filing due fall of 2020.", 
    "company": "Opko Health Inc.", 
    "indication": "Children - growth hormone deficiency", 
    "name": "Somatrogon (hGH-CTP)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Announced June 21 2016 FDA Approval", 
    "company": "Opko Health Inc.", 
    "indication": "Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4", 
    "name": "RAYALDEE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 2, 2015.", 
    "company": "Opko Health Inc.", 
    "indication": "Prevention of chemotherapy induced nausea and vomiting, or CINV", 
    "name": "Rolapitant", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 3Q 2020.", 
    "company": "Opko Health Inc.", 
    "indication": "Mild-to-moderate COVID-19", 
    "name": "RAYALDEE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released February 21, 2019. Endpoints not met.", 
    "company": "Opiant Pharmaceuticals Inc.", 
    "indication": "Bulimia Nervosa", 
    "name": "OPNT001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 recruitment has been delayed due to COVID-19 - noted March 25, 2020.", 
    "company": "Opiant Pharmaceuticals Inc.", 
    "indication": "Alcohol Use Disorder", 
    "name": "OPNT002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approved November 2015.", 
    "company": "Opiant Pharmaceuticals Inc.", 
    "indication": "Opioid Overdose Reversal", 
    "name": "NARCAN (naloxone HCl) Nasal Spray", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Pivotal PK trial to be initiated with NDA to be filed in 2021.", 
    "company": "Opiant Pharmaceuticals Inc.", 
    "indication": "Opioid Overdose", 
    "name": "OPNT003", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "OptiNose Inc.", 
    "indication": "Chronic sinusitis", 
    "name": "XHANCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced September 18, 2017 (prior to IPO).", 
    "company": "OptiNose Inc.", 
    "indication": "Nasal polyps", 
    "name": "XHANCE", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Commencement of enrolment announced December 10, 2018.", 
    "company": "OptiNose Inc.", 
    "indication": "Nasal polyps - pediatric ", 
    "name": "XHANCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b interim data due 1H 2021.", 
    "company": "Oric Pharmaceuticals Inc.", 
    "indication": "Prostate cancer", 
    "name": "ORIC-101 and Xtandi (enzalutamide)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b data due 2H 2021.", 
    "company": "Oric Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "ORIC-101 and Abraxane (nab-paclitaxel)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "Oramed Pharmaceuticals Inc.", 
    "indication": "Type 2 Diabetes", 
    "name": "ORMD-0801", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 trial completed. Assessing options for future development.", 
    "company": "Oramed Pharmaceuticals Inc.", 
    "indication": "Type 2 diabetes", 
    "name": "ORMD-0901", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 interim data presented at ADA 2020 Scientific Sessions - mean 6.9% reduction in liver fat content.", 
    "company": "Oramed Pharmaceuticals Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH)", 
    "name": "ORMD-0801", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data presented February 24, 2019. ", 
    "company": "Orchard Therapeutics plc", 
    "indication": "X-linked chronic granulomatous disease (X-CGD)", 
    "name": "OTL-102", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "BLA filing initially due 1H 2020 will be delayed due to COVID-19.", 
    "company": "Orchard Therapeutics plc", 
    "indication": "Adenosine deaminase severe combined immunodeficiency (ADA-SCID)", 
    "name": "OTL-101", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 data presented April 29, 2019.", 
    "company": "Orchard Therapeutics plc", 
    "indication": "Transfusion-dependent beta-thalassemia (TDBT)", 
    "name": "OTL-300", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "BLA filing due 1H 2021.", 
    "company": "Orchard Therapeutics plc", 
    "indication": "Metachromatic leukodystrophy (MLD)", 
    "name": "OTL-200", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "BLA filing due 2021.", 
    "company": "Orchard Therapeutics plc", 
    "indication": "Wiskott-Aldrich Syndrome (WAS)", 
    "name": "OTL-103", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Interim data from Phase 1/2 trial to be presented at EBMT Annual Meeting August 31, 2020.", 
    "company": "Orchard Therapeutics plc", 
    "indication": "MPS I", 
    "name": "OTL-203", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due 2021.", 
    "company": "Orchard Therapeutics plc", 
    "indication": "MPS-IIIA", 
    "name": "OTL-201", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced July 9, 2020.", 
    "company": "Osmotica Pharmaceuticals plc", 
    "indication": "Blepharoptosis", 
    "name": "Upneeq (RVL-1201)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date December 29, 2020.", 
    "company": "Osmotica Pharmaceuticals plc", 
    "indication": "Spasticity resulting from multiple sclerosis", 
    "name": "Ontinua ER (arbaclofen)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 1/2 data due 4Q 2020.", 
    "company": "Otonomy Inc.", 
    "indication": "Hidden hearing loss", 
    "name": "OTO-413", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data released August 30 failed to meet primary and key secondary endpoints.", 
    "company": "Otonomy Inc.", 
    "indication": "Meniere's disease", 
    "name": "OTO-104 AVERTS-1 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data released July 6, 2020. 43% of patients were responders at both Day 29 and Day 57 compared to 13% of placebo patients. Intends to advance to full Phase 2 development.", 
    "company": "Otonomy Inc.", 
    "indication": "Tinnitus", 
    "name": "OTO-313", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 1Q 2021.", 
    "company": "Otonomy Inc.", 
    "indication": "Ménière's disease", 
    "name": "OTIVIDEX", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved December 11, 2015", 
    "company": "Otonomy Inc.", 
    "indication": "Ear Tube Placement Surgery", 
    "name": "OTIPRIO (ciprofloxacin otic suspension) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced March 2, 2018.", 
    "company": "Otonomy Inc.", 
    "indication": "Acute otitis externa", 
    "name": "OTIPRIO", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released August 26, 2020. No statistical differences between Lucentis (ranibizumab) and ONS-5010.", 
    "company": "Outlook Therapeutics Inc.", 
    "indication": "Wet age-related macular degeneration (wet AMD)", 
    "name": "NORSE 1 (ONS-5010-001)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 3Q 2021.", 
    "company": "Outlook Therapeutics Inc.", 
    "indication": "Wet age-related macular degeneration (wet AMD)", 
    "name": "NORSE 2 (ONS-5010-002)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in 2020.", 
    "company": "Outlook Therapeutics Inc.", 
    "indication": "Branch retinal vein occlusion (BRVO)", 
    "name": "NORSE 4 (ONS-5010)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trials to be initiated in 2020.", 
    "company": "Outlook Therapeutics Inc.", 
    "indication": "Diabetic macular edema (DME)", 
    "name": "NORSE 5 and 6 (ONS-5010)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Outlook Therapeutics Inc.", 
    "indication": "Wet age-related macular degeneration (wet AMD)", 
    "name": "NORSE 3 ONS-5010 (open-label)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial met primary objective of safety and tolerability - May 7, 2020.", 
    "company": "Ovid Therapeutics Inc.", 
    "indication": "Fragile X syndrome", 
    "name": "OV101 (ROCKET)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data to be reported in 3Q 2020.", 
    "company": "Ovid Therapeutics Inc.", 
    "indication": "Developmental and Epileptic Encephalopathies (dEE)", 
    "name": "OV935 ENDYMION", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Ovid Therapeutics Inc.", 
    "indication": "Adolescents with Angelman syndrome", 
    "name": "OV101 - NEPTUNE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint met. Statistically significant reduction in Dravet syndrome patients. Lennox-Gastaut syndrome cohort was not statistically significant - August 25, 2020.", 
    "company": "Ovid Therapeutics Inc.", 
    "indication": "Dravet Syndrome / Lennox-Gastaut Syndrome", 
    "name": "TAK-935/OV935 (ELEKTRA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 3Q 2020.", 
    "company": "Ovid Therapeutics Inc.", 
    "indication": "CDKL5 Deficiency", 
    "name": "TAK-935/OV935 - ARCADE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data met primary endpoint - January 12, 2020.", 
    "company": "Oyster Point Pharma Inc.", 
    "indication": "Dry eye disease", 
    "name": "OC-01", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - May 11, 2020. NDA filing due 2H 2020.", 
    "company": "Oyster Point Pharma Inc.", 
    "indication": "Dry eye disease", 
    "name": "OC-01 (The ONSET-2 Study)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated late-4Q 2020 / early-1Q 2021. Initial biomarker and safety data due 2Q 2021.", 
    "company": "Passage Bio Inc.", 
    "indication": "GM1 gangliosidosis", 
    "name": "PBGM01", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 1H 2021.", 
    "company": "Passage Bio Inc.", 
    "indication": "Frontotemporal dementia", 
    "name": "PBFT02", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 1H 2021.", 
    "company": "Passage Bio Inc.", 
    "indication": "Krabbe disease", 
    "name": "PBFT03", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 further data 4Q 2020.", 
    "company": "Puma Biotechnology Inc", 
    "indication": "HER2 non-amplified breast cancer that has a HER2 mutation", 
    "name": "Neratinib SUMMIT", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 further data due 4Q 2020.", 
    "company": "Puma Biotechnology Inc", 
    "indication": "Extended adjuvant treatment of early stage HER2-positive breast cancer", 
    "name": "Neratinib monotherapy with high dose loperamide prophylaxis - CONTROL", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced February 26, 2020.", 
    "company": "Puma Biotechnology Inc", 
    "indication": "Third-line HER2-positive metastatic breast cancer", 
    "name": "Neratinib - NALA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced July 17, 2017. Advisory Committee Meeting May 24, 2017 voted 12-4 in favor of recommending approval.", 
    "company": "Puma Biotechnology Inc", 
    "indication": "Extended adjuvant HER2-positive early stage breast cancer", 
    "name": "Neratinib (NERLYNX)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Puma Biotechnology Inc", 
    "indication": "HER2 positive breast cancer with brain metastases", 
    "name": "Kadcyla plus neratinib (TBCRC-022)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved October 31, 2011.", 
    "company": "Pacira BioSciences Inc.", 
    "indication": "Postsurgical pain", 
    "name": "EXPAREL", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced April 6, 2018.", 
    "company": "Pacira BioSciences Inc.", 
    "indication": "Post surgical pain", 
    "name": "EXPAREL", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date March 22, 2021.", 
    "company": "Pacira BioSciences Inc.", 
    "indication": "Postoperative Pain Management", 
    "name": "EXPAREL - pediatric patients", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 2H 2021 with data due 2022.", 
    "company": "Vaxcyte Inc.", 
    "indication": "Pneumococcal conjugate vaccine", 
    "name": "VAX-24", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial will not be initiated - noted October 1, 2019.", 
    "company": "PDS Biotechnology Corporation", 
    "indication": "Cervical intraepithelial neoplasia (CIN)", 
    "name": "PDS0101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial initiation delayed due to COVID-19 pandemic.", 
    "company": "PDS Biotechnology Corporation", 
    "indication": "Head and neck cancer", 
    "name": "PDS0101 VERSATILE-002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a trial to be initiated within a few months - noted June 4, 2020.", 
    "company": "PDS Biotechnology Corporation", 
    "indication": "Cervical cancer", 
    "name": "PDS0101 and chemoradiotherapy", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced June 15, 2020.", 
    "company": "PDS Biotechnology Corporation", 
    "indication": "Human papillomavirus (HPV) associated cancers", 
    "name": "PDS0101 and Bintrafusp alfa (M7824)/ NHS-IL12", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated in Brazil.", 
    "company": "PDS Biotechnology Corporation", 
    "indication": "COVID-19 Vaccine", 
    "name": "Versamune-CoV-2FC (PDS0204)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approval announced December 13, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Remicade (infliximab) biosimilar", 
    "name": "IXIFI", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released November 28, 2017 - primary endpoint not met.", 
    "company": "Pfizer Inc.", 
    "indication": "Gastric cancer", 
    "name": "Avelumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Hemophilia A", 
    "name": "Giroctocogene fitelparvovec (SB-525) AFFINE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced October 12, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Postherpetic neuralgia (PHN)", 
    "name": "LYRICA (pregabalin) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Advisory Committee Meeting held November 7, 2017. No votes cast.", 
    "company": "Pfizer Inc.", 
    "indication": "", 
    "name": "Staphylococcus aureus vaccine", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approval announced September 1, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "Mylotarg (gemtuzumab ozogamicin)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued June 22, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "", 
    "name": "Epoetin alfa biosimilar", 
    "stage": "crl"
  }, 
  {
    "newstxt": "FDA approval announced November 2, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "ALK+ NSCLC", 
    "name": "Lorlatinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 9, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Urothelial Carcinoma", 
    "name": "Avelumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 17, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Relapsed or Refractory Acute Lymphoblastic Leukemia in Adults", 
    "name": "Inotuzumab Ozogamicin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 16, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Metastatic hormone sensitive prostate cancer", 
    "name": "XTANDI (ARCHES)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial terminated - noted May 17, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Triple negative breast cancer", 
    "name": "XTANDI (ENDEAR)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced July 13, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "Non-metastatic high risk hormone-sensitive prostate cancer", 
    "name": "XTANDI (PROSPER)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced May 30, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "Xeljanz", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 14, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Psoriatic arthritis", 
    "name": "Xeljanz", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 16, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "BRCA-mutated breast cancer", 
    "name": "Talazoparib ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced 16 November, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Renal cell carcinoma (RCC)", 
    "name": "Sutent (Sunitinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 20, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Type 2 diabetes", 
    "name": "Ertugliflozin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 19, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "First-Line Treatment of Philadelphia Chromosome Positive Chronic Myeloid Leukemia", 
    "name": "BOSULIF (BOSUTINIB)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Priority review announced November 29, 2016. Approval announced March 23, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "Metastatic Merkel cell carcinoma", 
    "name": "Avelumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA acceptance announced December 21, 2016. Approval announced March 31, 2017.", 
    "company": "Pfizer Inc.", 
    "indication": "HR+, HER2- Metastatic Breast Cancer", 
    "name": "IBRANCE (palbociclib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released February 19, 2019. 10mg dose met primary endpoint. 5mg dose did not meet endpoint.", 
    "company": "Pfizer Inc.", 
    "indication": "Chronic low back pain", 
    "name": "Tanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date December 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Osteoarthritis", 
    "name": "Tanezumab", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Cancer pain", 
    "name": "Tanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced June 27, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "BRAF mutant melanoma cancer", 
    "name": "Binimetinib - COLUMBUS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial enrolling -  November 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "LMNA A/C-related dilated cardiomyopathy (DCM)", 
    "name": "ARRY 797", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data failed to meet endpoints - August 2, 2019. Biomarker data to be presented at FSCDR meeting September 23-25, 2020,", 
    "company": "Pfizer Inc.", 
    "indication": "Vaso-occlusive crisis of sickle cell disease", 
    "name": "GMI-1070 (rivipansel)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved Sept 10 2014", 
    "company": "Pfizer Inc.", 
    "indication": "Cancer - mCRPC who have not received chemotherapy", 
    "name": "XTANDI", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 8, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "BRAF-Mutant Colorectal Cancer", 
    "name": "Encorafenib and cetuximab - BEACON CRC", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 6, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Transthyretin amyloid cardiomyopathy (ATTR-CM)", 
    "name": "Tafamidis (tafamidis free acid form)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced September 27, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC) ", 
    "name": "Dacomitinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Complete Response Letter issued December 21, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "HIV", 
    "name": "Dolutegravir + rilpivirine", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to futility.", 
    "company": "Pfizer Inc.", 
    "indication": "Recurrent renal cell carcinoma (RCC) ", 
    "name": "INLYTA (axitinib)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Duchenne muscular dystrophy (DMD)", 
    "name": "PF-06939926", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced November 21, 2018.", 
    "company": "Pfizer Inc.", 
    "indication": "Acute myeloid leukemia (AML)", 
    "name": "Glasdegib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 development terminated due to lack of efficacy.", 
    "company": "Pfizer Inc.", 
    "indication": "Duchenne muscular dystrophy (DMD)", 
    "name": "Domagrozumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced May 14, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Renal cell carcinoma (RCC)", 
    "name": "BAVENCIO (avelumab) and INLYTA (axitinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced April 22, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Renal cell carcinoma", 
    "name": "KEYTRUDA and Inlyta - KEYNOTE-426", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval March 11, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Herceptin biosimilar", 
    "name": "PF-05280014 TRAZIMERA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to be terminated due to lack of efficacy.", 
    "company": "Pfizer Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Avelumab - JAVELIN Ovarian 100 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Pfizer Inc.", 
    "indication": "Alopecia areata", 
    "name": "PF-06651600 - JAK3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced May 6, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Transthyretin amyloid cardiomyopathy (ATTR-CM)", 
    "name": "Tafamidis", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval of sNDA announced April 4, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "HR+/HER2- advanced breast cancer in men", 
    "name": "IBRANCE (palbociclib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Early stage breast cancer", 
    "name": "IBRANCE (palbociclib) - PENELOPE-B", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial unlikely to show a statistically significant improvement in the primary endpoint following futility analysis - May 29, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Early stage breast cancer", 
    "name": "IBRANCE (palbociclib) - PALLAS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "C. difficile Infection", 
    "name": "PF-06425090", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released May 24, 2019 did not meet primary endpoint.", 
    "company": "Pfizer Inc.", 
    "indication": "Primary generalized tonic-clonic (PGTC) seizures - epilepsy", 
    "name": "LYRICA (pregabalin)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 28, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Biosimilar bevacizumab", 
    "name": "PF-06439535", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - June 28, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Persistent Pulmonary Hypertension (PPHN)", 
    "name": "Sildenafil and inhaled nitric oxide (iNO)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced July 23, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "CD20-positive, low tumor burden, follicular lymphoma.", 
    "name": "Ruxience (Biosimilar to Rituxan)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Regulatory filing due 3Q 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Atopic Dermatitis", 
    "name": "Abrocitinib", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 endpoint not met - November 8, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Gastric cancer", 
    "name": "Avelumab - JAVELIN Gastric 100", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint.", 
    "company": "Pfizer Inc.", 
    "indication": "Juvenile idiopathic arthritis (JIA)", 
    "name": "Tofacitinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced November 18, 2019.", 
    "company": "Pfizer Inc.", 
    "indication": "Bosimilar to Humira (adalimumab)", 
    "name": "ABRILADA (adalimumab-afzb)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced July 2, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "HIV", 
    "name": "Fostemsavir", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced June 30, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Bladder cancer", 
    "name": "Bavencio (Avelumab) - JAVELIN Bladder 100", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Ankylosing spondylitis", 
    "name": "Tofacitinib - Xeljanz", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "BRAF V600E-mutant Metastatic Colorectal Cancer", 
    "name": "Encorafenib, Binimetinib and Cetuximab  (ANCHOR-CRC)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Atopic Dermatitis", 
    "name": "PF-06700841", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Psoriasis", 
    "name": "PF-06700841", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial terminated - unlikely to show a statistically significant improvement in the primary endpoint of progression-free survival (PFS).", 
    "company": "Pfizer Inc.", 
    "indication": "Head and Neck Cancer", 
    "name": "Avelumab (JAVELIN Head and Neck100)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced July 27, 2020. Data due October 2020. On track to seek regulatory review in October 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "BNT162b2", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Clinical trials to commence 3Q 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "COVID-19 Coronavirus", 
    "name": "Protease inhibitor against SARS-CoV-2", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "FDA Approval announced June 11, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Biosimilar to Neulasta (pegfilgrastim)", 
    "name": "NYVEPRIA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 initiation announced June 22, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Pneumococcal Disease", 
    "name": "PF-06482077", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiated in June 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Respiratory Syncytial Virus (RSV)", 
    "name": "PF-0692831", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiated June 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Meningococcal Vaccine", 
    "name": "PF-06886992", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met progression-free survival primary endpoint - August 5, 2020.", 
    "company": "Pfizer Inc.", 
    "indication": "Anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)", 
    "name": "Lorlatinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced October 7, 2019 - additional comparative use human factors (CUHF) data required before Therapeutic Equivalence (TE) can be determined.", 
    "company": "Pfenex Inc.", 
    "indication": "Osteoporosis ", 
    "name": "PF708", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial of partnered product met primary endpoint - March 6, 2019.", 
    "company": "Pfenex Inc.", 
    "indication": "Pneumococcal conjugate vaccine", 
    "name": "CRM197", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "BLA filing due 4Q 2020.", 
    "company": "Pfenex Inc.", 
    "indication": "Acute lymphoblastic leukemia (ALL)", 
    "name": "PF743 (JZP-458)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 trial met safety and immunogenicity objectives - June 22, 2020.", 
    "company": "Pfenex Inc.", 
    "indication": "Pneumococcal disease", 
    "name": "PCV-15 (V114)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 additional data due 2H 2020.", 
    "company": "Precigen Inc.", 
    "indication": "Heart failure", 
    "name": "INXN-4001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2H 2020.", 
    "company": "Precigen Inc.", 
    "indication": "Myelodysplastic Syndromes, Acute Myeloid Leukemia", 
    "name": "PRGN-3006", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b primary endpoint met demonstrating safety and tolerability - August 10, 2020.", 
    "company": "Precigen Inc.", 
    "indication": "Type 1 diabetes", 
    "name": "AG019", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced August 5, 2019.", 
    "company": "Precigen Inc.", 
    "indication": "Ovarian cancer", 
    "name": "PRGN-3005", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 initiation of dosing announced August 17, 2020.", 
    "company": "Precigen Inc.", 
    "indication": "HPV+ solid tumors", 
    "name": "PRGN-2009", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2b data due 2021. Delayed due to COVID-19.", 
    "company": "PhaseBio Pharmaceuticals Inc.", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "PB1046", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b commencement of dosing announced October 15, 2019. ", 
    "company": "PhaseBio Pharmaceuticals Inc.", 
    "indication": "Reversal agent for ticagrelor", 
    "name": "PB2452", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 trial initiated 1Q 2020.", 
    "company": "PhaseBio Pharmaceuticals Inc.", 
    "indication": "Uncontrolled bleeding", 
    "name": "PB2452", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "PhaseBio Pharmaceuticals Inc.", 
    "indication": "COVID-19 / acute respiratory distress syndrome (ARDS)", 
    "name": "PB1046 - VANGARD", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2021.", 
    "company": "Phathom Pharmaceuticals Inc.", 
    "indication": "Erosive esophagitis / Gastroesophageal reflux disease (GERD)", 
    "name": "Vonoprazan PHALCON-EE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2021.", 
    "company": "Phathom Pharmaceuticals Inc.", 
    "indication": "H. pylori", 
    "name": "Vonoprazan PHALCON-HP", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a data presented at EHA June 16, 2019.", 
    "company": "Pieris Pharmaceuticals Inc.", 
    "indication": "Anemia of chronic disease", 
    "name": "PRS-080", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "Pieris Pharmaceuticals Inc.", 
    "indication": "Asthma", 
    "name": "PRS-060", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 partial clinical hold announced July 20, 2020. Phase 2 gastric cancer trial to commence later in 2020.", 
    "company": "Pieris Pharmaceuticals Inc.", 
    "indication": "HER2-positive solid tumors", 
    "name": "PRS-343", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 dose escalation data to be presented at ESMO September 20, 2020, 10:32 AM EDT.", 
    "company": "Pieris Pharmaceuticals Inc.", 
    "indication": "HER2-positive solid tumors", 
    "name": "PRS-343 and atezolizumab (Tecentriq)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2a trial enrolling.", 
    "company": "Pliant Therapeutics Inc.", 
    "indication": "Idiopathic pulmonary fibrosis", 
    "name": "PLN-74809", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2a trial enrolling.", 
    "company": "Pliant Therapeutics Inc.", 
    "indication": "Primary sclerosing cholangitis", 
    "name": "PLN-74809", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Pliant Therapeutics Inc.", 
    "indication": "Liver fibrosis associated with NASH", 
    "name": "PLN-1474", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned. IND to be filed 2H 2019.", 
    "company": "ePlus inc.", 
    "indication": "Small cell lung cancer", 
    "name": "DocePLUS", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved May 1, 2012.", 
    "company": "Protalix BioTherapeutics Inc. (DE)", 
    "indication": "Gaucher disease", 
    "name": "Taliglucerase alfa", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 interim data due 1H 2021.", 
    "company": "Protalix BioTherapeutics Inc. (DE)", 
    "indication": "Fabry disease", 
    "name": "Pegunigalsidase alfa  (PRX-102) - BALANCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 interim data released January 3, 2017. Full data released April 12, 2017. Company noted data were positive but results showed efficacy down on January data.", 
    "company": "Protalix BioTherapeutics Inc. (DE)", 
    "indication": "Cystic Fibrosis", 
    "name": "AIR DNase (PRX-110)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released March 13, 2018 - key endpoints met. Data presented at DDW Meeting - 67% of patients experienced a clinical response.", 
    "company": "Protalix BioTherapeutics Inc. (DE)", 
    "indication": "Ulcerative Colitis", 
    "name": "OPRX-106", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date under priority review January 27, 2021.", 
    "company": "Protalix BioTherapeutics Inc. (DE)", 
    "indication": "Fabry disease", 
    "name": "Pegunigalsidase alfa  (PRX-102)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 final data due 4Q 2020.", 
    "company": "Protalix BioTherapeutics Inc. (DE)", 
    "indication": "Fabry disease", 
    "name": "Pegunigalsidase alfa (PRX-102) - BRIGHT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data did not meet endpoints - October 25, 2016. ", 
    "company": "PLx Pharma Inc.", 
    "indication": "Mild infections of diabetic foot ulcers", 
    "name": "Locilex", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA filing due mid-November 2020.", 
    "company": "PLx Pharma Inc.", 
    "indication": "Aspirin - cardiovascular and stroke patients patients", 
    "name": "VAZALORE 325 mg and 81 mg doses", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Principia Biopharma Inc.", 
    "indication": "Pemphigus", 
    "name": "Rilzabrutinib PRN1008 - PEGASUS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated by the end of 2020.", 
    "company": "Principia Biopharma Inc.", 
    "indication": "Immune thrombocytopenic purpura (ITP)", 
    "name": "Rilzabrutinib (PRN1008)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced June 23, 2020.", 
    "company": "Principia Biopharma Inc.", 
    "indication": "Multiple sclerosis", 
    "name": "SAR442168 (PRN2246)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 Part B open label data presented at AAD June 12, 2020. 60 and 87 percent of patients achieved control of disease activity by the 4th and 12th week, respectively.", 
    "company": "Principia Biopharma Inc.", 
    "indication": "Pemphigus", 
    "name": "Rilzabrutinib PRN1008", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Principia Biopharma Inc.", 
    "indication": "IgG4-related disease (IgG4-RD)", 
    "name": "Rilzabrutinib PRN1008", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "Principia Biopharma Inc.", 
    "indication": "Immune-mediated diseases", 
    "name": "PRN473", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 trial delayed due to COVID-19. ", 
    "company": "ProQR Therapeutics N.V.", 
    "indication": "Leber's Congenital Amaurosis (LCA) - Genetic blindness ", 
    "name": "Sepofarsen (QR-110 )", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1b top-line data released September 25, 2017. FEV levels not significant across four doses. One of four doses showed significance in subgroup.", 
    "company": "ProQR Therapeutics N.V.", 
    "indication": "Cystic Fibrosis", 
    "name": "QR-010 ", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 interim analysis announced March 26, 2019. Future development to be conducted by Wings Therapeutics.", 
    "company": "ProQR Therapeutics N.V.", 
    "indication": "Epidermolysis bullosa", 
    "name": "QR-313", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data due 2021.", 
    "company": "ProQR Therapeutics N.V.", 
    "indication": "autosomal dominant retinitis pigmentosa (adRP)", 
    "name": "QR-1123", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 interim data March 31, 2020. 2/8 patients demonstrated benefit across multiple concordant outcome measures. ", 
    "company": "ProQR Therapeutics N.V.", 
    "indication": "Usher Syndrome Type 2", 
    "name": "QR-421a - STELLAR", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 (Part 1) trial did not meet primary endpoint - April 22, 2020. Data to be presented at International Congress of Parkinson’s Disease and Movement Disorders Society (MDS) meeting on September 14, 2020; 14:30 – 16:30 GMT..", 
    "company": "Prothena Corporation plc", 
    "indication": "Parkinson's disease", 
    "name": "PRX002 (PASADENA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data released September 28, 2017 - insufficient meaningful clinical effect for further development.", 
    "company": "Prothena Corporation plc", 
    "indication": "Psoriatic Arthritis", 
    "name": "PRX003", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to futility - April 23, 2018.", 
    "company": "Prothena Corporation plc", 
    "indication": "AL Amyloidosis", 
    "name": "NEOD001 VITAL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet primary endpoint - April 23, 2018.", 
    "company": "Prothena Corporation plc", 
    "indication": "Previously-treated patients with AL amyloidosis and persistent cardiac dysfunction", 
    "name": "NEOD001 PRONTO", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1 additional data from the dose-escalation and long-term extension portions due 4Q 2020.", 
    "company": "Prothena Corporation plc", 
    "indication": "ATTR amyloidosis", 
    "name": "PRX004", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approved November 23, 2011.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Insomnia", 
    "name": "Intermezzo", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sNDA filing submitted July 2020.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Acute bacterial skin and skin structure infections (ABSSSI)", 
    "name": "Omadacycline - oral", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced October 2, 2018.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Acute bacterial skin and skin structure infections (ABSSSI)", 
    "name": "Omadacycline", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 2, 2018.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Community-acquired bacterial pneumonia (CABP)", 
    "name": "Omadacycline", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 2, 2018.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Severe acne vulgaris", 
    "name": "Sarecycline", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Urinary tract infections", 
    "name": "Omadacycline", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.", 
    "company": "Paratek Pharmaceuticals Inc.", 
    "indication": "Complicated urinary tract infections (cUTI) / acute pyelonephritis", 
    "name": "Omadacycline", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b top-line data May 8, 2019 noted primary safety and tolerability endpoint met but efficacy and other secondary endpoints were not met.", 
    "company": "Provention Bio Inc.", 
    "indication": "Ulcerative Colitis", 
    "name": "PRV-300", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Commencement of BLA filing announced April 16, 2020. To be completed 4Q 2020.", 
    "company": "Provention Bio Inc.", 
    "indication": "Type 1 diabetes", 
    "name": "PRV-031 (teplizumab)", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2a data did not meet primary endpoint - October 22, 2019.", 
    "company": "Provention Bio Inc.", 
    "indication": "Crohn's disease", 
    "name": "PRV-6527", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2b trial to commence 2020.", 
    "company": "Provention Bio Inc.", 
    "indication": "Celiac disease", 
    "name": "PRV-015", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1b data released March 12, 2020 - well tolerated. Phase 2a portion to commence 1H 2021.", 
    "company": "Provention Bio Inc.", 
    "indication": "Systemic Lupus Erythematosus (SLE) and Lupus nephritis (LN)", 
    "name": "PRV-3279", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 2H 2020.", 
    "company": "Prevail Therapeutics Inc.", 
    "indication": "Type 2 Gaucher disease", 
    "name": "PR001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due mid-2021.", 
    "company": "Prevail Therapeutics Inc.", 
    "indication": "Parkinsonâ€™s disease with GBA1 mutation", 
    "name": "PR001 - Propel", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated 2H 2020.", 
    "company": "Prevail Therapeutics Inc.", 
    "indication": "Frontotemporal Dementia Patients with GRN Mutations", 
    "name": "PR006 (PROCLAIM)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial postponed until additional clinical data from the PROPEL and PROVIDE trials is available to inform the clinical development strategy.", 
    "company": "Prevail Therapeutics Inc.", 
    "indication": "Type 3 Gaucher disease", 
    "name": "PR001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020.", 
    "company": "Pluristem Therapeutics Inc.", 
    "indication": "Critical limb ischemia (CLI)", 
    "name": "PLX-PAD (stem cells)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released June 12, 2018 - primary endpoint met.", 
    "company": "Pluristem Therapeutics Inc.", 
    "indication": "Intermittent claudication, or IC", 
    "name": "PLX-PAD (stem cells)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 top-line data due 1Q 2021.", 
    "company": "Pluristem Therapeutics Inc.", 
    "indication": "Incomplete hematopoietic recovery following hematopoietic cell transplantation (HCT)", 
    "name": "PLX-R18", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due 3Q 2021.", 
    "company": "Pluristem Therapeutics Inc.", 
    "indication": "Muscle injury following hip fracture", 
    "name": "PLX-PAD", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line 28-day follow-up data due 4Q 2020.   ", 
    "company": "Pluristem Therapeutics Inc.", 
    "indication": "COVID-19 / Acute Respiratory Distress Syndrome (ARDS)", 
    "name": "PLX-PAD", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "PLUS THERAPEUTICS Inc.", 
    "indication": "Platinum-sensitive small cell lung cancer", 
    "name": "DocePLUS (ATI-1123)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2H 2020.", 
    "company": "PLUS THERAPEUTICS Inc.", 
    "indication": "Glioma", 
    "name": "Rhenium NanoLiposomes (ReSPECT)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial ongoing.", 
    "company": "Poseida Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "P-BCMA-101", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial initiated May 2020. Clinical hold announced August 17, 2020.", 
    "company": "Poseida Therapeutics Inc.", 
    "indication": "Castrate-resistant prostate cancer (CRPC)", 
    "name": "P-PSMA-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Received a Refusal to File letter February 23 2016. Appeal rejected October 17, 2016.  Decision made to resubmit NDA during 1Q 2017 under protest. Further CRL October 25, 2017. NDA to be refiled.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy caused by nonsense mutations (nmDMD)", 
    "name": "Translarna", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 5, 2018,", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "NEURO-TTR - familial amyloid polyneuropathy (FAP).", 
    "name": "Inotersen (IONIS-TTRRx)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released March 2, 2017 - endpoints not met. Development to be discontinued.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "Nonsense mutation cystic fibrosis", 
    "name": "Translarna", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced August 7, 2020.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "Spinal Muscular Atrophy (SMA) Type 1", 
    "name": "Risdiplam (RG7916)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "BLA filing due 2H 2020.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "AADC deficiency", 
    "name": "PTC-AADC", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "FDA Approval announced for label expansion June 7, 2019.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy (age 2-5)", 
    "name": "Emflaza", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2/3 initiation announced June 17, 2020. Data due 1H 2021.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "PTC299", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced July 8, 2020. Data due by the end of 2020.", 
    "company": "PTC Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "PTC857", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b trial discontinued following interim analysis - March 26, 2018. However, company noted August 6, 2018 that human error by CRO contributed to this decision. ", 
    "company": "Protagonist Therapeutics Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "PTG-100", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data presented at EHA June 12, 2020.", 
    "company": "Protagonist Therapeutics Inc.", 
    "indication": "Beta-thalassemia", 
    "name": "PTG-300", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 ongoing - conducted by Janssen.", 
    "company": "Protagonist Therapeutics Inc.", 
    "indication": "Crohn's disease", 
    "name": "PTG-200", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial screening has been initiated - August 6, 2020.", 
    "company": "Protagonist Therapeutics Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "PN-943", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation announced January 6, 2020.", 
    "company": "Protagonist Therapeutics Inc.", 
    "indication": "Hereditary hemochromatosis", 
    "name": "PTG-300", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initial data released May 7, 2020.", 
    "company": "Protagonist Therapeutics Inc.", 
    "indication": "Polycythemia vera", 
    "name": "PTG-300", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%. Phase 2 28-day data released December 11, 2017 - showed improvements in FEV1 of 5.2%.", 
    "company": "Proteostasis Therapeutics Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "PTI-428", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued due to lack of efficacy - March 25, 2019.", 
    "company": "Proteostasis Therapeutics Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "PTI-801 + Symdeko", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 negative data released December 17, 2019. Mean changes in ppFEV1 were not statistically significant in the heterozygous population. Phase 3 trial to be initiated in 2020.", 
    "company": "Proteostasis Therapeutics Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "PTI-428 + PTI-801 + PTI-808", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued due to lack of efficacy.", 
    "company": "Proteostasis Therapeutics Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "PTI-428 + Symdeko", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA approval announced June 21, 2019.", 
    "company": "Palatin Technologies Inc.", 
    "indication": "Female sexual dysfunction (FSD)", 
    "name": "Vyleesi (Bremelanotide)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Palatin Technologies Inc.", 
    "indication": "Heart failure", 
    "name": "PL-3994", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2021.", 
    "company": "Palatin Technologies Inc.", 
    "indication": "Non-infectious uveitis", 
    "name": "PL-8177", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 1H 2021 with data due 1H 2022.", 
    "company": "Palatin Technologies Inc.", 
    "indication": "Ulcerative colitis", 
    "name": "PL-8177", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Palatin Technologies Inc.", 
    "indication": "Dry eye disease (DED)", 
    "name": "PL9643", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "Palatin Technologies Inc.", 
    "indication": "COVID-19", 
    "name": "PL8177", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Current Phase 2 trial terminated and replaced by a Phase 2b trial to be initiated 3Q 2021.", 
    "company": "Pulmatrix Inc.", 
    "indication": "Allergic bronchopulmonary aspergillosis in patients with asthma. ", 
    "name": "Pulmazole (PUR1900)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b trial to commence 2H 2020.", 
    "company": "Pulmatrix Inc.", 
    "indication": "Acute exacerbation of chronic obstructive pulmonary disease (AECOPD)", 
    "name": "PUR1800", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced July 1, 2020 with data due by end of 2021.", 
    "company": "PolyPid Ltd.", 
    "indication": "Abdominal (soft tissue) sternal surgical site infections", 
    "name": "D-PLEX100 - SHILED I", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiated December 2019. Enrolment paused due to COVID-19.", 
    "company": "PolyPid Ltd.", 
    "indication": "Sternal (bone) sternal surgical site infections", 
    "name": "D-PLEX100", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data failed to meet primary endpoint - September 12, 2019.", 
    "company": "Qualigen Therapeutics Inc.", 
    "indication": "Lactose intolerance", 
    "name": "RP-G28", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial to commence in 2021.", 
    "company": "Qualigen Therapeutics Inc.", 
    "indication": "Acute myeloid leukemia", 
    "name": "ALAN", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 commencement of dosing announced June 19, 2020.", 
    "company": "uniQure N.V.", 
    "indication": "Huntington's disease", 
    "name": "AMT-130", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 26-week data due by the end of 2020.", 
    "company": "uniQure N.V.", 
    "indication": "Hemophilia B", 
    "name": "AMT-061 (HOPE-B)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b enrolment has been paused due to COVID-19. Data due at the end of 2020.", 
    "company": "RAPT Therapeutics Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "RPT193", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "RAPT Therapeutics Inc.", 
    "indication": "Advanced Cancer", 
    "name": "FLX475 + Keytruda", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data from Cohort 4 due by the end of 2020. Phase 3 trial to commence 1H 2021.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Ornithine Transcarbamylase (OTC) Deficiency", 
    "name": "DTX301", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Approved under priority review November 15, 2017.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Mucopolysaccharidosis 7 (MPS 7)", 
    "name": "MEPSEVII (vestronidase alfa)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released October 26, 2018 - endpoints not met.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Glut1 DS patients with the movement disorder phenotype", 
    "name": "UX007 (triheptanoin)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released August 22, 2017 - endpoints not met.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "GNE Myopathy", 
    "name": "Aceneuramic acid extended release (Ace-ER)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced April 17, 2018.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "X-Linked Hypophosphatemia (XLH) ", 
    "name": "Crysvita (Burosumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 18, 2020.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Tumor-induced osteomalacia (TIO)", 
    "name": "Burosumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 30, 2020.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)", 
    "name": "UX007 (triheptanoin)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 additional data from Cohort 3 due 2H 2020. Phase 3 trial to commence early 2021.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Glycogen Storage Disease Type Ia (GSDIa)", 
    "name": "DTX401", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 preliminary data due 1H 2021.", 
    "company": "Ultragenyx Pharmaceutical Inc.", 
    "indication": "Angelman Syndrome", 
    "name": "GTX-102", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data released January 3, 2017. Primary endpoint not met.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Primary open-angle glaucoma (POAG)", 
    "name": "Trabodenoson", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial failed - noted July 7, 2017.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Glaucoma", 
    "name": "Trabodenoson and latanoprost", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data update 4Q 2020.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Leukocyte Adhesion Deficiency-I (LAD-I)", 
    "name": "RP-L201", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 4Q 2020.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Danon disease", 
    "name": "RP-A501", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data due 4Q 2020.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Pyruvate Kinase Deficiency (PKD)", 
    "name": "RP-L301", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 update on Process B data due 4Q 2020.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Fanconi Anemia (FA)", 
    "name": "RP-L102", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial has commenced enrollment - noted August 5, 2020.", 
    "company": "Rocket Pharmaceuticals Inc.", 
    "indication": "Infantile Malignant Osteopetrosis (IMO)", 
    "name": "RP-L401", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b/2 trial initiated 2Q 2020.", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Metastatic castrate-resistant prostate cancer (mCRPC)", 
    "name": "AB928, AB680 and zimberelimab - ARC-6", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initiation announced September 4, 2019.", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Triple negative breast cancer (TNBC) and ovarian cancer", 
    "name": "AB298 + IPI-549 + Doxil", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 initial data due 4Q 2020.", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Colorectal Cancer", 
    "name": "AB928 (Morpheus-CRC)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b trial ongoing.", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Solid tumors", 
    "name": "AB928 + Zimberelimab (AB122)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 randomization data due 4Q 2020", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "AB154 + Zimberelimab (AB122) (ARC-7)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 recommended dose from escalation portion due 2H 2020.", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Pancreatic Cancer", 
    "name": "AB680 +Zimberelimab (AB122) - ARC-8", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/1b data to be presented at ESMO September 19-22, 2020.", 
    "company": "Arcus Biosciences Inc.", 
    "indication": "Non-small cell lung cancer", 
    "name": "Etrumadenant, carboplatin, pemetrexed", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated.", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "Nontuberculous mycobacteria (NTM) infections", 
    "name": "RHB-204", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a enrolment of second arm has been initiated - March 11, 2020.", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "Cholangiocarcinoma", 
    "name": "YELIVA", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data released July 30, 2018. Primary endpoint met but further trial required. ", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "Crohnâ€™s disease", 
    "name": "RHB-104 MAP", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced November 4, 2019.", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "H. pylori", 
    "name": "Talicia RHB-105", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 additional trial planned. ", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "Gastroenteritis", 
    "name": "BEKINDA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data released October 3, 2017 - primary endpoint met (borderline) - p=0.05. Follow up analysis identfied p value = 0.036. Phase 3 trial planned.", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "IBS-D", 
    "name": "BEKINDA ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a U.S. trial data due 4Q 2020.", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "COVID-19", 
    "name": "Opaganib", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2/3 global trial data due 4Q 2020.", 
    "company": "Redhill Biopharma Ltd.", 
    "indication": "COVID-19", 
    "name": "Opaganib", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Radius Health Inc.", 
    "indication": "Male Osteoporosis", 
    "name": "Abaloparatide-SC ATOM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2H 2021.", 
    "company": "Radius Health Inc.", 
    "indication": "Breast cancer", 
    "name": "Elacestrant - EMERALD", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date originally scheduled for March 30 2017 delayed by three months to June 30, 2017. Approval announced April 28, 2017.", 
    "company": "Radius Health Inc.", 
    "indication": "Osteoporosis", 
    "name": "TYMLOS (Abaloparatide)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Radius Health Inc.", 
    "indication": "Osteoporosis", 
    "name": "Abaloparatide -Transdermal Patch (wearABLe)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced September 28, 2018.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Cutaneous squamous cell carcinoma", 
    "name": "Cemiplimab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 17, 2018.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Wet AMD", 
    "name": "EYLEA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA Approval announced April 25, 2017.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "High low-density lipoprotein (LDL) cholesterol", 
    "name": "Praluent (alirocumab) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 26, 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Atopic dermatitis 6-11 year-olds", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced March 11, 2019.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Atopic dermatitis 12-17 year-olds", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced April 26, 2019.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Cardiovascular events", 
    "name": "Praluent (alirocumab) ODYSSEY OUTCOMES", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 19, 2018.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Asthma", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Pivotal Phase 2/3 trial ongoing.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Cutaneous squamous cell carcinoma", 
    "name": "REGN2810", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to significant improvement in overall survival - April 27, 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Cemiplimab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolling.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "REGN2810", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data achieved the co-primary endpoints for fasinumab 1 mg monthly. Fasinumab every two months did not reach statistical significance - August 5, 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Osteoarthritis pain of the hip or knee", 
    "name": "Fasinumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released August 14, 2017 - primary endpoint not met.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Respiratory syncytial virus (RSV)", 
    "name": "REGN2222", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 13, 2019.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Nonproliferative Diabetic Retinopathy", 
    "name": "EYLEA - PANAROMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 ongoing.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Diabetic Retinopathy", 
    "name": "EYLEA - PROTOCOL-W", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Asthma - 6-11 year-olds", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 26, 2019.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Nasal polyps", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b placed on clinical hold. Phase 3 trial to be initiated that excludes patients with advanced osteoarthritis 2H 2017.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Osteoarthritis and chronic low back pain", 
    "name": "Fasinumab", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Diabetic macular edema (DME)", 
    "name": "EYLEA + nesvacumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released November 27, 2017 - insufficient efficacy shown to warrant further development.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "AMD - age-related macular degeneration ", 
    "name": "EYLEA + nesvacumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Peanut Allergy", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Data from Phase 2 portion of Phase 2/3 trial met co-primary endpoints - May 22, 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Eosinophilic esophagitis", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Approved under priority review - March 28, 2017.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Rheumatoid arthritis", 
    "name": "Sarilumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 further data due 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Follicular Lymphoma", 
    "name": "REGN1979", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "PDUFA date under priority review February 11, 2021.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Homozygous familial hypercholesterolemia (HoFH)", 
    "name": "Evinacumab (ANGPTL3 Antibody)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 2 pivotal data showed objective response rate (ORR) of 29%. Regulatory submission due 2020\n", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Basal cell carcinoma", 
    "name": "Cemiplimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2H 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Libtayo - Cemiplimab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 interim data due 2020. Phase 3 trial to be initiated in 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Paroxysmal nocturnal hemoglobinuria (PNH", 
    "name": "Pozelimab (REGN3918)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint p=0.07 - January 9, 2020. Patient-reported flare-ups were reduced by 50% (nominal p=0.03).", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Fibrodysplasia ossificans progressiva (FOP)", 
    "name": "Garetosmab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "PDUFA date under priority review October 25, 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Ebola", 
    "name": "REGN-EB3", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 1/2 updated data due 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "REGN5458", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 2, 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Coronavirus COVID-19", 
    "name": "Kevzara (Sarilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 initial virology and biomarker data due September 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "COVID-19 (Anti-viral antibody)", 
    "name": "REGN-COV2", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2/3 data of global trial due 3Q 2020.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Coronavirus COVID-19", 
    "name": "Kevzara (sarilumab)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "sBLA filing has been submitted. ", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Homozygous familial hypercholesterolemia (HoFH) ", 
    "name": "Praluent (alirocumab)", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Prurigo nodularis (PN)", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial has been initiated. Data likely due 2022.", 
    "company": "Regeneron Pharmaceuticals Inc.", 
    "indication": "Bullous pemphigoid (BP)", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 update June 3, 2020 noted ORR 31%.", 
    "company": "Replimune Group Inc.", 
    "indication": "Melanoma", 
    "name": "RP1 and nivolumab", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced October 15, 2019.", 
    "company": "Replimune Group Inc.", 
    "indication": "Cutaneous squamous cell carcinoma (CSCC)", 
    "name": "RP1 and cemiplimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initial data due by the end of 2020.", 
    "company": "Replimune Group Inc.", 
    "indication": "Solid tumors", 
    "name": "RP2 and nivolumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiated May 2020.", 
    "company": "Replimune Group Inc.", 
    "indication": "Liver and kidney transplant recipients with recurrent Cutaneous squamous cell carcinoma", 
    "name": "RP1 (ARTACUS)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2020.", 
    "company": "Replimune Group Inc.", 
    "indication": "", 
    "name": "RP3", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 Year 2 data due 4Q 2020.", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "Chronic Kidney Disease Caused by Alport Syndrome", 
    "name": "Bardoxolone methyl - CARDINAL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial stopped following DSMB recommendation. Primary endpoint unlikely to be met.", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "Pulmonary arterial hypertension associated with connective tissue disease - CTD-PAH", 
    "name": "Bardoxolone methyl - CATALYST", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing due 1Q 2021 assuming FDA views crossover study data as sufficiently positive to provide confirmatory evidence for filing. Data due 4Q 2020.", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "Friedreichâ€™s ataxia (FA)", 
    "name": "Omaveloxolone", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initial data released March 1, 2018 - endpoints not met.", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "Mitochondrial myopathies (MM)", 
    "name": "Omaveloxolone - MOTOR", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrollment has recommenced following pause due to COVID-19.", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "Chronic Kidney Disease", 
    "name": "Bardoxolone - FALCON", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 initiation announced June 20, 2018. ", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "Healthy Volunteers", 
    "name": "RTA 1701", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 initiation announced July 28, 2020.", 
    "company": "Reata Pharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "Bardoxolone (BARCONA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 PFS of 5.4 months. ORR 23%. Final data due 2020.", 
    "company": "Rexahn Pharmaceuticals Inc.", 
    "indication": "First-line pancreatic cancer", 
    "name": "RX-3117 in combination with Abraxane", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "CRL received June 22, 2012.", 
    "company": "Repligen Corporation", 
    "indication": "Detection of pancreatic duct abnormalities", 
    "name": "RG1068", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2 enrollment has been paused due to financial conditions - noted July 5, 2018.", 
    "company": "Regulus Therapeutics Inc.", 
    "indication": "Alport Syndrome", 
    "name": "RG-012 - HERA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial completion of dosing announced July 22, 2020. Well-tolerated with no serious adverse events reported. Phase 1b trial planned.", 
    "company": "Regulus Therapeutics Inc.", 
    "indication": "Autosomal dominant polycystic kidney disease (ADPKD)", 
    "name": "RGLS4326", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development to be discontinued - noted August 6, 2020.", 
    "company": "REGENXBIO Inc.", 
    "indication": "Homozygous familial hypercholesterolemia (HoFH)", 
    "name": "RGX-501", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 update due 2H 2020.", 
    "company": "REGENXBIO Inc.", 
    "indication": "Mucopolysaccharidosis Type I (MPS I)", 
    "name": "RGX-111", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to commence enrollment 3Q 2020 with interim data from first cohort due by the end of 2020.", 
    "company": "REGENXBIO Inc.", 
    "indication": "Wet AMD using using subretinal delivery", 
    "name": "RGX-314", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 additional data due 2H 2020.", 
    "company": "REGENXBIO Inc.", 
    "indication": "MPS II", 
    "name": "RGX-121", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020 with interim data due in 2021.", 
    "company": "REGENXBIO Inc.", 
    "indication": "Diabetic retinopathy ", 
    "name": "RGX-314 - ALTITUDE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to commence dosing 3Q 2020.Interim data from the first cohort due by the end of 2020", 
    "company": "REGENXBIO Inc.", 
    "indication": "Wet AMD using suprachoroidal delivery ", 
    "name": "RGX-314 (AAVIATE)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 final data due mid-2021.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Cancer related diarrhea (CRD)", 
    "name": "Mytesi (crofelemer) HALT-D", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - June 20, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "First-line BRAF wild-type metastatic or unresectable locally advanced melanoma", 
    "name": "IMspire170 - cobimetinib and atezolizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Huntington's Disease", 
    "name": "Tominersen (IONIS-HTT Rx)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released May 10, 2018. Primary endpoint not met.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Third-line advanced or metastatic colorectal cancer", 
    "name": "IMblaze370 - cobimetinib and atezolizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Crenezumab - CREAD 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced June 11, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)", 
    "name": "Venclexta (MURANO)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial terminated following interim analysis indicating primary endpoint would not be met.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "Crenezumab - CREAD 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced May 6, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "HER2-positive breast cancer - residual invasive disease", 
    "name": "Kadcyla (KATHERINE)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 15, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Solid tumors and ROS1-positive non-small cell lung cancer (NSCLC)", 
    "name": "Entrectinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 7, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Spinal Muscular Atrophy (SMA) Type 1", 
    "name": "Risdiplam (RG7916)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 PFS endpoint met - PFS=6.3 vs. 5.6 months for chemo. HR 0.71.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Squamous non-small cell lung cancer (NSCLC)", 
    "name": "Tecentriq+cb+pac/nab-pac - IMpower131", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced December 6, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Non-squamous non-small cell lung cancer (NSCLC)", 
    "name": "Tecentriq + Avastin - IMpower150", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PFS endpoint met. HR 0.74 - February 6, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Kidney cancer - renal cell carcinoma (mRCC)", 
    "name": "TECENTRIQ (atezolizumab) - IMmotion151", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approval announced June 7, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Pemphigus vulgaris", 
    "name": "MabThera/ Rituxan (rituximab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced March 18, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Squamous non-small cell lung cancer (NSCLC)", 
    "name": "Tecentriq+cb+etoposide - IMpower133", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced December 3, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Squamous non-small cell lung cancer (NSCLC)", 
    "name": "TECENTRIQ (atezolizumab) plus chemotherapy (carboplatin and Abraxane) - IMpower130", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced July 30, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "BRAF V600 mutation-positive metastatic or unresectable locally advanced melanoma", 
    "name": "IMspire150 - cobimetinib, atezolizumab and vemurafenib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 4, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Hemophilia", 
    "name": "Hemlibra", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 updated data at ESMO noted HR 0.43. PFS 34.8 months vs 10.9 months for crizotinib.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Anaplastic lymphoma kinase (ALK)-positive metastatic (advanced) non-small cell lung cancer (NSCLC)", 
    "name": "Alecensa - ALEX", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced June 11, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Solid tumors", 
    "name": "Cabozantinib + atezolizumab (TECENTRIQ) CONTACT-01", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced June 13, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Ovarian cancer", 
    "name": "Avastin (bevacizumab) + chemo", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrollment has commenced - noted June 14, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Early Alzheimer's disease", 
    "name": "Gantenerumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced October 24, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Influenza", 
    "name": "Baloxavir marboxil", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced June 29, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "HER2-positive early breast cancer", 
    "name": "Subcutaneous Pertuzumab And Trastuzumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced November 21, 2018.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "First line unfit AML", 
    "name": "Venclexta", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced May 15, 2019. ", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Chronic Lymphocytic Leukemia", 
    "name": "Venetoclax and obinutuzumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced March 8, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Triple-negative breast cancer", 
    "name": "TECENTRIQ (atezolizumab) plus Abraxane", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - June 18, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Neoadjuvant triple negative breast cancer", 
    "name": "Tecentriq + chemo - IMpassion 031", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 29, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Hepatocellular carcinoma", 
    "name": "Tecentriq + Avastin - IMbrave 150", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Multiple myeloma", 
    "name": "Venclexta BELLINI", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced June 10, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 18, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Influenza", 
    "name": "Baloxavir marboxil", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 OS update at ASCO June 4, 2019 - median OS=21.0 vs 18.7 months; HR=0.86.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Triple-negative breast cancer", 
    "name": "Tecentriq plus nab-paclitaxel - IMpassion 130", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sBLA acceptance announced December 11, 2019. No PDUFA date supplied. Estimate 3Q 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Chronic rhinosinusitis with nasal polyps (CRSwNP)", 
    "name": "Xolair (omalizumab)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "FDA Approval announced September 27, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Granulomatosis with polyangiitis (GPA) / microscopic polyangiitis (MPA)", 
    "name": "MabThera/ Rituxan (rituximab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary and secondary endpoints - June 13, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Pemphigus vulgaris", 
    "name": "Mabthera/Rituxan (rituximab) - PEMPHIX", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - 2Q 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Neovascular Age-Related Macular Degeneration", 
    "name": "Ranibizumab - Archway", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - January 24, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Urothelial cancer", 
    "name": "Tecentriq - IMvigor010", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 PFS co-primary endpoint met - August 5, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Urothelial carcinoma", 
    "name": "Tecentriq (atezolizumab) plus chemotherapy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced August 15, 2019.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Solid tumors - NTRK gene fusion", 
    "name": "Entrectinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced August 14, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Neuromyelitis optica spectrum disorder (NMOSD)", 
    "name": "Satralizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced May 18, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tecentriq - IMpower110", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data at ESMO 2019 noted median PFS=8.2 versus 6.3 months; hazard ratio (HR)=0.82.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Urothelial carcinoma", 
    "name": "Tecentriq IMvigor130", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 10, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Inherited Alzheimer's disease", 
    "name": "Solanezumab", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 13, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Ovarian cancer", 
    "name": "Tecentriq IMaGYN050", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Triple negative breast cancer and HR+ breast cancer", 
    "name": "Ipatasertib - IPATunity130", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met one of two co-primary endpoints - June 19, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Castration-resistant prostate cancer", 
    "name": "Ipatasertib - IPATential150", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Diabetic Macular Edema", 
    "name": "Faricimab (RG7716) - (YOSEMITE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "HIBISCUS I induction study, in people without prior anti-tumor necrosis factor (anti-TNF) treatment, etrolizumab met the primary endpoint. HIBISCUS II induction study, including people without prior anti-TNF treatment, did not meet its primary endpoint.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Ulcerative colitis", 
    "name": "Etrolizumab HIBISCUS I", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met dual primary endpoints of overall survival and composite complete remission rate - March 23, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "Venclexta (VIALE-A)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did meet primary endpoint - July 29, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Coronavirus COVID-19", 
    "name": "Actemra (COVACTA)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date for sNDA filing November 23, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Acute uncomplicated influenza (age 1-12 years old)", 
    "name": "Xofluza (baloxavir marboxil)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Diabetic macular edema", 
    "name": "Faricimab (RG7716) - RHINE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data presented at ASCO May 29, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tiragolumab and atezolizumab - CITYSCAPE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced May 28, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "COVID-19", 
    "name": "Actemra/RoActemra plus remdesivir", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - October 6, 2020.", 
    "company": "Roche Holding Ltd ADR (Sponsored)", 
    "indication": "Triple-negative breast cancer (TNBC)", 
    "name": "Tecentriq and paclitaxel - Mpassion131", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released April 3, 2018. Primary endpoint not met.", 
    "company": "Rigel Pharmaceuticals Inc.", 
    "indication": "IgA nephropathy", 
    "name": "Fostamatinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet endpoints", 
    "company": "Rigel Pharmaceuticals Inc.", 
    "indication": "Chronic dry eye disease - as a result of patients with acute or chronic graft vs. host disease (GvHD)", 
    "name": "R348", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved April 17, 2018.", 
    "company": "Rigel Pharmaceuticals Inc.", 
    "indication": "Immune Thrombocytopenic Purpura (ITP)", 
    "name": "Tavalissetm (Fostamatinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrollment sites are back open following pause due to COVID-19.", 
    "company": "Rigel Pharmaceuticals Inc.", 
    "indication": "Warm Autoimmune hemolytic anemia (WAIHA)", 
    "name": "Fostamatinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial has been completed - noted October 23, 2019.", 
    "company": "Rigel Pharmaceuticals Inc.", 
    "indication": "Autoimmune and inflammatory diseases", 
    "name": "R835", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated.", 
    "company": "Rigel Pharmaceuticals Inc.", 
    "indication": "COVID-19", 
    "name": "Fostamatinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial initiated 1Q 2020. Update due 2021.", 
    "company": "Relay Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "RLY-1971", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2H 2020.", 
    "company": "Relay Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "RLY-4008", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Relmada Therapeutics Inc.", 
    "indication": "Treatment Resistant Depression", 
    "name": "REL-1017", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved January 26, 2015.", 
    "company": "Rockwell Medical Inc.", 
    "indication": "Anemia", 
    "name": "Soluble Ferric Pyrophosphate", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced date March 27, 2020.", 
    "company": "Rockwell Medical Inc.", 
    "indication": "Anemia", 
    "name": "IV Triferic", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 dosing of first patient announced July 29, 2020.", 
    "company": "Repare Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "RP-3500", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Development to be discontinued - noted August 6, 2019.", 
    "company": "Retrophin Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "CNSA-001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data did not meet endpoints - August 22, 2019.", 
    "company": "Retrophin Inc.", 
    "indication": "Pantothenate kinase-associated neurodegeneration (PKAN)", 
    "name": "Fosmetpantotenate", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1Q 2021.", 
    "company": "Retrophin Inc.", 
    "indication": "Focal segmental glomerulosclerosis (FSGS)", 
    "name": "Sparsentan - DUPLEX", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved Mar 18 2015", 
    "company": "Retrophin Inc.", 
    "indication": "Rare Bile Acid Synthesis Disorders", 
    "name": "Cholbam", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Retrophin Inc.", 
    "indication": "IgA nephropathy", 
    "name": "Sparsentan", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 28, 2019.", 
    "company": "Retrophin Inc.", 
    "indication": "Cystinuria", 
    "name": "New formulation of Thiola (tiopronin)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 patients have been randomized - noted February 24, 2020.", 
    "company": "Retrophin Inc.", 
    "indication": "Cerebrotendinous xanthomatosis (CTX).", 
    "name": "Chenodal (chenodeoxycholic acid)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b trial to be discontinued - noted March 12, 2020", 
    "company": "Rubius Therapeutics Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "RTX-134", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 initiation of dosing announced May 7, 2020.", 
    "company": "Rubius Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "RTX-240", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b/2 trial ongoing.", 
    "company": "Revolution Medicines Inc - Ordinary Shares", 
    "indication": "Solid tumors", 
    "name": "RMC-4630 and cobimetinib - RMC-4630-02", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b initiation of dosing announced June 9, 2020.", 
    "company": "Revolution Medicines Inc - Ordinary Shares", 
    "indication": "Solid tumors", 
    "name": "RMC-4630 and AMG 510", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Revolution Medicines Inc - Ordinary Shares", 
    "indication": "Solid tumors", 
    "name": "RMC-4630 - RMC-4630-01", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/1b trial to be initiated 2H 2020.", 
    "company": "Revolution Medicines Inc - Ordinary Shares", 
    "indication": "Pancreatic cancer", 
    "name": "RMC-4630 SHERPA", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b initiation of dosing announced June 22, 2020.", 
    "company": "Revolution Medicines Inc - Ordinary Shares", 
    "indication": "Non-small cell lung cancer (NSCLC) and colorectal cancer ", 
    "name": "RMC-4630 and Keytruda", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 data due fall of 2020.", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Plantar fasciitis", 
    "name": "DAXI  (RT002)", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 top-line data released June 30, 2020. 88% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group.", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Lateral Canthal (Crowâ€™s Feet) Lines", 
    "name": "DAXI  (RT002)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due fall of 2020.", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Cervical dystonia", 
    "name": "DAXI  (RT002) - ASPEN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date November 25, 2020.", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Moderate to severe glabellar (frown) lines", 
    "name": "DAXI  (RT002)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 top-line data due early-2021.", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Upper limb spasticity", 
    "name": "DAXI  (RT002) - JUNIPER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data noted 100% of subjects achieved a score of none or mild wrinkle or line severity at Week 4 in at least one treatment group - June 30, 2020.", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Forehead lines", 
    "name": "DAXI  (RT002)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020. ", 
    "company": "Revance Therapeutics Inc.", 
    "indication": "Full Upper Face", 
    "name": "DAXI  (RT002)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 3Q 2020 with initial data due 4Q 2020.", 
    "company": "Revive Therapeutics Ltd.", 
    "indication": "COVID-19", 
    "name": "Bucillamine", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data updates expected in 2020.", 
    "company": "Rhythm Pharmaceuticals Inc.", 
    "indication": "POMC Heterozygous Deficiency Obesity, Alstrom Syndrome, POMC Epigenetic Disorders", 
    "name": "Setmelanotide (basket)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2020 or early 1Q 2021.", 
    "company": "Rhythm Pharmaceuticals Inc.", 
    "indication": "Alstrom Syndrome and Bardet-Biedl Syndrome", 
    "name": "Setmelanotide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review November 27, 2020.", 
    "company": "Rhythm Pharmaceuticals Inc.", 
    "indication": "POMC deficiency obesity / Leptin Receptor Deficiency Obesity", 
    "name": "Setmelanotide", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "FDA approval announced March 19, 2018.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Postpartum Depression - moderate", 
    "name": "Brexanolone - SAGE-547 (202C)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data did not meet primary endpoint - December 5, 2019.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Major Depressive Disorder (MDD)", 
    "name": "SAGE-217 - MOUNTAIN", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - January 7, 2019.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Postpartum depression (PPD)", 
    "name": "SAGE-217", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released November 9, 2017. Primary endpoint met.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Postpartum Depression (Severe)", 
    "name": "Brexanolone - SAGE-547 (202B)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released September 12, 2017 - primary endpoint not met.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "SRSE", 
    "name": "SAGE-547", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment paused 4Q 2020.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Insomnia", 
    "name": "SAGE-217 - RAINFOREST", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 Part A data July 24, 2019 noted MADRS score of 15.5 points at Day 15 (n=23; p<0.0001) - secondary endpoint.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Bipolar depression", 
    "name": "SAGE-217 - ARCHWAY", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a trial planned for 2H 2020.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Huntington's disease", 
    "name": "SAGE-718", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2020. Data due 2021.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Essential tremor", 
    "name": "SAGE-324", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Major Depressive Disorder (MDD)", 
    "name": "SAGE-217 - SHORELINE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment paused 4Q 2019.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Major Depressive Disorder", 
    "name": "SAGE-217 - REDWOOD", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 1H 2021.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Major depressive disorder (MDD)", 
    "name": "Zuranolone (SAGE-217) - WATERFALL Study (MDD-301B)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiated 2Q 2020.", 
    "company": "Sage Therapeutics Inc.", 
    "indication": "Postpartum depression (PPD)", 
    "name": "Zuranolone (SAGE-217) - SKYLARK Study (PPD-301)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet primary endpoint - May 15, 2020. Detailed data due September 2020.", 
    "company": "Cassava Sciences Inc.", 
    "indication": "Alzheimerâ€™s disease", 
    "name": "PTI-125", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 top-line data expected September 2020.", 
    "company": "Strongbridge Biopharma plc", 
    "indication": "Endogenous Cushingâ€™s syndrome", 
    "name": "COR-003 (levoketoconazole) - LOGICS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released August 8, 2018. Primary endpoint met.", 
    "company": "Strongbridge Biopharma plc", 
    "indication": "Endogenous Cushingâ€™s syndrome", 
    "name": "COR-003 (levoketoconazole) - SONICS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1a/1b dose escalation to next planned monotherapy dose level following Safety Review Committee recommendation - June 3, 2020. Presentation at ImmunoTherapy of Cancer (ITOC7) conference from October 3-5, 2020.", 
    "company": "Spring Bank Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "SB 11285", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development discontinued due to safety concerns (patient death).", 
    "company": "Spring Bank Pharmaceuticals Inc.", 
    "indication": "Hepatitis B (HBV)", 
    "name": "Inarigivir - (CATALYST 1 and CATALYST 2)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "PDUFA date December 30, 2020.", 
    "company": "scPharmaceuticals Inc.", 
    "indication": "Heart failure", 
    "name": "Furoscix", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "NDA filing due 2021.", 
    "company": "scPharmaceuticals Inc.", 
    "indication": "Baceteria infections", 
    "name": "Ceftriaxone", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 3 data presented at ECCMID April 13, 2019.", 
    "company": "SCYNEXIS Inc.", 
    "indication": "Candida Auris", 
    "name": "SCY-078 - oral - CARES", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiated 3Q 2018. Enrollment continues to enroll as of August 2020.", 
    "company": "SCYNEXIS Inc.", 
    "indication": "Invasive aspergillosis", 
    "name": "Ibrexafungerp (SCY-078) -  SCYNERGIA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - November 7, 2019.", 
    "company": "SCYNEXIS Inc.", 
    "indication": "Vulvovaginal candidiasis (VVC)", 
    "name": "SCY-078 - oral ibrexafungerp - VANISH 303", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 second interim analysis January 8, 2020. Overall response rate 56%.", 
    "company": "SCYNEXIS Inc.", 
    "indication": "Invasive candidiasis", 
    "name": "SCY-078 - oral (FURI)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data and sNDA filing due 2H 2021.", 
    "company": "SCYNEXIS Inc.", 
    "indication": "Recuurent Vulvovaginal candidiasis (VVC)", 
    "name": "SCY-078 - ibrexafungerp - CANDLE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing 4Q 2020.", 
    "company": "SCYNEXIS Inc.", 
    "indication": "Vulvovaginal candidiasis (VVC)", 
    "name": "SCY-078 - oral ibrexafungerp - VANISH 306", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "CRL issued for NDA resubmission - February 16, 2018. Noted April 16, 2017 two further Phase 3 trials required. Will need partner to finance trials.", 
    "company": "Seelos Therapeutics Inc.", 
    "indication": "Erectile dysfunction", 
    "name": "Vitaros", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 2b/3 open-label trial to proceed soon. IND filing accepted August 22, 2019.", 
    "company": "Seelos Therapeutics Inc.", 
    "indication": "Sanfilippo syndrome/MPS III", 
    "name": "Trehalose (SLS-005)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 DDI initial data released January 10, 2020 - generally safe and well-tolerated.", 
    "company": "Seelos Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "SLS-002-101", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 update June 23, 2020. Safe and well tolerated. Proof of concept trial to commence fall of 2020.", 
    "company": "Seelos Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "SLS-002-102", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 top-line data due 3Q 2020.", 
    "company": "Selecta Biosciences Inc.", 
    "indication": "Tophaceous gout", 
    "name": "SEL-212 (COMPARE) - Head to head trial vs Krystexxa", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Grade 5 SAE reported October 17, 2018.", 
    "company": "Selecta Biosciences Inc.", 
    "indication": "Mesothelioma", 
    "name": "SEL-403", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Rolling BLA filing to be completed 4Q 2020.", 
    "company": "Sesen Bio Inc.", 
    "indication": "Non-muscle invasive bladder cancer (NMIBC)", 
    "name": "Vicinium", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Neoadjuvant for newly diagnosed Stage 2 or 3 HER2 negative breast cancer", 
    "name": "SGN-LIV1A (I-SPY 2)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 trial initiated early 2018.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "First-line triple negative breast cancer (TNBC)", 
    "name": "SGN-LIV1A + KEYTRUDA", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data noted 24% ORR with a median duration of response of 8.3 months.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Cervical Cancer", 
    "name": "Tisotumab Vedotin (innovaTV 204 )", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced December 18, 2019.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Urothelial cancer", 
    "name": "Enfortumab vedotin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 19, 2011.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Hodgkin lymphoma and Anaplastic large cell lymphoma", 
    "name": "ADCETRIS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 17, 2020.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "HER2+ Metastatic Breast Cancer (MBC)", 
    "name": "Tucatinib in combination with trastuzumab and capecitabine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued due to higher rate of deaths - June 19, 2017.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Acute myeloid leukemia (AML) - cancer", 
    "name": "Vadastuximab Talirine (CASCADE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Frontline Hodgkin lymphoma", 
    "name": "ADCETRIS  in combination with chemotherapy ECHELON-1", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 16, 2018.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Frontline CD30-positive mature T-cell lymphomas - cancer", 
    "name": "ADCETRIS in combination with chemotherapy - ECHELON-2", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved August 17, 2015 under priority review.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Post-transplant Hodgkin lymphoma (HL) cancer", 
    "name": "ADCETRIS - AETHERA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced November 9, 2017.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Cancer - ALCANZA trial for relapsed CD30-positive cutaneous T-cell lymphoma", 
    "name": "ADCETRIS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 enrolment completed in January 2020.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Urothelial cancer", 
    "name": "Enfortumab vedotin and Keytruda - EV-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced July 9, 2018.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Urothelial cancer", 
    "name": "Enfortumab vedotin - EV-301", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 dosing has commenced - noted July 12, 2018.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Solid tumors", 
    "name": "Tisotumab Vedotin (innovaTV 207)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 updated data presented at ESMO October 20. 2018.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Recurrent Cervical Cancer", 
    "name": "Tisotumab Vedotin (innovaTV 201)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA approval granted August 5, 2020.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "GSKâ€™916 - belantamab mafodotin (BCMA)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced June 10, 2019.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Diffuse large B-cell lymphoma (DLBCL)", 
    "name": "Polatuzumab vedotin and bendamustine plus Rituxan (rituximab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 presentation at EHA June 15, 2019.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Relapsed/Refractory Classical Hodgkin Lymphoma", 
    "name": "ADCETRIS and Opdivo CM-744", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 initial data presented at IASLC 2019 WCLC September 8, 2019.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Solid tumors", 
    "name": "Enapotamab vedotin", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data at ESMO noted 52% ORR, median PFS 8.1 months, OS of 18.7 months. ", 
    "company": "Seattle Genetics Inc.", 
    "indication": "HER2 amplified metastatic colorectal cancer", 
    "name": "Tucatinib - MOUNTAINEER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial initiation announced October 10, 2019.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "HER2+ Metastatic Breast Cancer (MBC)", 
    "name": "Tucatinib + ado-trastuzumab emtansine (T-DM1, Kadcyla), - HER2CLIMB-02", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial initiated January 2020.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Solid tumors", 
    "name": "Enfortumab vedotin - EV-202", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data noted Overall response rate 73%; Complete response rate 16% (partial response rate 58%).", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Urothelial cancer", 
    "name": "Enfortumab vedotin and Keytruda EV-103", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced June 18, 2020.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Solid tumors", 
    "name": "SEA-TGT", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced June 18, 2020.", 
    "company": "Seattle Genetics Inc.", 
    "indication": "Solid Tumors", 
    "name": "SGN-B6A", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2020.", 
    "company": "Sangamo Therapeutics Inc.", 
    "indication": "Hemophilia A", 
    "name": "Giroctocogene fitelparvovec (SB-525) AFFINE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 further data due 1H 2021.", 
    "company": "Sangamo Therapeutics Inc.", 
    "indication": "beta-thalassemia", 
    "name": "ST-400", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Next trial to be initiated in 2020.", 
    "company": "Sangamo Therapeutics Inc.", 
    "indication": "MPS Type 1", 
    "name": "SB-318", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 ongoing.", 
    "company": "Sangamo Therapeutics Inc.", 
    "indication": "MPS Type 2", 
    "name": "SB-913", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 ongoing.", 
    "company": "Sangamo Therapeutics Inc.", 
    "indication": "Fabry disease", 
    "name": "ST-920", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial to be initiated in 2020.", 
    "company": "Sangamo Therapeutics Inc.", 
    "indication": "Kidney transplantation", 
    "name": "TX200", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA approval announced July 13, 2018.", 
    "company": "SIGA Technologies Inc.", 
    "indication": "Smallpox", 
    "name": "TPOXX", 
    "stage": "approved"
  }, 
  {
    "newstxt": "NDA filing due 2020.", 
    "company": "SIGA Technologies Inc.", 
    "indication": "Smallpox", 
    "name": "TPOXX  - IV", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1/2 trial remains on clinical hold - noted July 24, 2020.", 
    "company": "Solid Biosciences Inc.", 
    "indication": "Duchenne Muscular Dystrophy", 
    "name": "SGT-001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "NDA filing due 2H 2020.", 
    "company": "Sol-Gel Technologies Ltd.", 
    "indication": "Acne", 
    "name": "Twyneo", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "NDA submitted in June 2020.", 
    "company": "Sol-Gel Technologies Ltd.", 
    "indication": "Papulopustular rosacea", 
    "name": "VERED (Epsolay)", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1 data due 2021.", 
    "company": "Sol-Gel Technologies Ltd.", 
    "indication": "Palmoplantar keratoderma (PPK)", 
    "name": "SGT-210", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet its primary endpoint - June 8, 2020.", 
    "company": "Soleno Therapeutics Inc.", 
    "indication": "Prader-Willi syndrome (PWS)", 
    "name": "Diazoxide Choline Controlled-Release (DCCR) - DESTINY PWS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data due before the end of 2020.", 
    "company": "Salarius Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "Seclidemstat", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 data due 2020.", 
    "company": "Salarius Pharmaceuticals Inc.", 
    "indication": "Ewing sarcoma", 
    "name": "Seclidemstat", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial planned.", 
    "company": "SELLAS Life Sciences Group Inc.", 
    "indication": "Breast cancer - 1+/2+", 
    "name": "NeuVax in combination with Herceptin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 interim data from basket trial due 1H 2021.", 
    "company": "SELLAS Life Sciences Group Inc.", 
    "indication": "Solid tumors", 
    "name": "Galinpepimut-S and Keytruda (pembrolizumab)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 interim data due 4Q 2021.", 
    "company": "SELLAS Life Sciences Group Inc.", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "Galinpepimut-S - REGAL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 commencement of enrolment announced February 11, 2020. Data due YE 2020.", 
    "company": "SELLAS Life Sciences Group Inc.", 
    "indication": "Malignant pleural mesothelioma (MPM)", 
    "name": "Galinpepimut-S and nivolumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 initial data released March 18, 2020.", 
    "company": "SELLAS Life Sciences Group Inc.", 
    "indication": "Ductal Carcinoma in Situ (DCIS)", 
    "name": "Nelipepimut-S and GM-CSF (VADIS)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data released June 27, 2018. Primary endpoint not met.", 
    "company": "Summit Therapeutics plc", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "Ezutromid", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing. Timing of release of data uncertain due to COVID-19.", 
    "company": "Summit Therapeutics plc", 
    "indication": "C. difficile infection (CDI)", 
    "name": "Ridinilazole", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Seneca Biopharma Inc.", 
    "indication": "Chronic ischemic stroke", 
    "name": "NSI-566", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data March 7, 2019 failed to meet endpoints.", 
    "company": "Syndax Pharmaceuticals Inc.", 
    "indication": "Ovarian cancer", 
    "name": "Entinostat plus Tecentriq - ENCORE 603", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 top-line data March 7, 2019 failed to meet endpoints.", 
    "company": "Syndax Pharmaceuticals Inc.", 
    "indication": "Triple negative breast cancer (TNBC)", 
    "name": "Entinostat plus Tecentriq - ENCORE 602", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 updated data to be presented September 24, 2018 did not meet prespecified ORR endpoint.", 
    "company": "Syndax Pharmaceuticals Inc.", 
    "indication": "Recurrent non-small cell lung cancer (NSCLC), colorectal cancer", 
    "name": "Entinostat plus Keytruda - ENCORE 601", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 did not meet overall survival primary endpoint - May 21, 2020.", 
    "company": "Syndax Pharmaceuticals Inc.", 
    "indication": "HR+, HER2- breast cancer", 
    "name": "E2112", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data to be presented 4Q 2020.", 
    "company": "Syndax Pharmaceuticals Inc.", 
    "indication": "Chronic graft versus host disease", 
    "name": "Axatilimab (SNDX-6352)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 full data due early 2021.", 
    "company": "Syndax Pharmaceuticals Inc.", 
    "indication": "Relapsed/refractory (R/R) acute leukemias", 
    "name": "SNDX-5613 (AUGMENT-101)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 trial complete.", 
    "company": "Soligenix Inc.", 
    "indication": "Radiation Enteritis", 
    "name": "SGX201", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data met primary endpoint - March 19,2020. Results from Cycle 3 and the subsequent 6-month follow-up due 4Q 2020.", 
    "company": "Soligenix Inc.", 
    "indication": "Cutaneous T-Cell Lymphoma (CTCL) cancer", 
    "name": "SGX301 (synthetic hypericin)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 4Q 2020.", 
    "company": "Soligenix Inc.", 
    "indication": "Oral Mucositis in Patients with Head & Neck Cancer", 
    "name": "SGX942 (dusquetide)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 dependent on funding.", 
    "company": "Soligenix Inc.", 
    "indication": "Pediatric Crohnâ€™s Disease", 
    "name": "SGX203 ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1c trial initiation announced December 12, 2019.", 
    "company": "Soligenix Inc.", 
    "indication": "Ricin toxin vaccine", 
    "name": "RiVax", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Currently pre-clinical. Intends to advance development.", 
    "company": "Soligenix Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "CiVax", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 program will not be advanced into the Phase 2 part of the trial - June 23, 2020.", 
    "company": "Sunesis Pharmaceuticals Inc.", 
    "indication": "Advanced B-Cell Malignancies", 
    "name": "Vecabrutinib (SNS-062)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Endpoint not met Oct 2014. Additional trials required.", 
    "company": "Sunesis Pharmaceuticals Inc.", 
    "indication": "Cancer - Acute myeloid leukemia AML", 
    "name": "Voreloxin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date under priority review November 13, 2020.", 
    "company": "Sanofi", 
    "indication": "Cold agglutinin disease", 
    "name": "Sutimlimab (BIVV009) - Cardinal", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "FDA Approval announced September 28, 2018.", 
    "company": "Sanofi", 
    "indication": "Cutaneous squamous cell carcinoma", 
    "name": "Cemiplimab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 11, 2017.", 
    "company": "Sanofi", 
    "indication": "Diabetes", 
    "name": "Admelog (insulin lispro injection)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 further data due 1H 2021.", 
    "company": "Sanofi", 
    "indication": "beta-thalassemia", 
    "name": "ST-400", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "sBLA Approval announced April 25, 2017.", 
    "company": "Sanofi", 
    "indication": "High low-density lipoprotein (LDL) cholesterol", 
    "name": "Praluent (alirocumab) ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial commenced 4Q 2017.  Seeking partner to take over and commercialize efpeglenatide.\n", 
    "company": "Sanofi", 
    "indication": "Type 2 diabetes", 
    "name": "Efpeglenatide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced May 26, 2020.", 
    "company": "Sanofi", 
    "indication": "Atopic dermatitis 6-11 year-olds", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced March 11, 2019.", 
    "company": "Sanofi", 
    "indication": "Atopic dermatitis 12-17 year-olds", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced April 26, 2019.", 
    "company": "Sanofi", 
    "indication": "Cardiovascular events", 
    "name": "Praluent (alirocumab) ODYSSEY OUTCOMES", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced March 2, 2020.", 
    "company": "Sanofi", 
    "indication": "Refractory Multiple Myeloma", 
    "name": "Isatuximab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data presented June 16, 2020 met the primary endpoint demonstrating non-inferiority in improving respiratory function compared to alglucosidase alfa (standard of care) but not superiority. ", 
    "company": "Sanofi", 
    "indication": "Pompe disease", 
    "name": "Avalglucosidase alfa (NeoGAA) - COMET", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced October 19, 2018.", 
    "company": "Sanofi", 
    "indication": "Asthma", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Pivotal Phase 2/3 trial ongoing.", 
    "company": "Sanofi", 
    "indication": "Cutaneous squamous cell carcinoma", 
    "name": "REGN2810", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial stopped early due to significant improvement in overall survival - April 27, 2020.", 
    "company": "Sanofi", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Cemiplimab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met two independent primary endpoints- January 30, 2020. Combination endpoint was not met.", 
    "company": "Sanofi", 
    "indication": "Acid sphingomyelinase deficiency (ASMD)", 
    "name": "Olipudase alfa", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "CRL October 28, 2016. Resubmitted with FDA Approval announced May 22, 2017.", 
    "company": "Sanofi", 
    "indication": "Rheumatoid arthritis", 
    "name": "Sarilumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "Sanofi", 
    "indication": "Asthma - 6-11 year-olds", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced June 26, 2019.", 
    "company": "Sanofi", 
    "indication": "Nasal polyps", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data due 2020.", 
    "company": "Sanofi", 
    "indication": "Peanut Allergy", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Data from Phase 2 portion of Phase 2/3 trial met co-primary endpoints - May 22, 2020.", 
    "company": "Sanofi", 
    "indication": "Eosinophilic esophagitis", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Approved under priority review - March 28, 2017.", 
    "company": "Sanofi", 
    "indication": "Atopic dermatitis", 
    "name": "Dupixent (dupilumab)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 10, 2018.", 
    "company": "Sanofi", 
    "indication": "Familial Amyloidotic Polyneuropathy (FAP) in Patients with ATTR", 
    "name": "Patisiran ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Sanofi", 
    "indication": "Hemophilia A/B", 
    "name": "Fitusiran (ATLAS)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved January 23, 2019.", 
    "company": "Sanofi", 
    "indication": "Influenza A - children 6-35 months of age.", 
    "name": "Fluzone Quadrivalent (Influenza Vaccine)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced June 23, 2020.", 
    "company": "Sanofi", 
    "indication": "Multiple sclerosis", 
    "name": "SAR442168 (PRN2246)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced May 1, 2019.", 
    "company": "Sanofi", 
    "indication": "Dengue", 
    "name": "Dengvaxia", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced February 6, 2019.", 
    "company": "Sanofi", 
    "indication": "Acquired thrombotic thrombocytopenic purpura (aTTP) ", 
    "name": "Caplacizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 primary endpoint met - May 12, 2020.", 
    "company": "Sanofi", 
    "indication": "Refractory Multiple Myeloma", 
    "name": "Isatuximab - IKEMA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA approval announced April 24, 2020.", 
    "company": "Sanofi", 
    "indication": "Meningococcal meningitis", 
    "name": "MenQuadfi", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 pivotal data showed objective response rate (ORR) of 29%. Regulatory submission due 2020\n", 
    "company": "Sanofi", 
    "indication": "Basal cell carcinoma", 
    "name": "Cemiplimab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed 2H 2020.", 
    "company": "Sanofi", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Libtayo - Cemiplimab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Sanofi", 
    "indication": "Breast Cancer - third line", 
    "name": "SAR439859", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - July 2, 2020.", 
    "company": "Sanofi", 
    "indication": "Coronavirus COVID-19", 
    "name": "Kevzara (Sarilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial to commence by the end of 2020.", 
    "company": "Sanofi", 
    "indication": "COVID-19 vaccine", 
    "name": "mRNA vaccine", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2/3 data of global trial due 3Q 2020.", 
    "company": "Sanofi", 
    "indication": "Coronavirus COVID-19", 
    "name": "Kevzara (sarilumab)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence September 2020. Late-stage trial to commence late-2020.", 
    "company": "Sanofi", 
    "indication": "COVID-19 vaccine", 
    "name": "Adjuvanted COVID-19 vaccine", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Sanofi", 
    "indication": "Prurigo nodularis (PN)", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial has been initiated. Data likely due 2022.", 
    "company": "Sanofi", 
    "indication": "Bullous pemphigoid (BP)", 
    "name": "Dupixent (dupilumab)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2021.", 
    "company": "Sanofi", 
    "indication": "Fabry disease", 
    "name": "Venglustat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial is ongoing.", 
    "company": "Sanofi", 
    "indication": "Gaucher disease type 3 ", 
    "name": "Venglustat", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 trial initiated early 2020.", 
    "company": "Sanofi", 
    "indication": "Tay-Sachs disease / GM-2 gangliosidoses", 
    "name": "Venglustat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 data due by 4Q 2021.", 
    "company": "Sanofi", 
    "indication": "Autosomal dominant polycystic kidney disease (ADPKD)", 
    "name": "Venglustat", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "Sanofi", 
    "indication": "Breast Cancer", 
    "name": "SERD â€˜859", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Proof of concept data due 1H 2021", 
    "company": "Sanofi", 
    "indication": "Sickle Cell Disease", 
    "name": "BIVV003", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021", 
    "company": "Sanofi", 
    "indication": "Glucocerebrosidase Parkinsonâ€™s Disease", 
    "name": "Venglustat", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data due 1H 2021.", 
    "company": "Sanofi", 
    "indication": "Solid tumors", 
    "name": "SAR442720 and cobimetinib", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Exploring business development opportunities.\n\n ", 
    "company": "Sonnet BioTherapeutics Holdings Inc.", 
    "indication": "Diabetic Peripheral Neuropathy", 
    "name": "SON-081", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1a/2b trial to be initiated 1H 2021.", 
    "company": "Sonnet BioTherapeutics Holdings Inc.", 
    "indication": "Chemotherapy Induced Peripheral Neuropathy (CIPN)", 
    "name": "SON-080", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint from Cohort 1 was not met - December 26, 2019. Cohort 2 primary endpoint met - July 27, 2020. Cohort 3 data due by year-end 2020.", 
    "company": "Spectrum Pharmaceuticals Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC) with exon 20 insertion mutation in EGFR or HER2", 
    "name": "Poziotinib - Zenith20", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL received October 9, 2009. Approved April 29, 2011.", 
    "company": "Spectrum Pharmaceuticals Inc.", 
    "indication": "Colorectal cancer", 
    "name": "FUSILEV", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL received July 5, 2009.", 
    "company": "Spectrum Pharmaceuticals Inc.", 
    "indication": "Non-Hodgkinâ€™s lymphoma", 
    "name": "ZEVALIN", 
    "stage": "crl"
  }, 
  {
    "newstxt": "CRL October 23 2015. Approved March 15 2016.", 
    "company": "Spectrum Pharmaceuticals Inc.", 
    "indication": "Conditioning treatment prior to autologous stem cell transplant for patients with multiple myeloma", 
    "name": "EVOMELA (melphalan) for Injection", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date October 24, 2020.", 
    "company": "Spectrum Pharmaceuticals Inc.", 
    "indication": "Chemotherapy-Induced Neutropenia", 
    "name": "SPI-2012 (ROLONTIS)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approved July 7, 2014.", 
    "company": "Spectrum Pharmaceuticals Inc.", 
    "indication": "Peripheral T-Cell Lymphoma cancer", 
    "name": "Belinostat", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1b top-line data released May 23, 2018 - supportive of further development.", 
    "company": "Spero Therapeutics Inc.", 
    "indication": "Healthy Volunteers (safety trial)", 
    "name": "SPR741", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 data due 3Q 2020.", 
    "company": "Spero Therapeutics Inc.", 
    "indication": "Complicated urinary tract infections (cUTI)", 
    "name": "SPR994 (ADAPT-PO)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Spero Therapeutics Inc.", 
    "indication": "Nontuberculous mycobacterial (NTM) pulmonary disease", 
    "name": "SPR720", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 BAL trial to be initiated 1H 2021.", 
    "company": "Spero Therapeutics Inc.", 
    "indication": "MDR Gram-negative bacterial infections", 
    "name": "SPR206", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Approval announced February 28, 2018.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Pain associated with post-herpetic neuralgia (PHN)", 
    "name": "ZTlido (lidocaine patch 1.8%)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Data analysis suggests that Cynviloq meets the bioequivalence (BE) criteria for both total and unbound paclitaxel", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Cancer", 
    "name": "Cynviloq", 
    "stage": ""
  }, 
  {
    "newstxt": "Phase 1 data due 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "Anti-CD38 CAR-T", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2H 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Lumbosacral radicular pain (sciatica)", 
    "name": "SP-102", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "BLA filing due 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Remicade (infliximab) biosimilar", 
    "name": "STI-002", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 1 data presented at American Academy of Pain Medicine - February 27, 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Intractable Pain Associated with Cancer", 
    "name": "Resiniferatoxin", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 IND filing due to be filed in the coming months - noted March 20, 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "Coronavirus COVID-19", 
    "name": "STI-4398", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial to commence immediately - noted April 2, 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "COVID-19 Coronavirus", 
    "name": "CYNK-001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "Abivertinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned. IND filed August 19, 2020.", 
    "company": "Sorrento Therapeutics Inc.", 
    "indication": "COVID-19", 
    "name": "STI-1499 (COVI-GUARD)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "PDUFA date under priority review February 25, 2021.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "Casimersen", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 1/2 ongoing.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "rAAVrh74.MCK.GALGT2", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Data due 2H 2020.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "SRP-5051", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced December 12, 2019.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "Golodirsen - Exon 53", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved September 19, 2016.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "Eteplirsen - Exon 51", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy - (LGMD2B)", 
    "name": "MYO-201", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 complete.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy - LGMD2D", 
    "name": "MYO-102", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 one-year functional results from the low dose cohort presented June 8, 2020. Three patients showed improvement in functional mobility of 4,6 and 7 points. Pivotal trial to commence in 2021.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Limb-girdle Muscular Dystrophy Type 2E (LGMD2E)", 
    "name": "SRP-9003", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2/3 dosing to be completed mid-2020.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Mucopolysaccharidosis type IIIA (MPS IIIA)", 
    "name": "LYS-SAF302", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data due 1Q 2021.", 
    "company": "Sarepta Therapeutics Inc.", 
    "indication": "Duchenne muscular dystrophy", 
    "name": "SRP-9001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Discontinued following poor efficacy - June 2016", 
    "company": "Sierra Oncology Inc.", 
    "indication": "Relapsed or refractory diffuse large B-cell lymphoma (DLBCL) - cancer", 
    "name": "PNT2258", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development suspended - June 2016", 
    "company": "Sierra Oncology Inc.", 
    "indication": "Richter's Transformation", 
    "name": "PNT2258 ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 preliminary data ASCO June 1, 2019 noted stable disease rate of 32%.", 
    "company": "Sierra Oncology Inc.", 
    "indication": "Advanced Solid Tumors or Non-Hodgkin's Lymphoma (NHL)", 
    "name": "SRA737", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 preliminary data of ORR 30% at ASCO June 1, 2019. 8am.", 
    "company": "Sierra Oncology Inc.", 
    "indication": "Solid Tumors", 
    "name": "SRA737 + Low-Dose Gemcitabine", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2022.", 
    "company": "Sierra Oncology Inc.", 
    "indication": "Myelofibrosis", 
    "name": "Momelotinib - MOMENTUM", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 interim efficacy data due 4Q 2020.", 
    "company": "Scholar Rock Holding Corporation", 
    "indication": "Spinal muscular atrophy (SMA)", 
    "name": "SRK-015 - TOPAZ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced May 5, 2020. Update on dose escalation 4Q 2020; clinical response and safety data anticipated in 2021.", 
    "company": "Scholar Rock Holding Corporation", 
    "indication": "Solid Tumors", 
    "name": "SRK-181", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 trial has been initiated. ", 
    "company": "Stoke Therapeutics Inc.", 
    "indication": "Dravet syndrome", 
    "name": "STK-001 - MONARCH", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 additional data due 2H 2020.", 
    "company": "Sutro Biopharma Inc.", 
    "indication": "Non-Hodgkin lymphoma (NHL)", 
    "name": "STRO-001", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 updated data due 2H 2020.", 
    "company": "Sutro Biopharma Inc.", 
    "indication": "Ovarian and Endometrial Cancer", 
    "name": "STRO-002", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data due late-September or early-October 2020.", 
    "company": "Satsuma Pharmaceuticals Inc.", 
    "indication": "Migraine", 
    "name": "STS101 (EMERGE)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 open-label trial commencement of enrollment announced August 6, 2020.", 
    "company": "Satsuma Pharmaceuticals Inc.", 
    "indication": "Migraine", 
    "name": "STS101 (ASCEND)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved October 22, 2017.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Epilepsy", 
    "name": "Oxtellar", 
    "stage": "approved"
  }, 
  {
    "newstxt": "PDUFA date November 8, 2020", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "ADHD", 
    "name": "SPN-812 (P301)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - November 5, 2019.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Impulsive Aggression in ADHD", 
    "name": "SPN-810", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved Aug 19, 2013.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Epilepsy", 
    "name": "Trokendi ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Tentative approval August 19 2016, subject to the pediatric exclusivity which expires March 28, 2017. Final approval announced April 6, 2017.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Migraine", 
    "name": "Trokendi ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced December 14, 2018 to expand label to include monotherapy treatment. ", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Epilepsy", 
    "name": "Oxtellar XR", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 development has been terminated - May 5, 2020.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Bipolar depression", 
    "name": "SPN-604", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 25, 2020.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Attention Deficit Hyperactivity Disorder (ADHD)", 
    "name": "SPN-810 (P302)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 1Q 2021.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "ADHD", 
    "name": "SPN-812 (adult)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "NDA filing due 4Q 2020.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Motor fluctuations in Parkinsonâ€™s disease (PD)", 
    "name": "SPN-830", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2021.", 
    "company": "Supernus Pharmaceuticals Inc.", 
    "indication": "Treatment-resistant depression ", 
    "name": "SPN-820", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data presented at SITC meeting November 9, 2019.", 
    "company": "Surface Oncology Inc.", 
    "indication": "Hematologic malignancies, solid tumors", 
    "name": "SRF231", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial is ongoing.", 
    "company": "Surface Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "NZV930", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced March 17, 2020 with initial data due by the end of 2020.", 
    "company": "Surface Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "SRF617", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation announced April 23, 2020 with initial data due by the end of 2020.", 
    "company": "Surface Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "SRF388", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1a/b trial planned.", 
    "company": "Surface Oncology Inc.", 
    "indication": "Solid tumors", 
    "name": "SRF617 and Keytruda", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 preliminary data noted neutralizing antibody seroconversion rate above 90% - June 13, 2020. Phase 2 trial to be completed at the end of 2020.", 
    "company": "Sinovac Biotech Ltd.", 
    "indication": "COVID-19 vaccine", 
    "name": "COVID-19 vaccine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data released March 12, 2020.", 
    "company": "Savara Inc.", 
    "indication": "Nontuberculous mycobacteria (NTM)", 
    "name": "Molgradex - OPTIMA", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 top line data presented March 11, 2018 failed to meet primary endpoint.", 
    "company": "Savara Inc.", 
    "indication": "Heart failure with preserved ejection fraction (HFpEF)", 
    "name": "Aironite - INDIE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data June 12, 2019 did not meet primary endpoint. Second Phase 3 trial to commence 1Q 2021.", 
    "company": "Savara Inc.", 
    "indication": "Autoimmune pulmonary alveolar proteinosis (PAP)", 
    "name": "Molgradex - IMPALA", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment has been terminated due to COVID-19. Top line results are still expected in early 2021.", 
    "company": "Savara Inc.", 
    "indication": "MRSA in cystic fibrosis", 
    "name": "AeroVanc - AVAIL", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a initiation announced April 1, 2019. Enrolment has been terminated due to COVID-19.", 
    "company": "Savara Inc.", 
    "indication": "Nontuberculous mycobacterial (NTM) lung infection with cystic fibrosis (CF)", 
    "name": "Molgradex - ENCORE", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2Q or 3Q 2021.", 
    "company": "SpringWorks Therapeutics Inc.", 
    "indication": "Desmoid tumors", 
    "name": "Nirogacestat", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b update 4Q 2020 / 1Q 2021.", 
    "company": "SpringWorks Therapeutics Inc.", 
    "indication": "Neurofibromas", 
    "name": "Mirdametinib", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1b/2 initial data due 2021.", 
    "company": "SpringWorks Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "Mirdametinib and lifirafenib", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 trial to commence 2H 2020.", 
    "company": "SpringWorks Therapeutics Inc.", 
    "indication": "Multiple myeloma", 
    "name": "ALLO-715 with nirogacestat", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 data due 2021.", 
    "company": "SpringWorks Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "BGB-3245", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b commencement of dosing announced June 22, 2020.", 
    "company": "SpringWorks Therapeutics Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "Nirogacestat and Belantamab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2020.", 
    "company": "Synlogic Inc.", 
    "indication": "Phenylketonuria (PKU)", 
    "name": "SYNB1618", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued due to lack of efficacy.", 
    "company": "Synlogic Inc.", 
    "indication": "Cirrhotic patients with elevated ammonia", 
    "name": "SYNB1020", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 monotherapy data due by the end of 2020.", 
    "company": "Synlogic Inc.", 
    "indication": "Solid tumors", 
    "name": "SYNB1891 and atezolizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b interim futility analysis due 3Q 2020 with top-line data due 1Q 2021.", 
    "company": "Synthetic Biologics Inc.", 
    "indication": "Constipation-Predominant Irritable Bowel Syndrome (C-IBS)", 
    "name": "SYN-010", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "License terminated following lack of efficacy shown February 2016", 
    "company": "Synthetic Biologics Inc.", 
    "indication": "Relapsing-remitting MS in women", 
    "name": "Trimesta", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial being considered.", 
    "company": "Synthetic Biologics Inc.", 
    "indication": "C. difficile Infection", 
    "name": "SYN-004 (ribaxamase)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1b/2 initiation under evaluation.", 
    "company": "Synthetic Biologics Inc.", 
    "indication": "Allogeneic hematopoietic cell transplantation (HCT)", 
    "name": "SYN-004", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Synthetic Biologics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "SYN-020", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 AML data due 4Q 2020.", 
    "company": "Syros Pharmaceuticals Inc.", 
    "indication": "Acute Myeloid Leukemia / Myelodysplastic Syndrome", 
    "name": "SY-1425 and azaciditine", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued - noted October 17, 2019.", 
    "company": "Syros Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "SY-1365", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced January 28, 2020 with initial safety data due 4Q 2020. Dose escalation data due mid-2021.", 
    "company": "Syros Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "SY-5609", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "sNDA filing announced August 24, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "First-line renal cell carcinoma", 
    "name": "CABOMETYX (cabozantinib) with Opdivo and Yervoy - CheckMate 9ER", 
    "stage": "sndaFiling"
  }, 
  {
    "newstxt": "Approval announced August 19, 2011.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Hodgkin lymphoma and Anaplastic large cell lymphoma", 
    "name": "ADCETRIS", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved November 29, 2012.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Medullary thyroid cancer", 
    "name": "Cabozantinib", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced January 14, 2019.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Advanced hepatocellular cancer (HCC)", 
    "name": "Cabozantinib (CELESTIAL)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "sBLA approval announced March 20, 2018. PDUFA date under priority review was May 1, 2018.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Frontline Hodgkin lymphoma", 
    "name": "ADCETRIS  in combination with chemotherapy ECHELON-1", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 16, 2018.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Frontline CD30-positive mature T-cell lymphomas - cancer", 
    "name": "ADCETRIS in combination with chemotherapy - ECHELON-2", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved August 17, 2015 under priority review.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Post-transplant Hodgkin lymphoma (HL) cancer", 
    "name": "ADCETRIS - AETHERA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due 2H 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Thyroid Carcinoma", 
    "name": "Cabozantinib - COSMIC-311", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line data due late-4Q 2020 or early-1Q 2021.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Renal cell carcinoma", 
    "name": "CB-839 + Cabozantinib (CANTATA)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 1H 2021.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Hepatocellular Carcinoma", 
    "name": "CABOMETYX (cabozantinib) + atezolizumab (TECENTRIQ) - (COSMIC-312)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Renal Cell Carcinoma", 
    "name": "Cabozantinib and Nivolumab and Ipilimumab (COSMIC-313)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 4 PFS data due 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Medullary Thyroid Cancer", 
    "name": "Cabozantinib", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial has completed enrolment.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "non-small cell lung cancer (NSCLC)", 
    "name": "Mobocertinib (TAK-788) - EXCLAIM", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial is enrolling.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "NSCLC with EGFR exon 20 insertion mutations", 
    "name": "Mobocertinib EXCLAIM-2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 trial has completed enrolment.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Non-Small Cell Lung Cancer", 
    "name": "Mobocertinib (TAK-788)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced May 22, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "ALK+ Metastatic Non-Small Cell Lung Cancer", 
    "name": "ALUNBRIG (brigatinib)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial is enrolling.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "ALK+ Advanced NSCLC", 
    "name": "ALUNBRIG versus alectinib ALTA 3", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - March 10, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Multiple myeloma ", 
    "name": "NINLARO (ixazomib) lenalidomide and dexamethasone - TOURMALINE-MM2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Registration-enabling trial to commence in the coming weeks - noted July 31, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "COVID-19", 
    "name": "CoVIg-19", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "CRL issued December 21, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Ulcerative Colitis", 
    "name": "Entyvio", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - July 22, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Crohn's Disease", 
    "name": "Vedolizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - November 8, 2019.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Multiple myeloma", 
    "name": "Ixazomib - TOURMALINE-MM4", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data presented at EHA June 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Chronic Myeloid Leukemia", 
    "name": "Ponatinib (OPTIC)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial is ongoing.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Negative symptoms of schizophrenia", 
    "name": "TAK-831", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Treatment-resistant depression", 
    "name": "TAK-653", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Anhedonia in depression", 
    "name": "TAK-041", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 4Q 2020 / 1Q 2021.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Higher-risk myelodysplastic syndromes (HR-MDS)", 
    "name": "Pevonedistat (TAK-924)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Currently in preparatory stages for a NDA submission - noted July 31, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "Hunter Syndrome", 
    "name": "TAK-609", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 2 trial initiation announced August 3, 2020.", 
    "company": "Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of)", 
    "indication": "COVID-19 (severe)", 
    "name": "Cenicriviroc + Otezla (apremilast) + Firazyr (icatibant)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial complete. ", 
    "company": "Protara Therapeutics Inc.", 
    "indication": "Lymphatic Malformations (LMs)", 
    "name": "TARA-002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial complete.", 
    "company": "Protara Therapeutics Inc.", 
    "indication": "Intestinal Failure Associated Liver Disease (IFALD)", 
    "name": "IV choline chloride", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 MAD data due likely due 2020. ", 
    "company": "Translate Bio Inc.", 
    "indication": "Cystic fibrosis", 
    "name": "MRT5005", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 IND placed on clinical hold - January 22, 2019. Development to be discontinued - noted September 9, 2019.", 
    "company": "Translate Bio Inc.", 
    "indication": "OTC deficiency", 
    "name": "MRT5201", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial to commence by the end of 2020.", 
    "company": "Translate Bio Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "mRNA vaccine", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Approved June 21, 2013.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Hospital-acquired and ventilator-associated bacterial pneumonia (HABP/VABP)", 
    "name": "VIBATIV  (telavancin hydrochloride) for injection", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved April 30, 2015.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Asthma", 
    "name": "BREO ELLIPTA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data due 2021.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "nOH", 
    "name": "Ampreloxetine (TD-9855)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "sNDA filing announced October 2, 2019. Estimate August 2, 2020 using 10-month timeline. However, Advisory Committee meeting was postponed due to COVID, resulting in a likely extension. Estimate 2H 2020. ", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Asthma", 
    "name": "Closed Triple - CAPTAIN", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Approval announced September 19, 2017.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "COPD", 
    "name": "Closed Triple", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced November 9, 2018.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "COPD", 
    "name": "Revefenacin", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b data released August 2, 2017. Primary endpoint not met.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Gastroparesis", 
    "name": "Velusetrag (TD-5108)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 trial discontinued following recent interim analysis.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Bacteremia", 
    "name": "Telavancin", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Crohn's Disease", 
    "name": "TD-1473", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 2021.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Ulcerative Colitis", 
    "name": "TD-1473", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 Part C data due 4Q 2020.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Asthma", 
    "name": "TD-8236", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due 4Q 2020.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Asthma", 
    "name": "TD-8236", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 commencement of dosing announced June 25, 2020.", 
    "company": "Theravance Biopharma Inc.", 
    "indication": "Acute Lung Injury (ALI) caused by COVID-19", 
    "name": "TD-0903", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "CRL announced August 24, 2020.", 
    "company": "Tricida Inc.", 
    "indication": "Chronic kidney disease ", 
    "name": "TRC 101", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Enrolment to be terminated - April 12, 2019.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "TRC105 + Opdivo", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 ready.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Prostate cancer", 
    "name": "TRC253", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Development to be discontinued - March 9, 2020.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Wet age-related macular degeneration (Wet-AMD)", 
    "name": "DE-122 and Lucentis - AVANTE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data December 21, 2018 did not meet primary endpoint.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Renal Cell Carcinoma (RCC) - cancer", 
    "name": "TRC105 and Inlyta", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released February 9, 2017 - primary endpoint not met.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Glioblastoma - cancer", 
    "name": "TRC105 and Avastin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint not met - November 19, 2018.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Glioblastoma - cancer", 
    "name": "TRC102 and Temodar", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiated October 2015. Data are due in 2020.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Mesothelioma cancer", 
    "name": "TRC102", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim analysis April 12, 2019 noted trial to be terminated due to futility.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Angiosarcoma cancer", 
    "name": "TRC105 (TAPPAS)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 data due 2H 2020.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "TJ4309", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to commence 4Q 2020 with interim data due 2021 and final data in 2022.", 
    "company": "TRACON Pharmaceuticals Inc.", 
    "indication": "Sarcomas", 
    "name": "Envafolimab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 interim update 2H 2020.", 
    "company": "TCR2 Therapeutics Inc.", 
    "indication": "Mesothelin-positive solid tumors", 
    "name": "TC-210", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 interim update due 2H 2020.", 
    "company": "TCR2 Therapeutics Inc.", 
    "indication": "CD19+ non-Hodgkin lymphoma or adult acute lymphoblastic leukemia", 
    "name": "TC-110", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 top-line data released June 2, 2020. Primary endpoint (Pulmonary Capillary Wedge Pressure (PCWP) with bicycle exercise) not met. Various secondary endpoints met. Additional data due later in 2020.", 
    "company": "Tenax Therapeutics Inc.", 
    "indication": "Pulmonary Hypertension associated with Heart Failure and preserved Ejection Fraction (PH-HFpEF)", 
    "name": "Levosimendan", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet primary endpoint.", 
    "company": "Tenax Therapeutics Inc.", 
    "indication": "Septic shock", 
    "name": "Levosimendan", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 top line data released January 31, 2017 - primary endpoints not met. ", 
    "company": "Tenax Therapeutics Inc.", 
    "indication": "Reduce the incidence of low cardiac output syndrome during cardiac surgery", 
    "name": "Levosimendan", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data achieved the co-primary endpoints for fasinumab 1 mg monthly. Fasinumab every two months did not reach statistical significance - August 5, 2020.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Osteoarthritis pain of the hip or knee", 
    "name": "Fasinumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "FDA Approval announced November 28, 2018.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Rituxan (rituximab) biosimilar", 
    "name": "TRUXIMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced December 14, 2018.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Herceptin biosimilar", 
    "name": "HERZUMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved January 15, 2018.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Acute Promyelocytic Leukemia", 
    "name": "Trisenox", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced September 14, 2018.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Migraine", 
    "name": "Fremanezumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2/3 trial did not meet primary endpoint - February 19, 2020.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Tourette Syndrome", 
    "name": "AUSTEDO (deutetrabenazine)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Post-Traumatic Headache", 
    "name": "Fremanezumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 ongoing", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Lower back pain", 
    "name": "Fasinumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to be terminated due to lack of efficacy - noted June 15, 2018.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Cluster headache", 
    "name": "Fremanezumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due in 2021.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Dyskinetic cerebral palsy (DCP)", 
    "name": "AUSTEDO (deutetrabenazine)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2021.", 
    "company": "Teva Pharmaceutical Industries Limited American Depositary Shares", 
    "indication": "Fibromyalgia", 
    "name": "Fremanezumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 SAD/MAD top-line data due September 2020.", 
    "company": "TFF Pharmaceuticals Inc - Ordinary Shares", 
    "indication": "Invasive Pulmonary Aspergillosis (IPA)", 
    "name": "Voriconazole Inhalation Powder", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation announced June 29, 2020.", 
    "company": "TFF Pharmaceuticals Inc - Ordinary Shares", 
    "indication": "Prophylaxis of lung allograft rejection", 
    "name": "Tacrolimus Inhalation Powder", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 initiation announced November 27, 2017.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Relapsing or refractory Follicular Lymphoma", 
    "name": "TGR-1202 (umbralisib) plus obinutuzumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 long term follow up data presented at ECTRIMS, September 12, 2019.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Relapsing forms of Multiple Sclerosis (RMS)", 
    "name": "TG-1101 (ublituximab)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Multiple Sclerosis", 
    "name": "TG-1101 - ULTIMATE II", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 updated data noted 91% ORR for CLL patients; 38% for Richterâ€™s transformation.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Relapsed or refractory Chronic Lymphocytic Leukemia (CLL)", 
    "name": "Umbralisib (TGR-1202) + Pembrolizumab + Ublituximab (TG-1101)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2020.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Multiple Sclerosis", 
    "name": "TG-1101 - ULTIMATE I", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date June 15, 2021.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Follicular lymphoma (FL)", 
    "name": "Umbralisib", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoint - March 6, 2017. Data presented at ASCO 2017.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Chronic Lymphocytic Leukemia (CLL) cancer", 
    "name": "TG-1101 and IMBRUVICA (GENUINE trial)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 PFS primary endpoint met. Trial to be stopped due to superior efficacy - May 5, 2020. Full data to be presented 2H 2020.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Chronic Lymphocytic Leukemia (CLL) and non-Hodgkin's Lymphoma (NHL)", 
    "name": "TG-1101 and TGR-1202 - UNITY-CLL study", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced February 26, 2019.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Relapsed or Refractory B-cell Lymphoma", 
    "name": "TG-1801", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 data presented at ASH December 8, 2019 noted 100% ORR (9/9) including 44% CR after cycle 12 for the combination.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Chronic Lymphocytic Leukemia", 
    "name": "Umbralisib + Ublituximab + Venetoclax", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 data presented at ASH December 9, 2019. ORR 86%.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Non Hodgkin Lymphoma / Chronic Lymphocytic Leukemia", 
    "name": "TG-1701", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "PDUFA date under priority review February 15, 2021.", 
    "company": "TG Therapeutics Inc.", 
    "indication": "Marginal zone lymphoma (MZL)", 
    "name": "Umbralisib", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be completed around the end of 2020 with data due late-2021.", 
    "company": "Taiwan Liposome Company Ltd.", 
    "indication": "Osteoarthritis", 
    "name": "TLC599", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released May 31, 2020 - statistically significant pain relief over both placebo (p<0.001) and bupivacaine (p=0.0188) from 0 to 24 hours. The differences in AUC0-72hrs did not reach statistical significance.", 
    "company": "Taiwan Liposome Company Ltd.", 
    "indication": "Postsurgical pain", 
    "name": "TLC590", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial planned.", 
    "company": "Tiziana Life Sciences plc", 
    "indication": "Hepatocellular carcinoma (HCC)", 
    "name": "Milciclib and Sorafenib (Nexavar)", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Tiziana Life Sciences plc", 
    "indication": "Crohnâ€™s Disease", 
    "name": "Foralumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial planned.", 
    "company": "Tiziana Life Sciences plc", 
    "indication": "Coronavirus COVID-19", 
    "name": "TZLS-501", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b data June 25, 2019 met endpoints.", 
    "company": "Timber Pharmaceuticals Inc.", 
    "indication": "Rosacea", 
    "name": "BPX-04", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b enrollment to be completed early 2021.", 
    "company": "Timber Pharmaceuticals Inc.", 
    "indication": "Congenital Ichthyosis", 
    "name": "TMB-001", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b enrollment to be completed early 2021.", 
    "company": "Timber Pharmaceuticals Inc.", 
    "indication": "Facial angiofibromas in tuberous sclerosis complex ", 
    "name": "TMB-002", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 3 trial halted due to insufficient efficacy - July 27, 2018.", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "Post-traumatic stress disorder (PTSD)", 
    "name": "TNX-102 SL (Tonmya)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data released February 2016 did not meet primary endpoint", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "Episodic tension-type headache", 
    "name": "TNX-201", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 interim analysis due September 2020. Top-line data due 4Q 2020.", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "Fibromyalgia", 
    "name": "TNX-102 SL (Tonmya)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 enrolment to be stopped due to futility - February 5, 2020. Top-line data has been delayed - June 19, 2020. No updated timeline.", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "Post-traumatic stress disorder (PTSD)", 
    "name": "Tonmya (TNX-102 SL)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "In-licensed - noted May 23, 2019.", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "Cocaine intoxication", 
    "name": "TNX-1300 (RBP-8000)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Efficacy trial to commence in 2020.", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "PK trial", 
    "name": "TNX-601", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial planned. IND acceptance announced August 6, 2020.", 
    "company": "Tonix Pharmaceuticals Holding Corp.", 
    "indication": "Alcohol Use Disorder", 
    "name": "TNX-102 SL", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 primary and secondary endpoints missed - September 12, 2019.", 
    "company": "Tocagen", 
    "indication": "Recurrent brain cancer", 
    "name": "Toca 511 & Toca FC - Toca 5", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1b at SITC 2019 noted median overall survival was 9.6 months.", 
    "company": "Tocagen", 
    "indication": "Solid tumors", 
    "name": "Toca 511 (Toca 6)", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 updated data at AACR April 3, 2019.", 
    "company": "Tocagen", 
    "indication": "Glioma", 
    "name": "Toca 511 & Toca FC", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2/3 enrolment to commence late 2019.", 
    "company": "Tocagen", 
    "indication": "Glioblastoma (GBM)", 
    "name": "Toca 511 & Toca FC - (NRG-BN006)", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 3 top-line data did not meet primary endpoint - November 15, 2019.", 
    "company": "resTORbio Inc.", 
    "indication": "Respiratory Tract Infections", 
    "name": "RTB101 - PROTECTOR 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 data from first four cohorts due mid-2020 - noted in 1Q earnings release. Cohort 5 terminated due to COVID. No update provided in 2Q earnings release July 30, 2020.", 
    "company": "resTORbio Inc.", 
    "indication": "Parkinson's disease", 
    "name": "RTB101 and sirolimus", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2b data presented at IDSA October 3, 2019.", 
    "company": "resTORbio Inc.", 
    "indication": "Respiratory Tract Infections", 
    "name": "RTB101", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 interim data released August 18, 2020. ORR 6/7 in ROS1-positive TKI-naïve NSCLC; ORR 2/5 ROS1-positive TKI-naïve NSCLC; ORR 4/6 ROS1-positive NSCLC population pretreated with one prior TKI without prior chemotherapy.", 
    "company": "Turning Point Therapeutics Inc.", 
    "indication": "Non-small-cell lung cancer (NSCLC) and solid tumors", 
    "name": "Repotrectinib (TPX-0005) - TRIDENT-1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 interim data due 4Q 2020.", 
    "company": "Turning Point Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "TPX-0022", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 interim data due early 2021.", 
    "company": "Turning Point Therapeutics Inc.", 
    "indication": "RET-altered NSCLC", 
    "name": "TPX-0046", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 update due at ASH December 2020.", 
    "company": "Trillium Therapeutics Inc.", 
    "indication": "Diffuse Large B-cell Lymphoma (DLBCL), Cutaneous T-cell lymphoma (CTCL)", 
    "name": "TTI-621-01", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Trillium Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "TTI-621-02", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 update due at ASH December 2020.", 
    "company": "Trillium Therapeutics Inc.", 
    "indication": "Refractory lymphoma or multiple myeloma", 
    "name": "TTI-622", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2b/3 enrolment to be completed in 3Q 2021 with top-line data due 4Q 2021.", 
    "company": "Trevi Therapeutics Inc.", 
    "indication": "Prurigo Nodularis", 
    "name": "Nalbuphine ER - PRISM", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Trevi Therapeutics Inc.", 
    "indication": "Pruritus associated with primary biliary cholangitis (PBC)", 
    "name": "Nalbuphine ER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial halted due to COVID-19. To restart 2H 2020.", 
    "company": "Trevi Therapeutics Inc.", 
    "indication": "Chronic cough - Idiopathic pulmonary fibrosis (IPF)", 
    "name": "Nalbuphine ER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "Trevi Therapeutics Inc.", 
    "indication": "Levodopa-induced dyskinesia - Parkinson's disease", 
    "name": "Nalbuphine ER", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced August 7, 2020.", 
    "company": "Trevena Inc.", 
    "indication": "Moderate to severe acute pain", 
    "name": "Oliceridine (TRV130)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2b endpoints not met - May 2016", 
    "company": "Trevena Inc.", 
    "indication": "Acute heart failure", 
    "name": "TRV027 - BLAST-AHF", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1 enrolment has been paused due to COVID-19 - noted March 26. 2020.", 
    "company": "Trevena Inc.", 
    "indication": "Acute migraine", 
    "name": "TRV250", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Proof of concept trial initiation announced December 23, 2019.", 
    "company": "Trevena Inc.", 
    "indication": "Opioid use disorder", 
    "name": "TRV734", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b trial initiation announced August 24, 2020 with top-line data due 1Q 2021.", 
    "company": "Trevena Inc.", 
    "indication": "COVID-19", 
    "name": "TRV027", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1/2 treatment has commenced - noted October 11, 2017. DSMB recommended trial to continue - July 2, 2018 but further enrollment has been postponed due to lack of resources.", 
    "company": "Titan Pharmaceuticals Inc.", 
    "indication": "Parkinson's disease", 
    "name": "Ropinirole implant", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "CRL issued April 30, 2013. Approved May 26 2016", 
    "company": "Titan Pharmaceuticals Inc.", 
    "indication": "Opioid dependence", 
    "name": "Probuphine", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced October 29, 2018.", 
    "company": "TherapeuticsMD Inc.", 
    "indication": "Moderate to severe vasomotor symptoms (VMS)", 
    "name": "TX-001HR: BIJUVA", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "CRL announced May 8, 2017. NDA resubmitted with approval announced May 30, 2018.", 
    "company": "TherapeuticsMD Inc.", 
    "indication": "Moderate-to-severe vaginal pain", 
    "name": "Yuvvexy - TX-004HR", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced August 10, 2018.", 
    "company": "TherapeuticsMD Inc.", 
    "indication": "Contraception", 
    "name": "Segesterone Acetate/ Ethinyl Estradiol", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial to complete enrolment by late-2020 to early-2021.", 
    "company": "Tyme Technologies Inc.", 
    "indication": "Pancreatic cancer", 
    "name": "SM-88", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Pivotal stage initiation announced September 25, 2019.", 
    "company": "Tyme Technologies Inc.", 
    "indication": "Prostate cancer", 
    "name": "SM-88", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to continue as planned following futility review - August 11, 2020.", 
    "company": "Tyme Technologies Inc.", 
    "indication": "Ewingâ€™s sarcoma", 
    "name": "SM-88 - HopES", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data failed to meet primary endpoint - August 17, 2020.", 
    "company": "Unity Biotechnology Inc.", 
    "indication": "Osteoarthritis of the knee", 
    "name": "UBX0101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 2H 2020 with data in 2021.", 
    "company": "Unity Biotechnology Inc.", 
    "indication": "Diabetic macular edema / Age-related macular degeneration", 
    "name": "UBX1325", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1b data due 2H 2020.", 
    "company": "Unity Biotechnology Inc.", 
    "indication": "Osteoarthritis of the knee", 
    "name": "UBX0101", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 dose escalation suspended - noted November 4, 2019.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "Multiple Myeloma", 
    "name": "ACTR087 + SEA-BCMA (ATTCK-17-01)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development to be stopped - noted March 2, 2020.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "CD20+ Non-Hodgkin Lymphoma (NHL) ", 
    "name": "ACTR707 + rituximab (ATTCK-20-03)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial placed on clinical hold - July 2, 2019. Program to be deprioritized.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "Non-Hodgkin Lymphoma (NHL)", 
    "name": "ACTR087 + rituximab (ATTCK-20-2)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Development to be stopped - noted March 2, 2020.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "Solid tumors", 
    "name": "ACTR T cells (ATTCK-34-01)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 2H 2021.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "Gastrointestinal Stromal Tumors (GIST) ", 
    "name": "PLX9486 and sunitinib", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 1H 2021.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "Advanced Systemic Mastocytosis", 
    "name": "PLX9486", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 2H 2021.", 
    "company": "Unum Therapeutics Inc.", 
    "indication": "Indolent Systemic Mastocytosis", 
    "name": "PLX9486", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial ongoing.", 
    "company": "UroGen Pharma Ltd.", 
    "indication": "Overactive Bladder (OAB) ", 
    "name": "RTGel in combination with BOTOX", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial planned for 2H 2020.", 
    "company": "UroGen Pharma Ltd.", 
    "indication": "Low grade non-muscle invasive bladder cancer (LG-NMIBC)", 
    "name": "VesiGel UGN-102", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "FDA Approval announced April 15, 2020.", 
    "company": "UroGen Pharma Ltd.", 
    "indication": "Urothelial Carcinoma", 
    "name": "MitoGel - UGN-101", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2a top-line data due 4Q 2020.", 
    "company": "Urovant Sciences Ltd.", 
    "indication": "Irritable bowel syndrome (IBS)", 
    "name": "Vibegron", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 top-line data due 2021", 
    "company": "Urovant Sciences Ltd.", 
    "indication": "Overactive bladder (OAB) in men with benign prostatic hyperplasia (BPH)", 
    "name": "Vibegron -  COURAGE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date December 26, 2020.", 
    "company": "Urovant Sciences Ltd.", 
    "indication": "Overactive bladder (OAB)", 
    "name": "Vibegron", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Data and safety monitoring board data review and decision to move from cohort 1 to cohort 2 expected in early 2021.", 
    "company": "Urovant Sciences Ltd.", 
    "indication": "Overactive bladder (OAB)", 
    "name": "URO-902", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "PDUFA date estimate April 16, 2020.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary hypertension associated with interstitial lung disease (PH-ILD) (WHO Group 3)", 
    "name": "Tyvaso", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 data released April 8, 2019 did not meet primary endpoint.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "Esuberaprost - BEAT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data released August 8, 2018. Primary endpoint met.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "Orenitram ", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL announced April 29, 2020. NDA to be resubmitted in 2021.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary Arterial Hypertension (PAH)", 
    "name": "Trevyent", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Approved Dec 20 2013", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "Oral treprostinil", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 ongoing. ", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary Arterial Hypertension", 
    "name": "Ralinepag ADVANCE OUTCOMES", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 trial did not meet primary endpoint - February 3, 2020.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Small cell lung cancer", 
    "name": "Unituxin - DISTINCT", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 data due 2020.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary Arterial Hypertension (PAH)", 
    "name": "Treprostinil Technosphere (BREEZE)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial ongoing.", 
    "company": "United Therapeutics Corporation", 
    "indication": "Pulmonary Hypertension associated with chronic obstructive pulmonary disease (PH-COPD).", 
    "name": "Inhaled treprostinil", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1/2 presentation at AACR June 22, 2020. 1/6 partial responses recorded. Part B immunologic and tumor data of VBI-1901 in combination with AS01 due 4Q 2020.", 
    "company": "VBI Vaccines Inc.", 
    "indication": "Recurrent glioblastoma multiforme (rGBM)", 
    "name": "VBI-1901 and GM-CSF or AS01", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data met co-primary endpoints but missed key secondary endpoint. ", 
    "company": "VBI Vaccines Inc.", 
    "indication": "Hepatitis B vaccine", 
    "name": "Sci-B-Vac - PROTECT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "VBI Vaccines Inc.", 
    "indication": "Congenital Cytomegalovirus (CMV)", 
    "name": "VBI-1501", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint - January 9, 2020. Data to be presented at EASL August 29, 2020.", 
    "company": "VBI Vaccines Inc.", 
    "indication": "Hepatitis B vaccine", 
    "name": "Sci-B-Vac - CONSTANT", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020.", 
    "company": "VBI Vaccines Inc.", 
    "indication": "Hepatitis B vaccine", 
    "name": "BRII-179 (VBI-2601)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Clinical trials to commence by the end of 2020.", 
    "company": "VBI Vaccines Inc.", 
    "indication": "COVID-19 vaccine", 
    "name": "VBI-2900", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 interim analysis noted trial to continue as planned - August 12, 2020. Next review 1Q 2021.", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Recurrent platinum resistant ovarian cancer", 
    "name": "VB-111", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 top-line data released March 8, 2018 - primary endpoint not met.", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Recurrent glioblastoma (rGBM) cancer", 
    "name": "VB-111", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 failed to meet endpoints - Feb 2015 data", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Ulcerative colitis", 
    "name": "VB-201", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 failed to meet endpoints - Feb 2015 data", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Psoriasis", 
    "name": "VB-201", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initial data due 2021.", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Colon cancer", 
    "name": "VB-111", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated following COVID-19.", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Recurrent glioblastoma multiforme (rGBM)", 
    "name": "VB-111", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 initiation announced February 20, 2020.", 
    "company": "Vascular Biogenics Ltd.", 
    "indication": "Colorectal Cancer", 
    "name": "VB-111 and Nivolumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "BLA filing announced June 30, 2020.", 
    "company": "Vericel Corporation", 
    "indication": "Severe burns", 
    "name": "NexoBrid", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2b topline data released March 2016. Full data released April 2016", 
    "company": "Vericel Corporation", 
    "indication": "Stem cells - Dilated Cardiomyopathy", 
    "name": "ixmyelocel-T", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "FDA Approval announced December 13, 2016 ahead of PDUFA date of January 3 2017. ", 
    "company": "Vericel Corporation", 
    "indication": "Focal chondral cartilage defects in the knee.", 
    "name": "MACI ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 top-line data due October 2020.", 
    "company": "Vaccinex Inc.", 
    "indication": "Huntingtonâ€™s disease", 
    "name": "VX15 - Signal", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 interim analysis due at ASCO June 2020.", 
    "company": "Vaccinex Inc.", 
    "indication": "Pancreatic and Colorectal Cancer", 
    "name": "VX15 Yervoy and Opdivo", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1/2 updated data presented April 27, 2020 at AACR noted 81% of immunotherapy-naÃ¯ve patients (17/21) experienced disease control - partial response (5/21 patients) or stable disease (12/21 patients).", 
    "company": "Vaccinex Inc.", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Pepinemab (VX15) and avelumab - CLASSICAL", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 enrollment to commence September 2020.", 
    "company": "Vaccinex Inc.", 
    "indication": "Alzheimerâ€™s Disease (AD)", 
    "name": "Pepinemab (VX15/2503)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial to commence late-2020.", 
    "company": "Veru Inc.", 
    "indication": "Hot flashes", 
    "name": "Zuclomiphene citrate", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "NDA filing due 4Q 2020 or early 2021.", 
    "company": "Veru Inc.", 
    "indication": "Benign prostatic hyperplasia (BPH)", 
    "name": "Tadalafil and Finasteride combo", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1b/2 data to be presented at ESMO September 19-21, 2020. ", 
    "company": "Veru Inc.", 
    "indication": "Castration Resistant Prostate Cancer", 
    "name": "VERU-111 (bisindole)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated 4Q 2020.", 
    "company": "Veru Inc.", 
    "indication": "Prostate cancer", 
    "name": "VERU-100", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 commencement of enrolment announced June 19, 2020.", 
    "company": "Veru Inc.", 
    "indication": "COVID-19 / Severe Acute Respiratory Syndrome", 
    "name": "VERU-111", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced June 11, 2020.", 
    "company": "Viela Bio Inc.", 
    "indication": "Neuromyelitis Optica Spectrum Disorder", 
    "name": "Inebilizumab", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 enrolment paused due to COVID-19.", 
    "company": "Viela Bio Inc.", 
    "indication": "Kidney transplant desensitization ", 
    "name": "Inebilizumab", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 4Q 2020.", 
    "company": "Viela Bio Inc.", 
    "indication": "Myasthenia gravis", 
    "name": "Inebilizumab", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2b trial to resume enrollment in 4Q 2020.", 
    "company": "Viela Bio Inc.", 
    "indication": "Sjögren’s syndrome", 
    "name": "VIB4920", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2a trial has resumed enrollment following pause due to COVID-19.", 
    "company": "Viela Bio Inc.", 
    "indication": "Kidney transplant rejection", 
    "name": "VIB4920", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b interim data released May 13, 2020. Final data from Cohort 3 due 3Q 2020.", 
    "company": "Viela Bio Inc.", 
    "indication": "Cutaneous lupus erythematosus", 
    "name": "VIB7734", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2b trial to be initiated 4Q 2020.", 
    "company": "Viela Bio Inc.", 
    "indication": "IgG4-related disease", 
    "name": "Inebilizumab", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 1b trial to be initiated 3Q 2020 with data due 1Q 2021.", 
    "company": "Viela Bio Inc.", 
    "indication": "COVID-19-Related Acute Lung Injury", 
    "name": "VIB7734", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 preliminary antiviral activity and safety data to be presented at EASL August 28, 2020.", 
    "company": "Vir Biotechnology Inc.", 
    "indication": "Chronic hepatitis B virus (HBV)", 
    "name": "VIR-2218", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Vir Biotechnology Inc.", 
    "indication": "Influenza", 
    "name": "VIR-2482", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2/3 trial to commence August 2020. Initial data due by end of 2020.", 
    "company": "Vir Biotechnology Inc.", 
    "indication": "COVID-19 antibody", 
    "name": "VIR-7831", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Human trials to commence around the end of 2020.", 
    "company": "Vir Biotechnology Inc.", 
    "indication": "COVID-19", 
    "name": "VIR-2703", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced May 27, 2020. Data are due in 2021.", 
    "company": "Vir Biotechnology Inc.", 
    "indication": "Hepatitis B", 
    "name": "VIR-3434", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2b enrolment to be completed 1H 2021.", 
    "company": "Viking Therapeutics Inc.", 
    "indication": "Non-alcoholic steatohepatitis (NASH) and fibrosis", 
    "name": "VK2809 VOYAGE", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 trial met endpoints - November 28, 2017. Data at ASBMR September 30, 2018.", 
    "company": "Viking Therapeutics Inc.", 
    "indication": "Acute Hip Fracture", 
    "name": "VK5211", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial to be initiated 3Q 2020.", 
    "company": "Viking Therapeutics Inc.", 
    "indication": "X-linked adrenoleukodystrophy", 
    "name": "VK0214", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 additional data due at EASL August 28, 2020.", 
    "company": "Viking Therapeutics Inc.", 
    "indication": "NAFLD", 
    "name": "VK2809", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrollment to be completed 1H 2021.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Gastroparesis", 
    "name": "Tradipitant", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved May 26, 2016.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Supplemental New Drug Application (sNDA) as a maintenance treatment of schizophrenia in adults.", 
    "name": "Fanapt ", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved January 31, 2014.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Insomnia", 
    "name": "HETLIOZ (tasimelteon)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued August 19, 2019.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Jet Lag Disorder", 
    "name": "HETLIOZ (tasimelteon)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "PDUFA date under priority review December 1, 2020.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Smith-Magenis Syndrome", 
    "name": "HETLIOZ (tasimelteon)", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Phase 3 trial did not meet primary endpoint - February 25, 2020.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "Tradipitant - EPIONE 1", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 new enrolment on hold due to COVID-19.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Motion sickness", 
    "name": "Tradipitant", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial on hold due to COVID-19.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Bipolar Disorder", 
    "name": "Fanapt", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial on hold due to COVID-19.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Delayed sleep phase disorder (DSPD)", 
    "name": "HETLIOZ (tasimelteon)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 enrolment commenced October 2019. On hold due to COVID-19.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Atopic dermatitis", 
    "name": "Tradipitant - EPIONE 2", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data August 18, 2020 noted statistically significant improvement by Day 7. However, improvement was not statistically significant at Day 28.", 
    "company": "Vanda Pharmaceuticals Inc.", 
    "indication": "Pneumonia associated with COVID-19", 
    "name": "Tradipitant - ODYSSEY VLY-686-3501", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "CRL announced July 14, 2020.", 
    "company": "Verrica Pharmaceuticals Inc.", 
    "indication": "Molluscum contagiosum", 
    "name": "VP-102", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 1H 2020.", 
    "company": "Verrica Pharmaceuticals Inc.", 
    "indication": "Common warts", 
    "name": "VP-102", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data due 2H 2020", 
    "company": "Verrica Pharmaceuticals Inc.", 
    "indication": "Genital warts", 
    "name": "VP-102", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial to be initiated mid-2020.", 
    "company": "Verrica Pharmaceuticals Inc.", 
    "indication": "Plantar Warts", 
    "name": "VP-103", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2a data released March 2, 2018.", 
    "company": "Verona Pharma plc", 
    "indication": "Cystic fibrosis", 
    "name": "RPL554", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint - January 14, 2019.", 
    "company": "Verona Pharma plc", 
    "indication": "COPD", 
    "name": "RPL554", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data met primary endpoint - August 5, 2019.", 
    "company": "Verona Pharma plc", 
    "indication": "Maintenance treatment of COPD", 
    "name": "RPL554 DPI formulation", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b additional data to be presented at ESMO September 8, 2020. Phase 3 trial to be initiated 2H 2020.", 
    "company": "Verona Pharma plc", 
    "indication": "Chronic obstructive pulmonary disease (COPD)", 
    "name": "Ensifentrine (RPL554) and tiotropium", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 MDI second part of trial initiation announced August 19, 2020 with data due 1H 2021.", 
    "company": "Verona Pharma plc", 
    "indication": "Maintenance treatment of COPD", 
    "name": "Ensifentrine (RPL554) - Metered Dose Inhaler", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Label expanded to now include all patients over 6 years old - June 21, 2019.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis - Two Copies of the F508del Mutation", 
    "name": "Tezacaftor / ivacaftor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved December 29, 2014.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) ages 6 and older who have the R117H mutation", 
    "name": "KALYDECO", 
    "stage": "approved"
  }, 
  {
    "newstxt": "CRL issued February 5, 2016.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations.", 
    "name": "KALYDECO (ivacaftor)", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Approved July 2, 2015.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) ages 12 and older who have two copies of the F508del mutation", 
    "name": "Lumacaftor and ivacaftor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved March 17, 2015.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Children ages 2 to 5 with cystic fibrosis who have the G551D or one of the eight additional gating mutations", 
    "name": "KALYDECO (ivacaftor)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 data released October 25, 2017 - primary endpoint not met.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in a gating mutation", 
    "name": "Tezacaftor (VX-661) / ivacaftor", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial terminated August 2016", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis - one copy of the F508del mutation and a second mutation that results in minimal CFTR Function", 
    "name": "VX-661", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved September 28, 2016.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) ages 6-11 who have F508del mutation", 
    "name": "ORKAMBI", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced October 21, 2019.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) who have one copy of the F508del mutation and one minimal function mutation and patients with two copies of the F508del mutation", 
    "name": "VX-445 in combination with tezacaftor and ivacaftor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1/2 data presented at EHA June 12, 2020. Patient was free of vaso-occlusive crises at 9 months after CTX001 infusion. Further data due 2H 2020.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Sickle cell disease", 
    "name": "CTX001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1/2 data presented at EHA June 12, 2020. Two patients are transfusion independent at 5 and 15 months after infusion. Further data due 2H 2020.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Beta-thalassemia", 
    "name": "CTX001", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "FDA Approval announced August 7, 2018.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) ages 2 to 5.", 
    "name": "Ivacaftor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced August 15, 2018.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic fibrosis (CF) ages 1-2.", 
    "name": "Lumacaftor and ivacaftor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA Approval announced April 30, 2019.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Cystic Fibrosis (6-12 mths)", 
    "name": "Ivacaftor", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 trial has resumed at some sites following pause due to COVID-19 - July 30, 2020.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "alpha-1 antitrypsin (AAT) deficiency", 
    "name": "VX-814", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial has been initiated - noted April 29, 2020.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Focal segmental glomerulosclerosis (FSGS)", 
    "name": "VX-147", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 trial ongoing.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Alpha-1 antitrypsin (AAT) deficiency", 
    "name": "VX-864", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 data and sNDA filing due 2H 2020.", 
    "company": "Vertex Pharmaceuticals Incorporated", 
    "indication": "Children ages 6 to 11 years who have two F508del mutations and one F508del mutation and one minimal function mutation", 
    "name": "Elexacaftor, tezacaftor and ivacaftor", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 top-line results from the expansion cohorts due early 2021.", 
    "company": "Verastem Inc.", 
    "indication": "Peripheral T-Cell Lymphoma (PTCL)", 
    "name": "Duvelisib (PRIMO)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released June 2016 - short of expectations", 
    "company": "Verastem Inc.", 
    "indication": "Indolent non-Hodgkin lymphoma", 
    "name": "Duvelisib (IPI-145) DYNAMO", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced September 24, 2018.", 
    "company": "Verastem Inc.", 
    "indication": "Chronic lymphocytic leukemia (CLL)//Small Lymphocytic Lymphoma (SLL)/Follicular Lymphoma", 
    "name": "Duvelisib - DUO", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 interim analysis showed lack of efficacy. Trial stopped. September 2015", 
    "company": "Verastem Inc.", 
    "indication": "Mesothelioma prior to surgery", 
    "name": "VS-6063", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 failed to meet endpoint - Jan 2015", 
    "company": "Verastem Inc.", 
    "indication": "Rheumatoid arthritis", 
    "name": "Duvelisib (IPI-145)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 data to be presented at the RAS-Targeted Drug Development Conference on September 16, 2020", 
    "company": "Verastem Inc.", 
    "indication": "KRAS mutant advanced solid tumors", 
    "name": "VS-6766 and Defactinib - FRAME", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data did not meet primary endpoint - November 14, 2019.", 
    "company": "VistaGen Therapeutics Inc.", 
    "indication": "Adjunctive Treatment Major Depressive Disorder", 
    "name": "AV-101 - ELEVATE", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned.", 
    "company": "VistaGen Therapeutics Inc.", 
    "indication": "Neuropathic pain", 
    "name": "AV-101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 pivotal program planned.", 
    "company": "VistaGen Therapeutics Inc.", 
    "indication": "Social Anxiety Disorder (SAD)", 
    "name": "PH94B nasal spray", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 1b data released December 19, 2019 - well-tolerated.", 
    "company": "VistaGen Therapeutics Inc.", 
    "indication": "Healthy volunteers", 
    "name": "AV-101", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2b trial planned.", 
    "company": "VistaGen Therapeutics Inc.", 
    "indication": "Major depressive disorder", 
    "name": "PH10", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2a trial planned.", 
    "company": "VistaGen Therapeutics Inc.", 
    "indication": " COVID-19 ", 
    "name": "PH94B", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 Part 2 data met primary endpoint - February 10, 2020. Next trial to commence by the end of 2020.", 
    "company": "vTv Therapeutics Inc.", 
    "indication": "Type 1 Diabetes", 
    "name": "TTP399", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2 data released August 2016. Primary endpoint met.", 
    "company": "vTv Therapeutics Inc.", 
    "indication": "Type 2 Diabetes", 
    "name": "TTP399 - AGATA", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2 primary endpoint met - December 14, 2016.", 
    "company": "vTv Therapeutics Inc.", 
    "indication": "Type 2 Diabetes", 
    "name": "TTP273 - LOGRA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints. ", 
    "company": "vTv Therapeutics Inc.", 
    "indication": "Mild Alzheimerâ€™s disease", 
    "name": "Azeliragon - STEADFAST", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2/3 top-line data due 2Q 2021.", 
    "company": "vTv Therapeutics Inc.", 
    "indication": "Mild Alzheimerâ€™s disease with type 2 diabetes", 
    "name": "Azeliragon", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Approved July 17, 2012.", 
    "company": "", 
    "indication": "Obesity", 
    "name": "Qnexa", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved Apr 27 2012. sNDA label change also approved 17 Sept 2014", 
    "company": "", 
    "indication": "Erectile dysfunction", 
    "name": "Avanafil", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 trial completed July 2018.", 
    "company": "", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "VI-0106", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 trial did not meet primary endpoint.", 
    "company": "Vaxart Inc.", 
    "indication": "Condyloma", 
    "name": "BTA074 5% topical gel (teslexivir)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial planned. Initiation placed on hold with focus to be placed on COVID-19 vaccine.", 
    "company": "Vaxart Inc.", 
    "indication": "Norovirus vaccine", 
    "name": "Norovirus vaccine", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1 IND filing announced August 10, 2020.", 
    "company": "Vaxart Inc.", 
    "indication": "COVID-19 Vaccine", 
    "name": "Covid-19 vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Universal influenza vaccine collaboration study with Janssen has been completed and a report is being compiled for Janssen.", 
    "company": "Vaxart Inc.", 
    "indication": "Universal Influenza vaccine", 
    "name": "Universal Influenza vaccine", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 final Phase 1b to presented at MDS Virtual Congress 2020 being held in September 12 - 16, 2020.", 
    "company": "Voyager Therapeutics Inc.", 
    "indication": "Advanced Parkinsonâ€™s disease", 
    "name": "VY-AADC02", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 2 trial to re-enroll 2H 2020. Phase 3 trial to commence 1H 2021.", 
    "company": "Voyager Therapeutics Inc.", 
    "indication": "Parkinson's Disease", 
    "name": "VY-AADC02 (RESTORE-1)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b/2a top line data 1Q 2021.", 
    "company": "Wave Life Sciences Ltd.", 
    "indication": "Huntingtonâ€™s disease", 
    "name": "WVE-120101 (PRECISION-HD1)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b/2a top line data released December 30, 2019 noted statistically significant reduction of 12.4% (p<0.05) in mutant huntingtin (mHTT) protein but no difference in total HTT (tHTT) protein. 32 mg data due 1Q 2021.", 
    "company": "Wave Life Sciences Ltd.", 
    "indication": "Huntingtonâ€™s disease", 
    "name": "WVE-120102  (PRECISION-HD2)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 2/3 development discontinued - December 2020.", 
    "company": "Wave Life Sciences Ltd.", 
    "indication": "Duchenne muscular dystrophy - Exon 51", 
    "name": "Suvodirsen (WVE-210201) - DYSTANCE 51", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 development to be discontinued following interim analysis - December 16, 2019.", 
    "company": "Wave Life Sciences Ltd.", 
    "indication": "DMD Exon 51", 
    "name": "Suvodirsen (WVE-210201)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 enrolment closed in March 2019 due to slow enrolment.", 
    "company": "Xenetic Biosciences Inc.", 
    "indication": "Endometrial cancer", 
    "name": "XBIO-101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data due 1H 2021", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "Adult focal seizures", 
    "name": "XEN1101", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released March 24, 2017 - endpoints not met.", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "Acne", 
    "name": "XEN801", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b data released June 27, 2017. Endpoints not met.", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "Postherpetic neuralgia", 
    "name": "TV-45070", 
    "stage": "phase2b"
  }, 
  {
    "newstxt": "Phase 2b trial did not meet endpoints - July 2015", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "Osteoarthritis", 
    "name": "TV-45070", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 2 trial to commence 2H 2020.", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "SCN8A developmental and epileptic encephalopathy (SCN8A-DEE)", 
    "name": "NBI-921352", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated in 2020.", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "Epilepsy", 
    "name": "XEN496", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data due 1H 2021.", 
    "company": "Xenon Pharmaceuticals Inc.", 
    "indication": "Childhood absence epilepsy", 
    "name": "XEN007", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Approved March 2016", 
    "company": "Intersect ENT Inc.", 
    "indication": "Frontal Sinus Disease", 
    "name": "Propel", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approval announced December 11, 2017.", 
    "company": "Intersect ENT Inc.", 
    "indication": "Recurrent sinus obstruction", 
    "name": "SINUVA Sinus Implant", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 trial met primary endpoints - February 25, 2019.", 
    "company": "Intersect ENT Inc.", 
    "indication": "Nasal polyps", 
    "name": "SINUVA - ENCORE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Data released October 7, 2019 did not meet primary endpoint.", 
    "company": "Intersect ENT Inc.", 
    "indication": "Sinus Balloon", 
    "name": "ASCEND", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data showed no statistically significant differences between the treatment arms. Program to be discontinued - November 21, 2019.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Hypoglycemia-Associated Autonomic Failure", 
    "name": "Continuous glucagon", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated 2H 2019.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Congenital Hyperinsulinism", 
    "name": "Continuous glucagon", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial met primary endpoints - June 15, 2020.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Exercise-Induced Hypoglycemia", 
    "name": "Self administered glucagon", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b outpatient data released May 22, 2020.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Post-Bariatric Hypoglycemia", 
    "name": "Self administered glucagon", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced September 10, 2019.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Severe hypoglycemia", 
    "name": "Glucagon Rescue Pen", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data released June 18, 2020. 62% reduction of hyperglycemia after a glucose challenge.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Type 1 diabetes", 
    "name": "Pramlintide and insulin", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b data released April 20, 2020 - safe and well-tolerated", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Seizures", 
    "name": "Diazepam", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 1b trial complete. Partner required for Phase 3 development.", 
    "company": "Xeris Pharmaceuticals Inc.", 
    "indication": "Epilepsy", 
    "name": "XP-0863", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Phase 3 data due 2022.", 
    "company": "X4 Pharmaceuticals Inc.", 
    "indication": "WHIM syndrome", 
    "name": "Mavorixafor (X4P-001)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2a data presented at ESMO 2019 - TKI therapy PFS 7.4 months; ORR 18%. ", 
    "company": "X4 Pharmaceuticals Inc.", 
    "indication": "Renal Cell Carcinoma (RCC) - cancer", 
    "name": "Mavorixafor and axitinib", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 1/2 initial data due towards the end of 2020.", 
    "company": "X4 Pharmaceuticals Inc.", 
    "indication": "WaldenstrÃ¶m macroglobulinemia", 
    "name": "Mavorixafor and ibrutinib", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1b top-line data due 2021.", 
    "company": "X4 Pharmaceuticals Inc.", 
    "indication": "Severe Congenital Neutropenia (SCN)", 
    "name": "Mavorixafor (X4P-001)", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated by end of 2020.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "Sotatercept - STELLAR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2022+.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "First-line, lower-risk Myelodysplastic syndromes (MDS)", 
    "name": "Luspatercept - COMMANDS", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 trial to commence by end of 2020 or early-2021.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Myelofibrosis", 
    "name": "Luspatercept - INDEPENDENCE", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 data did not meet primary endpoint - March 9, 2020.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Charcot-Marie-Tooth disease (CMT)", 
    "name": "ACE-083", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced April 3, 2020.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Myelodysplastic syndromes (MDS) cancer", 
    "name": "Luspatercept", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 data did not achieve statistically significant improvements in functional endpoints relative to placebo - September 16, 2019.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Facioscapulohumeral muscular dystrophy", 
    "name": "ACE-083", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released June 12, 2017 - primary endpoint not met.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Renal Cell Carcinoma (RCC) - cancer", 
    "name": "Dalantercept - DART Study", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Announced April 4, 2019 intention to discontinue development.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Healthy volunteers", 
    "name": "ACE-2494", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due YE 2020 or early-2021.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Non-transfusion-dependent beta-thalassemia", 
    "name": "Luspatercept - BEYOND", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced November 8, 2019.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Beta-thalassemia", 
    "name": "Luspatercept", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 2 initial data due 1H 2021.", 
    "company": "Acceleron Pharma Inc.", 
    "indication": "Pulmonary arterial hypertension (PAH)", 
    "name": "Sotatercept - SPECTRA", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data released October 5, 2018. Primary endpoint not met.", 
    "company": "Xencor Inc.", 
    "indication": "Systemic Lupus Erythematosus (SLE)", 
    "name": "XmAb5871", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 3 trial to be initiated - partner required.", 
    "company": "Xencor Inc.", 
    "indication": "IgG4-Related Disease (IgG4-RD)", 
    "name": "XmAb5871", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced July 31, 2020.", 
    "company": "Xencor Inc.", 
    "indication": "Relapsed or refractory diffuse large B cell lymphoma", 
    "name": "Tafasitamab (MOR208/XmAb5574)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 1 trial placed on partial clinical hold - February 20, 2019.", 
    "company": "Xencor Inc.", 
    "indication": "Acute Myeloid Leukemia (AML)", 
    "name": "XmAb14045", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data at ASH December 9, 2019 - generally well tolerated.", 
    "company": "Xencor Inc.", 
    "indication": "Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma", 
    "name": "Plamotamab (XmAb13676)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2020.", 
    "company": "Xencor Inc.", 
    "indication": "Neuroendocrine tumors (NET) and gastrointestinal stromal tumors (GIST)", 
    "name": "Tidutamab (XmAb18087)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initiation of dosing announced May 6, 2019.", 
    "company": "Xencor Inc.", 
    "indication": "Solid tumors", 
    "name": "XmAb23104-01 (DUET-3)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 commencement of dosing announced June 3, 2019.", 
    "company": "Xencor Inc.", 
    "indication": "Solid tumors", 
    "name": "XmAb22841", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data due presented at ASCO May 29, 2020.", 
    "company": "Xencor Inc.", 
    "indication": "Solid tumors", 
    "name": "XmAb20717 (DUET-2)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "CRL announced October 18, 2018.", 
    "company": "XOMA Corporation", 
    "indication": "CV risk reduction", 
    "name": "ACZ885 (canakinumab) ", 
    "stage": "crl"
  }, 
  {
    "newstxt": "Rolling BLA filing to be completed 4Q 2020.", 
    "company": "XOMA Corporation", 
    "indication": "Non-muscle invasive bladder cancer (NMIBC)", 
    "name": "Vicinium", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 2 proof-of-concept results released April 24, 2017.", 
    "company": "XOMA Corporation", 
    "indication": "Hyperprolactinemia", 
    "name": "XOMA 213", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 initiation of patient dosing announced June 13, 2019.", 
    "company": "XOMA Corporation", 
    "indication": "Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma", 
    "name": "Gevokizumab", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 planned.", 
    "company": "XTL Biopharmaceuticals Ltd.", 
    "indication": "Systemic Lupus Erythematosus (SLE)", 
    "name": "hCDR1 ", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Tobacco Products Scientific Advisory Committee (TPSAC) to met February 14, 2020, regarding MRTP application.", 
    "company": "22nd Century Group Inc.", 
    "indication": "MRTP application", 
    "name": "VLN cigarettes", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "PDUFA date November 30, 2020", 
    "company": "Y-mAbs Therapeutics Inc.", 
    "indication": "Relapsed/Refractory High-Risk Neuroblastoma", 
    "name": "Naxitamab", 
    "stage": "pdufaPriorityReview"
  }, 
  {
    "newstxt": "Rolling BLA filing has been completed - August 6, 2020.", 
    "company": "Y-mAbs Therapeutics Inc.", 
    "indication": "CNS/Leptomeningeal Metastases from Neuroblastoma", 
    "name": "Omburtamab", 
    "stage": "blaFiling"
  }, 
  {
    "newstxt": "Phase 3 data due in 2020.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Congenital hyperinsulinism", 
    "name": "Dasiglucagon", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data due 2H 2021.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Short bowel syndrome", 
    "name": "Glepaglutide", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date scheduled for March 27, 2021.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Severe hypoglycemia in diabetes", 
    "name": "Dasiglucagon", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 3 trial to commence in 2021.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Type 1 Diabetes", 
    "name": "Dasiglucagon dual-hormone pump therapy", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 commencement of enrolment announced May 7, 2019.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Short bowel syndrome", 
    "name": "Glepaglutide - extension trial", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 2 initiation of dosing announced June 24, 2020.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Obesity / diabetes", 
    "name": "BI 456906", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1a data due 2020 with Phase 1b trial to commence 2021.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Short bowel syndrome (SBS)", 
    "name": "ZP7570", 
    "stage": "phase1a"
  }, 
  {
    "newstxt": "Phase 2 data released March 30, 2020.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Post bariatric surgery hypoglycemia", 
    "name": "Dasiglucagon", 
    "stage": "phase2a"
  }, 
  {
    "newstxt": "Phase 3 data due 2020.", 
    "company": "Zealand Pharma A/S", 
    "indication": "Congenital hyperinsulinism", 
    "name": "Dasiglucagon", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Phase 3 data met primary endpoint with high dose, low dose secondary endpoint not met - February 6, 2020.", 
    "company": "Zogenix Inc.", 
    "indication": "Lennox-Gastaut syndrome", 
    "name": "ZX008 - (Study 1601)", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "Approved July 16, 2009.", 
    "company": "Zogenix Inc.", 
    "indication": "Migraine", 
    "name": "Sumavel", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved October 25, 2013.", 
    "company": "Zogenix Inc.", 
    "indication": "Moderate to severe pain", 
    "name": "Zohydro ER", 
    "stage": "approved"
  }, 
  {
    "newstxt": "FDA approval announced June 25, 2020.", 
    "company": "Zogenix Inc.", 
    "indication": "Dravet syndrom", 
    "name": "FINTEPLA (ZX008)", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Approved January 30, 2015.", 
    "company": "Zogenix Inc.", 
    "indication": "Moderate to severe pain", 
    "name": "Abuse deterrent formulations of Zohydro ER", 
    "stage": "approved"
  }, 
  {
    "newstxt": "NDA filing due 1H 2022.", 
    "company": "Zogenix Inc.", 
    "indication": "Thymidine kinase 2 deficiency", 
    "name": "MT1621", 
    "stage": "ndaFiling"
  }, 
  {
    "newstxt": "Phase 1 interim data at ASCO noted mOS has not been reached, with mean follow-up at 8.3 months.", 
    "company": "ZIOPHARM Oncology Inc", 
    "indication": "Refractory glioblastoma multiforme (GBM)", 
    "name": "Ad-RTS-hIL-12 plus veledimex in combination with OPDIVO (nivolumab)", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 patient screening has commenced - noted March 2, 2020.", 
    "company": "ZIOPHARM Oncology Inc", 
    "indication": "Solid tumors", 
    "name": "Sleeping beauty - TCR-T cell therapy", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 completion of enrolment announced June 22, 2020. Initial data to be presented later in 2020.", 
    "company": "ZIOPHARM Oncology Inc", 
    "indication": "Refractory glioblastoma multiforme (GBM)", 
    "name": "Ad-RTS-hIL-12 plus veledimex plus Libtayo", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1/2 initiation of dosing announced July 8, 2020.", 
    "company": "ZIOPHARM Oncology Inc", 
    "indication": "Diffuse intrinsic pontine glioma (DIPG)", 
    "name": "Ad-RTS-hIL-12 with veledimex", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 trial initiation announced July 9, 2020.", 
    "company": "ZIOPHARM Oncology Inc", 
    "indication": "CD19+ leukemias and lymphomas", 
    "name": "CD19-Specific T Cells - Sleeping Beauty", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 data due late-2020 or early-2021.", 
    "company": "Zai Lab Limited", 
    "indication": "Gastric and gastro-esophageal junction cancer", 
    "name": "FPA144 +  chemo (FIGHT)", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "FDA Approval announced April 29, 2020.", 
    "company": "Zai Lab Limited", 
    "indication": "Ovarian cancer", 
    "name": "Niraparib - PRIMA", 
    "stage": "approved"
  }, 
  {
    "newstxt": "Phase 3 interim data 2021. Final data 2023.", 
    "company": "Zai Lab Limited", 
    "indication": "Non-small cell lung cancer (NSCLC)", 
    "name": "Tumor Treating Fields (TTFields) LUNAR", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date December 18, 2020. FDA will not require an Oncologic Drugs Advisory Committee (ODAC) meeting.", 
    "company": "Zai Lab Limited", 
    "indication": "Metastatic breast cancer", 
    "name": "Margetuximab", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.", 
    "company": "Zai Lab Limited", 
    "indication": "Urinary tract infections", 
    "name": "Omadacycline", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released October 31, 2019. Comparable levels of clinical success but microbiological responses were generally lower than comparators.", 
    "company": "Zai Lab Limited", 
    "indication": "Complicated urinary tract infections (cUTI) / acute pyelonephritis", 
    "name": "Omadacycline", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 monotherapy trial to be initiated in the first half of 2021.", 
    "company": "Zentalis Pharmaceuticals Inc.", 
    "indication": "ER+/HER2- breast cancer", 
    "name": "ZN-c5", 
    "stage": "phase1.5"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2021.", 
    "company": "Zentalis Pharmaceuticals Inc.", 
    "indication": "Solid tumors", 
    "name": "ZN-c3", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 initial data due 2021.", 
    "company": "Zentalis Pharmaceuticals Inc.", 
    "indication": "Non-small cell lung cancer", 
    "name": "ZN-e4", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 3 trial data due released February 13, 2017 - primary endpoints met.", 
    "company": "Zosano Pharma Corporation", 
    "indication": "Migraine", 
    "name": "M207", 
    "stage": "phase3"
  }, 
  {
    "newstxt": "PDUFA date October 20, 2020.", 
    "company": "Zosano Pharma Corporation", 
    "indication": "Migraine", 
    "name": "Qtrypta (M207)", 
    "stage": "pdufa"
  }, 
  {
    "newstxt": "Phase 2/3 trial initiation announced October 24, 2019.", 
    "company": "Zosano Pharma Corporation", 
    "indication": "Cluster headache", 
    "name": "C213", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 1 initial data released October 28, 2019. 5/9 partial responses.", 
    "company": "Zymeworks Inc.", 
    "indication": "HER2-expressing Gastroesophageal Adenocarcinoma", 
    "name": "ZW25", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1 data due 2020.", 
    "company": "Zymeworks Inc.", 
    "indication": "HER2-Expressing Cancers", 
    "name": "ZW49", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 1 trial is ongoing.", 
    "company": "Zymeworks Inc.", 
    "indication": "HER2-expressing cancers", 
    "name": "ZW25 + chemo", 
    "stage": "phase1"
  }, 
  {
    "newstxt": "Phase 2 initiation announced January 12, 2020.", 
    "company": "Zymeworks Inc.", 
    "indication": "HER2-positive, HR-positive breast cancer", 
    "name": "ZW25 and Ibrance", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 1b/2 initiation of dosing announced April 1, 2020.", 
    "company": "Zymeworks Inc.", 
    "indication": "Breast Cancer / Gastric / Gastroesophageal Junction Cancer", 
    "name": "ZW25 + Chemotherapy + Tislelizumab", 
    "stage": "phase1b"
  }, 
  {
    "newstxt": "Development to be discontinued - noted January 2018.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Fibromyalgia", 
    "name": "ZYN001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Development to be discontinued - noted January 2018.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Peripheral Neuropathic Pain (PNP)", 
    "name": "ZYN001", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2/3 trial did not meet primary endpoint - June 30, 2020.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Fragile X syndrome", 
    "name": "Zygel ZYN002", 
    "stage": "phase23"
  }, 
  {
    "newstxt": "Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Osteoarthritis", 
    "name": "ZYN002 - STOP", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2b trial initiation postponed until after the completion of childhood neuropsychiatric studies.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Adult Epilepsy Patients with Refractory Focal Seizures", 
    "name": "ZYN002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 top-line data released September 18, 2019. 10/46 patients reported a serious adverse event (SAE). Intends to meet with FDA 2Q 2020 to discuss path forward.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Developmental and Epileptic Encephalopathies (DEE)", 
    "name": "ZYN002 BELIEVE 1", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 trial delayed due to COVID-19.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "22q11.2 Deletion Syndrome ", 
    "name": "Zygel ZYN002", 
    "stage": "phase2"
  }, 
  {
    "newstxt": "Phase 2 data released May 27, 2020. Trial achieved statistically significant and improvements from in all subscales of the Aberrant Behavior Checklist.", 
    "company": "Zynerba Pharmaceuticals Inc.", 
    "indication": "Autism Spectrum Disorder (ASD) ", 
    "name": "Zygel ZYN002 - BRIGHT", 
    "stage": "phase2"
  }
]`;